DEPARTMENT OF MEDICINE 2014 Annual

Transcription

DEPARTMENT OF MEDICINE
2014 Annual Report
DIVISIONS AND INSTITUTES
The D ivisi ons
»» Allergy
John Ohman, MD
»» Cardiology
James Udelson, MD
»» C
linical Decision Making, Informatics
Telemedicine»
John Wong, MD
T h e I n st it u tes
»» Institute for Clinical Research and
Health Policy Studies
Harry Selker, MD
»» Molecular Cardiology Research Institute*
Richard Karas, MD, PhD
»» Molecular Oncology Research Institute*
Philip Tsichlis, MD
»» Clinical Nutrition
Edward Saltzman, MD
»» Endocrinology
Ron Lechan, MD
»» Gastroenterology
Joel Weinstock, MD
»» Geographic Medicine and Infectious Disease
David Snydman, MD
»» Hematology/Oncology
Andrew Evens, DO, MSc
»» Internal Medicine and Adult Primary Care
Deborah Blazey-Martin, MD, MPH
»» Nephrology
Andrew Levey, MD
»» Pulmonary, Critical Care and Sleep Medicine
Nicholas Hill, MD
»» Rheumatology
Timothy McAlindon, MD
Photography by Martha Stewart Photography.
Design and production by Mark Vincent Communications, Inc. — www.markvincent.net.
TUFTS MEDICAL CENTER DEPARTMENT OF MEDICINE — ANNUAL REPORT 2014
TABLE OF CONTENTS
The Department of Medicine
Chairman’s Message
4
Departmental Organization Chart
6
Departmental Leadership 6
Clinical Activity 10
Research Activity 11
Internal Medicine Training Program
13
The Divisions 14
Allergy 16
Cardiology 18
Clinical Care Research 33
Clinical Decision Making, Informatics
and Telemedicine 34
Clinical Nutrition 38
Endocrinology, Diabetes and Metabolism 41
Gastroenterology 49
Geographic Medicine and Infectious Diseases 54
Hematology/Oncology 63
Internal Medicine and Adult Primary Care
80
Geriatrics
90
William B. Schwartz Division of Nephrology 91
Pulmonary, Critical Care and Sleep Medicine 100
Rheumatology 108
The Institutes 116
Institute for Clinical Research and
Health Policy Studies 118
Molecular Cardiology Research Institute (MCRI) 132
Molecular Oncology Research Institute (MORI) 140
Publications 145
CHAIRMAN’S MESSAGE
2014 saw a change in the administrative leadership of the Department of Medicine.
Matthew Larkin, Administrative Director, was promoted to Vice President of
Operations for the Tufts Medical Center Physicians Organization. He was replaced
by Allison Ankeny, JD, MPH, whose administrative experience in both clinical and
research endeavors at prestigious medical institutions will be of great value to
the department.
Clinical activity for the Department of Medicine showed a decrease in inpatient
activity and an increase in outpatient activity for virtually all divisions, in keeping
with trends throughout the country. There was gratifying growth in our two new
community-based practices, i.e. in Quincy and Framingham.
Deeb N. Salem, MD, FACP, FACC, FACCP—
The Sheldon M. Wolff Professor and
Chairman, Department of Medicine
Research activity grants and contracts grew from a total of $34 million in FY 2013 to
$36 million in 2014, a significant accomplishment in light of the expiration of many
grants that were part of the fiscal stimulus and the generally harsher climate for
government-funded research. The Institutes and Divisions have responded to the decrease in NIH-funded research by
actively pursuing diversification of funding sources, which has resulted in significant growth in industry-funded projects
and clinical trials, and awards from private foundation.
The Division of Cardiology stood out for its cardiac transplantation, ventricular assist and hypertrophic cardiomyopathy
programs, the largest such programs in New England. Its referral network for complex catheter-based coronary
structural heart failure and electrophysiology procedures grew as did its trans-aortic valve program. Many members of
the Division were named among Boston Magazine’s Top Doctors.
John Wong, chief of the Division of Clinical Decision-Making, was named to the Institute of Medicine committee on
Diagnostic Error in Health Care and served as a member of the AASLD committee on guidelines for the management of
Hepatitis B. Jerome Kassirer was keynote lecturer at the European meeting of the Society for Medical Decision Making.
Stephen Pauker served as a member of the End-of-Life committee of the Institute of Medicine.
Edward Saltzman, chief of the Division of Nutrition, was named Academic Dean for Education at the Friedman School of
Nutrition Science and Policy. The Division of Endocrinology received a grant renewal from the Friedman Foundation for
Medical Research to support research and fellowship training.
The Division of Gastroenterology substantially expanded its food hypersensitivity consultation center, under the
directorship of John Leung. A new gastrointestinal motility service was established under the supervision of Harmony
Allison.
The Division of Geographic Medicine and Infectious Diseases received renewed funding of a 5 year training grant for the
study of Microbial Pathogenesis. New faculty members were recruited to bring additional expertise to the study of
hepatitis C and Lyme disease. Sherwood Gorbach was named Emeritus Professor of Medicine and Susan Hadley was
awarded the Zucker Prize for outstanding accomplishment in teaching. Helen Boucher was named to the Infectious
Disease subspecialty board of the ABIM.
The Division of Hematology/Oncology recruited two faculty members with expertise in neuro-oncology and thoracic
cancers and melanoma. A new electronic medical record was launched to integrate adult and pediatric hematology/
oncology, radiation oncology and gynecological oncology. An initiative was developed to facilitate navigation by the center’s
Asian population. Other programs with philanthropic support will address cancer fatigue, holistic cancer care and sickle cell
disease. Additional gifts include a sophisticated fluorescence resonance microscopy unit, a seed pledge for a multiple
myeloma program, prostate research, and a survivorship program for adolescents and young adults.
The Division of Internal Medicine and Adult Primary Care added 3 new primary care physicians and entered into the New
England Quality Care Alliance ACO. The Division received an award from Blue Cross/Blue Shield for the detection of
depression and a grant to initiate point-of-care testing for HbA1c in diabetic patients. Its new outpatient offices in Quincy
and Framingham showed promising growth.
The William B. Schwartz Division of Nephrology received a number of significant honors. Dr. Levey was recognized by
Thomson Reuters as a highly influential researcher, Dr. Meyer received a Distinguished Faculty Award from the medical
school and Dr. Perrone was the recipient of the Physician of the Year Award from the Polycystic Kidney Foundation and of
the Seldin Award for clinical excellence from the National Kidney Foundation.
Members of the Division of Pulmonary, Critical Care and Sleep Medicine also received notable honors. Nicholas Hill was
appointed Chair of the steering committee of the NIH-sponsored Pulmonary Vascular Diseasomics project and Ioana
Preston was appointed Chair of the Educational Committee of the Pulmonary Hypertension Association.
In the Division of Rheumatology, Dr. Arabelovic received a medical student preceptorship grant. Other members were
honored by academic promotions and appointments.
Among the three Institutes, The Institute for Clinical Research and Health Policy Studies (ICRHPS) received over $6
million in new funding for 25 new research projects. Several faculty members were appointed to major national panels.
Investigators in The Molecular Cardiology Research Institute (MCRI) identified a critical predictor of risk for heart disease
and sudden death in diabetics. Gordon Huggins was named Principal Investigator of the Tufts Medical Center Regional
Heart Failure Network and Iris Jaffee received a prestigious Established Investigator Award from the American Heart
Association. Members of the Molecular Oncology Research Institute received 7 new research awards for a total of $1.23
million, delivered numerous invited lectures and were authors of 55 publications.
For details of these and many other achievements, please read the full report and the list of publications.
Sincerely, Deeb Salem
5
DEPARTMENTAL LEADERSHIP
Deeb N. Salem, MD, FACP, FACC, FACCP
Dr. Deeb Salem has had a distinguished career as an academic cardiologist. In 1987, he was appointed
Professor of Medicine at Tufts University School of Medicine. He served as Chief of Cardiology at the
Tufts New England Medical Center from 1987 to 1995 and was appointed the Sheldon M Wolff Professor
and Chairman of the Department of Medicine at Tufts University School of Medicine and Physician-inChief of Tufts Medical Center in 1999. He is a Fellow of the American College of Cardiology, the
American College of Physicians, and the American College of Chest Physicians.
Dr. Salem was the founding President of the New England Affiliate of the American Heart Association. His academic
accomplishments include over one hundred and seventy scientific publications. He is recognized as a national expert in
coronary artery disease, valvular heart disease and congestive heart failure. Dr. Salem received the Distinguished
Alumni Award from Boston University School of Medicine in 1998, the Distinguished Faculty Award from Tufts University
School of Medicine in 1998, an American Heart Association Great Communicator Award in 1999 and an American Heart
Association Distinguished Leadership Award in 2000. He received the Massachusetts Physician Health Service
Distinguished Service Award in 2003. In 2007, Dr. Salem was the recipient of the American Heart Association’s Paul
Dudley White Lifetime Achievement award. In August of 2007, Dr. Salem received the Champions in Healthcare, Lifetime
Achievement Award from the Boston Business Journal. He has repeatedly been listed in Boston Magazine as one of
“Boston’s Best” physicians. In 2010 Dr Salem was awarded the Working Wonders Lifetime Achievement Award by Tufts
Medical Center.
He is on the Executive Board of the Board of Trustees of Tufts Medical Center and is an emeritus member of the Board of
Directors of the Northeast Affiliate of the American Heart Association. Dr Salem is also on the Board of Director of the Wang
Chinatown YMCA, the Asian American Civic Association, the New England Quality Care Alliance (NEQCA), the Tufts Medical
Center Physicians Organization, the Tufts Health Care Institute. He was elected to the Publications Committee of the New
England Journal of Medicine in 2003 and became Vice Chair of that Committee in the spring of 2009. In 2010, Dr. Salem was
elected Chairman of the Mass Medical Society’s Committee on Sponsored Programs and Chairman of the Tufts University
School of Medicine's Graduate Medical Education Committee. He currently is on the Executive Advisory Board of the New
England Journal of Medicine, Chairman of the NEQCA Finance Committee and a member of the Tufts Medical Center's Quality
of Care Committee, Finance Committee and Strategic Planning Committee. In 2014, Dr. Salem was elected to the Board of
Trustees of the Massachusetts Hospital Association and in 2015 became a member of the Wellforce Finance Committee.
M i c h a e l B a rza , MD, FAC P
Dr. Michael Barza is Vice Chair for Clinical Affairs at Tufts Medical Center and Professor of Medicine
at Tufts University School of Medicine. In 2012, he was named the Sara Murray Jordan Professor of
Medicine at Tufts University School of Medicine.
Dr. Barza joined the faculty of Tufts-New England Medical Center in 1972. He served as Associate Chief
of the Division of Geographic Medicine and Infectious Disease as well as hospital epidemiologist. He is
a Fellow of the American College of Physicians and of the Infectious Diseases Society of America.
Dr. Barza has been an author or coauthor of over 200 peer-reviewed papers in infectious diseases. Supported by NIH
grants, he undertook a number of fundamental studies of the pharmacology of antibiotics in the eye. He also became
known as a superior clinician and teacher with a special interest in complex infections. He is named in all recent
editions of the national compendium of “Best Doctors”. In 1998, Dr. Barza left T-NEMC to go to the Carney Hospital
where he served as Chief of Medicine through 2014. In 2008, while retaining his positions at Carney Hospital, he
returned to Tufts Medical Center to assume his current positions.
Having a longstanding interest in the publication of scientific information, Dr. Barza has served as Editor of Antimicrobial
Agents and Chemotherapy, Associate Editor for the Yearbook of Infectious Diseases and Senior Editor of Infectious Diseases in
Clinical Practice, and was a member of the Institute of Medicine scientific panel on Human Health Risks with Penicillin or
Tetracyclines in Animal Feed. He is currently Deputy Editor of Clinical Infectious Diseases, a premier infectious disease journal.
Dr. Barza has made major teaching contributions to the School of Medicine. He has taught for over 25 years in the
Infectious Disease Pathophysiology course and has consistently received outstanding evaluations by students. He is the
recipient of the Distinguished Faculty Award for 2007, the Zucker Clinical Teaching Prize for Outstanding
Accomplishment in 2008 and Outstanding Tufts University School of Medicine Lecturer for 2009-2010.
L i n d e n H u, MD
Linden T. Hu, MD, was appointed Vice-Chairman for Faculty Development for the Department of Medicine
in 2008. He is also Associate Chief for Research in the Division of Geographic Medicine and Infectious
Diseases at Tufts Medical Center. He is a Professor of Medicine at Tufts University School of Medicine.
After receiving his MD from Brown University, Dr. Hu did an internship and residency in internal
medicine at St. Elizabeth’s Medical Center in Boston. He completed a fellowship in Infectious Diseases
at Tufts Medical Center.
Dr. Hu is involved in both clinical and laboratory based research into Lyme disease. His focus is on the mechanisms by
which the spirochete adapts to its various natural hosts and evades the host immune responses. His laboratory is also
developing reservoir-targeted vaccines to reduce transmission of tick borne diseases in the wild. Recently, his laboratory
has begun to investigate interactions in bacterial communities using a dental model of periodontitis. He is an author or
co-author of over 40 peer-reviewed publications and his laboratory is supported by 7 grants from the NIH.
Dr. Hu has been a member or Chairman of numerous peer review committees for the NIH and the National Research
Fund for Tick-borne Diseases. He has received a Daland Fellowship from the American Philosophical Society and the
Maxwell Finland Award from the Massachusetts Infectious Disease Society and is a Fellow of the Infectious Disease
Society of America. In 2010, he was elected to the American Society for Clinical Investigation. Dr. Hu teaches at Tufts
Medical School and at the Sackler School of Graduate Biomedical Studies where he is training faculty in the Programs in
Microbiology and in Immunology.
R i ch a rd Ka ra s, MD, Ph D
Richard H. Karas, MD, PhD, has served as Vice-Chairman for Research for the Department of Medicine
since 2008. He is also the Chief Scientific Officer at Tufts Medical Center, where he also serves as the
Executive Director of the Molecular Cardiology Research Institute, and Co-director of the Women’s Heart
Center. He is the Elisa Kent Mendelsohn Professor of Medicine at Tufts University School of Medicine.
7
Before earning his medical degree from the Tufts University School of Medicine, Dr Karas received a PhD in comparative
physiology of exercise from Harvard University. After internship and residency in internal medicine at the Brigham and
Women’s Hospital, Boston, he completed a clinical fellowship in cardiology at Duke University Medical Center and a
research fellowship in cardiology at the University of Texas Southwestern Medical Center, Dallas.
Dr Karas’ main areas of research, supported by grants from the NIH and American Heart Assocation, are the effects of
steroid sex hormones on vascular cell biology, mouse models of cardiovascular disease, and the effects of lipid-lowering
and hormone therapies on vasomotor function. He has been an author or co-author of over 180 scientific articles,
reviews, and book chapters.
Dr Karas serves on the National American Heart Association Research Committee and he currently Chairs the Policy and
Evaluation Sub-committee. He was most recently the Chairman of the National American Heart Association committee
on Cardiovascular Diseases in Women and Special Populations. At the Howard Hughes Medical Institute, he was a
member of the Review Committee for Research Training Fellowships for Medical Students. He also has been an ad hoc
member of peer review committees for the NIH and the Swiss National Science Foundation. He has been an editorial
board member for Endocrinology and Atherosclerosis. He was awarded the Pfizer Postdoctoral Fellowship in Cardiology,
the Young Investigators Award from the American College of Cardiology, and the Established Investigator Award from
the American Heart Association. Dr. Karas is also the recipient of the Kynett Foundation Award and he received the
Distinguished Faculty Award from Tufts University School of Medicine in 2012.
Dr Karas is a fellow of the American Heart Association and of the American College of Cardiology. He is a member of the
Endocrine Society, the North American Menopause Society, and the American Heart Association’s Basic Science Council,
Council on Epidemiology and Prevention, and the Clinical Cardiology Council.
J e rom e P. Ka ss i re r, M D
Dr. Kassirer has been a member of the faculty of Tufts University School of Medicine for more than five
decades, and served as Vice Chairman of the Department of Medicine for 20 years. His research has
encompassed diverse fields including acid-base balance, medical decision-making, and cognitive
science. Dr. Kassirer has served as a governor and regent of the American College of Physicians, chair
of the American Board of Internal Medicine, and from 1991 to 1999, as Editor-in-Chief of the New
England Journal of Medicine. He currently serves on the Journal Oversight Committee of the Canadian
Medical Association Journal and on the Human Factors Subcommittee of the National Commission on Forensic Science.
He is the recipient of numerous awards, several honorary degrees, and a Mastership in the American College of
Physicians. He is a member of the Institute of Medicine of the National Academy of Sciences, the Association of
American Physicians, and the American Academy of Arts and Sciences. He is currently a Distinguished Professor at
Tufts University School of Medicine and Consultant, Department of Medicine at Stanford University and the Center for
Outcomes Research and Evaluation at Yale University. Dr. Kassirer has written extensively about health care, for-profit
medicine, and financial conf lict of interest. He is the author of the current Oxford University Press book, “On the Take:
How Medicine’s Complicity with Big Business Can Endanger Your Health.” and a co-author of the book “Learning
Clinical Reasoning.”
R i ch a rd Kop e l m a n , M D, FAC P
Richard Kopelman, MD, is the Vice-Chairman for Education in the Department of Medicine and the
Louisa C. Endicott Professor of Medicine at Tufts University School of Medicine. He began his academic
career at Tufts as one of the first faculty members in the newly created Division of General Medicine in
the early 1980s. He has been acting chief of that division on several occasions. He has been Director of
the Medical House Staff Training Program since 1981, overseeing the growth of the house staff from 30
members to its current total of 72 interns and residents. He is an active member of the Association of
Program Directors in Internal Medicine (APDIM)as well as a past Council member and participant in numerous
committees and task forces. For the past several years he has been the leader of the Assembly of University Program
Directors in that organization. In 2014, he was chosen to be featured in the APDIM Spotlight series for his role as a mentor.
Dr. Kopelman received his undergraduate degree magna cum laude in economics from Harvard College in 1970 and his
medical school degree from Duke University School of Medicine in 1974. He did his house staff training at Tufts- New
England Medical Center followed by a fellowship in hypertension at Massachusetts General Hospital.
His academic pursuits have been in the areas of hypertension and clinical problem solving. With Dr. Kassirer he was the
co-editor of the Clinical Problem Solving series in Hospital Practice for many years and subsequently co-authored two
editions of Learning Clinical Reasoning with Drs. Kassirer and Wong. In addition to his administrative responsibilities
Dr. Kopelman maintains an active practice in general internal medicine and for the past several years has been regularly
listed in the Best Doctors in America and by Boston Magazine in its lists of top physicians. In 2010, he received the Tufts
University School of Medicine Distinguished Faculty Award.
Al l i s on Anke ny, J D, M PH
Allison Ankeny, JD, MPH is the Director for the Department of Medicine and Cancer Center at Tufts
Medical Center, an Assistant Professor of Medicine at Tufts University School of Medicine, and has a
secondary appointment as an Assistant Professor of Medicine at Tufts University School of Public
Health and Community Medicine.
Ms. Ankeny, although new to Tufts Medical Center, has become quickly integrated and is already a
highly regarded member of the Tufts Medical Center team. She brings with her a wealth of experience as an accomplished senior administrator: from overseeing Cardiology at New York University to four Divisions of Pediatrics at
Columbia University (Allergy/Immunology, Rheumatology, Endocrinology and Emergency Medicine – including
opening the new Pediatric Emergency Department, a 55,000 square foot state-of-the-art facility during her tenure). In
Ohio, she worked at the James Cancer Institute, an NCI-designated Cancer Center at The Ohio State University, overseeing Radiation Medicine.
Ms. Ankeny earned her law degree from Capital University Law School (2005), a Masters of Public Health from Columbia
University’s Joseph Mailman School of Public Health (2013), and her Bachelor of Arts undergraduate degree magna cum
laude in psychology from Kent State University in 2001.
Ms. Ankeny has been active in academic research, having served as Key Personnel and Co-Investigator on several NIH
R01s (including ARRA and HRSA grants) as well as serving as the interim Nodal Administrator for the Pediatric
Emergency Care Alliance Network (PECARN) – a nationwide collaboration of top-tier academic medical centers. Her
research interests are varied, including the intersection of healthcare ethics, medicine, business and law.
This coming summer, Ms. Ankeny will be teaching Healthcare Organizational Structure and Behavior, and
Organizational Change at Tufts School of Medicine, helping to launch what is expected to be a certificate course for
1st/4th year medical students and medical residents, in a Business Enrichment Program. In addition, Allison is active
and will continue to be instrumental in overseeing Tufts University School of Medicine’s MD/MBA students in
departmental projects relating to health care strategy, policy, and quality/process improvements.
Da n i e l l e R i g gs, BS
Danielle Riggs joined the Department of Medicine administrative leadership team in the fall of 2008 as
the Director of Research Administration. She oversees the pre- and post-award administration for all
federal, foundation, and industry grant funds and clinical trials across the Divisions of Medicine. She
was previously the Director of Administration and Finance for the Molecular Oncology Research
Institute and Associate Director of Finance for the Tufts Cancer Center, where she helped grow the
cancer research program. Danielle holds a bachelor’s degree from Stonehill College.
9
CLINICAL ACTIVITY
The Department’s clinical revenue base is derived from several sources: in-patient daily care and consults, outpatient
care, procedures, and certain off-site revenue for clinical activities. The Department is organized as part of Tufts
Medical Center Physician Organization as Pratt Medical Group.
The table below shows the inpatient volumes for the Department of Medicine at Tufts Medical Center. Overall, total Medicine inpatient
discharges decreased by 12.3% from FY13 to FY14.
Inpatient Ac t i v i ty a t Tufts Me d ic a l C en ter
Attending Service
Fiscal Year 2013 Actual
% Change
Cardiology
2,075
1,802
-13.2%
Gastroenterology
673
633
-5.9%
Internal Medicine and Adult
Primary Care
981
759
-22.6%
Geographic Medicine and
Infectious Disease
636
556
-12.6%
Hematology/Oncology
935
888
-5.0%
Nephrology
1,153
1,008
-12.6%
Pulmonary, Critical Care and
Sleep Medicine
845
768
-9.1%
Geriatrics
652
558
-14.4%
Grand Totals
7,950
6,972
-12.3%
The table below outlines the outpatient visit volumes for the Department of Medicine at Tufts Medical Center. Ambulatory visits
increased by 5.9% from FY13 to FY14.
Outpatient Act i v i ty a t Tufts Medic a l C en ter
Division
% Change
Cardiology
11,565
12,285
6.2%
Endocrine
6,521
7,190
10.2%
Gastroenterology
6,422
7,240
12.7%
Primary Care – Boston (GMA)
65,982
66,838
1.3%
Primary Care – Quincy
1,664
3,843
130.9%
Primary Care – Framingham
n/a
754
n/a
Infectious Disease
4,771
4,970
4.17%
GI/Nutrition-Obesity Clinic
93
143
53.7%
Hematology/Oncology
6,323
6,692
5.8%
Nephrology
5,174
5,271
1.8%
Pulmonary, Critical Care and
Sleep Medicine
4,521
4,827
6.7%
Rheumatology
6,075
6,031
-0.7%
Grand Totals
119,111
126,084
5.9%
Clinical professional revenue has grown by 11.6% between FY 2013 and FY 2014, as shown below.
C linical Profess i ona l Reve nu e
Division
% Change
Cardiology
6,659,911
6,999,658
5.1%
Endocrine
912,745
1,065,879
16.8%
Gastroenterology
2,955,358
3,557,783
20.4%
General Internal Medicine (includes all
Primary Care sites)
8,338,031
8,907,439
6.8%
Geographic Medicine and Infectious
Disease
2,450,050
2,589,657
5.7%
GI/Nutrition-Obesity Clinic
58,493
76,126
30.1%
Hematology/Oncology
2,372,623
2,597,898
9.5%
Nephrology
3,199,977
3,148,033
-1.6%
Pulmonary, Critical Care and Sleep
Medicine
2,490,144
2,978,927
19.6%
Rheumatology
828,926
868,401
4.8%
Grand Totals
30,265,121
33,767,428
11.6%
RESEARCH ACTIVITY
The Department of Medicine has a wide variety of clinical and basic research programs. Most basic research is conducted
in the Tupper Research Institute, whereas clinical research programs are based primarily at 35 Kneeland Street and in
Tufts Medical Center. Many members of the Department of Medicine conduct their research within the Molecular
Cardiology Research Institute (located on 7 f loors of the Tupper Building), the Molecular Oncology Research Institute
(located on 3 f loors at 75 Kneeland Street), and the Institute for Clinical Research and Health Policy Studies (located at 35
Kneeland Street). Each of these research-focused institutes has close ties with the Department of Medicine.
The table below summarizes the grant and contract activity across the Divisions and Institutes in FY 2014, with increase/
decreases from the prior year noted in parentheses. Further specific details are shown in the individual Division/
Institute reports.
20 14 Res earc h Awa rd s 1
Division
R Series
K Series
(incl.
supplements)
U Awards
(incl.
supplements)
Training
Grants
(iT & F series)
Contracts
& Subcontracts
Foundation
& Internal
Grants
Clinical
Trials2
Cardiology
1 (0)
0 (0)
0 (0)
0 (0)
7 (0)
0 (0)
24 (-4)
Clinical Decision Making
1 (0)
0 (0)
0 (0)
0 (0)
4 (-2)
0 (0)
N/A
Endocrinology
1 (0)
0 (0)
1 (0)
0 (0)
0 (0)
2 (0)
1 (-2)
Gastroenterology
2 (0)
1 (0)
0 (0)
0 (0)
2 (+1)
3 (0)
9 (-3)
Infectious Disease
5 (-4)
2 (-2)
1 (+1)
2 (-2)
8 (-9)
3 (-2)
16 (-3)
Internal Medicine & Adult
Primary Care
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
2 (0)
0 (0)
Hematology/Oncology &
Cancer Center
2 (+2)
0 (0)
0 (0)
1 (0)
2 (+1)
0 (-2)
43 (-6)
Nephrology
6 (+1)
0 (-3)
1 (0)
2 (+1)
9 (-1)
3 (-1)
14 (+2)
11
RESEARCH ACTIVITY (continued)
Division
R Series
K Series
U Awards
(incl.
supplements)
(incl.
supplements)
Training
Grants
Contracts
& Subcontracts
(iT & F series)
Foundation
& Internal
Grants
Clinical
Trials2
Pulmonary
2 (-1)
0 (0)
0 (0)
0 (0)
3 (-1)
0 (0)
26 (-4)
Rheumatology
4 (0)
2 (0)
1 (+1)
0 (0)
1 (-3)
1 (-1)
8 (+4)
Institute for Clinical
Research and Health
Policy Studies
5 (0)
0(-1)
2 (+1)
1 (-1)
40 (-7)
21 (-26)
N/A
Molecular Cardiology
Research Institute
13 (-13)
1 (0)
0 (0)
1 (0)
12 (+6)
14 (+2)
N/A
Molecular Oncology
Research Institute
14 (-4)
1 (+1)
2 (0)
0 (0)
7 (-2)
12 (-2)
N/A
1
Support from the National Institutes of Health constitutes the major source of funding for the Department of Medicine. The table above is a summary of the
number of individual active Grants & Contracts and Clinical Trials awards for the Department of Medicine as of the close of 2014.
2
Clinical Trial numbers reflect trials with activity during the fiscal year (not # of executed agreements).
F Y 14 Total G ra n ts a nd C ont ra cts Reven u e ( $ 3 6 M )
(in thousands)
$7,000
$6,000
$5,000
$4,000
$3,000
$2,000
$1,000
F Y 14 Reven u e Sou rces
12%
13%
Federal
Foundation/Other
75%
Corporate
M
OR
I
I
CR
M
at
o
eu
m
RH
PS
lo
ar
on
Rh
Pu
lm
IC
gy
y
y
og
ph
ro
l
Ne
m
On
c/
CC
D
He
M
ed
/I
GI
Ge
o
in
e
M
CD
cr
En
do
Ca
rd
i
ol
og
y
$0
THE INTERNAL MEDICINE TRAINING PROGRAM
The internal medicine training program at Tufts Medical Center attracts superior applicants from medical schools across
the United States. Each year, 24 interns are recruited from a pool of over 2,000 applicants with diverse backgrounds, talents
and aspirations. The program is unusual for the configuration of the ward services along subspecialty lines. The hospital
has a strong primary care referral base as well as many well-known subspecialists, which results in a diverse population of
patients with unusual as well as common illnesses. House officers are supervised and taught by attending physicians with
exceptional expertise in the subspecialties of interest. Many graduates become primary care physicians. Others, who seek
subspecialty training, match with excellent fellowship programs. Over the upcoming year, the program will add two tracks, one
a business track and the other a combined medical education track in conjunction with the pediatric residency program.
13
THE DIVISIONS
T he De pa rtmen t of M edi c i ne i s orga n i ze d i n 13 d i v i si on s. A l t h ou g h m ost fa ll
i nto trad i ti o na l ca tego ri es, t h e D i v i si on of C l i n i ca l C a re Resea rch a n d t h e
Di vi si on of C l i n i ca l Dec i s i o n M a ki n g a n d Te l e m e d i ci n e a re u n u su a l i n t h eir
scope. The Di v i s i o n of Geo gra p h i c M e d i ci n e a n d I n fe ct i ou s D i sea ses s ig n a ls
i ts i nte rn a ti o na l i n terests by i ts n a m e. M a ny of t h e d i v i si on s h ave i m p ress ive
hi stori es a s ca n be seen i n th e i r i n t rod u ctor y ove r v i ews.
15
DIVISION OF
ALLERGY
»» DIVISION OF ALLERGY
The Allergy Division is a part of the Division of
Internal Medicine and Adult Primary Care at Tufts
Medical Center. The Division offers programs that address common conditions
including allergic rhinitis, allergic asthma, eczema, food allergy, drug allergy, sinusitis,
urticarial, angioedema and adult immunodeficiency.
Division members work closely with the otolaryngology, dermatology and gastroenterology
departments to coordinate the evaluation of allergic disorders that are common to those
John Ohman, MD
specialties. The Food Allergy Center at Tufts Medical Center and Floating Hospital for Children
was established in 2013 in collaboration with the pediatric and adult Gastroenterology Divisions.
Highlights of 2014
» » Implementation of intravenous drug desensitization procedures for chemotherapy agents, collaborating with
Pharmacy and Infusion Clinic.
Faculty
Name
Academic Rank
Special Responsibility
John L. Ohman, MD, FACP
Clinical Professor, Medicine
Chief of Division
Weihong Zheng, MD
Assistant Professor, Medicine
John Leung, MD
Assistant Professor, Medicine & Pediatrics
Director, Food Allergy Center
Co-Director, Food Allergy Center at
Floating Hospital for Children
C linical Pro g ra m s
The outpatient clinics provide evaluation and treatment of allergic diseases through referrals from staff physicians and
from an increasing base of community physicians. A wide range of diseases are seen and evaluated. Assessment of the
allergic component of asthma, chronic rhinitis, food allergy, drug allergyand eczema accounts for approximately 50%
of outpatient activity. Division members also treat diverse conditions such as anaphylaxis from insect stings, other
anaphylactic syndromes such as exercise induced anaphylaxis, angioedema and eosinophilic syndromes including
eosinophilic esophagitis and vasculitis.
Specialized treatments are available through the Allergy Division including allergen immunotherapy for inhalant and
insect sting allergy. Outpatient oral desensitization procedures have been developed for drug allergy. These procedures
include desensitization to aspirin for asthmatic patients with nasal polyps.
Adult immunodeficiency is evaluated and immunoglobulin replacement treatments are administered.
Inpatient consultations for drug allergy and other allergic disorders are provided. Inpatient desensitization treatments
are prescribed and monitored by the division.
C ommunity Ou t re a ch Prog ra m s
Division staff have given presentations to community health center, on local TV and radio stations about the prevention
and treatment of allergic diseases. The staff reach out to the Mandarin and Cantonese speaking population of Boston
through seminars and educational articles in Chinese language newspapers to increase local awareness of the services
offered by the Allergy Division.
Res earch S u p p or t
Recipient
Funding source
Purpose of award
National Institutes of Health
(NIH)
The primary aims of this prospective, multi-center, longitudinal and
exploratory pediatric and adult study are to determine the correlation of
clinical outcome measures (patient reported outcomes, quality of life and
endoscopy) with the established biomarker of peak mucosal eosinophil count
(Phase 1), and to compare the transcriptomes (eosinophilic esophagitistranscriptome, eosinophilic gastritis-transcriptome and eosinophilic colitistranscriptome) with their respective peak mucosal eosinophil counts and
respective clinical outcome measures.
Swiss National Science
Foundation
AstraZeneca AG
(Switzerland)
John Leung, MD
Aptalis
Dr. Falk Pharma GmbH
(Germany)
The primary aim of this multicenter study is to develop, validate and evaluate
an eosinophilic esophagitis activity index for pediatric and adult patients.
Glaxo Smith Kline AG
Nestlé S. A. (Switzerland)
The International
Gastrointestinal Eosinophil
Researchers (TIGERS)
Regeneron
Pharmaceuticals, Inc.
The primary aim of this multicenter, double-blind, randomized, placebocontrolled study is to investigate the efficacy, safety, tolerability,
pharmacokinetic, and immunogenicity of dupilumab in adult patients with
eosinophilic esophagitis.
17
»» DIVISION OF ALLERGY
The Food Allergy Center at Tufts Medical Center and Floating Hospital for Children was established in 2013, in
collaboration with the pediatric and adult Gastroenterology Divisions. It provides an integrative, patient-oriented, and
multidisciplinary care for patients with known or suspected food allergies. Through the Food Allergy Center,
eosinophilic esophagitis, eoinsophilic gastrointestinal disorders, celiac disease, other food intolerance syndromes are
evaluated, in coordination with the GI Division.
DIVISION OF
CARDIOLOGY
»» DIVISION OF CARDIOLOGY
The Division of Cardiology at Tufts Medical Center
is a world-wide leader in patient care, research and
education in cardiology. Under the guidance of its first chief, Dr. Herbert
Levine, the Division of Cardiology developed into a Center of Excellence in each of the major
subdivisions of cardiology, including clinical cardiology, cardiac catheterization and
intervention, noninvasive cardiac imaging, and electrophysiology. Later, under the direction of
Deeb Salem MD, and subsequently Marvin Konstam MD, Tufts Medical Center began a
program in advanced heart failure and cardiac transplantation. Today, under the leadership of
James Udelson, MD
James Udelson MD, the Division of Cardiology continues to prosper. The advanced heart
failure and cardiac transplantation program is the largest in New England, the Hypertrophic Cardiomyopathy (HCM)
Center remains among the most active in the United States, and the cardiac catheterization, electrophysiology and
cardiovascular imaging laboratories show steady growth in the number of patients served and in the use of advanced
techniques.
The Division of Cardiology maintains many outreach programs across New England. Attending physicians provide
cardiovascular expertise to numerous regional sites. Cardiology fellows spend time at neighboring institutions to
complement their training. In addition, visiting students, residents, fellows and attending staff from other institutions
spend time at Tufts Medical Center to learn the latest techniques in cardiovascular care.
Cardiologists at Tufts Medical Center participate in a wide variety of clinical, translational and basic science research
projects sponsored by the NIH, industry, and other sources. There is extensive collaboration and shared faculty with the
Molecular Cardiology Research Institute. Clinical trials are underway to study improved techniques for percutaneous
interventions, ventricular assist devices, automated external defibrillators, nuclear imaging for assessment of infarct
viability and remodeling, approaches to the assessment of vascular function, and novel therapies for atherosclerosis.
Teaching at all levels remains a strong part of the Division’s academic mission. All faculty are involved in bedside and
didactic teaching as well as serving as education and research mentors. The Division of Cardiology is consistently rated
amongst the highest for teaching Tufts University students and house officers. In addition, fellows take great pride in
teaching residents and students.
Highlights of 2014
» » Largest cardiac transplantation and ventricular assist programs in the New England region
» » The busiest Hypertrophic Cardiomyopathy Center in the Northeast, including surgical myectomies
» » Growing referral network for complex catheter-based coronary, structural, heart failure and
electrophysiology procedures
» » Growth of multi-disciplinary transcutaneous aortic valve replacement (TAVR) program
» » Superior graduate medical educational training in all disciplines of cardiovascular medicine
» » Outpatient community outreach within the model of the distributed academic medical center
» » Numerous Tufts Medical Center cardiologists listed as Boston Magazine’s 2014 Top Doctors
Faculty
Academic Rank
Title and Special Interest
Marvin Konstam, MD
Professor
Chief Physician Executive, Cardiovascular Center
James Udelson, MD
Professor
Chief, Division of Cardiology
Director, Nuclear Cardiology
James Alderman, MD
Assistant Clinical
Professor
Interventional Cardiology, Heart Center of MetroWest
Elizabeth Ascher, MD
Assistant Clinical
Professor
General Cardiology, Heart Center of MetroWest
Robert Blanton, MD
Assistant Professor
Molecular Cardiology Research Center
Associate Program Director, Cardiovascular Education and
Fellowship Training
Director, Preventive Cardiology
Patrick Blomberg, MD
Assistant Professor
Electrophysiology, Heart Center of MetroWest
William Castelli, MD
Assistant Clinical
Professor
Laurence Conway, MD
Assistant Professor
Interventional Cardiology
Gregory Corrodi, MD
Assistant Professor
Cardiovascular Imaging
Eric Davidson, MD
Assistant Clinical
Professor
Cardiovascular Imaging, Heart Center of MetroWest
David DeNofrio, MD
Associate Professor
Medical Director, Cardiac Transplantation Program; Medical
Director, Cardiomyopathy Center
Program Director, Advanced Heart Failure Fellowship
Brian Downey, MD
Assistant Professor
General Cardiology, Cardiovascular Imaging
Mohamad El-Zaru, MD
Assistant Professor
N. A. Mark Estes, MD
Professor
Director, Cardiac Electrophysiology
Solomon Gabbay, MD
Assistant Professor
General Cardiology
Jonas Galper, MD, PhD
Professor
Christopher Gange, MD
Assistant Clinical
Professor
Interventional Cardiology, Heart Center of MetroWest
Harvey Goldfine, MD
Assistant Clinical
Professor
Jessica Haffajee, MD
Assistant Professor
General Cardiology, Norwood
Munther Homoud, MD
Associate Professor
Director, Electrophysiology Fellowship Program; Director, Tufts
University School of Medicine Cardiac Pathophysiology Course
Gordon Huggins, MD
Associate Professor
Iris Jaffe, MD, PhD
Associate Professor
Co-Director, Molecular Cardiology Research Center
Name
19
Faculty (con t i n u e d )
Name
Academic Rank
Assistant Professor
Assistant Director, Interventional Cardiology; Director, Acute
Circulatory Support Program; Director, Surgical Research
Laboratory – Interventional Division Investigator, Molecular
Cardiology Research Institute
Professor
Elisa Kent Mendelsohn Professor of Molecular Medicine,
Tufts University School of Medicine
Chief Scientific Officer
Executive Director, Molecular Cardiology Research Institute
Vice-Chairman of Medicine
Co-Director, Women’s Heart Center
Michael Kiernan, MD
Assistant Professor
Medical Director, Ventricular Assist Device Program
Carey Kimmelstiel, MD
Associate Professor
Director, Cardiac Catheterization Laboratory
Director, Interventional Cardiology Fellowship Program
George Kinzfogl III, MD
Assistant Clinical
Professor
Alan Kono, MD
Assistant Professor
Heart Failure
Jeffrey Kuvin, MD
Associate Professor
Associate Chief of Cardiology
Associate Chief Medical Officer for GME Director, Cardiovascular
Education and Fellowship Training
Co-Director, Center for Adults with Congenital Heart Disease
Douglas Laidlaw, MD
Assistant Professor
Cardiac Electrophysiology
Mark Link, MD
Professor
Director, Heart Station; Co-Director Hypertrophic
Cardiomyopathy Center
Donald Love
Assistant Clinical
Professor
Electrophysiology, Heart Center of MetroWest
Anthony Marks, MD
Assistant Professor
Martin Maron, MD
Assistant Professor
Director, Hypertrophic Cardiomyopathy Center; Co-Director,
Cardiovascular CT and MRI
Nicole Orr, MD
Instructor
General Cardiology, Norwood
Natesa Pandian, MD
Professor
Director, Valve Clinic; Director, Cardiovascular Ultrasound
Research; Co-Director, Comprehensive Cardiovascular Imaging
Ayan Patel, MD
Professor
Director, Cardiovascular Imaging Center; Director,
Echocardiography Laboratory; Director, Women’s Heart Center
Stephen Pauker, MD
Professor
General Cardiology
Yuheng Ruan, MD
Assistant Professor
General Cardiology, Cardiovascular Imaging
Deeb Salem, MD
Professor
Chairman of Medicine
Navin Kapur, MD
Academic Rank
Gordon Saperia, MD
Assistant Professor
General Cardiology
Sushil Singh, MD
Assistant Professor
Cardiac Electrophysiology
Jeffrey Shih, MD
Assistant Professor
Heart Failure
Howard Sussman, MD
Assistant Clinical
Professor
David Venesy, MD
Assistant Professor
Heart Failure
Jonathan Weinstock, MD
Assistant Professor
Director, Cardiac Rhythm Management Devices
Andrew Weintraub, MD
Assistant Professor
Medical Director, Cardiac Care Unit
Medical Director, Valve and Structural Heart Health Center
Associate Director, Cardiac Catheterization Laboratory Associate
Director, Vascular Medicine Center
David Young, MD
Assistant Clinical
Professor
Name
M ajor Clinic a l Prog ra m s
The Division of Cardiology at Tufts Medical Center remains committed to the academic missions of excellence in patient
care, research and teaching. The following are the major clinical programs in Cardiology:
»» The Interventional Cardiology Program
»» The New England Cardiac Arrhythmia Center
»» The Heart Failure and Cardiac Transplant Center
»» The Comprehensive Cardiovascular Imaging Center
»» The Hypertrophic Cardiomyopathy (HCM) Center
»» The Preventive Cardiology Center
»» The Women’s Heart Center
»» The Heart Station
These clinical programs are among the premier cardiovascular programs throughout the country. This report
summarizes the Division’s clinical activities and recent program developments, as well as the academic growth.
The Interventional Cardiology Program
Carey Kimmelstiel, MD – Director
The nationally-renowned Interventional Cardiology Program provides advanced technologies and therapies for
patients with cardiovascular disease. The Interventional Cardiology staff regularly perform state-of-the-art procedures
such as septal ablation for hypertrophic cardiomyopathy (HCM), valvuloplasty, catheter based valve replacement,
percutaneous mechanical support for high risk coronary intervention and adv anced heart failure. The program also
offers transcatheter treatment of a variety of congenital defects such as patent foramen ovale, and atrial septal defects,
as well as endovascular treatment of peripheral arterial disease and aortic coarctation. In recognition of its ongoing
programmatic excellence, the Tufts Medical Center Interventional Cardiology Program has, over the past five years,
received continuous funding for their trainees from national societies and corporate sources.
The Interventional Cardiology Program participates in major multi-center clinical trials as well as in investigatorinitiated research. In the past year, the laboratory has continued to recruit patients into trials of newer-generation
drug-eluting stents as well as pharmacologic studies examining the impact of adjunctive therapies on platelet function.
The interventional research staff has received accolades for the scope and quality of their enrollment efforts. Examples
of this type of investigation include Dr. Carey Kimmelstiel’s collaboration with Dr. David Thaler, of the Department of
Neurology, which led to data documenting a significant reduction in migraine symptoms in patients who underwent
21
closure of a patent foramen ovale. This collaboration led to the Tufts Medical Center being the third highest enroller in
the ground-breaking RESPECT trial with Dr. Kimmelstiel being the highest volume implanter of PFO closure devices in
the entire study. The same group has continued this line of Investigation and Is among the highest enrolling centers in
the REDUCE trial - a multicenter, international study again focusing on assessing stroke reduction following PFO
closure utilizing the Gore HELEX occluder. Drs. Kimmelstiel, Kapur and Weintraub have recently collaborated with
basic scientists in the Tufts Molecular Oncology Research Institute in a mechanistic study which has defined the antiplatelet effects of bivalirudin specifically elucidating the inhibitory effect of this drug on platelet thrombin receptors.
They have recently completed a single-center study of the differential effects of two thienopyridines on platelet
aggregation in bivalirudin-treated patients.
The Hypertrophic Cardiomyopathy Center provides a large number of physiologic studies for HCM and alcohol septal
ablation. Several current studies involving alcohol septal ablation allow collaboration between the interventional staff
and colleagues in the heart failure arena. In addition, Drs. Kimmelstiel, Kapur and Weintraub are initiating their
participation Is a clinical study assessing the effect of percutaneous mitral valve repair in heart failure patients with
functional mitral regurgitation.
Dr. Navin Kapur directs the acute circulatory support program at Tufts, which focuses on the clinical application of
percutaneous mechanical support devices (pMSD) for cardogenic shock and advanced heart failure. As a dual boardcertified interventional cardiologist and advanced heart failure/transplant specialist, Dr. Kapur has developd a
combined training pathway option for fellows to become Interventional Heart Failure (IHF) specialists. Since 2009, this
IHF pathway has grown in reputation and Tufts Medical Center has established an international presence through the
SCAI, AHA, TCT, CRF, ACC, and ESC as a leader in the field of interventional therapies for heart failure. Tufts has
become a highly sought after program to participate in clinical trials evaluating interventional devices for heart failure.
Tufts Medical Center was one of only 15 sites in the US involved in the Recover Right Trial investigating a pMSD
designed for right ventricular failure. Tufts is also the only site in Boston participating in the PARACHUTE IV Trial
evaluating a novel interventional device for apical left ventricular aneurysms and was recently invited to participate in
the COAPT trial evaluating the Mitra-clip devices for functional mitral regurgiation in heart failure. Through
collaborations with the division of Cardiac Surgery, Heart Failure, and several industry partners, the catheterization
laboratory is developing novel approaches to diagnosis and management of percutaneously and surgically implanted
cardiac assist devices. Dr. Kapur is also Director of the Interventional Division of the Surgical Research Laboratories
and an Investigator at the Molecular Cardiology Research Institute (MCRI). Dr. Kapur's NIH-funded molecular research
laboratory focuses on basic and translational research involving angiogenic peptides and molecular remodeling in heart
failure. Since 2010, multiple international, national presentations, publications, and four patents have been submitted
from Dr. Kapur’s laboratory. The Kapur Lab also has established important funded research projects with several
industry leaders in the field of pMSDs (Cardiac Assist, Heartware, Thoratec, and Abiomed).
The Interventional Cardiology Training Program at Tufts Medical Center has received consecutive Fellow in-Training
Grant Awards from the SCAI and Abbott Industries for excellence in fellow education since 2009. The laboratory
participates in benchmarking outcomes with the American College of Cardiology and the National Catheterization Data
Registry. This allows the Division to compare its interventional outcomes with those of other programs throughout the
country and fosters a high standard of quality.
Dr. Andrew Weintraub, Associate Director of the Cardiac Catheterization Laboratory and the Director of the Coronary
Care Unit, supervises the diagnostic and therapeutic services offered to patients with lower and upper extremity
vascular disease, carotid artery disease, and hypertension secondary to renal artery stenosis. The program offers care
for patients with claudication and critical limb ischemia. Together with vascular surgery, the Cardiac Catheterization
Laboratory is participating in investigation of a novel arterial access closure device. In addition, Dr. Weintraub has
designed a trial to estimate the size of vessels in a novel and precise manner. He served as the site investigator for a
clinical trial studying the effect of a cardiac device on infarct size in patient suffering from ST elevation myocardial
infarction. Tufts Medical Center was the third leading enrolling site in the United States. The interventional cardiology
service also participates in the multi-disciplinary Valvular and Structural Heart Health Center. This service evaluates
patients with valvular and structural heart disease who are considered high risk for conventional surgical procedures.
This service integrates multi-modality testing and state of the art therapies for these exceptional risk patients.
Dr. Kimmelstiel is active in clinical trials and he serves on many safety monitoring committees. The Tufts Medical
Center Catheterization Laboratory is expanding the interventional device trials to include newer PFO closure devices,
left atrial appendage closure devices and bio-reabsorbable stenting platforms. In addition, Dr. Kimmelstiel has been the
local leader in numerous industry-sponsored coronary disease studies. He has recently completed a single-center study
documenting previously un-described anti-platelet effects of bivalirudin. He has recently served as national principle
investigator of a large drug-eluting stenting trial.
The New England Cardiac Arrhythmia Center
N. A. Mark Estes, MD – Director
Three cardiac electrophysiology laboratories provide the full spectrum of invasive electrophysiology studies,
radiofrequency ablations, defibrillator and pacemaker implantations, tilt table tests, and cardioversions. Two ablation
laboratories provide the most advanced imaging and mapping capabilities to address supraventricular arrhythmias and
many ventricular arrhythmias. With the advanced mapping system, more radiofrequency ablation cases are being
referred for cure of supraventricular and ventricular arrhythmias as well as atrial fibrillation.
The staff electrophysiologists oversee a fellowship program consisting of three fellows in clinical cardiac
electrophysiology. Members of the Arrhythmia Center have served on guidelines writing groups and held leadership
positions in national and international professional organizations. The fellows routinely present abstracts at national
meetings and the attendings serve as invited faculty at the major national and international meetings.
Staff electrophysiologists participate extensively In clinical research. The EP attendings have participated on the
Executive Committees and as Principal Investigators on the major cardiac rhythm device trials including the CABG
Patch, DEFINITE, MADIT II, MADIT-CRT,MADIT-RIT, and MADIT Diabetes Trials as well as the NIH-funded
“Multidisciplinary Study of Right Ventricular Dysplasia” (ARVD). This last-named trial is a multidisciplinary, multicenter, study of the cardiac, clinical, and genetic aspects of arrhythmogenic right ventricular dysplasia (ARVD). Dr.
Estes conducts research on the prevention of sudden death by means of Automated External Defibrillators (AEDs) with
several publications related to program development, clinical utility, legislative policy, and legal risks of the devices.
Dr. Mark Link's research into sudden death from chest wall impact (commotio cordis) has advanced efforts to prevent
sudden deaths resulting from precordial chest blows. Over 30 publications have been produced recently from this
laboratory. Together with colleagues in the Tufts-MCRI, he performs electrophysiologic investigations on knock-out
mouse models. He is investigating the association between air pollution and atrial and ventricular arrhythmias. He also
investigates arrhythmias in patients with Hypertrophic Cardiomyopathy. Dr Link is a member of the 2015 AHA Writing
Group for Advanced Cardiac Life Support (ACLS) Guidelines, as well as the Writing Committee for the 2011 AHA
Hypertrophic Cardiomyopathy Guidelines and 2012 AHA PPM and ICD Implant Guidelines. Dr. Link is also the principal
investigator of the RAID trial, assessing the efficacy of ranolazine in prevention of ICD shock. Dr. Weinstock served as
the principal investigator in the Replace Trial and is serving in a similar role in the ongoing Echo CRT and VEST Trials.
The Heart Failure and Cardiac Transplant Center
David DeNofrio, MD – Director
The Heart Failure and Cardiac Transplant Center is nationally renowned for its clinical and research activities. The
Center Is a regional leader in therapies for severe heart failure, including cardiac transplantation and mechanical
ventricular assist device therapy.
23
The New England Cardiac Arrhythmia Center offers outpatient consultative services for patients with arrhythmias and
conducts research on arrhythmias. The Center is staffed by five full time and four visiting board-certified
electrophysiologists. Physicians and staff provide comprehensive evaluation and management of patients with cardiac
arrhythmia with an emphasis on communicating timely with patients and members of the health care team. Nurse
practitioners respond to routine patient inquiries and educational needs. Daily outpatient pacemaker and implantable
cardioverter defibrillator clinics are available for those with implantable devices. The Center provides trans-telephonic
monitoring of pacemakers and loop monitors.
The Center’s cardiac transplantation program performed 24 transplant procedures in the 2014 calendar year.
Additionally, over the last five-year period, the program has been the highest volume cardiac transplantation center in
New England, having performed 94 procedures. Following approval by the Center for Medicare and Medicaid Services
(CMS) in 2001, the transplant program has met or exceeded CMS thresholds each year for both transplant volume and
outcomes. With a steady stream of new referrals for transplantation, the program performs over 100 formal transplant
evaluations per year.
The Center also maintains a vibrant mechanical ventricular assist device program to support patients with Stage D heart
failure. Since 1998 over 325 patients have been supported using ventricular assist devices for both “bridge-totransplantation” and “destination therapy” indications. Following the approval by CMS of the left ventricular assist
device (LVAD) program in 2003, a steadily increasing number of procedures have been performed under this new
indication. The two main LVADs that are employed at this institution are the Thoratec HeartMate II and the HeartWare
HVAD devices. The HeartWare device is currently under investigation and Tufts Medical Center was the first center In
the Northeast to use this pump for permanent therapy. In 2014, 56 LVADs were placed for the treatment of Stage D heart
failure, the greatest number since the program’s inception.
The Division maintains heart failure outreach programs at Lahey Clinic, Rhode Island Hospital, the University of
Massachusetts Medical Center and Dartmouth Hitchcock Medical Center. In addition, cardiologists from Lahey Clinic,
Dartmouth-Hitchcock, Beth Israel Deaconess Medical Center, University of Massachusetts Medical Center and Rhode
Island Hospital participate in the inpatient and outpatient services at Tufts Medical Center. Cardiovascular fellows from
a variety of neighboring institutions spend time at Tufts Medical Center to learn more about the management of
advanced heart failure. The Advanced Heart Failure and Transplant Cardiology Fellowship Program is one of only a
limited number or programs in the country receive ACGME accreditation for its heart failure training.
The Center participates in several clinical research investigations of new therapies for the treatment of all stages of heart
failure as well as new immunosuppressive agents for heart transplantation. The Center has been an active study site for
the National Heart and Lung Institute’s Heart Failure Clinical Trials Network and is currently engaged in multiple
Network protocols. The FIGHT trial is evaluating a novel therapeutic approach to stabilize acute heart failure syndromes
at the time of transition from hospital to home. Liraglutide is a glucagon-like-peptide 1 (GLP-1) receptor agonist. The
Network is investigating the hypothesis that liraglutide will improve metabolism in energy depleted cardiomyocytes and
help to reduce heart failure rehospitalizations. The ATHENA trial is examining spironolactone, a standard heart failure
medication for patients with chronic, stable heart failure. The role of spironolactone in the treatment of acutely
decompensated heart failure has not yet been studied. ATHENA will investigate the hypothesis that high-dose
spironolactone may be beneficial in patients with acute heart failure and may augment effective diuresis. In addition,
the Center is participating in the CTOT-11 trial examining the efficacy of rituximab in preventing the development of
allograft coronary disease In heart transplant recipients. The development of premature coronary disease has been a
major limitation to long-term survival following heart transplantation. CTOT-11 is sponsored by the National Heart,
Lung and Blood Institute. Finally, the group is collaborating with Amgen on a retrospective study to evaluate the costs
associated with heart failure hospitalizations and re-hospitalizations.
The CardioVascular Imaging Center: The Cardiovascular Imaging and Hemodynamic Laboratory
(Echocardiography Lab)
Ayan R. Patel, MD – Director
This laboratory is nationally known for its innovative approaches to cardiac diagnosis and has made major advances in
the echocardiographic and Doppler assessment of myocardial, valvular, congenital, and ischemic heart disease. Dr.
Natesa Pandian, Director of Cardiovascular Ultrasound Research, is internationally renowned for echocardiographyrelated research studies and lectures at educational seminars worldwide. Dr. Patel has extensive experience in the
conduct of echocardiography-related research.
The Laboratory provides a unique array of advanced services including: three-dimensional transthoracic and
transesophageal imaging; stress echocardiography for specialized evaluation of heart failure, valvular disease, cardiac
hemodynamics and assessment of ischemia; it also uses myocardial contrast imaging for evaluation of cardiac function.
The clinical research activities of the laboratory include three-dimensional assessment of cardiac chambers and the
relationship with hemodynamics, investigation of three-dimensional speckle tracking for evaluation of cardiac disease,
the use of imaging for evaluation of valvular disease, and vascular ultrasound assessment of peripheral vascular
endothelial function. Fellows play an integral role in the clinical and research activities of the laboratory.
Nuclear Cardiology Laboratory
James Udelson, MD – Director
The Cardiac Imaging Core Laboratory completed work on the multi-center NHLBI-funded Occluded Artery Trial
ancillary nuclear study (OAT-NUC), in which patients from the parent OAT trial underwent SPECT imaging for
assessment of infarct zone viability and inf luence on remodeling. The IMMEDIATE Trial assessed infarct size from
SPECT imaging in a subset of the patients enrolled in the NHLBI study of glucose-insulin-potassium given to patients
with acute coronary syndromes in ambulances. The Core Lab also serves as a central quality control and analysis center
for SPECT imaging performed in conjunction with 2 major federally-funded comparative effectiveness trials - the
PROMISE trial, randomizing 10,000 patients with suspected CAD to an initial evaluation with functional testing
(including stress SPECT perfusion imaging) or to an anatomic evaluation strategy (CT angiography), and RESCUE, a
4,000 patient trial of those with suspected CAD randomized to an initial evaluation with stress SPECT perfusion imaging
or to CT angiography.
Cardiac Computed Tomography and Magnetic Resonance Imaging
Martin Maron, MD, Kent Yucel, MD and Neil Halin, DO – Co-Directors
At Tufts Medical Center, a complete non-invasive assessment of the coronary arteries is performed with a 10- second
breath hold without the need for beta-blockers with the use of the 64-slice Siemens Definition dual source scanner. In
addition, Tufts Medical Center has two Phillips MRI magnets capable of the most advanced cardiac imaging. The
cardiac MRI program focuses on imaging for cardiomyopathies as well as structure/function and myocardial viability.
Fellows participate in all aspects of advanced imaging, including image acquisition and analysis.
The Hypertrophic Cardiomyopathy Center
Martin S. Maron, MD - Director; Mark Link, MD, James E. Udelson, MD – Co-Directors
2014 marks the thirteenth year of the first comprehensive Hypertrophic Cardiomyopathy (HCM) Center in the Northeast.
The Center provides state-of-the-art diagnostic and therapeutic modalities for patients with HCM, the most common
genetic cardiovascular disease. The HCM center utilizes traditional imaging techniques and advanced cardiac imaging
techniques to accurately assess the extent of disease as well as to determine optimal treatment. Surgeons working with
the HCM center perform close to 60 surgical myectomies per year for relief of left ventricular outf low obstruction. The
Division’s interventional cardiology team was the first in the Boston area to perform an alcohol septal ablation for relief
of heart failure symptoms in patients with obstructive HCM and is a leader in this area. The HCM Center’s cardiologists
provide multidisciplinary patient care for problems as diverse as heart failure, syncope, arrhythmias and prevention of
sudden death.
The Center is a major research center for patients with HCM. Dr. Martin Maron recently completed a major multicenter
study demonstrating that the amount of fibrosis detected by MRI is a novel risk marker for predicting future sudden
death in patients with this disease. Members of the Center have contributed to the current understanding of HCM
through their work on exertional ischemia, the use of implantable cardioverter defibrillators (ICD) to prevent sudden
death, the role of left ventricular outf low tract obstruction to prognosis, and the use of cardiac MRI in diagnosis and
prognosis. To date, over 100 manuscripts have been published from the HCM center at Tufts. The center has become
established as one of the top HCM centers in the country.
25
Clinical imaging interpretation in this laboratory routinely is performed using 4DM-SPECT software, providing readers
with fully quantitative analysis to support image interpretations. The lab is accredited by ICANL (Intersocietal
Commission on the Accreditation of Nuclear Laboratories).
The Preventive Cardiology Center
Robert M Blanton, MD – Director
The Preventive Cardiology Center (PCC) provides risk factor assessment and management for patients with heart disease
and those at an increased risk for cardiovascular disorders. The staff is composed of a multi-disciplinary team of
cardiologists, fellows, pharmacists, and other health professionals. Staff members have instituted a number of new
measures to enhance patients’ medication compliance.
The Center functions as the primary outpatient training experience for cardiovascular fellows at Tufts Medical Center.
Numerous clinical research projects are based in the PCC, including the evaluation of vascular endothelial function to
assess cardiovascular risk. The Vascular Function Study Group is a research team focused on preventive cardiology and
is comprised on physicians, scientists, nurses, house officers and students. This group performs translational research
focusing on surrogate markers of vascular endothelial function in a variety of patient populations. The group also
participates in multi-center research projects focused on lipids and other novel prevention therapies. The team was one
of the top enrolling centers for the IMPROVE-IT Study, a multi-center, multi-national study examining ultra-low LDL
levels in patients at risk for atherosclerosis, and STABILITY, a study focusing on a novel anti-inf lammatory mechanism
to treat coronary artery disease. The group has also participated in novel lipid-altering research with PCSK9 Inhibition,
and currently is enrolling patients for the ongoing ODYSSEY OUTCOMES study to test the effect of additional lipid
lowering with the PCSK9 inhibitor alirocumab in patients with prior acute coronary syndrome. An additional ongoing
study enrolling patients through PCC is CAMELLIA-TIMI61, which seeks to evaluate the effect of long-term treatment
with Belviq (lorcaserin) on the incidence of major adverse cardiovascular events in obese and overweight subjects with
cardiovascular disease or multiple cardiovascular risk factors.
The Women’s Heart Center
Ayan R. Patel, MD – Director
The goal of the Women’s Heart Center is to provide consultative support to primary physicians, as well as to
cardiologists, regarding prevention, diagnosis, and management of cardiovascular diseases in women. The center
consists of a team of physicians with expertise in the management of lipid disorders and other cardiovascular risk
factors, management of cardiac arrhythmias, and cardiovascular imaging/diagnostic testing in women. Nutritional
counseling is also available in collaboration with the Frances Stern Nutrition Center. Dr. Richard Karas (Co-Director)
and Dr. Ayan Patel have had a long-standing research interest in vascular health in women and Dr. Karas is
internationally recognized as an expert on the effects of estrogen on the vasculature.
The Heart Station
Mark Link, MD – Director
The Heart Station is the epicenter for cardiovascular testing for electrocardiography and arrhythmia monitors. The
Heart Station performed nearly 30,000 electrocardiograms amongst a variety of other cardiovascular tests, such as
Holter and loop monitors, and cardiopulmonary stress tests.
Teaching Ac t i v i t i es
Jeffrey Kuvin, MD-Director, Cardiovascular Education and Fellowship Training
The Division of Cardiology is dedicated to the highest level of teaching and training of medical students, house staff and
fellows. Members of the Division participate in all aspects of teaching, including didactic lectures, bedside diagnosis,
small group discussions, and other interactive methods of teaching at all levels.
Cardiology faculty are involved with individual preceptorships and "selectives" with first year medical students. In
addition, attending cardiologists teach small group lecture series on topics in cardiology. Faculty provide didactic
courses on the cardiovascular physical examination and also provide research mentorship to students throughout their
medical school years. Cardiology fellows work with students as they learn physical diagnosis.
Under the direction of Munther Homoud, MD, the cardiovascular pathophysiology course for second year Tufts medical
students is a comprehensive series of lectures and small group discussions. Cardiology staff and fellows are involved in
teaching third students and fourth year medical sub-interns on inpatient ward services and in the outpatient setting.
Cardiology fellows also teach a weekly lecture on electrocardiography and mentor students on clinical rotations.
Bedside and didactic teaching of internal medicine house officers occurs daily during attending rounds as well as
dedicated teaching conferences. Numerous attending cardiologists have received recognition for outstanding teaching
by the house staff. In addition, fellows are encouraged to attend conferences and to conduct research within the
Division. Numerous house officers present research at national research meetings and publish articles in the field.
Res earch Gra n t Su p p or t
Recipient
Funding Source
Purpose of award
NIH – Institute of Aging
“Cardiac Myocyte-Specific Role of PKG I Alpha in AgingDependent Cardiac Remodeling”
ACC/ASP Geriatric
Cardiology Career
Development Award
Chief, Division of Cardiology
Director, Nuclear Cardiology
NIH
“Identifying Heart-Specific Anti-Remodeling Molecules”
Amgen
Acute Heart Failure Database
NHLBI/NIAID
COTO-11 Transplant Trial
N. A. Estes, MD
NIH
Multidisciplinary Study of Right Ventricular Cardiomyopathy
Michael J Fox Foundation
Study of new mechanisms in dopaminergic cell death in mouse
models for Parkinson’s disease
Gordon Huggins, MD
NIH/NHLBI R01
HL114794-01, Basic
Mechanisms of Human
Calcific Aortic Valve
Disease (PI)
Define the role of the retinoblastoma pathway in
aortic valve disease
NIH R01 HL119290,
Total Costs: $2,394,163;
2014-2018.
“Smooth Muscle Mineralocorticoid Receptors in Vascular
Aging and Hypertension”.
American Heart
Association Established
Investigator Award,
EIA18290005, Total
Costs: $400,000;
2014-2018.
“Extra-Renal Mineralocorticoid Receptors in Hypertension and
Atherosclerosis”.
American Heart
Association, Predoctoral
Award, 13PRE16920014,
Total Costs $44,000;
2013-2015.
“Role of Endothelial Mineralocorticoid Receptors in Early Morning
Hypertension”.
Robert Blanton, MD
David DeNofrio, MD
Iris Jaffe, MD, PhD (PI)
Kathleen Barrett Meuler (PI),
Iris Jaffe, MD, PhD (Mentor)
27
Cardiovascular fellowship training and education at Tufts Medical Center is under the direction of Jeffrey Kuvin, MD.
Dr. Kuvin is also the Medical Center's Associate Chief Medical Officer for Graduate Medical Education. In this role, he
oversees all of the hospital's ACGME-approved training programs. Dr. Robert Blanton is the Associate Director of the
Fellowship Program and Candace Scanlon is the Education Coordinator. Fellowship positions remain extremely
competitive. The three-to-four year fellowship program provides advanced training in all aspects of cardiovascular
disease. Fellows participate in research within the Division, from basic science to translational and clinical projects. All
fellows participate in an annual research proposal competition. In addition, fellows present findings at regional and
national meetings and publish their work in peer-reviewed journals. Graduating fellows from the Division of Cardiology
move on to successful careers in all aspects of academic and clinical cardiology.
Reas earch Gra n t Su p p or t (con t in u ed)
Recipient
Funding Source
Purpose of award
Jennifer Dupont (PI),
Iris Jaffe, MD, PhD (Mentor)
American Heart
Association, Postdoctoral
Award, 15POST2130000,
Total Costs $87,600,
2015-2017.
“SMC-Mineralocorticoid Receptor Regulation of Aging-Associated
Hypertension: Role of Vascular LTCC and Ang II Signaling”.
Novartis Pharmaceuticals
Co, Preclinical Research
Study RLX030AUSNC14T
Total Cost: $192,020;
2014-2015.
“Acute and Sustained Cardiac and Vascular Effects of Serelaxin in
the Angiotensin II/L-NAME Heart Failure Model”.
NIH R01 HL095590, Total
Costs: $2,062,500; 2009
– 2014, No cost extension
to June 30, 2015.
“The Role of Vascular MR-Regulated Genes in Vascular Function
and Disease”.
Abiomed
Translational research
Tracon Pharma
Maquet
Cardiac Assist
Merck
“The Role of PKG-1a in cGMP Signaling Mechanisms through the
Evaluation pf the Effects of cGMP Modulations in Normal and
Disease Studies in the PKG1-LZM Mouse”
Merck
“TAC LKR140269”: Testing the ability of experimental therapeutics
on heart remodeling
Eli Lilly/Daiichi Sankyo
The Effect of Prasugrel as Compared to Clopidogrel on Platelet
Function Immediately Following the Termination of Intravenous
Bivalirudin in Patients Undergoing Percutaneous Coronary and
Structural Cardiac Intervention
Eisai Pharmaceuticals
A Randomized, Double-blind, Placebo-controlled, Parallel-group
Study to Evaluate the Effect of Long-term Treatment with BELVIQ
(lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular
Events and Conversion to Type 2 Diabetes Mellitus in Obese and
Overweight Subjects with Cardiovascular Disease or Multiple
Cardiovascular Risk Factors
Sanofi Pharmaceuticals
A Randomized, Double-Blind, Placebo-Controlled, ParallelGroup Study to Evaluate the Effect of SAR236553/REGN727 on
the Occurrence of Cardiovascular Events in Patients who have
Recently Experienced an Acute Coronary Syndrome (Odyssey).
NHLBI
Subcontract for SPECT image core lab for the PROMISE trial
Iris Jaffe, MD, PhD
Navin Kapur, MD
Richard Karas, MD, PhD /
Robert Blanton, MD
Carey Kimmeltstiel, MD
Jeffrey Kuvin, MD
James Udelson, MD
H onors and Awa rd s
Robert Blanton, MD
»» Awarded Citation for “top 10% of abstracts,” American Heart Association Basic Cardiovascular Sciences
David DeNofrio, MD
»» Co-Chair, Program Committee, Heart Failure Society of America
»» UNOS Region 1 Review Committee for Heart Transplantation
»» Boston Magazine’s Top Doctors List for Cardiology
N. A. Mark Estes, MD
»» Editorial Boards, Circulation, Arrhythmias and Electrophysiology, Circulation, Journal of the American College of Cardiology,
American Journal of Cardiology, US Cardiology, Journal of Cardiovascular Electrophysiology, Pacing and Clinical Electrophysiology,
Hellenic Journal of Cardiology, Associate Editor, Journal of Interventional Cardiac Electrophysiology, Heart Rhythm
»» Section Editor, Controversies in Cardiology, Circulation
»» Editor in Chief, Cardiology Up to Date
»» Co-Chair ACC/AHA Task Force on Performance Measures for Atrial Fibrillation
»» Named in “Best Doctors in America”, Best Doctors in Boston
»» ACC Quality in Technology Committee
»» HRS Performance Measures Task Force
»» Paul Dudley White Award- AHA
»» Distinguished Leadership Award- AHA
»» President’s Award- Heart Rhythm Society
»» Editorial Board Journal of Biological Chemistry
»» Patient Care assessment committee, Tufts Medical Center
»» MCRI training grant committee, vice chair
»» ESTA Study Section NIH Ad hoc Reviewer
Munther Homoud, MD
»» Recognized for Excellence in Teaching, Tufts University School of Medicine
»» Division of Cardiology Fellowship Teaching Award
»» Boston Magazine “Top Doctors” List
»» Reviewer, American Journal of Cardiology, Heart Rhythm
Gordon Huggins, MD
»» Chair, Scientific Review Committee for non-cancer studies at Tufts Medical Center
»» Vice Chair, Institutional Review Board Tufts Medical Center
»» Co-Director, Tufts University School of Medicine MD PhD Program
Iris Zamir Jaffe, MD, PhD
»» Editorial Board: Endocrinology
»» American Society of Hypertension (ASH) 2013 Young Scholar Award
»» American Society of Clinical Investigation Elected Member (2013)
»» American Heart Association Established Investigator Award (2014)
»» AHA High Blood Pressure Research Council Mid-Career Award for Research Excellence (2014)
Navin Kapur, MD
»» Vice-Chair: American Heart Association, Clinical Cardiology – Interventional Committee 2013-2015
»» Section Leader: AHA Interventional Cardiology Track – Heart Failure/Hemodynamics 2011-2014
»» Co-Chair: SCAI Interventional Heart Failure Committee 2013-2015
»» Elected Member: AHA Basic Cardiovascular Sciences Section – 2014-2015
»» Co-Chair ACC/SCAI/HFSA Consensus Statement Committee: Invasive Hemodynamics 2013/2014
»» Chair: Cardiogenic Shock Symposium: Heart Failure Society of America 2013-2014
»» Chair: Mechanical Support for Cardiogenic Shock: C3 Symposium 2013-2014
29
»» Elected Member: Scientific Affairs Committee of Tufts University School of Medicine
»» Elected Member: Cardiovascular Research Foundation: Scientific Advisory Board on High Risk Cardiac Interventions 2013-2015
»» Editorial Board Member: Catheterization and Cardiovascular Interventions
»» Editorial Board Member: Journal of Invasive Cardiology
»» Editorial Board Member: Heart : Journal of the British Cardiovascular Society
»» Chief Scientific Officer, Tufts Medical Center
»» Vice Chairman for Scientific Affairs, Department of Medicine
»» Executive Director, Molecular Cardiology Research Institute
»» Chairman, Evaluation and Policy Subcommittee, National Research Committee, American Heart Association
»» AHA National Research Committee
Michael Kiernan, MD
»» American Heart Association, Council on Clinical Cardiology Committee on Heart Failure / Transplantation
»» American Heart Association, Council on Clinical Cardiology Committee: Fellow in Training / Early Career Subcommittee
»» AHA Writing Group: Biomarkers for the prevention, assessment, and management of heart failure: a consensus statement from the
American Heart Association.
»» AHA Writing Group: Cardiovascular function and treatment in ß-thalassemia major: a consensus statement from the American Heart
Association.
»» AHA Writing Group: Recommendations for the Use of Mechanical Circulatory Support
»» AHA Writing Group: Antibody Mediated Rejection in Cardiac Transplantation
»» Co-Chair: NIH Heart Failure Network Cardiorenal Syndrome Working Group
Carey Kimmelstiel, MD
»» Editorial Board: Journal of Thrombosis and Thrombolysis Editorial Board - Catheterization and Cardiovascular Interventions
»» Abstract Grader: American College of Cardiology; American Heart Association; Transcatheter Therapeutics
»» Manuscript reviewer: Cardiology, Journal of Investigative Medicine, Journal of Thrombosis and Thrombolysis, Journal of
Interventional Cardiology, Circulation, American Heart Journal, Catheterization and Cardiovascular Interventions, Journal of the
American College of Cardiology, New England Journal of Medicine
»» Grant reviewer/grader – SCAI FIT (Fellowship In Training) Grant
»» Named in “Best Doctors in America” and Best of Boston Magazine
»» National Co-PI of ION Drug-Eluting Stent Trial
»» SCAI Fellow in Training Grant
»» Abbott Fellow in Training Grant
Marvin Konstam, MD
»» Named in “Best Doctors in America” 2005-2013
»» Member, Association of University Cardiologists
»» Past President, Association of Professors of Cardiology
»» Past President, Heart Failure Society of America
»» Clinical Practice Guideline Committees, Heart Failure Society of America, Agency for Health Care Policy and Research, and AHA/ACC
»» Former Senior Advisor in Cardiovascular Diseases, National Heart Lung and Blood Institute
»» Member, CMS/The Joint Commission/ACC/AHA AMI/Heart Failure Technical Expert Panel
»» Member, ACGME Advisory Committee for Advanced Heart Failure and Transplant Cardiology
»» Chair, American College of Cardiology, Council on Academic Cardiology
»» Co-Chair National Heart Lung and Blood Institute, Workshop on Heart Failure Prevention
»» Distinguished Faculty Award, Tufts University School of Medicine
Jeffrey Kuvin, MD
»» Boston Magazine’s “Top Doctors” (Cardiology)
»» American College of Cardiology, COCATS Task Force
»» American College of Cardiology, Lifelong Learning Oversight Committee
»» American College of Cardiology, Competency Development Work Group
»» American College of Cardiology, Faculty Development Work Group
»» American College of Cardiology, Curriculum Development Work Group
»» American College of Cardiology, Co-Chair, Annual Scientific Session Program
»» American Heart Association, Vice-Chair, Laennec and Post-Graduate Education Committee
»» American Heart Association, Professional Education Committee
»» American Heart Association, Paul Dudley White Award Committee
»» NRMP Specialties Matching Service, Liaison for Cardiovascular Disease
»» ACGME Standing Panel for Accreditation Appeals
»» Nominating Committee, Tufts Medical Center Physicians’ Organization Board of Trustees
Mark Link, MD
»» Chair: AHA Writing Group-Adult Cardiac Life Support Guidelines, 2015
»» AHA Emergency Care Committee, 2013-2015
»» Heart Rhythm Society: Education Committee Member. 2014-5
»» Chair: Heart Rhythms Society: CME Compliance Committee. 2014-5
»» AHA Writing Group 2012-2015: Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular
Abnormalities
»» Task Force 2: Hypertrophic Cardiomyopathy, Other Cardiomyopathies, and Myocarditis; Task Force 8: Arrhythmias and Conduction
Defects; Chair: Task Force 11: Emergency Action Plans, Resuscitation, CPR, and AEDs; Chair: Task Force 12: Commotio Cordis; Task
Force 15: Classification of Sport: Dynamic, Static and Impact
»» Listed as one of Boston Magazines “Best Doctors”-2010-2014
»» Associate Editor-Journal Watch Cardiology
»» Editorial Board-EP Lab Digest
»» Editorial Board-Heart Rhythm
»» Editorial Board-Journal of Innovations in Cardiac Rhythm Management
»» Clinical Events Committee for multi-center trials
Martin Maron, MD
»» Editorial Board: American Journal of Cardiology
»» Editorial Board: Journal of the American College of Cardiology
Natesa Pandian, MD
»» ACC Writing Group on Rheumatic Fever
»» ACC Scientific Sessions, Program Committee, 2014, 2015
»» Invited speaker, Cardiology Grand Rounds, Cedars Sinai Hospital, Los Angeles, 2014
»» Invited Faculty, ACC Annual Scientific Sessions, 2014
»» Invited Faculty at ASE Board Review Courses, 2014
»» Invited Faculty at the ASE Annual Scientific Sessions, 2014
31
»» Invited Faculty at the annual Japanese Echocardiography Society Conference 2014
»» Invited Faculty at the European Society of Cardiology Annual Scientific Sessions, 2014
»» Invited Faculty at the Conference on Aortic Stenosis, Ascoli, 2014
»» Invited Faculty at the Italian Society of Echocardiography Annual Conference, 2014
»» Invited Faculty at the Indian Academy of Echocardiography Annual Conference, 2014
»» Invited Faculty at the Cardiology Rounds 2014, Hoag Hospital
»» Invited Faculty at the Cardiological Society of India Annual Scientific Sessions, 2014
Ayan Patel, MD
»» Associate Editor: Circulation Heart Failure
»» FASE, American Society of Echocardiography
Deeb Salem, MD
»» Chairman, Mass Medical Society’s Committee on Sponsored Programs
»» Chairman, Tufts University School of Medicine Continuing Education Committee
»» Massachusetts Hospital Association, Board of Trustees
James Udelson, MD
»» Distinguished Faculty Award, Tufts University School of Medicine 2012
»» Editor-in-Chief, Circulation: Heart Failure
»» Associate Editor, Circulation
»» Editorial Board – JACC, JACC Imaging, Journal of Nuclear Cardiology, Current Cardiovascular Imaging Reports, Heart Failure
Reviews, US Cardiology
»» U.S. Food and Drug Administration, Special Government Employee
»» Member, Association of University Cardiologists
»» Member, Association of Professors of Cardiology
»» Best Faculty Teacher Award from Tufts Medical Center Internal Medicine Residents
»» Ad-hoc Member, Cardiovascular and Renal Drugs Advisory Panel, Center for Drug Evaluation and Research,
United States Food and Drug Administration
»» Co-Chair, ACC/ACR Writing Committee for Appropriate Use Criteria to Assess Imaging Modalities to Evaluate Chest Pain in the
Emergency Department
»» Heart Failure Society of America, Executive Council
»» Best Doctors in Boston, Boston Magazine
»» Associate Editor, Practice Update in Cardiology
»» Co-Chair, ASNC/SNMMI Think Tank on Cardiovascular Molecular Imaging
Amanda Vest, MD
»» Heart Failure Society of America (HFSA) Guideline Committee
Jonathan Weinstock, MD
»» US News and World Report, Top Doctor
»» Abstract Reviewer, American Heart Association Scientific Sessions
»» Manuscript Reviewer, Heart Rhythm, Journal of Interventional Cardiac Electrophysiology
Andrew Weintraub, MD
»» Listed, Best Doctor in America
»» Listed, Best Doctors in Boston
»» Manuscript Reviewer, Circulation Heart Failure, Circulation Interventional Cardiology
DIVISION OF
CLINICAL CARE RESEARCH
»» DIVISION OF CLINICAL CARE RESEARCH
The Division of Clinical Care Research has no clinical
programs of its own. Physician-researcher Division
members have appointments in Medicine, Pediatrics
and Psychiatry where they are active participants in
clinical activities. The following physicians have primary appointments in clinical
divisions of the Department of Medicine:
Harry Selker, MD
» » Harry Selker, MD
Internal Medicine and Adult Primary Care Pratt Diagnostic Center
» » Karen Freund, MD
» » David Kent, MD
» » Susan Parsons, MD
Hematology-Oncology
For further details regarding their clinical, teaching and research responsibilities, please see the reports of those divisions
and of the Institute for Clinical Research and Health Policy Studies.
33
DIVISION OF
CLINICAL DECISION
MAKING
»» DIVISION OF CLINICAL DECISION MAKING, INFORMATICS AND TELEMEDICINE
“Tufts Medical Center has the only unit in the world that
ties the principles of logical decision analysis to the
care of individual patients. It is concerned with identifying strategies of
patient care that minimize unnecessary tests and procedures, increase patients’ participation
in decisions affecting their care, and decrease the cost of medical care.” —The Best Hospitals
in America: The Authoritative Reference Guide for Patients, Their Families and Medical
Professionals.”
John Wong, MD
The Division of Clinical Decision Making began as collaboration between computer scientists
at the Massachusetts Institute of Technology and physicians at Tufts Medical Center and Tufts
University School of Medicine. Under the guidance of Drs. Stephen Pauker and Jerome Kassirer, the Division was formally
established in 1980 to conduct research, teach students, train physicians and provide consultations. The Clinical
Consultation Service responds to requests from physicians who are uncertain as to the optimal management strategy
for a patient and provides advice based on literature review and formal decision analysis explicitly weighing the risks and
benefits of the alternatives.
The division has become a critical component of sophisticated medical systems and a crucial element of medical school
teaching. Many would agree that there is simply too much information available now for even subspecialists to master in
their own field. The student, the practitioner and the research scientist must learn how to efficiently access the huge
volume of information available, how to digest it critically, and how to use the information to make clinical decisions.
Highlights of 2014
» » Committee Member, Institute of Medicine, Diagnostic Error in Health Care (Dr. Wong)
» » Systematic Review Member, American Association for the Study of Liver Disease, Hepatitis B Guidelines (Dr. Wong)
» » Keynote Lecturer, Society for Medical Decision Making European Meeting, Antwerp, Belgium (Dr. Kassirer)
» » Member, Human Factors Subcommittee of the National Committee on Forensic Science (Dr. Kassirer)
» » Past President, Society for Clinical and Experimental Hypnosis (Dr. Pauker)
» » Committee Member, Institute of Medicine, End of Life (Dr. Pauker)
Faculty
Name
Academic Rank
Title and Special Responsibility
John B Wong, MD
Professor
Division Chief
Brian J Cohen, MD
Assistant Professor
Medical Director, Pratt Diagnostic Center
Jerome P Kassirer, MD
Distinguished Professor
Senior Advisor
Stephen G Pauker, MD
Professor
Division Chief Emeritus
Clinical Decision Consultation Service
The Division provides consultations to physicians who are uncertain as to the optimal management strategy for an individual patient.
The service provides advice based on literature review and formal decision analysis. The process explicitly weighs the harms and
benefits of the alternatives and often the preferences of the specific patient. Typical consultations involve complex clinical problems or
problems that involve difficult tradeoffs: patients with combinations of conditions that make traditional strategies of care problematic,
instances in which there is conflicting information, and decisions that need to reflect strongly individual patient preferences.
Clinical Hypnosis Consultation Service
This service provides consultation on the application of medical hypnosis for a wide variety of conditions including undesired habits,
anxiety, sleep disorders, chronic pain, and chemotherapy-related nausea.
Evidence-based Medicine
Tufts 1st year medical students are introduced to the general principles of evidence-based medicine (how to formulate well
constructed questions and then find and evaluate information).
Clinical Decision Making
In this elective course, 4th year Tufts medical students learn the rudiments of clinical decision-making, including the interpretation of
clinical data and test results using Bayes’ rule, the analysis of the risks, harms and benefits of clinical decisions, the estimation and use
of probabilities and of prognosis, and the evaluation of outcomes. Students also review the cognitive processes involved in clinical
reasoning, exploring the steps used by expert clinicians and identifying potential pitfalls in solving clinical problems. The student
participates in clinical consultations and learns how to critically evaluate the medical literature.
Medical Hypnosis
Dr. Pauker provides training in medical hypnosis at Tufts Medical Center for medical students and also teaches in annual workshops
given by the New England Society for Clinical Hypnosis.
Res earch
The Division focuses its research on clinical decision analysis, cost-effectiveness and health policy analysis. The studies examine
clinical and policy questions involving the information content of the medical history, physical examination and diagnostic tests,
determination of the optimal diagnostic test or test sequence, selection of the best therapy, and evaluation of new medical technologies
(tests, devices or drugs). It uses the tools of decision analysis, utility assessment, literature synthesis, medical informatics, Markov
model development, Monte Carlo simulation, Bayesian interpretation of diagnostic tests, measurement of patient preferences, costeffectiveness analysis, literature review, meta-analysis and discrete event simulation to assess comparative effectiveness.
Members of the Division are familiar with the use of techniques for assessing patient preferences and incorporating them into clinical
decision making. Current research projects include assessments of coronary heart disease treatments, colon cancer screening, HIV
and hepatitis C screening, screening for hypercholesterolemia in adolescents, epilepsy treatment, decision aids for shared decision
making, anticoagulation for atrial fibrillation, cost-effectiveness of Tai Chi for osteoarthritis and methodological recommendations for
performing decision analysis modeling.
35
C linical Rese a rc h Su p p or t
Recipient
John Wong, MD
Funding source
Purpose of award
AHRQ
Methods Research and Support in Decision and Simulation Modeling
CMS
ECHO: Increasing Capacity to Deliver Care to High Cost Medicaid Populations
NIH/NCCAM
Tai Chi and Physical Therapy for Knee Osteoarthritis
NIH/NCCAM
Mentoring and Research in Patient-Oriented Integrative Medicine
NIH/NCRR
Clinical and Translational Science Institute Award
NIH/NCI
A Prediction Model for Tailoring Use of Screening Colonoscopy
NIH/NIA
Comparative Effectiveness of Economic Incentives for Heart Disease
Prevention
NIH/NIA
Expanding the National Health Accounts
NIH/NIAA
RCT of an integrated Treatment of Persons with Co-Occurring HCV
and Alcohol Abuse
NIH/NIAAA
Value of Personalized Risk Information
NIH/NIDA
A Randomized Trial of Continued Methadone Maintenance vs. Detoxification
in Jail
NIH/NIDA
CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage and Care
PCORI
Integrating Causal Inference, Evidence Synthesis, and Research
Prioritization Methods
PCORI
Comparative Effectiveness of Adolescent Lipid Screening and
Treatment Strategies
PCORI
A Method for Patient-Centered Enrollment in Comparative Effectiveness
Trials: Mathematical Equipoise
PCORI
Funded Clinical Research Network Project with the Chicago Community Trust
H ealth Care Pol i cy a nd C l i ni ca l Pra c t ic e
The Division has been involved with numerous consensus conferences, guideline development processes and
appropriateness of care assessment for the National Institutes of Health (NIH), Office of Medical Applications Research
(OMAR), Institute of Medicine (IOM), American College of Cardiology (ACC), American College of Chest Physicians
(ACCP), American College of Physicians (ACP), Outcome Measures in Rheumatology (OMERACT), American Association
for the Study of Liver Disease, (AASLD), Centers for Disease Control and Prevention (CDC), Medicare Evidence
Development Advisory Committee (MedCAC), the CDC Working Group Evaluating Genetic and Genomic Testing
(EGAPP), European League Against Rheumatism (EULAR) and the World Health Organization (WHO). The Division has
also translated guidelines into quality improvement and performance measures through the AMA Physician
Consortium for Performance Improvement Work Group (AASLD/AGA/AHA/ACC/AMA) on Hepatitis C, Coronary Artery
Disease, Hypertension, Heart Failure, and Cardiac Imaging. In addition, the Division has been engaged in Patient
Outcome Research Teams (PORTs) sponsored by the then Agency for Health Care Policy and Research (AHCPR) on
Chronic Ischemic Heart Disease and Diabetes Mellitus. Lastly, the Division has developed decision aids for shared
decision making through the Informed Medical Decisions Foundation and Healthwise to increase patient knowledge
and help patients understand the role that their outcome preferences may play in their care decisions.
John Wong, MD, FACP
»» Co-chair, American Medical Association/American Gastroenterological Association/Association for the Study of Liver Disease,
Physician Consortium for Performance Improvement. Work Group on Hepatitis C
»» Committee Member, Institute of Medicine (IOM), Diagnostic Error in Health Care
»» Systematic Review Member, American Association for the Study of Liver Disease (AASLD), Hepatitis B Guidelines
»» Discussion Leader, Patient-Centered Outcomes Research Institute, Hepatitis C Workshop (Screening and Diagnostic Tests)
»» Chair, Awards Committee, Society for Medical Decision Making
Jerome Kassirer, MD, MACP
»» Keynote Lecturer, Society for Medical Decision Making European Meeting, Antwerp, Belgium
»» Member, Human Factors Subcommittee of the National Committee on Forensic Science
»» Senior Editorial Advisor for Circulation: Cardiovascular Quality and Outcomes
»» Visiting Professor at Stanford University; collaborating with Arnold Milstein's group on Care Redesign
»» Consultant, Center for Outcomes Research and Evaluation, Yale University
Stephen Pauker, MD, MACP, FACC, FACMI, ABMH
»» Past President, Society for Clinical and Experimental Hypnosis
»» Certified Consultant in Hypnosis, Active Commitment to Excellence (SCEH-ACE), Society for Clinical and Experimental Hypnosis
»» Re-Certification Approved Consultant, American Society of Clinical Hypnosis
»» Committee Member, Institute of Medicine, End of Life
»» Member, Institute of Medicine
»» Member, CDC Working Group for Evaluation of Genomic Applications for Populations and Prevention (EGAPP)
»» Member, American Board of Medical Hypnosis Examining Body
Brian Cohen, MD
»» Castle Connolly Top Doctor
37
DIVISION OF
CLINICAL NUTRITION
Nutrition plays a key role in disease risk as well as
in healing. There is increasing evidence for novel roles of nutrients in inflammation,
»» DIVISION OF CLINICAL NUTRITION
immune function, carcinogenesis, and cognitive decline. Members of the Division of Clinical
Nutrition are nationally known nutrition researchers and clinicians who provide an array of
consultative nutrition services to acutely and chronically ill patients.
Tufts University is a national and international leader in nutrition care, education and research.
Tufts Medical Center and Tufts University School of Medicine have long had a strong focus on
the clinical, training, and research aspects of human nutrition. The campus features a
Edward Saltzman, MD
remarkable array of resources, including the Division of Clinical Nutrition at Tufts Medical
Center, the Frances Stern Nutrition Center (FSNC), the Jean Mayer USDA Human Nutrition Research Center on Aging at
Tufts University (HNRCA), and the Friedman School of Nutrition and Science Policy
Highlights of 2014
» » Dr. Edward Saltzman appointed Academic Dean for Education, Friedman School of Nutrition Science and Policy.
» » Dr. Joel Mason selected by Boston Magazine as a Best of Boston gastroenterologist.
Faculty
Academic Rank
Edward Saltzman, MD
Associate Professor
Chief
Johanna Dwyer, PhD
Professor
Director, Frances Stern Nutrition Center
Joel Mason, MD
Professor
Director, GI Nutrition Clinic
Irwin Rosenberg, MD
University Professor
Adult Nutrition Support Service
The adult Nutrition Support Service (NSS), under the direction of Dr. Saltzman, provides expert nutritional
consultations for inpatients who require enteral or parenteral nutrition support and for patients who require continued
nutrition support after discharge. The attending staff also provides interpretation of indirect calorimetry (metabolic
rate) studies.
GI Nutrition Clinic
Under the supervision of Dr. Mason, a nationally recognized expert in nutritional management of malabsorptive
disorders, this clinic provides care for patients with complex nutritional disorders.
Tufts Medical Center Committee on Nutrition
To insure that nutrition practices at Tufts Medical Center are uniform and consistent with current best practices, the
Nutrition Committee monitors provision of nutrition care throughout the medical center and contributes to
development of policies and procedures.
Division members participate extensively in the education of students at Tufts University School of Medicine. Dr.
Saltzman directs the second-year course in Nutrition and Medicine. Residents and Fellows in multiple medical
subspecialties rotate through the inpatient Nutrition Support Service and GI Nutrition clinic. Dietetic interns who are
training to become Registered Dieticians in the Frances Stern Nutrition Center have required rotations on the inpatient
Nutrition Support Service.
Members of the division are also active in the Friedman School of Nutrition and Science Policy, where Dr. Saltzman is
Academic Dean for Education. Division member provide classroom teaching and serve as mentors for doctoral students.
Res earch Act i v i ty
Several members conduct research at the HNRCA, one of six USDA supported national nutrition research centers. Dr.
Mason directs the Vitamins and Carcinogenesis Laboratory and Dr. Rosenberg directs the Neuroscience and Aging
Laboratory. Dr. Saltzman is Medical Director of the Metabolic Research Unit, the HNRCA's inpatient unit, and is a
member of the Energy Metabolism laboratory at the HNRC. Dr. Dw yer serves a Senior Nutrition Scientist in the Office of
Dietary Supplements, National Institutes of Health.
39
Name
Johanna Dwyer, PhD
»» Trailblazer Award sponsored by the Institute of Food Technologies and the Academy of Nutrition and Dietetics
»» Editor, Nutrition Today
Joel Mason, MD
»» Received the E.V. McCullom Award from the American Society of Nutrition
»» Co-chair of the national annual conference, Advances and Controversies in Clinical Nutrition
»» Representative for nutrition and cancer, Research Executive Committee, Tufts Cancer Center
Irwin Rosenberg
»» Editor in Chief, Food and Nutrition Bulletin
Edward Saltzman, MD
»» Member, Board of Directors, American Society for Nutrition
»» Member, Editorial Board, American Journal of Clinical Nutrition
DIVISION OF
ENDOCRINOLOGY, DIABETES
AND METABOLISM
teaching activities for medical students, residents and endocrinology fellows, the Division
offers selective courses in clinical endocrinology and endocrine research for medical students
Ronald Lechan, MD
in order to foster interest in this subspecialty.
The Division has a distinguished history dating to the 1940’s when Dr. Edwin B. Astwood became its first Chief. During his
tenure, a number of advances were made including the introduction of drugs for the treatment of hyperthyroidism, the
use of thyroid hormone therapy for the treatment of thyroid nodules, the isolation and preparation of ACTH for clinical
use and the purification of human growth hormone, allowing the first treatment for pituitary dwarfism.
In 1972, Dr. Seymour Reichlin, a world-renowned leader in the field of neuroendocrinology and disorders of the thyroid gland,
became Chief of the Division. Outstanding achievements made during his tenure included the development of the first
radioimmunoassay for thyrotropin-releasing hormone (TRH), identification of the origin of the hypothalamic
tuberoinfundibular system, elucidation of the somatostatin and TRH genes and studies on the mechanisms of somatostatin,
TRH and prolactin secretion, demonstration of the role of the immune system in neuroendocrine regulation, studies on the
evaluation and treatment of hyperprolactinemia, and the diagnosis and treatment of patients with MEN II syndrome.
With the formation of the Human Nutrition Research Center on Aging, the Endocrinology Division gained prominence for
its studies of disorders of lipids, calcium metabolism and obesity. In 1990, Dr. A.E. Boyd, III became Chief and brought
expertise in diabetes mellitus and molecular biology. The Division grew rapidly when Dr. Boyd merged the Division of
Molecular Medicine with the Division of Endocrinology. After Dr. Boyd’s untimely death in 1995, Dr. Ronald Lechan
assumed leadership of the Division. During this time, the Division has continued its research interests in bone
metabolism, diabetes, neuroendocrinology, obesity and adipocyte function, and has substantially grown its clinical
program to involve offsite programs in Quincy, Norfolk and the Merrimack Valley. Division members have received
numerous grants, awards, prestigious lectureships and committee memberships.
Highlights of 2014
» » Grant renewal from the Gerald J. and Dorothy R. Friedman Foundation for Medical Research to support research
and fellowship training in Endocrinology, Diabetes and Metabolism
» » Discovery of a novel role for acyl CoA synthetase 5 in the development of obesity
» » Publication of 34 peer-reviewed papers, book chapters and reviews
» » Implementation of the Norfolk Specialty Center to provide care to patients with a variety of endocrine disorders in
the Norfolk and surrounding communities
41
»» DIVISION OF ENDOCRINOLOGY, DIABETES AND METABOLISM
The Division of Endocrinology at Tufts Medical Center
offers clinical services ranging from comprehensive
diabetes management to subspecialty outpatient
clinics devoted to pituitary, bone, thyroid, and adrenal
disorders and endocrine neoplasia. In addition to a wide variety of
Faculty
Name
Academic Rank
Ronald M. Lechan, MD, PhD
Professor
Chief of Division
Director, Fellowship Program
Director, Neuroendocrine Clinic
Co-director, Neuroendocrine & Pituitary Program
Lisa Ceglia, MD
Assistant Professor
Director, Bone Clinic
Michael Dansinger, MD
Assistant Professor
Director, Diabetes Reversal Program
Bess Dawson-Hughes, MD
Professor
Director, Bone-Metabolism Laboratory, HNRC
Csaba Fekete, MD, PhD
Adjunct Professor
Professor of Neurobiology, Hungarian Academy of Science
Andrew S. Greenberg, MD
Professor
Dr. Robert C and Veronica Atkins Professor in Metabolism and Nutrition
Director, Obesity and Metabolism Laboratory at Jean Mayer USDA
Human Nutrition Research Center at Tufts University
Jacqueline Kung, MD
Assistant Professor
Director, Thyroid Clinic and of Ultrasound and
Fine Needle Aspiration Thyroid Clinic
Anastassios G. Pittas, MD, MS
Professor
Director, Diabetes Clinic
Associate Director, Fellowship Program
Aruna Saraswat, MD
Professor Emeritus
General Endocrinologist
Consultant for Tufts Medical Center Primary Care-Quincy and Norfolk
Specialty Care Center
Seymour Reichlin, MD
Professor Emeritus
Richard Siegel, MD
Associate Professor
Director, Diabetes Clinic
Director, Internal Medicine Residency Endocrine Rotation
Director, 4th Year Medical Student Endocrine Elective
Co-Director, From Health To Disease III: 2nd Year Medical Student
Endocrine Course
Jeffrey Tatro, PhD
Associate Professor
Researcher
Roberto Toni, MD, PhD
Adjunct Professor
Professor of Human Anatomy, University of Parma School of Medicine
Mary Wenners, NP
Nurse Practitioner
and Certified Diabetes
Educator
Director of the Friedman Foundation Diabetes Education Program
Paula Dabenigno, RN
Certified Diabetes
Educator
Diabetes Educator
The Division of Endocrinology offers complete diagnostic and therapeutic services for common and complex endocrine
disorders. A variety of subspecialty outpatient clinics provide expert and investigational treatments, namely:
»» Bone Disease (Dr. Lisa Ceglia)
»» Thyroid Disease and Thyroid Cancer (Dr. Jacqueline Kung)
»» Diabetes and Metabolism (Drs. Richard Siegel, Anastassios Pittas, Lisa Ceglia)
»» Obesity (in collaboration with the Obesity Consultation Center, Dr. Richard Siegel)
»» Neuroendocrinology and Endocrine Neoplasia (Dr. Ronald Lechan)
»» Diabetes Reversal Program (Dr. Michael Dansinger)
»» General Endocrinology (Drs. Lisa Ceglia, Jacqueline Kung, Ronald Lechan, Aruna Saraswat, Richard Siegel)
In collaboration with the De partments of Neurosurgery, Radiology and Ophthalmology, a multidisciplinary
neuroendocrine pituitary program was developed under the direction of Drs. Ronald Lechan and Carl Heilman to facilitate
the evaluation and care of patients with hypothalamic and pituitary disorders. The Division is also working collaboratively
with the Division of Internal Medicine and Adult Primary Care to improve the care of patients with type 1 and type 2
diabetes mellitus, and with the Department of Orthopedics to improve bone health for patients with recent bone fractures,
and has established satellite clinics in Quincy, Norfolk and the Merrimack Valley to assist NEQCA physicians with the care
of their patients with diabetes and other endocrine disorders. Our newest faculty member, Dr. Aruna Saraswat, has been
particularly instrumental in overseeing the latter endeavor.
The Division offers fellowship training in Endocrinology, Diabetes and Metabolism, accepting two new Fellows each
year into a 2 year clinical or 3 year clinical/research program. One new Fellow each year is supported by a grant from
The Gerald J. and Dorothy R. Friedman New York Foundation for Medical Research. Included in the teaching activities
are formal lectures on topics in endocrinology, instruction in thyroid ultrasound and fine needle aspiration biopsy of
thyroid nodules, interpretation of bone densitometry studies, and interpretation of continuous glucose monitoring data.
The Division is also active in teaching house staff and medical students. Among the offerings are the following:
»» Selective courses in clinical endocrinology and endocrine research for medical students, supervised by Drs. Richard Siegel and
Ronald Lechan
»» Formal instruction in the endocrine pathophysiology course to second year medical students in the From Health to Disease III:
Endocrine Course, co-directed by Dr. Richard Siegel
»» Lectures at Noon Conference and participation in Morning Report for Internal Medicine Residents
»» A series of lectures for first year Fellows in the endocrinology training program
»» Electives in the endocrinology clinics and on the endocrinology consultation services for both medical students and Internal
Medicine Residents.
Faculty members have also been mentors, served on PhD and MS Thesis Committees, and participated in teaching in
the Medical School, Sackler School of Graduate Biomedical Sciences, USDA Human Nutrition Center, Dental School,
Friedman School of Nutrition and Health Policy, University of Parma and Hungarian Institute of Science. Division
members were also involved in teaching trainees at the American Thyroid Association Annual meeting, in evidencebased didactic training of dietitians at Boston Heart Diagnostics, in one-on-one mentoring of students and Residents
who rotate through the Diabetes Reversal Program in the Endocrinology Clinic, and in teaching engagements at the
University of Parma and the Janos Szentagothai Neuroscience School of the Semmelweis University. In addition, a series
of multimedia web lectures was developed on human embryology and the anatomy of the head and neck, (w w w.
anfamedmuseo.unipr.it). Dr. Andrew Greenberg is the PI on a NIH T32 award that provides research training in
nutrition, obesity and metabolic diseases to predoctoral students at the School of Nutrition at Tufts University.
43
The inpatient consultation team offers diabetes management services for hospitalized patients. Under the direction of Dr.
Richard Siegel, protocols for insulin management in the intensive care units and insulin order forms have been developed
and implemented on medical and surgical floors to improve diabetes management in the hospital. Dr. Siegel has begun a
novel telemedicine consult program with Patient Advocates in Maine, focused on the care of patients with diabetes mellitus.
Under the direction of Dr. Michael Dansinger, the Diabetes Reversal Program at Tufts Medical Center was introduced in
which diet and exercise is used to achieve remission in approximately 36% of patients with type 2 diabetes. Mary Wenners, NP
oversees an insulin pump program as well as an Asian Outreach Screening Program to identify patients in the local
community with diabetes mellitus. Under the direction of Dr. Jacqueline Kung, the thyroid cancer program has been
expanded to include mutational testing and gene expression classifier testing on fine needle biopsy aspirates of thyroid
nodules.
Res earch Act i v i t i es
The commitment to research by the faculty continues to be a major focus of the Division. Success in this endeavor is
indicated by the publication record of the faculty that includes 34 peer reviewed papers, book chapters and reviews, and
a major, $40 million award to Dr. Taso Pittas to study the effects of vitamin D on diabetes mellitus.
Support for faculty research is derived from 4 R01, 2 U01, 1 P30, 1 T32 and a contract from the NIH, 2 grants from the
USDA, 1 grant from the ADA, 1 grant from the Department of Defense, 2 grants from the Gerald J. and Dorothy R.
Friedman Foundation for Medical Research, grants from the Italian Ministry of Research, University of Parma,
Hungarian Academy of Science and European Union, as well as 9 other grants from foundations and industry. Six new
grants were awarded to Division members this year.
Highlights of recent research accomplishments include:
»» Discovery of a novel role of acyl CoA synthetase 5 in the development of obesity and regulation of cholesterol
»» Comparison of the effectiveness of Atkins, Zone, Weight Watchers and Ornish diets for increasing large HDL levels in plasma
»» Demonstration that vitamin D supplementation has beneficial effects on muscle fiber size and increases intramyonuclear vitamin D
receptor (VDR) expression in older women with low vitamin D status and moderate risk of disability
»» Demonstration that serum sclerostin levels are not associated with baseline or change in glucose or insulin levels in healthy
participants of the STOP-IT trial
»» Demonstration of a strong, inverse relationship between body weight, total adiposity and its compartments and 25OH vitamin D
concentration in a multi-racial cohort of adults with pre-diabetes
»» Demonstration that weight and BMI are associated with 25OH vitamin D level, in part by way of visceral body fat
»» Evidence that the absorption of vitamin D is 30% higher when the meal contains fat than when it contains no fat.
»» Demonstration that 43.4 million older adults in the US 50 years and older have low bone mass in the National Health and Nutrition
Examination Survey and are largely non-Hispanic white women
»» Development of a transgenic mouse model to detect tissue/organ-specific changes in thyroid hormone action (patent claim
#P1400563)
»» Mapping of the connections of the parabrachial and central nucleus of the amygdala with other feeding-activated neuronal groups in
the brain
»» Evidence to suggest replacement with a combination of L-T3 and L-T4 is required to normalize thyroid hormone-dependent markers
in thyroidectomized animals and that when replaced with only L-T4 to normalize TSH, the brain, liver and skeletal muscle exhibits
indications of hypothyroidism due to increased ubiquitination of type 2 deiodinase.
»» Demonstration of the potential importance of the parasubthalamic nucleus in appetite regulation
»» Demonstration that inflammation induces the expression of type 2 deiodinase in leptomeninges, choroid plexus and blood vessels in
the brain
»» Demonstration that the thyroid hormone transporters, OATP1 and MCT8, are downregulated by endotoxin at the blood-brain-barrier
indicating reduced thyroid hormone uptake into brain parenchyml tissue during inflammation
»» Differentiation of stem cells into mature thyrocytes
»» Characterization of subgroups of adult, rat, mesenchymal stromal cells obtained from the bone marrow for ex situ reconstruction of
bioartificial bone
»» Demonstration that the cryptic fragment 53-74 of rat preproTRH stimulates replication of GH4C1 cells
C linical Rese a rc h
Recipient
Lisa Ceglia, MD
Purpose of award
Regeneron Pharmaceuticals,
Inc* (Co-Investigator)
Multicenter study of effects of REGN1003 on body composition, muscle
strength and stair climb power
Regeneron
Pharmaceuticals, Inc.*
(Co-Investigator)
Safety and efficacy of REGN1033 in patients with sarcopenia
DSM Nutritional Products
(PI)
Effects of 25(OH)D supplementation on muscle fiber size, vitamin D receptor
concentration and satellite cell activation in younger postmenopausal women
with osteopenia.
Boston Heart Diagnostics
Effectiveness of lifestyle program for former NFL players at risk for heart
disease Heart
Boston Heart Diagnostics
(PI)
Effectiveness of lifestyle program for firefighters and police officers at risk for
heart disease
NIH (PI)
Musculoskeletal benefits of bicarbonate in older adults
NIH (Co-Investigator)
Define the effects of vitamin D and calcium supplementation on glucose
metabolism (with Dr. Pittas)
USDA (PI)*
Studies of nutrition and the aging skeleton
Pfizer (PI)*
Impact of supplemental vitamin D on serum 25OHD levels and short term
indicators of physical function
NIH* (Co-Investigator)
Multi-center clinical trial to evaluate the safety of oral daily vitamin D
supplementation and its effect on the time of onset of clinical diabetes
mellitus (with Dr. Pittas)
Gerald J. and Dorothy R.
Friedman Foundation for
Medical Research* (PI)
Clinical and research training in Endocrinology, Diabetes and Metabolism
NIH, TCGA Trial* (PI)
Study of pathophysiology and molecular biology of pheochromocytoma and
paraganglioma
Tercica (PI)
SODA study, Observational study of patients with acromegaly treated with somatuline
Novartis* (PI)
ACCESS study, Observational study of Pasireotide LAR in acromegaly
Eisai *(Co-Investigator)
CAMELLIA-TIMI study, Effect of lorcaserin on major cardiovascular events and
conversion to type 2 DM
Novartis* (Co-Investigator)
ACCESS study, Observational study of Pasireotide LAR in acromegaly (with Dr.
Lechan)
Tercica (Co-Investigator)
SODA study, Observational study of patients with acromegaly treated with
somatuline (with Dr. Lechan)
American Diabetes
Association* (PI)
D2d Co-Support Award
NIDDK (PI)
U01 implementation grant: Multi-center randomized trial of vitamin D
supplementation for prevention of type 2 diabetes
NIDDK (PI)
Role of vitamin D in established type 2 diabetes
Department of Defense
(Co-Investigator)
Develop more effective approaches to sustain weight loss
Michael Dansinger, MD
Bess Dawson-Hughes, MD
Ronald Lechan, MD, PhD
Richard Siegel, MD
Anastassios Pittas, MD
* New Award in 2014
45
Funding source
Bas ic Res ea rch
Recipient
Funding source
Purpose of award
European Union FP7
Study the effect of aging and high fat diet on parameters of the
hypothalamic-pituitary-thyroid axis
Hungarian Academy of
Sciences (PI)
Analysis of the transcriptome of hypothalamic paraventricular neurons in
fasting animals that have been refed
NIH (PI)
Age Dependent Role of Bisphenol A in Nonalcoholic Fatty Liver Disease
USDA* (PI)
Regulation of Adipocyte and Adipose Tissue Metabolism in ObesityRelated Inflammation and Metabolic Disorders
NIH, NIDDK (PI)
Research Training Program in Nutrition and Chronic Disease
NIH (Co-director)
Adipose Biology and Nutrient Metabolism Core
NIH* (PI)
Role of ACSL5 in Liver and Intestinal Triacyglycerol Metabolism
NIEHS (Co-PI)
Age Dependent Role of Bisphenol A in Obesity and Insulin Resistance
Tufts CTSI (Co-PI)
The Role of CDK6 in Adipogenesis, Obesity and Diabetes
Ronald M. Lechan, MD,
PhD
Gerald J. and Dorothy R.
Friedman Foundation for
Medical Research* (PI)
Characterization of POMC Neurons in the Hypothalamic Arcuate Nucleus
Jeffrey Tatro, PhD
NIH, Collaborator (Beasley, PI)
Atherogenic role of T cell modulation by intestinal bacteria
Museum of the Department of
Biomedicine, Biotechnologies
and Translational Sciences
Creation of a web archive showing artistic portrayal of endocrine diseases
in paintings and bas-reliefs throughout the world linking morphology and
endocrinology
Italian Ministry of Culture, Art
and Music
Development of restoration procedures for 17th-19th century anatomical
specimens
Italian Ministry of Research and
University (MIUR) (PI)
Development of biotechnology and bioengineering strategies to develop
ex situ bioartificial organs
University of Parma School of
Medicine
Molecular mechanisms regulating growth and differentiation of
neuroendocrine cells
Csaba Fekete, MD
Andrew Greenberg, MD
Roberto Toni, MD
* New Award in 2014
Dr. Lisa Ceglia
»» PhD Thesis Committee, Friedman School of Nutrition and Health Policy
»» MS Thesis Committee, Sackler School of Graduate Biomedical Sciences Speaker, Friedman Symposium, Annual Scientific Meeting
of ADA, San Francisco, CA
»» Grand Rounds Speaker, Lowell General, Hospital
»» Grand Rounds Speaker, Carney Hospital
»» Grand Rounds Speaker, Winthrop Hospital
»» Grand Rounds Speaker, Brockton Hospital
»» Scientific Advisor, Amgen Bone Health Team
Dr. Michael Dansinger
»» Keynote Speaker, Pri-Med Primary Care Conference, Miami, Los Angeles, Houston, Boston and Baltimore
»» Speaker, Boston Heart Diagnostics Customer Conference, Boston, MA and Charleston, SC
»» NECQA/Tufts Medical Center Diabetes Advisory Committee
Dr. Bess Dawson-Hughes
»» Editorial Board, Bone
»» Editorial Board, Osteoporosis International
»» Editorial Board, Calcified Tissue International
»» Chapter Writer, Up-to-Date
»» NOF Lawrence G. Raisz Memorial Lecture Award
»» Thomson Reuters Highly cited scientist
»» Scientific Advisor for BIRWCH grant at UC Davis
»» General Secretariat (VP) of the International Osteoporosis Foundation
»» Founding Director of the Center for the Advancement of Science in Space
»» Grant Reviewer, NIAMS and NIA
»» Speaker, International Society for Clinical Densitometry meeting
»» Speaker, Saudi Osteoporosis Society meeting
»» Speaker, National Osteoporosis Foundation meeting
»» Speaker, International Osteoporosis Foundation annual meeting, Seville, Spain
»» Presenter, NIH ODS workshop on vitamin D, Bethesda, MD
Dr. Csaba Fekete
»» Invited Speaker, Joint meeting of the Federation of European Physiological Society and Hungarian Physiological Society
»» Speaker, Annual Meeting of the Hungarian Society for Endocrinology and Metabolism
»» Editorial Board, Journal of Chemical Neuroanatomy
Dr. Andrew Greenberg
»» NYU School of Medicine Solomon Berson Medical Achievement Award for Basic Research
Dr. Jacqueline Kung
»» Member, Trainees and Career Advancement Committee, American Thyroid Association
»» Chair, Information Technology Subcommittee, American Thyroid Association
»» Member, Diabetes Clinical Advisory Committee, Tufts Medical Center and New England Quality Care Alliance
»» Speaker, Medical Grand Rounds, University of San Diego
»» Speaker, American Thyroid Association Annual Meeting Training Conference
»» Volunteer Attending, Tufts Medical Student Free Clinic Sharewood Project
Dr. Ronald Lechan
»» Organizing Committee and Co-Chair, Friedman Fellows Symposium on Nutrition and Human Health, San Francisco, CA
»» Organizing Committee, International Pituitary Congress, Chicago, IL
»» Editorial Board, Acta Biomedica
»» Boston Magazine 2014 list of Top Doctors
»» Top 10 Endocrinologists Award from American Registry
»» External Expert, PhD Program in Molecular Medicine, University of Parma School of Medicine
»» Member, International FIPA Consortium to study familial pituitary adenomas
47
Dr. Anastassios Pittas
»» Chair, NIH Study Section on Clinical & Integrative Diabetes and Obesity
»» Chair, NIH Special Emphasis Panel
»» Visiting Professor, University of Kansas
»» Speaker, 3rd International Conference on Vitamin D Deficiency, Abu Dhabi, UAE
»» Speaker, American Diabetes Association, San Francisco, CA
»» Speaker, Friedman Fellows Symposium on Nutrition and Human Health, San Francisco, CA
Dr. Aruna Saraswat
»» ABIM Certification in Endocrinology and Metabolism 2014
Dr. Richard Siegel
»» Boston Magazine Best Doctors 2014
Dr. Jeffrey Tatro
»» Inventor on licensing agreement pertaining to worldwide sales of α-MSH antiserum
Dr. Roberto Toni
»» Scientific Director, Museum of Biomedical, Biotechnological and Translational Sciences, University of Parma
»» Editorial Board and Section Editor on History of Endocrinology, L’Endocrinologo
»» Member of Scientific Committee for the PhD Program in Molecular Medicine at the University of Parma School of Medicine
»» Member of the Scientific and Clinical Committee of the Center for Sport and Exercise Medicine of the University of Parma
DIVISION OF
GASTROENTEROLOGY
NIH as an investigator of liver disease, succeeded Dr. Patterson as Division Chief in 1972.
During Dr. Kaplan’s thirty year tenure, the Division became widely known for the management
Joel Weinstock, MD
of primary biliary cirrhosis and sclerosing cholangitis and developed an academic and
research focus. Dr. Kaplan also was an Associate Editor of the New England Journal of
Medicine. In 2006, Dr. Joel Weinstock, who was well known for basic investigations of intestinal immunology, became
Chief of the Division. His appointment brought novel approaches to the treatment of inflammatory bowel disease and a
strong basic science interest in the mechanisms of immune regulation in the gut.
In 1984, the Division became one of the first awardees of an NIH Silvio O. Conte Digestive Disease Research Center grant.
This basic research program, known as the GRASP Center, became the central link among digestive disease researchers
throughout the medical center, the medical school and the veterinary school. The founding director of the GRASP Center
was Mark Donowitz MD; Andrew Plaut became director in 1987.
Many former members of the Division have made major contributions to the field of gastroenterology and three have
been presidents of the American Gastroenterological Association.
The members of the Division combine clinical and basic research talents. Members receive funding from the NIH and
pharmaceutical industry and patients are referred from a network of internists and gastroenterologists throughout New
England. Aside from the particular strengths in cholestatic liver disease and inflammatory bowel disease, the Division
offers advanced endoscopic procedures for a variety of gastrointestinal disorders. The liver transplant program has
merged with the program at Lahey Clinic so that the surgical procedures are now done at Lahey Clinic but the
identification of candidates and the pre-and post-operative care remain at Tufts Medical Center.
Highlights of 2014
» » John Leung, director for the GI food hypersensitivity center, has substantially expanded the service
» » Harmony Allison named director of our new GI motility service
» » Joel Mason awarded a grant from Prevent Cancer Foundation.
» » Hannah Lee awarded numerous grants to enhance her research program in Hepatitis
49
»» DIVISION OF GASTROENTEROLOGY
The Division of Gastroenterology was established in
the 1960s under the direction of Dr. James Patterson,
a dermatologist who became a gastroenterologist as
a result of his interest in the skin manifestations of
digestive diseases. Dr. Marshall Kaplan, who had established a reputation at the
Faculty
Name
Academic Rank
Joel V. Weinstock, MD
Professor
Division Chief
Sanjay Hegde, MD
Assistant Professor
Director, Endoscopy Unit
Harmony Alison, MD
Assistant Professor
Associate Director, Clinical Programs
Martin Beinborn, MD, PhD
Assistant Professor
Peter Bonis, MD
Adjunct Professor
Moises Guelrud, MD
Clinical Professor
Lori Olans, MD
Professor
Jatin Roper, MD
Instructor
Assistant Professor
John, Leung, MD
Assistant Professor,
Medicine & Pediatrics
Allen Hwang, MD
Assistant Professor
Alan Kopin, MD
Professor
Director, Molecular Pharmacology Research
Hannah Lee, MD
Assistant Professor
Director, Hepatology Programs
Joel B. Mason, MD
Professor
Professor of Medicine and Nutrition; Director,
Vitamins & Carcinogenesis Laboratory, USDA Human
Nutrition Research Center at Tufts University
Sonali Paul, MD
Assistant Professor
Andrew Plaut, MD
Professor
Kathleen Viveiros, MD
Assistant Professor
Director, Food Allergy Center
Co-Director, Food Allergy Center at Floating
Hospital for Children
Director, Fellowship Program
The clinical activities of the Gastroenterology Division of Tufts Medical Center include outpatient and inpatient management of
gastrointestinal disorders and liver diseases. The Division has an international reputation in chronic cholestatic liver diseases and
in inflammatory bowel disease, leading to referrals from worldwide.
The Division has special expertise in:
»» Esophageal motility studies and 24-hour pH monitoring of the esophagus
»» Endoscopic treatment of Barrett’s esophagus
»» Peptic ulcer disease
»» Gastrointestinal endoscopy, including transduodenal bile duct and advanced pancreatic endoscopic therapy
»» Colonoscopy and colonoscopic polypectomy, chromoendoscopy and magnification endoscopy
»» Management of patients with chronic liver disease including chronic hepatitis, cirrhosis, gallstones, primary sclerosing cholangitis
and primary biliary cirrhosis.
»» Chronic cholestatic liver disease
»» Inflammatory bowel disease
Physicians in the Division of Gastroenterology have pioneered innovative medical treatments for primary biliary cirrhosis and
primary sclerosing cholangitis. These therapies appear to induce remission in some patients with previously untreatable disease.
Other interests include malabsorption disorders, and the clinical evaluation of nutritional disorders and weight loss; sexually
transmitted intestinal and liver disease, including hepatitis and parasitic infections; and chronic secretory diarrhea. The
inflammatory bowel disease clinic applies an interdisciplinary approach for the care of complex diseases including faculty from
the Departments of Colorectal Surgery, Radiology and Pathology. A wide spectrum of inflammatory disorder is handled with
expertise including ulcerative colitis, Crohn’s disease, lymphocytic colitis, collagenous colitis and many others.
The GI motility service offers the latest technology for the study of motility problems of the gastrointestinal tract. Physician
exports applying this advance technology aid in the evaluation of non-cardiac chest pain, gastroesophageal reflux disease,
defecation disorders and more.
The Division of Gastroenterology is extensively involved in the teaching of medical students. In the preclinical years, the division
is responsible for the GI pathophysiology course. In the clinical years the division teaches students on both the Gastroenterology
subspecialty floor and on the inpatient consultation service.
Interns and residents at Tufts Medical Center rotate through the GI subspecialty ward and may also choose an elective on the GI
consultation service. These experiences expose residents to a wide variety of gastrointestinal disorders.
The Gastroenterology Fellowship Program is a joint fellowship program between Tufts Medical Center and St. Elizabeth’s Medical
Center of Boston, both of which are affiliates of Tufts University School of Medicine. This collaboration has significantly enriched
the educational experience of the teaching program. Most of the trainees seek academic careers.
Residents from Internal Medicine rotate through the Allergy Division. Those with a particular interest in Allergy and Clinical
Immunology are given opportunities to participate in extra clinical sessions and are also encouraged to do literature surveys and
extended evaluations of complicated patients. House staff members expressing interest in Allergy and Clinical Immunology have
been supported in applications for fellowship training in Allergy and recent house staff members have been accepted to such
fellowships in well-recognized programs including Scripps Clinic, Brigham and Women’s Hospital, Baylor College of Medicine
and University of Virginia College of Medicine.
The staff has provided General Medical Associates with Educational Seminars in topics pertinent to Allergy. The staff regularly
conducts consultations with Hospital Staff and physicians within the New England Quality Care Alliance, and educates dietary
interns rotating through the Food Allergy Center on management of food allergies and food intolerances.
C ommunity Ou t re a ch Prog ra m s
Division staff has given presentations to schools, community health center, such as the YMCA, and on local TV and radio stations
about the prevention and treatment of allergic diseases. The staff reaches out to the Mandarin and Cantonese speaking population
of Boston through health fairs, seminars and educational articles in Chinese language newspapers like Sampan, to increase local
awareness of the services offered by the Allergy Division.
C linical Rese a rc h
Recipient
Funding Source
Purpose of Award
Joel Mason, MD
Prevent Cancer Foundation.
Agricultural Research Service.
Nutrition and Cancer
Prevention.
Inflammatory cytokines mediate the enhanced risk of colon cancer in obesity
51
The Food Allergy Center at Tufts Medical Center and Floating Hospital for Children was established in 2013, in collaboration with
the pediatric and adult GI Division. It provides integrative, patient-oriented, multidisciplinary care for both adults and children
with known or suspected food allergies/intolerances. Division members treat diverse conditions like food anaphylaxis,
eosinophilic esophagitis and eosinophilic gastroenteritis.
Bas ic Res ea rch
Recipient
Funding Source
Purpose of Award
Harmony Allison, MD
Division of Allergy, Immunology,
and Transplantation (DAIT),
National Institute of Allergy and
Infectious Diseases (NIAID),
National Institutes of Health (NIH)
A Prospective, Randomized, Double-blind, Placebo-controlled Phase II Clinical
Study of Trichuris suis Ova Treatment in Left-sided Ulcerative Colitis and its
Effects on Mucosal Immune State and Microbiota
Gilead Sciences, Inc.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center
Study to Evaluate the Safety and Efficacy of GS-9620 for the Treatment of
Virally-Suppressed Subjects with Chronic Hepatitis B
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of
GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment
of Subjects with Chronic Hepatitis B and who are currently not on Treatment
A Long Term Follow-up Registry Study of Subjects Treated in A GileadSponsored Trial with Chronic Hepatitis B Infection
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy
of GS-4774 for the Treatment of Virally-Suppressed Subjects with Chronic
Hepatitis B
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy
of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate
(TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B
A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study
to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF)
in Combination with Peginterferon α-2a (PegasysR) versus Standard of
Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a
Monotherapy for 48 Weeks in Non-Cirrhotic Subjects with HBeAg-Positive
or HBeAg-Negative Chronic Hepatitis B (CHB)
Eisai Co., Ltd
A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study
to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the
Treatment of Adults with Thrombocytopenia Associated with Liver Disease
Prior to an Elective Procedure
Shionogi, Inc
A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess
the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment
ofThrombocytopenia in Patients with Chronic Liver Disease (CLD)
Undergoing Elective, Invasive Procedures.
National Institutes of Health
(NIH)
The primary aims of this prospective, multi-center, longitudinal and
exploratory pediatric and adult study are to determine the correlation of
clinical outcome measures (patient reported outcomes, quality of life and
endoscopy) with the established biomarker of peak mucosal eosinophil count
(Phase 1), and to compare the transcriptomes (eosinophilic esophagitistranscriptome, eosinophilic gastritis-transcriptome and eosinophilic colitistranscriptome) with their respective peak mucosal eosinophil counts and
respective clinical outcome measures.
Hannah Lee, MD
John Leung, MD
Swiss National Science
Foundation (grant no.
32003B_135665/1)
AstraZeneca AG (Switzerland)
Aptalis
Dr. Falk Pharma GmbH (Germany)
The primary aim of this multicenter study is to develop, validate and evaluate
an eosinophilic esophagitis activity index for pediatric and adult patients
Glaxo Smith Kline AG
Nestlé S. A. (Switzerland)
The International Gastrointestinal
Eosinophil Research
Recipient
John Leung, MD
Purpose of Award
Regeneron Pharmaceuticals, Inc
The primary aim of this multicenter, double-blind, randomized, placebocontrolled study is to investigate the efficacy, safety, tolerability,
pharmacokinetic, and immunogenicity of dupilumab in adult patients
with eosinophilic esophagitis.
NIH-RO1 DK 058755
Study immune regulation in the gut pertaining regulatory T cells and how this
adds the control of IBD
NIH-RO1-KD091987
Study the role of dendritic cells in the control of inflammation in the intestines
and how it relates to IBD
The Schneider Family
The Gilman Family
IBD
IBD
H onors and Awards
Peter Bonis, MD.
»» Investigator on a $6.2M five-year NIH grant (U54), awarded in 2014 (http://grantome.com/grant/NIH/U54-AI117804-01). It is aimed
at studying various aspects of eosinophilic gastrointestinal diseases.
»» Service on executive steering committees for The International Gastrointestinal Eosinophil (TIGERS), the Researchers and the
Registry for Gastrointestinal Disorders (REGID, https://regid.org/), and the Consortium of Eosinophil Gastrointestinal Disease
Researchers (CEGIRS, https://www.rarediseasesnetwork.org/CEGIR/index.htm
Moises Guelrud, MD
»» Named in “Top Doctors” in Boston Magazine 2014
»» Invited Lecturer: Rings, Webs and Something Else. Tufts Medical Center, GI Conference 10/9/2014
»» Committee Assignments in Professional Societies: International Editor, GastroHep.com UK
»» Attendance for Hand-On Course on Endoscopic Submucosal Disection, Brigham and Women’s Hospital. March 24, 2014
Joel Weinstock, MD
»» “Top Doctors” on the Boston Magazine, 2014
»» Keynote speaker, 7th Vaccine Renaissance, Providence, RI, 2013.
»» Invited speaker, Antigen Presentation and Host Defense-Bridging the Gap, University of Vienna, Vienna, Austria, 2014.
»» Invited speaker and section chairman, 9th International Conference on Autoimmunity, Nice, France, 2014.
»» Visiting Professor, Division of Gastroenterology, University of Arkansas, Little Rock, AK, 2013.
»» Visiting professor, Department of Medicine and Division of Gastroenterology, University of Cincinnati, Cincinnati, Ohio, 2014.
»» Visiting Professor, University of Antwerp, Belgium, 2014.
53
Joel Weinstock, MD
Funding Source
DIVISION OF
»» DIVISION OF GEOGRAPHIC MEDICINE AND INFECTIOUS DISEASES
GEOGRAPHIC MEDICINE
AND INFECTIOUS
DISEASES
The Division of Geographic Medicine and Infectious
Diseases at Tufts Medical Center is known for its
excellence in clinical care, teaching, and research.
The Division was created in 1957. Its first Chief, Dr. Louis Weinstein, was an internationally
renowned clinician and teacher whose clinical acumen and charismatic teaching style
attracted many young physicians to the relatively new subspecialty of infectious diseases.
Graduates of his training program occupied significant positions in academia. During the
tenure of his successor, Dr. Sherwood Gorbach, the cause and pathogenesis of C. difficileDavid Snydman, MD
associated disease were discovered by Drs. John Bartlett and Te-Wen Chang. In 2007, Dr.
Gorbach was awarded the Alexander Fleming Prize, a lifetime achievement award, from the Infectious Diseases Society
of America. Dr. Sheldon Wolff, the Chairman of Medicine at Tufts- New England Medical Center and an internationally
recognized infectious disease expert (and Fleming Prize recipient), together with Charles Dinarello of the Experimental
Medicine Division, discovered interleukin-1.
In 1986, the Divisions of Geographic Medicine, Experimental Medicine, and Infectious Diseases were merged into the
Division of Geographic Medicine and Infectious Diseases. The chief, Dr. Gerald Keusch, was well known for his work on the
pathogenesis of enteric infections, the effects of malnutrition on the immune response, and vaccine development. He,
too, has been awarded the Fleming Prize by IDSA.
Dr. David R. Snydman became chief of the Division in 1998. Dr. Snydman is known for the first clinical description of Lyme
disease, the first isolation of an organism consistent with B. burgdorferi from the joint of a patient with chronic Lyme
arthritis, and the development of Cytomegalovirus Immune Globulin, which is used in transplantation. Dr. Snydman has
expanded the division’s expertise in transplantation infectious disease, HIV care, and clinical research while maintaining
the international programs and basic science focus in research. Under his leadership, the Division secured its’ fourth NIH
training grant, this one in clinical research training in infectious diseases. In addition, the faculty has obtained 10 research
career development awards from the NIH and 3 faculty career mentor awards, and trains 3-5 new fellows each year. Tufts
University School of Medicine and Tufts Medical Center is the site for the editorial offices of Clinical Infectious Diseases,
a journal of the Infectious Disease Society of America. The Editor and Deputy Editor and several Associate Editors are
faculty members.
Highlights of 2014
» » Microbial Pathogenesis Training grant funded for another 5 years by the NIH (Linden Hu, Principal Investigator)
» » Shira Doron, MD, MS promoted to Associate Professor of Medicine
» » Alysse Wurcel, MD, MS joined the faculty with expertise in Hepatitis C treatment
» » Xin Li, PhD, with expertise in Lyme disease research, joined the division
» » Sherwood L. Gorbach, MD named Emeritus Professor Medicine by Tufts University School of Medicine
» » Yoav Golan, MD, MS and Simone Wildes elected to Fellowship in the Infectious Disease Society of America
» » Helen Boucher, MD named to the American Board of Internal Medicine Subspecialty Board of Infectious Disease as
well as the Board of Trustees of the Physicians Organization and the Board of Trustees of the College of the Holy Cross
Faculty
Name
Academic Rank
David R. Snydman, MD
Professor
Chief of Division
Hospital Epidemiologist
PI of Clinical Research Training Grant
Geneve Allison, MD
Assistant Professor
Director of OPAT (OutPatient Intravenous Antibiotic Therapy)
Program
Robert Arbeit, MD
Professor
Consultation Attending, Idera Pharmaceuticals
Jorge Barinaga, MD, MS
Assistant Professor
Milton Hospital consultant
Michael Barza, MD
Professor
Vice Chair for Clinical Affairs, Department of Medicine
Helen W. Boucher, MD
Associate Professor
Fellowship Program Director
Victor Boyartchuk, PhD
Assistant Professor
José A. Caro, MD
Assistant Professor
HPV Clinic
Jennifer K.L. Chow, MD, MS
Assistant Professor
Intercity Conference Director
Shira Doron, MD, MS
Assistant Professor
Antimicrobial Steward, Antimicrobial Management Program (AMT)
Associate Hospital Epidemiologist
Yoav Golan, MD, MS
Associate Professor
Sherwood L. Gorbach, MD
Professor, Public Health
and Medicine
Jeffrey K. Griffiths, MD, MPH&TM
Professor
Susan Hadley, MD
Professor
James Hellinger, MD, MSc
Assistant Professor
Steven Y. Hong, MD, MPH, MAR
Assistant Professor
Linden T. Hu, MD
Professor
Michael R. Jordan, MD, MPH
Assistant Professor
Anne V. Kane, MD
Assistant Professor
Director, Phoenix Lab
Laura Kogelman, MD
Associate Professor
Director of ID Clinic and Traveler’s Health Services
Rakhi Kohli, MD, MS
Assistant Professor
Morbidity and Mortality Conference Director
Xin Li, PhD
Assistant Professor
Emeritus Professor of Public Health and Medicine
Pathophysiology Course Director
Vice Chair for Faculty Development, Department of Medicine
Principal Investigator Microbial Pathogenesis Training Grant
Co-Director, CTRC
55
» » Susan Hadley, MD awarded the Natalie O. Zucker Prize from Tufts University School of Medicine for outstanding
accomplishment in teaching
Faculty (con t i nu e d )
Name
Academic Rank
Natalie E. Nierenberg, MD, MPH
Assistant Professor
The Center for Vascular, Wound Healing, and Hyperbaric Medicine
Transplant Infectious Diseases
VAD Infections
Roberta O’Connor, PhD
Assistant Professor
Debra D. Poutsiaka, MD, PhD
Associate Professor
David R. Stone, MD
Assistant Professor
Co-director Mycobacterial Treatment Unit – Tufts MC
Attending Physician, and Director of HIV Research at Lemuel
Shattuck Hospital
Cheleste Thorpe, MD
Associate Professor
Institutional Biosafety Committee Chair
Edouard Vannier, PhD
Assistant Professor
Gretchen Volpe, MD, MPH
Assistant Professor
Associate ID Fellowship Program Director,
Antimicrobial Stewardship
Christine Wanke, MD
Professor
Director of Clinical HIV Research Program
Associate Chair Dept. of Public Health
Director, Division of Nutrition and Infection
Professor School of Nutrition
Honorine D. Ward, MBBS
Professor
Program Director, HIV Pathogenesis Training Grant
Simone Wildes, MD
Assistant Clinical Professor
Attending Physician, South Shore Hospital
Alysse Wurcel, MD, MS
Instructor IN Medicine
HIV/HCV co-infection clinic
The Division provides comprehensive teaching for all levels of the medical school and for postgraduate education. Dr.
Susan Hadley is the director of the Infectious Disease pathophysiology course for the second year curriculum.
The fellowship program is comprehensive and includes training in transplant infectious diseases. From five to seven
fellows are recruited each year. The program is supported by four NIH training grants, more than had by any other
infectious disease training program in the United States. One grant is for microbial pathogenesis, one is for HIV
pathogenesis, one is for clinical research training in infectious diseases, and one is for HIV clinical research. The
training program is considered by the Infectious Disease Society of America to be a model for such programs.
The goal of the fellowship program is to train the next generation of academic infectious diseases specialists. The
clinical training comprises 12 months of inpatient consultation and a weekly clinic supervised by infectious disease
physicians. A rigorous didactic curriculum encompasses HIV medicine, nosocomial and community acquired
infections, transplantation-related infections and infections acquired during travel. The second program year is
devoted to research. Graduates of the program hold faculty positions at major academic medical centers, as well as
at the United States FDA, CDC, and in the pharmaceutical industry.
Although the minimum training period is two years, the majority of fellows pursue an additional year of research
training. The research program is funded by the NIH and provides a structured, supportive experience with formal
mentorship by division faculty. Trainees also have the opportunity to obtain an MPH or MS and PhD degree in clinical
research during fellowship, sponsored by the division. Outstanding research opportunities are available for fellows in
basic, clinical, and translational research as shown on the website, http://w w w.tuftsmedicalcenter.org/OurServices/
InfectiousDiseases/?Page=8
Current and past fellows have competed successfully for NIH-sponsored loan repayment and mentored career
development awards (K08, K23) that provide the foundation for a successful academic research career. There are a
number of international opportunities for research in which fellows can participate. In the past year fellows have
performed research in India, Africa, and Vietnam.
State of the art research conducted by divisional faculty in bacterial, HIV, other viral and parasitic diseases spans basic
science, clinical research, outcomes, and translational research both in the US and abroad. The annual research budget
for the division exceeds $4 million. The tables below provide an indication of the scope of these awards.
C linical Rese a rc h Awa rd s
Recipient
Funding Source
Purpose of grant
NIH
Chairperson, Clinical Endpoints Committee (CEC)
Industry
Endpoints Committees for several trials
José A. Caro, MD
Center for AIDS Research
(CFAR) 2014
Effect of oral Lactobacillus on Anal Dysplasia Biomarkers in HIV
Positive MSM
Shira Doron, MD, MS
Tufts Collaborates
Does weight loss surgery and probiotic supplementation lead to a lean
gut microbiota?
NIH (R21)
Role of Bile Acids in Human Susceptibility to Clostridium difficile
Infection
Forest Labs
Trends of Ceftaroline (CPT) Activity Among Consecutive Methicillinresistant Staphylococcus aureus (MRSA) Blood Isolates and
Correlation with Vancomycin (VAN) Activity
Forest Labs
Mortality and Hospital Length of Stay (HLOS) among Patients with
Community-Acquired Pneumonia (CAP): A Propensity Score-Matched
Analysis of Ceftaroline fosamil (CPT-F)-Treated vs. Ceftriaxone-treated
patients.
Merck & Co.
Validation of a simple clinical rule to predict recurrence of infection by
C. difficile. Step 2: Defining risk factors for multiple recurrences (>=3)
of C. difficile infection.
Cubist Pharmaceuticals
A risk of recurrence-stratified comparison of fidaxomicin vs. vancomycin
in adults with Clostridium difficile infection (CDI) and the costeffectiveness of fidaxomicin vs vancomycin or metronidazole in the
treatment of infection by Clostridium difficile
Susan Hadley, MD, FIDSA
CTSI
Antibiotic Spacer For Infected Joint Prostheses: A Pilot Study of
Antibiotic Doses & Kidney Function
Steven Y. Hong, MD, MPH,
MAR
NIH/NIAID (K23)
Namibia ART Patient Tracing Intensification and Predictors of Loss to
Follow-up
NIAID
Clinical research training grant in infectious disease
Industry Sources
US National Survey of susceptibility of Bacteroides fragilis, National
Survey of C. difficile antimicrobial susceptibility and epidemiology
R43 NIH/NIAID
Molecular Diagnosis of Bacterial Pathogens in VAP
Helen Boucher, MD
Yoav Golan, MD, MS, FIDSA
David R Snydman, MD,
FACP, FIDSA
57
Anne Kane, MD, manages the Phoenix Lab, a microbial products and services core facility for the Tufts community. The
core services are all based on the growth of micro-organisms and include large and small-scale bacterial culture,
protein expression and purification, preparation of complex bacterial media, and preparation of competent cells and
plasmid maxipreps by the cesium gradient technique. In response to the Human Microbiome Project, Drs. Kane and
Ward have founded the Microbiota Working Group to encourage microbiota projects in the Division. Dr. Kane has added
services to the core which are designed to facilitate research such as DNA extraction from clinical samples and the
subsequent generation and purification of PCR amplicons of 16S ribosomal DNA for deep sequencing.
C linical Rese a rc h Awa rd s (con t in u ed)
Recipient
David R Snydman, MD,
FACP, FIDSA (continued)
Christine Wanke, MD
Funding Source
Purpose of grant
Industry
Studies on CMV Viral Load
Industry
Probiotic Studies
Fogarty
HIV and Nutrition Training Program with University of Namibia
Fogarty
Training Program in Innovations in Global Health (with Dr. H Ward and
Christian Medical College)
R21
Joint Indo-US Collaborations, on HIV, ART, Intestinal Microbiota Food
and Nutrition Technical Assistance
USAID/WHO
Funding to prepare Nutrition and HIV Guidelines
R01 NIH/NHLBI
The Impact of Omega Three Fatty Acids on Vascular Function and cIMT
in HIV Infected Individuals
R01 NIH/NICHHD
Nutrition and HIV Progression
2 R01 NIH/NHLBI
Protease Inhibitor Related Dyslipidemia
NIH/NIAID
Brown-Tufts University Center for AIDS Research: Nutrition Core
NIH/Fogarty
Brown/Tufts/Miriam Fogarty AIDS International Training and
Research Program
Industry
Hepatitis C studies
Bas ic Res ea rch Su p p or t
In addition to clinical research, Division faculty carry out basic research in Lyme disease and babesiosis,
cryptosporidiosis, and Shiga toxin.
Funding Source
Purpose of grant
Victor Boyartchuk,
PhD
5R21 AI097855-02
Analysis of TGSL, A Novel Regulator of Macrophage Survival
5R01 DE024308-02
Physiological Interaction Between Probiotic Bacteria and Porphyromonas
gingivalis
R42AI078631 NIH
Delivery system development for a reservoir targeted vaccine
5R21 AI103905-02
Use of massively parallel sequencing for identification of B. burgdorferi
virulence factors
1R21 AI111317-01
Role of carbon availability in environmental adaptation by Borrelia
burgdorferi
5T32 AI007329-22
Infectious Disease Training – Pathogenesis/Host Response
5U01 AI109656-01
Searching for persistence in Lyme Disease
Roberta O’Connor,
PhD
NIH sponsored U01 subcontract
from Oregon Health and Science
University
Diverse Drug Lead Compounds from Bacterial Symbionts in
Tropical Marine Mollusks
Xin Li, PhD
7R01 AI103173-02
Critical Roles of Iron and Copper Detoxification in Borrelia Burgdorferi
Roberta O’Connor,
PhD
NIH Fogarty International Center
2U19TW00816306
Diverse Drug Lead Compounds from Bacterial Symbionts in Tropical Marine
Mollusks
Bill and Melinda Gates
Foundation OPP1108228
An Integrated Human Enteroid Model of Environmental Enteric Dysfunction
5R21 AI102813-02
O-Glycan Synthesis: Potential Targets for Intervention in Cryptosporidiosis
5D43TW009377-02
Tufts CMC Framework Program for Global Health Innovation
NIH/NIA
Babesiosis as a Model of Age-related Immunosenescence
The Gordon and Llura Gund
Family Foundation
Identification of Genetic Determinants of Susceptibility to Babesiosis
in Humans
The National Research Fund for
Tick-borne Diseases
Host Resistance to Babesia microti infection, an Emerging Infectious
Disease
Tufts Collaborates/Tufts
University
A novel genetic determinant of susceptibility to colonic inflammation
Linden Hu, MD, FIDSA
Honorine D. Ward,
MBBS
Recipient
Geneve Allison, MD, MS
»» National Panel on Outpatient Antimicrobial Therapy (OPAT) Guidelines, IDSA
»» Participant in national panel on OPAT Working Group: “The Value of ID-led OPAT”, IDSA
Helen Boucher, MD, FACP, FIDSA
»» Education and Steering Committees, Mycoses Study Group
»» Board of Directors, Infectious Diseases Society of America
»» Clinical Trials Transformation Initiative, Bethesda, MD
»» American Board of Internal Medicine Test Committee, Subspecialty Board of Infectious Disease
»» American Board of Internal Medicine, Subspecialty Board of Infectious Disease
»» Consulting Editor, Infectious Diseases Clinics of North America
»» Editorial Board Antimicrobial Agents and Chemotherapy
59
»» ICAAC Program Committee
»» Board of Trustees, College of the Holy Cross
»» Committees:
−− Member, Credentials Committee, Tufts Medical Center
−− Member, Graduate Medical Education Committee and GME Quality Subcommittee, Tufts Medical Center
−− Member, Admissions Committee, Tufts University School of Medicine
−− Board of Trustees Tufts Medical Center Physicians Organization
»» A New Pathway for Antibiotic Innovation: Exploring Drug Development for Limited Populations, Pew Charitable Trust, Washington, DC
»» Mock Drug Development Exercise (CME), 41st Annual Postgraduate Course in Clinical Pharmacology, Drug Development and
Regulation, Boston, MA
»» ICAAC Fellows Program Faculty. 54th ICAAC, Washington, DC
»» ID Quiz Team Leader, 54th ICAAC, Washington, DC
»» New Antibiotics, ID week, Philadelphia, Pa
»» Modernizing Antibacterial Drug Development and Promoting Stewardship. Brookings Council on Antibacterial Drug Development.
Washington, DC
»» Pros and Cons of Streamlined Development Programs for Antibacterial Drugs: Balancing Uncertainty and Risk with Patient Needs
and the Practical Realities of Antibacterial Drug Development. NIH/FDA Workship: The Development of New Antibacterial Products:
Charting a Course for the Future. Workshop, July 30-31, 2014
»» Visiting Professor, Providence Medical Center, Portland, Oregon
Jennifer K. Chow, MD, MS
»» Scientific Affairs Committee, Tufts University School of Medicine
Shira Doron, MD, MS
»» Planning Committee and Speaker, Improving Evaluation & Treatment of UTI in the Elderly: a Cross-Continuum Approach to Antibiotic
Stewardship. December 2012-July 2014. Massachusetts.
Yoav Golan, MD, MS, FIDSA
»» Elected to Fellowship, IDSA
»» Influenza and Pneumococcal Vaccine Committee, Chairman
»» The Australian Society of Antimicrobials Conference, Melbourne, Australia, February 22, 2014. Clostridium difficileThe Latest Hospital
»» Scourge: Risk-Based Management Strategies with fidaxomicin
»» GTC: ID World Summit 2014, 11th Anti-infective Partnering and Deal Making, Boston, MA July 9, 2014. Keynote Lecture:
Antibacterials- The Gap
»» PriMed East, Boston, MA, The Annual Primary Care Meeting, Pneumococcal vaccination, September 12, 2014
Susan Hadley, MD, FIDSA
»» Awarded CTSI pilot grant to investigate AKI related to antibiotic impregnated spacers for treatment of prosthetic joint infections
Natalie O.
»» Zucker Award for Outstanding Accomplishment in Medical Education, Tufts University School of Medicine, 2014
»» Best Doctors 2014
»» Castle Connolly Top Doctor 2014
»» IDSA Program Committee 2014
Steven Y. Hong, MD, MPH, MAR
»» Member, Tufts Global Health Faculty Council
»» Center for AIDS Research: HIV Prevention Core Faculty, Lifespan/Tufts/Brown Center for AIDS Research
»» Center for AIDS Research Namibia Country Director
»» Member, Republic of Namibia HIV Drug Resistance Technical Working Group
»» World Health Organization (WHO) Consultant for HIV drug resistance in sub-Saharan Africa
»» National Institutes of Health Clinical Research Loan Repayment
»» Protocol Reviewer for Republic of Namibia Ministry of Health and Social Services Ethics and Research Committee (E&RC),
Linden T. Hu, MD, FIDSA
»» Member, NIH study section (HIBP)
»» Co-Director, CTRC
Laura Kogelman, MD
»» 2014 Infectious Disease Attending of the year
Rakhi Kohli, MD, MS
»» Women in Medicine Committee
»» NIH Loan Repayment Award
Debra D. Poutsiaka, MD, PhD, FIDSA
»» Best Doctors Selection
»» Member, Research Committee, Infectious Disease Society of America
»» Mentor, Learning Communities, Tufts University School of Medicine
David R. Snydman, MD, FACP, FIDSA
»» Boston Magazine Best Doctors Selection 2014
»» Best Doctor’s in Amer ica Selection 2014
»» Castle Connolly Best Doctors Selection 2014
»» Editorial Board, Clinical Infectious Disease (Immunocompromised host section)
»» Editorial Board, Transplantation
»» Data Safety Monitoring Board for Chimerix (Brindcidofovir in stem cell transplant recipients)
»» Data Safety Monitoring Board for Millenium Pharmaceuticals (vedolizumab)
»» Data Safety Monitoring Board Genentech (CMV agent in renal transplantation)
»» Consultant to Merck for Letermovir Development
»» 54th ICAAC Symposium Anaerobes Not Your Orphan Organisms Any Longer: Antibiotic Resistance Among Bacteroides spp. and
Evolving Multidrug Resistance, Washington, DC
»» European Congress of Clinical Microbiology and Infectious Diseases Meeting Abstract Reviewer
»» American Transplant Congress Meeting Abstract Reviewer
David Stone, MD
»» Admissions Committee, Tufts University School of Medicine
Christine Wanke, MD
»» Consortium of Universities for Global health, member, annual meeting planning committee
»» Member, Vellore Christian Medical College, Foundation Board
»» Invited Reviewer for King Foundation
61
Honorine D. Ward, MBBS
»» Reviewer, NIH AIDS Opportunistic Infections and Cancer Study Section
»» Chair, Vellore Christian Medical College Foundation Board
»» Invited lecture: Drug Targets for Cryptosporidium. 16th International Conference on Emerging InfectiDiseases in ous the Pacific Rim.
Dhaka, Bangladesh, February 2014
»» Invited lecture: Cryptosporidiosis: From Bench to Bedside and Beyond
»» MassBiologics, Boston, MA April 2014
»» NIH loan repayment award
»» Invited Lecture to the Boston Area Parasitology Symposium on “Immune basis for resolution of severe babesiosis”, November 2014.
»» Reviewer for Emerging Infectious Diseases, Emerging Microbes & Infections, and PLoS One.
DIVISION OF
HEMATOLOGY/ONCOLOGY
The William Dameshek Division of Hematology/Oncology
was established in the 1940s by Dr. William G. Dameshek,
Schwartz assumed the directorship of the Division of Hematology and oversaw its merger in
1978 with the Division of Oncology. Dr. Schwartz conducted seminal studies demonstrating the
feasibility of pharmacological immunosuppression, which ushered in the era of organ and
marrow transplantation. In 1990, he became Deputy Editor of the New England Journal of
Medicine. His successor, Dr. Bruce Furie, made major contributions to the fields of hemostasis
and cell adhesion, and discovered P–selectin, an important platelet and vascular adhesion
Andrew Evens, DO, MSc
molecule. From 1998 to 2006, Dr. John Erban, an internationally recognized clinical breast
cancer researcher, served as Division Chief, and was followed in 2006 by Dr. Richard Van Etten, who served in this role
through 2013 and also was a founding Director of the Tufts Cancer Center He was succeeded in 2013 by Dr. Andrew
Evens, an internationally recognized clinical and translational researcher in lymphoproliferative malignancies. Dr. Evens
was appointed Director of the Tufts Cancer Center in 2014.
The Division has trained multiple hematology and oncology leaders. These individuals now head major cancer centers
and divisions of hematology and oncology throughout the world. They hold leadership positions in professional societies
including the American Society of Hematology, the American Society of Clinical Oncology, and the American Association
of Blood Banks. Division faculty oversee the treatment of patients with a wide array of cancers in both ambulatory and
inpatient settings and play a leading role in post-graduate education as well as clinical and translational research for the
Tufts Cancer Center.
Highlights of 2014
» » Dr. Andrew Evens became Director of the Tufts Cancer Center
» » Two new faculty members joined the Division: Dr. Suriya Jeyapalan and Dr. Lori Pai; Dr. Jeyapalan is the new
Director of the Tufts Neuro-Oncology Program and Dr. Lori Pai is a junior faculty Medical Oncologist with specialty
in thoracic cancers and melanoma
» » Six Division faculty were named to the “Best Doctors in Boston” list published annually by Boston Magazine
» » A new cancer Electronic Medical Record (MOSAIQ®) uniting Hematology/Oncology, Pediatric Oncology, Radiation
Oncology, and Gynecologic Oncology is integrated for patient care
» » A Community Oncology Disparities Initiative continued with philanthropic support from the Yawkey Foundation,
the Asian Healthcare Foundation of Massachusetts, and the Avon Foundation to support the creation of a Patient
Navigation Program helping Tufts Cancer Center’s Asian population navigate their healthcare
» » The Program for Adolescents and Young Adults with cancer and hematologic diseases enjoyed significant growth,
with philanthropic support from the Reid R. Sacco AYA Cancer Alliance
» » The clinical program on Cancer Fatigue and Holistic patient care was enhanced with philanthropic support from
the Donaldson Family Trust
» » A formalized Sickle Cell Program including outpatient day clinic was launched under the leadership of Dr. Hedy Smith
» » The Division activated over 75 therapeutic clinical trials in cancer and hematology with cumulative budgets
exceeding $5 million
» » The Tufts Cancer Center was a partner and key participant with the Division of Pediatric Hematology/Oncology
Floating Hospital for Children in 2014 for the annual Cycle for Life event for Tufts Medical Center
» » Several philanthropic gifts were received in 2014 to support research programs as detailed below
63
»» DIVISION OF HEMATOLOGY/ONCOLOGY
a world-renowned hematologist and founder of the American Society of Hematology (ASH).
Recent Canc e r C e nte r G i ft H i g h ligh ts
Aid for Cancer Research
Aid for Cancer Research awarded to John Erban MD and Naomi Rosenberg PhD representing (Tufts Medical Center and
Tufts Medical School) a $145,000 Grant to fund a Fluorescence Resonance Energy Transfer (FRET) Microscopy unit in
support of Research Scientists at MORI. The unit was dedicated in early 2014
John C. Davis Multiple Myeloma Program
A seed pledge gift of $500,000 was generously given by John C. Davis to establish a Multiple Myeloma Program. Led by
Dr. Ray Comenzo, the program will focus on highly personalized and focused care in a multidisciplinary setting and
will be launched the Spring of 2015.
Julie Person
Julie Person from Austin, TX gave a gift of $250,000 in support of Dr. Mathew’s Prostate Research Fund and in memory of
her husband Will. Julie’s husband was treated by Dr. Mathew when he was at MD Anderson and followed him for his care
when he joined Tufts Medical Center.
Reid R. Sacco Cancer Alliance
The Reid R. Sacco Cancer Alliance made a $500,000 pledge to establish the Reid R. Sacco AYA (adolescents and young
adults) Cancer Clinic. The Clinic, under the leadership of Dr. Susan Parsons, opened in 2013 and sees patients ages 18-39
for survivorship care. This gift was generously given by Gene and Lorraine Sacco and their son Weston, in memory of
their son and brother, Reid Sacco, who lost his battle with Cancer.
Amyloidosis and Myeloma Research Program
The Demarest Lloyd Jr. Foundation pledged a generous gift of $483,000 over three years in support of Dr. Comenzo’s
research program.
Yawkey Foundation
The Yawkey Foundation made a two-year pledge of $100,000 pledge gift to support a Patient Navigation Program helping
Tufts Cancer Center’s Asian population navigate their healthcare. Over 4 years, the Yawkey Foundation has donated
$200,000 in support of this program, which is led by Dr. Susan Parsons.
Avon Foundation
The Avon Foundation, under its Safety Net Program, made a $100,000 donation to the Patient Navigation Program,
allowing the program to expand its focus to patients of lower socio-economic status in addition to patients of Chinese or
Vietnamese origin.
Asian Healthcare Foundation of Massachusetts
The Asian Healthcare Foundation of Massachusetts provided the cancer center with a $50,000 donation to defray the full
cost of hiring a multilingual patient navigator.
Cycle for Life
The Tufts Cancer Center was a partner and participant with the Division of Pediatric Hematology/Oncology Floating Hospital
for Children for the annual Cycle for Life event for Tufts Medical Center; in 2014, approximately $250,000 was raised.
Faculty
Academic Rank
Title and Special Responsibilities
Andrew M. Evens, DO, MSc
Professor
Chief, Division of Hematology/Oncology
Director, Lymphoma Program
Director, Tufts Cancer Center
Kenneth B. Miller, MD
Professor
Associate Chief, Division of Hematology/Oncology
Eugene Berkman, MD
Professor, Emeritus
Rachel Buchsbaum, MD
Associate Professor
Director, Hematology/Oncology Fellowship Program;
Zaniboni Scholar in Breast Cancer Research
Diane Connolly, PhD
Assistant Professor
Associate Director, Hemostasis and Thrombosis Research
Laboratory
Raymond Comenzo, MD
Professor
Director, Blood Bank and Stem Cell Processing Laboratory
Lidija Covic, PhD
Assistant Professor
Associate Director, Hemostasis and Thrombosis Research
Laboratory
John K. Erban, MD
Professor
Associate Director for Clinical Science and Clinical Director,
Tufts Cancer Center
Suriya Jeyapalan, MD*
Assistant Professor
Director, Medical Neuro-Oncology
Grace Shih-Hui Kao, MD
Associate Professor
Director of The Neely Cell Therapy Collection Center and
Stem Cell Processing Laboratory
Andreas Klein, MD
Associate Professor
Chairman, Institutional Review Board, Tufts Health
Sciences Campus
Director, Hematologic Malignancies
Associate Director, Fellowship Program
Acting Chairman and Principal Investigator,
Cancer Center Tissue Repository Oversight Committee
Athan Kuliopulos, MD, PhD
Professor
Director, Hemostasis and Thrombosis
Research Laboratory
Stuart Levy, MD
Professor
Director, Center for Adaptation Genetics and Drug
Resistance, Tufts University School of Medicine
Robert Martell, MD, PhD
Adjunct Associate Professor of
Medicine
Leader, Hepatobiliary Tumor Boards
Paul Mathew, MD
Associate Professor
Prostate Cancer and Genitourinary Malignancies
Lori Pai, MD *
Assistant Professor
Attending Physician
Susan Parsons, MD, MRP
Professor
Associate Director for Population Science and Community
Involvement, Tufts Cancer Center
Director, Reid R. Sacco AYA Cancer Program
Director, Patient Navigation Program
Director, Center for Health Solutions, Institute for Clinical
Research and Health Policy Studies
Wasif Saif, MD
Professor
Program Director, GI Oncology
Program Leader, Experimental Therapeutics
Zack Spigelman, MD
Lecturer in Medicine
Head and Neck Cancer and Rare Enzyme Disorders
David Schenkein, MD
Clinical Professor
Senior Consultant in Hematology
Chief Executive Officer, Agios Pharmaceuticals
Robert Schwartz, MD
Professor (Associate Staff)
Emeritus Chief, Division of Hematology/Oncology
Hedy Smith, MD, PhD
Assistant Professor
Director, Benign Hematologic Disorders Program
65
Name
Name
Academic Rank
Kellie Sprague, MD
Assistant Professor
Clinical Director, Leukemia Program
Director, Bone Marrow and Hematopoietic
Cell Transplant Program
Gary Strauss, MD, MPH
Professor
Associate Director, Hematology/Oncology Fellowship
Program
Medical Director of Lung Cancer Program
Philip Tsichlis, MD
Jane F. Desforges Professor
Executive Director, Molecular Oncology Research Institute
Lynne Taylor, MD
Adjunct Associate Professor
Neuro-Oncology and Palliative Care
*New faculty in 2014
The faculty of the Hematology/Oncology Division supervises over 25,000 outpatient visits and treatments annually and
oversees three complex inpatient services: the Bone Marrow Transplant/Hematologic Malignancies service, the
Inpatient Oncology Service, and the Hematology/Oncology Consultation service. Clinical laboratory services under the
direction of Division members include a blood bank with stem cell processing capability and a Special Hematology
Laboratory that processes blood and bone marrow specimens for clinical and research purposes. The Neely Center Cell
Processing and Collection Center provides state of the art services in cell collection, processing, and therapy, apheresis,
and transfusion support for the entire Medical Center. The 20-bed infusion center provides state-of-the-art infusion
support for chemotherapy, parenteral solutions, and antibiotics, in addition to education and psychosocial services. In
addition, the Center for Extracorporeal Photopheresis provides novel therapy with a nationally recognized clinical
research program in allogeneic stem cell transplantation and cell processing.
A Holistic and Integrative Therapy program was established in the Tufts Cancer Center primarily with funding from the
Donaldson Charitable Trust Foundation. The Integrative Therapy program is led in part by Mary Beth Singer MS, ANP-BC,
AOCN, ACHPN; it aims to decrease symptom distress, promote healing, and improve the overall experience of cancer
treatment for our patients. Acupuncture and massage are provided free of charge to cancer patients each week through
by certified clinicians from Pathways to Wellness. Additionally, an annual lectureship and patient-focused workshop on
fatigue, related symptoms, and supportive therapies has been established and a program of research led by Nadine
Linendoll, PhD, RN, was initiated focused on cancer related fatigue and the impact of integrative therapy on cancer.
The Reid R. Sacco Adolescent and Young Adult (AYA) Program for Cancer and Blood Diseases at Tufts Medical Center was
established and launched in 2013. The AYA clinic, led by Dr. Susan Parsons, provides age-appropriate, comprehensive
care in a designated physical space where our team can focus on both the clinical and transitional needs of cancer
survivors ages 18-39 years. This program was started through generous support from the Reid R. Sacco AYA Alliance.
This program represents one of the few such specialty programs in New England dedicated to the care of patients within
this age group.
Multidisciplinary Cancer Care is the paradigm for cancer treatment offered by the Division. Division physicians
participate in several multidisciplinary clinics with concurrent and coordinated care by multiple cancer specialists
provide multispecialty care and access to psychosocial and genetic counseling. Included in this was the launch of a
formalized Sickle Cell Program including outpatient day clinic in 2014 directed under the leadership of Dr. Hedy Smith;
this program includes coordination with Tufts Medical Center Emergency Room and other key contributing services.
Below are additional multidisciplinary programs at Tufts.
Multidisciplinary programs and clinics for cancer treatment (in 2014) include:
»» Adolescent Young Adult Program for Cancer and Blood Diseases – Susan Parsons, MD, Director
»» Benign Hematological Disorders Clinic – Hedy Smith, MD, PhD, Clinical Director
»» Bone Marrow and Stem Cell Transplant Program – Kellie Sprague, MD Director
»» Brain Tumor and Neuro-Oncology Program – Suriya Jeyapalan, MD, Director
»» Breast Cancer and The Breast Health Center – Roger Graham, Director and John Erban, MD, Medical Oncology Director
»» Genitourinary Malignancies Tumor Board – Paul Mathew, MD, Director
»» Head and Neck Tumor Clinic – Zachary Spigelman, MD
»» Hepatobiliary Tumor Clinic – Robert Martell, MD, PhD, Clinical Director
»» Lung Cancer Multidisciplinary Clinic – Gary Strauss, MD, MPH, Clinical Director
»» Lymphoma Program – Andrew Evens, DO, MS, Director
»» The Neely Cell Therapy Center and Extracorporeal Photopheresis Program – Raymond Comenzo, MD, Director
»» The Neely Center for Clinical Cancer Research – John Erban, MD, Medical Director
»» GI Tumor Board – Wasif Saif, MD
Te a c hi ng Act iv it ies
Faculty from the Hematology/Oncology Division participates extensively in the teaching of medical students, house officers, and
fellows at Tufts Medical Center. Teaching of Tufts University School of Medicine (TUSM) students includes both preclinical lectures
and clinical clerkship teaching. Dr. Rachel Buchsbaum is course director for the TUSM course entitled “Introduction to
Hematology and Oncology, and serves as the Vice-Chair of the TUSM Curriculum Committee. Dr. Sprague serves as Preceptor for
the Ambulatory Medicine Elective for TUSM 3rd year students in the Breast Health Clinic and is the Director of the HematologyOncology Clerkship for TUSM 4th year students. Dr. Susan Parsons is co-course director of the Public Health Integration course for
1st, 2nd, and 3rd year students in the combined MD/MPH program at TUSM. She also is course director of the Research Ethics course
in the Clinical and Translational Science Graduate Program at the Sackler School of Graduate Biomedical Sciences at Tufts
University (Sackler). Several faculty are mentors and thesis advisors for PhD graduate students enrolled in Sackler programs.
Currently, there are 5 PhD students doing thesis research in laboratories/research programs of Division faculty.
The Division is also the home of the Hematology/Oncology Fellowship Training Program at Tufts Medical Center that is the
centerpiece of Division teaching activities. As the Institute of Medicine and the American Society of Clinical Oncology have
predicted a major physician shortage in hematology/oncology in the next decade, the Fellowship Program serves a critical
educational need. Five clinical fellows per year are selected from over 300 applicants. The first year is devoted to clinical training
in hematology and oncology, with an intense focus on ambulatory care. Members of the Division join physicians from other
specialties and ancillary services to offer fellowship training and complex therapy in a multidisciplinary environment. In the
second and third years of the Program, fellows are exposed to the inpatient consultation service and the bone marrow
transplant/hematologic malignancies service, both of which provide essential clinical experiences and rigorous training in
managing complex diseases while maintaining a continuity outpatient clinic one half-day per week. During their clinical year,
fellows are exposed to the breadth of basic and translational cancer research at Tufts Medical Center through the MORI Lecture
series, Cancer Center Grand Rounds, and direct contact with clinician-scientist faculty. These experiences allow fellows to begin
to consider and plan research projects for their second year.
The research portion of the Clinical Fellowship begins in the second year. Typically, about half of the fellows in each class express
an interest in basic and translational research, while the other half pursue clinical research projects. Under the supervision of an
advisory committee, fellows make periodic presentations of their research progress to Division faculty. In the third year, the writing
of at least one research paper that summarizes the trainee’s data and findings is a major priority. In 2014, 6 fellows in the Division
presented their research work at national meetings and international meetings (Drs. Chaulagain, Kaul, Khagi, Kritharis, Pai, Shah),
3 fellows earned travel awards (Drs. Chaulagain, Kaul and Shah), and 2 fellows earned merit or achievement awards (Dr. Shah,
Conquer Cancer Foundation Merit Award: Dr. Kritharis, American Society of Hematology Abstract Achievement Award).
A training grant from the National Cancer Institute (T32 CA09429), entitled “Research Training in Oncology”, supports the training
of Hematology/Oncology fellows who pursue a basic or translational cancer research track. This grant is in its 31st continuous year.
67
»» Hematologic Malignancies Program (Tufts Cancer Center) – Andreas Klein, MD
Over 135 Hematology/Oncology Fellows have been trained in the Division, with approximately 40% of these trainees directly
supported during their research years by the Training Grant. Of Program graduates, 20 are now Division Chiefs, head major
programs at NCI–designated Cancer Centers or at the National Cancer Institute, or hold leadership positions at major
pharmaceutical companies. Of 24 program graduates in the last 5 years, 16 are on the faculty of academic medical centers and one is
a program leader in a major pharmaceutical company. Directed by Rachel Buchsbaum, MD, the Tufts Hematology/Oncology
Fellowship program received a full 5-year accreditation with commendation by the Accreditation Council for Graduate Medical
Education at its last site review in May 2010 and continuing subsequent accreditation under the ACGME Next Accreditation System.
Res earch Ac t i v i t i es
Faculty members and fellows of the Division of Hematology/Oncology as well as investigators at MORI continue vibrant
research endeavors in cancer. Research spans the spectrum from basic, translational, and patient-oriented research to
numerous therapeutic and interventional clinical trials in cancer and blood diseases. Below is a summary of these
research efforts in 2014.
C linical Res e a rc h
Clinical research in hematology and oncology takes the form of cooperative group trials, industry-sponsored trials, and
investigator-initiated trials. Tufts Medical Center is a member of the Eastern Cooperative Oncology Group (ECOG), a
prominent national clinical oncology research consortium. A number of the Division faculty serve in key leadership positions
on ECOG committees and are principal investigators for ECOG National clinical trials (e.g., Dr. Evens leading NCT01216683: A
3-Arm Randomized Phase II Trial of Rituximab/Bendamustine (BR) Followed by Rituximab vs Bortezomib (Velcade®)-BR
(BVR) Followed by Rituximab vs. BR Followed by Lenalidomide (Revlimid®)/Rituximab in High Risk Follicular Lymphoma).
Dr. Parsons is a member of the study committee for Children’s Oncology Group trial AHOD1331, a randomized controlled trial
of Brentuximab vedotin in the treatment of children and adolescents with high risk Hodgkin Lymphoma. She leads two
embedded studies within the trial on chemotherapy-induced peripheral neuropathy and cost effectiveness analysis.
Collectively, the Division has > 75 active therapeutic clinical trials in cancer and hematology and > 20 new cancer clinical
studies are awaiting activation. Many of these clinical studies are “investigator-initiated” and are examining novel and
targeted anti-cancer treatments (see table below). The cumulative budgets for these clinical studies total over $5 million with
the annual clinical trial funding in 2014 based on patient accrual was over $600,000. This clinical research activity supports
basic and translational research within the Division. All patients in the clinic and inpatient areas are asked to consent to
donation of specimens (blood, bone marrow, biopsy material) for research purposes as part of an IRB–approved protocol, and
these specimens are de–identified and banked. The Tissue Repository, a Core Facility of the Tufts Cancer Center, is a valuable
resource for meeting the translational research interests of qualified Tufts Medical Center investigators. The following is a
highlight of selected clinical cancer trials, with an emphasis on Investigator-Initiated Trials (IITs) that are being conducted
within the Division.
C linical Rese a rch /C l i ni ca l Tr i a l s ( pa rt ia l list in g)
Investigator
Sponsor/Trial number
Title
Rachel Buchsbaum,
MD
Tufts CTSI
Development of a minimally invasive biomarker for breast cancer
development and metastasis.
Millennium Pharmaceuticals
A Phase III randomized controlled open-label multicenter Safety and Efficacy Study
of Dexamethasone Plus MLN9708 or Physician’s choice of treatment administered
to patients with relapsed or refractory systemic light chain (AL) amyloidosis
Array
A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients
With Advanced Multiple Myeloma
Prothena Biosciences
A Phase I, Open Label, Dose Escalation Study of Intravenous Administration of
Single Agent NEOD001 in Subjects with Light Chain (AL) Amyloidosis
Columbia University
Phase II Study of the Combination of Bendamustine and Dexamethasone in
Patients with Relapsed AL Amyloidosis
Janssen
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody)
in Combination With Backbone Treatments for the Treatment of Patients with
Multiple Myeloma
Raymond Comenzo,
MD
Title
Raymond Comenzo,
MD
ECOG-acrin
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in
Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
NRG Oncology
NSABP B-49: A Phase III Clinical Trial Comparing the Combination of
Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy
Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2Negative Breast Cancer
Janssen
JNJ-212082 Randomized, Open-Label Study of Abiraterone Acetate (JNJ212082) Plus Prednisone With or Without Exemestane in Postmenopausal
Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or
Anastrozole Therapy
Novartis
A randomized double-blind, placebo-controlled study of LEE011 in
combination with letrozole for the treatment of postmenopausal women with
hormone receptor positive, HER2-negative, advanced breast cancer who
received no prior therapy for advanced disease
Macrogenics
A Single Arm, Open-Label, Phase 2 Study of MGAH22 (Fc-optimized Chimeric
Anti-HER2 Monoclonal Antibody) in Patients with Relapsed or Refractory
Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by
Immunohistochemistry and Lack Evidence of HER2 Gene Amplification by FISH
Tesaro
TESARO PR-30-5010-C (BRAVO): A phase III, randomized, open label,
multicenter, controlled trial of niraparib versus physician's choice in
previously-treated, HER2 negative, germline BRCA mutation-positive breast
cancer patients
NRG Oncology
NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing
Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four
Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel)
to Chemotherapy Plus Trastuzumab in Women with Node-Positive or HighRisk Node-Negative HER2-Low Invasive Breast Cancer
Synta Pharmaceuticals
An Open Label Multicenter Phase 2 Window of Opportunity Study Evaluating
Ganetespib (STA-9090) Monotherapy in Women with Previously Untreated
Metastatic HER2 Positive or Triple Negative Breast Cancer
CPPB
Asian Americans with advanced cancer: preferences and care experiences
The proposed research is to address the major gaps in our understanding of
how to better meet the healthcare needs of Asian Americans with advanced
cancer, a historically understudied population.
ECOG-ACRIN
Intergroup Randomized Phase 2 Four Arm Study In Patients With Previously
Untreated Mantle Cell Lymphoma
Northwestern University
A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy
for Patients With CD30+ and/or EBV+ Lymphomas
ECOG-ACRIN
A 3 Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed
by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed
by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
Millennium Pharmaceuticals
An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients
With Relapsed and/or Refractory Follicular Lymphoma
Northwestern University
A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine,
and Dacarbazine (S-AVD) for Older Patients with Untreated Hodgkin
Lymphoma
University of Chicago
A Single-Arm Phase II Clinical Trial with the Novel MEK Inhibitor AZD-6244 for
the Treatment of MCT-1 Related Relapsed or Refractory Diffuse Large B-cell
Lymphoma
John Erban, MD
Andrew Evens, DO
69
Investigator
C linical Rese a rc h /C l i ni ca l Tr i a l s ( pa rt ia l list in g) c o n t in u ed
Investigator
Andreas Klein, MD
Robert Martell, MD,
PhD
Paul Mathew, MD
Title
Tufts Medical Center
A Phase II Study of Umbilical Cord Blood Transplantation Following
Myeloablative or Reduced-Intensity Conditioning (PI Initiated)
Alliance for Clinical Trials in
Oncology
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus
Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients
(>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Millennium
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline
Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Glaxo SmithKline
A phase III, randomised, observer-blind, placebo-controlled, multicentre,
clinical trial to assess the prophylactic efficacy, safety, and immunogenicity
of GSK Biologicals™ herpes zoster gE/AS01B candidate vaccine when
administered intramuscularly on a two-dose schedule to adult autologous
haematopoietic stem cell transplant (HCT) recipients
ECOG-ACRIN
E1912: A Randomized Phase III Study of Ibrutinib(PCI-32765)-based
Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab
(FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic
Lymphocytic Leukemia (CLL).
A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy
(Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients with Incomplete
Response to Chemotherapy Prior to Autologous Stem Cell Transplant for
Multiple Myeloma (PI Initiated)
Gilead
GS-US-339: A Phase 2, Open-Label Study Evaluating the Efficacy, Safety,
Tolerability, and Pharmacodynamics of GS 9973 in Subjects with Relapsed or
Refractory Hematologic Malignancies
Plerixafor: Pilot Study of Lymphoid Tumor Microenvironmental Disruption
Prior to Autologous Stem Cell Transplantation (PI Initiated)
ECOG-ACRIN
E1A11: Randomized Phase III Trial of Bortezomib, LENalidomide and
Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone
(CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in
Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Tufts CTSI
Randomized clinical trial evaluating the impact of pretreatment
with metformin on colorectal cancer stem cells (CCSC) and related
pharmacodynamic markers
Tufts CTSI
Prospective evaluation of clinical safety of combining metformin with
anticancer chemotherapy
Progenics Pharmaceuticals
PSMA ADC 2301: A Phase 2, open-label, multicenter study of PSMA ADC in
subjects with metastatic castration-resistant prostate cancer (mCRPC)
Sanofi-Aventis
TAXYNERGY: Phase II Trial to Evaluate Benefit of Early Switch from first-Line
Docetaxel/Prednisone to Cabazitaxel/Prednisone and the opposite sequence,
exploring molecular markers and mechanisms of taxane resistance in men
with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have not
received prior chemotherapy
Alliance
A031201: Phase III Trial of Enzalutamide (NSC # 766085) versus
Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic
Prostate Cancer
CALGB
CALGB 90203: Randomized Phase III Study of Neo-Adjuvant Docetaxel and
Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate
Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate
Cancer
Hoosier Oncology Group
HOG GU09-145: Phase I/II Study of BNC105P in Combination with Everolimus
or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell
Carcinoma Following Prior Tyrosine Kinase Inhibitors
Investigator
Susan Parsons, MD
Title
Leukemia & Lymphoma Society
The proof of paradigm in CEA of Novel Therapeutics in treatment of
hematologic malignancies.
Avon Foundation
Patient Navigation of Newly Diagnosed Patients with Breast Cancer:
Surmounting the Cultural and Socio-economic Divide
FDA
Familial T-Cell Depleted Stem Cell Transplant in High-Risk Sickle Cell Anemia
Asian Healthcare Foundation
Asian Patient Navigation in Cancer Care
Imclone
Multicenter, Randomized, Double-blind, Phase 3 Study of Ramucirumab (IMC1121(B)) Drug Product and Best Supportive Care (BSC) versus Placebo and
BSC as Second-time Treatment in Patients With Hepatocellular Carcimoma
Following First-line Therapy With Sorafenib
Imclone
Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects
With Advanced Solid Tumors Refractory to Standard Therapy or for Which No
Standard Therapy is Available
Gilead
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate
the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line
Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma that Has
Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing
Regimen
Genentech
STEAM (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/
Bevacizumab Regimens (Concurrent and Sequential) vs. Folfox/Bevacizumab
in First-Line Metastatic Colorectal Cancer
Merrimack
Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with or
without Trastuzumab in Patients with ‘Traditional’ and ‘Non-Traditional’ HER2
Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE)
Junction and Stomach Who Have Failed Front Line Metastatic or Locally
Advanced Therapy
Halozyme
HALO: A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated
Recombinant Human Hyaluronidase) Combined with nab-Paclitaxel Plus
Gemcitabine Compared With nab-Paclitaxel Plus Gemcitabine in Subjects With
Stage IV Previously Untreated Pancreatic Cancer
Eli Lily
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients
with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
TAS102-106
TAS102-107
Pre-ECOG Gem-Abraxane in Cholangiocarcinoma
LAPAC Study: Gem-A braxane in LA PC
Agios Pharmaceuticals
Translational Study of the Efficacy of Novel Compounds in Erythrocytes
Affected by Pyruvate Kinase Deficiency or Chronic Hemolytic Processes
Selexys Pharmaceutical
SelG1-00005 trial: Antibody Targeting P-Selectin in Sickle Cell disease
Inspirations / Baxter
Pharmaceuticals
Phase II study of Recombinant Porcine factor VIII (OBI-1) for treatment of
Acquired Hemophilia A
Wasif Saif, MD
Hedy Smith, MD, PhD
71
C linical Rese a rc h /C l i ni ca l Tr i a l s ( pa rt ia l list in g) c o n t in u ed
Investigator
Title
National Marrow Donor Program
Research Sample Repository for Allogeneic Unrelated Hematopoietic Stem
Cell Transplantation
National Marrow Donor Program
A Research Database for Hematopoietic Stem Cell Transplantation, Other
Cellular Therapies, and Marrow Toxic Injuries
ECOG-ACRIN
E2906: Phase III Trial of Clofarabine as Induction and Post-Remission Therapy
vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose
Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs.
Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age
>60 Years)
Amgen
Amgen 00103311: A Phase III, Randomized, Open Label Study Investigating
the Efficacy of the BiTE Antibody blinatumomab versus Chemotherapy in
Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic
Leukemia (ALL)
Pfizer
A Phase 1b Study to Evaluate the Safety and Preliminary Efficacy of PF04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive
Chemotherapy, Low Dose Ara-C, or Decitabine in Patients with Acute Myeloid
Leukemia or High-Risk Myelodysplastic Syndrome
Kellie Sprague, MD
Bas ic/ Transl a t i ona l Res e a rch
Division members collaborate with a variety of prominent and talented researchers and research institutes throughout
the Tufts campuses. The basic and translational cancer research activities at Tufts Medical Center are based in the
Molecular Oncology Research Institute (MORI). The Institute, now in its 13th year, serves as the focus for basic and
translational cancer research within Tufts Medical Center. MORI occupies more than 33,000 square of its 75 Kneeland
Street building. It has 18 faculty members, including five clinician-scientists, and employs about 65 FTEs. Its mission is
to explore the molecular mechanisms of neoplastic transformation and to promote the translation of basic research
findings into the clinic. To achieve this goal, MORI scientists carry out research that spans the spectrum from gene
discovery to target validation for drug development. MORI investigators have received over 180 grants and published
over 350 papers since the Institute began. Current Division faculty with research laboratories at MORI include: Drs.
Buchsbaum, Covic, Kuliopulos, Mathew, Tsichlis, and Evens.
In 2014, investigators at the Molecular Oncology Research Institute (MORI) gave more than 40 invited lectures, produced
more than 50 peer reviewed research publications, and faculty received 7 new research awards (totaling $1.23 million).
Furthermore, in 2014, MORI faculty research was supported by >10 peer-reviewed grants from the NIH, DOD, and
various foundations and industry sponsors. Faculty research spans the spectrum from basic, translational, and patientoriented research to numerous therapeutic and interventional clinical trials in cancer and blood diseases.
The Cummings School of Veterinary Medicine at Tufts University (TCSVM) is the only veterinary school in the New
England region providing high-quality clinical care services and original research. The research includes shared models
to study cancer in animals that may have direct application to humans (i.e., Comparative Oncology). Researchers at
TCSVM are members and active participants of the National Cancer Institute Clinical Oncology Trials Consortium. They
have contributed to numerous clinical trials utilizing dogs, cats, and other small animals with various spontaneous
cancers to inform human cancer therapy. Likewise, they have succeeded in establishing and participating in a national
effort to collect and bank cancer tissue for post hoc research through the Canine Comparative Oncology Genetics
Consortium. Though these and other collaborations, the TCSVM have established their abilities to conduct critically
important comparative oncology research studies.
Additionally, the Division is pleased to have arranged a scientific collaborative relationship with Northeastern
University (NU) as a research partner for the Division of Hematology/Oncology and the Tufts Cancer Center. Tufts has
had a close research relationship with NU over the past 10 years in particular with the Tufts CTSI. Collaborations with
the NU School of Science are focused in the Departments of Pharmaceutical Sciences and of Chemistry and Chemical
Biology. Graham Jones, PhD, DSc (Chair of Department of Chemistry at NU) was named Associate Director of the Tufts
CTSI in 2013 charged as leader of T1 research for the CTSI. Dr. Jones is also a member of the Tufts Cancer Center
Research Executive Committee. In addition Dr. Jones and 6 other NU faculty now serve as mentors or co-mentors for the
Tufts Hematology/Oncology T32 program (i.e., Dr’s Amiji, Chen, Karger, Murthy, Sitkovsky, and Torchilin). The
programs led by these faculty members are focused on the discovery, design, and use of drugs—finding new targets for
drug development, researching how drugs work at a molecular level and the harmful effects of drugs, and determining
how drugs’ properties, dosages, and delivery systems affect their performance. In addition, the integration of NU adds
significant and unique research resources to the Hematology/Oncology T32 such as state-of-the-art proteomics as well
as a Center of Cancer Nanotechnology Excellence.
Laborator y/ Tra ns l a t i on a l Res e a rc h G ra n ts ( pa rt ia l list )
Investigator
Rachel Buchsbaum,
MD
Raymond Comenzo,
MD
Funding Source
Grant title
Tufts Clinical and Translational
Science Institute
Identifying factors regulating the Tiam-1 osteopontin pathway in the breast
cancer microenvironment.
Department of Defense CDMRP
– Breast Cancer
Development of Technologies for Early Detection and Stratification
of Breast Cancer
Diane Connolly-Zaniboni
Resarch Scholarship in
Breast Cancer
The role of Tiam-1 in the tumor microenvironment.
Russo Family Pilot Project, Tufts
University
In vivo investigation of stromal Tiam1 effects on breast cancer stem cells.
Lymphoma Foundation
Applications of Proteasome Inhibition in Clonal Plasma Cell Diseases.
NIH/NCI
EMR Adverse Drug Event Detection for Pharmacovigilance (subcontract): This
multicenter projects aims to refine/improve existing Bio-Natural Language
Processing (Bio-NLP) and
develop new innovative BioNLP algorithms order to identify serious adverse
events during cancer treatments
NIH/NCI
MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm: The goal
of the proposed research project is to investigate the biology and clinical
efficacy of targeting the MAP Kinase MEK/ERK pathway in lymphoma through
in vitro and in vivo mouse models as well as through an early-phase clinical
trial in relapsed/refractory non-Hodgkin’s lymphoma (DLBCL).
Andrew Evens, DO
73
The Jean Mayer USDA Human Nutrition Research Center on Aging (HNRCA) at Tufts University is a unique national
resource and asset devoted to diseases of an aging population, including cancer. The HNRCA is operated by Tufts
University through a cooperative agreement with the Agricultural Research Service (ARS), and is one of six human
nutrition research centers in the United States. It is supported by the United States Department of Agriculture (USDA).
The HNRCA is a recognized leader in nutritional research and occupies a 14-story building on the Health Sciences
campus. The interaction between nutrition and the onset and progression of cancer has been a special interest of several
scientists at the HNRCA. These investigators use cell and molecular biology techniques, genomics, and sophisticated
animal models. The focus on Cancer within the HNRCA was bolstered when cancer was selected in 2011 as an area of
future emphasis and investment for the Center, triggering the formation of a Cancer–Cluster within the HNRCA. This
Cluster, headed by Dr. Jimmy Crott, a faculty member of this Training Program, is the focus of increased cancer
collaborations and investments.
Laborator y/ Tra ns l a t i on a l Res e a rc h G ra n ts ( pa rt ia l list ) c o n t in u ed
Investigator
Andrew Evens, DO
(continued)
Andreas Klein, MD
Stuart Levy, MD
Robert Martell, MD,
PhD
Paul Mathew, MD
Philip Tsichlis, MD
Wasif Saif, MD
Funding Source
Grant title
NIH/NCI
Computerized quantitative imaging assessment of tumor burden: A
multidisciplinary team has been assembled comprising radiologists,
informaticians, and oncologists, including an industrial partnership with
General Electric (GE) Medical Systems to integrate and analyze a spectrum of
quantitative imaging biomarkers (e.g., quantitative PET).
NIH/NCI (T32)
Research Training in Oncology: This training grant supports basic and
translational cancer research by hematology/oncology fellows at Tufts Medical
Center in their second and third years of fellowship training.
University of Chicago and
NIH/NCI
A Single-Arm Phase II Clinical Trial with the Novel MEK Inhibitor AZD-6244
for the Treatment of MCT-1 Related Relapsed or Refractory Diffuse Large
B-cell Lymphoma
Northwestern Univ./
Seattle Genetics
A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin,
Vinblastine, and Dacarbazine (S-AVD) for Older Patients with
Untreated Hodgkin Lymphoma
Northwestern Univ. /
Seattle Genetics
A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy
for Patients With CD30+ and/or EBV+ Lymphomas
An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients
With Relapsed and/or Refractory Follicular Lymphoma
Genzyme
Lysomal Disorders Fellowship Programmatic Support
CTSI Catalyst Award
Characterization of a naïve T-cell (CD45RA)-depleted stem cell graft for
allogeneic stem cell transplant with reduced risk for graft-versus-host disease
Charlton Fund, TUSM
Construction and Evaluation of Novel Palmitoylated Peptides (Pepducins)
Targeting ZAP70 Signaling in Chronic Lymphocytic Leukemia
NIH/NHLBI
Stage 2 TRIP: PAR1 Pepducin-Based Interventions in Arterial Thrombosis
NIH/NIAID
5R01 AI056021
The Multiple Antibiotic Resistance (mar) regulon
USDA 2011-67019-30187
Microbial community activity: communication among soil microbes
CTSI High Impact Project
Metabolism and Cancer
Pfizer Center of Technology
Innovation Award
Development of angiogenin receptor antibodies as prostate cancer
therapeutic
Agency for Healthcare Research
and Quality (AHRQ) Task Order
#10
Role of active surveillance in the management of early stage, low-risk prostate
cancer
NIH/NCI
R01 CA124835
Tpl2 in intestinal tumorigenesis
NIH/NCI
5R01 CA057436
Akt in T cell development and function
CTSI NDY1/DKM2B
Development of an enxymatic assay and initial screening for inhibitors
CTSI
Effect of Metformin on Cancer.
H onors and Awa rd s (pa r t i a l l i st )
Dr. Buchsbaum
»» Tufts University School of Medicine, Outstanding Lecturer
»» Tufts University School of Medicine, Accomplished Teaching
»» Invited speaker, AACR Meeting, April 2014. Tiam1 and the Breast Cancer Microenvironment
Dr. Comenzo
»» Boston Magazine, Best Doctors 2014
»» 2014 Physician Humanitarian Award, ROFEH International
»» Founding Director and Co-Chairman, Amyloidosis Research Consortium (ARC)
»» Invited Speaker – Advances in Diagnosis and Treatment of Systemic AL Amyloidosis. Columbia University Medical Center.
New York, NY.
»» Invited Speaker - When are Alternatives to High Dose Chemotherapy Reasonable? Amyloidosis: Should Our Treatment Approaches
Be More Personalized? 2014 BMT Tandem Meetings, Dallas, TX.
»» Invited Speaker – Risk Management in Plasma Cell Neoplasms. ECOG-Acrin Annual Meeting. Chicago, IL.
»» Invited Speaker – Amyloidosis 2014: Use the Tools We Have and Save Lives. Heart Failure and Transplant Consortium Dinner
Meeting. Massachusetts Medical Society, Waltham Woods, MA.
»» Invited Speaker – Mastering Clinical Challenges in Relapsed Refractory Multiple Myeloma. Myeloma Workshop. North Arlington, VA.
»» Invited Speaker – Overcoming Challenges in the Treatment of Multiple Myeloma. Myeloma Workshop. Houston, TX.
»» Invited Speaker – Smoldering myeloma - Who and when to treat: Should smoldering high risk myeloma be immediately treated?
MetroWest Medical Center. Natick, MA.
Dr. Erban
»» Member, Tufts-China-Taiwan Delegation February 2014 (with Dean Harris Berman, Trustee Olivia Cheng, Philip Hinds,
John Erban, Rebecca Scott)
»» Associate Editor, American Journal of Clinical Oncology
»» Medical Editor Tufts MedicineBoston Magazine, Best Doctors –Oncology 2014
»» Tufts Medical School Teaching Recognition Award -3rd Year
»» Vitals Top 10 Doctors by State.-2014
»» Castle Connolly America’s Top Doctors for Cancer 2014
»» Patient’s Choice Award- 2014
Dr. Evens
»» Hodgkin Lymphoma Working Group- primary member: NIH/NCI Steering Committee Subgroup
»» Primary/voting member, Developmental Therapeutics committee, ECOG
»» Primary/voting member, Protocol Review Committee and Data Safety and Monitoring Committee, Tufts Cancer Center, Boston, MA
»» Clinical Trial Design & Development Working Group, Quantitative Imaging Network (QIN) with CTEP and NIH
»» Chair, New England Lymphoma Rounds Steering Committee (Sponsor: Lymphoma Research Foundation)
»» Member, Scientific Advisory Board (SAB), for Lymphoma Research Foundation (LRF)
»» Primary Hematology Review Panel (Standing Member and Chair), for VA Scientific Merit Review (R01). NIH and NCI
»» Faculty member – European School of Oncology and Ulm University. Certificate of Competence in Lymphoma (CCL) programme.
Post-transplant lymphoproliferative disorder
»» Faculty member/mentor. MIT-Tufts Physician Shadow Program
75
»» Top Doctor, Hematology, Castle Connolly
»» Faculty member/mentor (Group Leader), Lymphoma Research Foundation (LRF) Annual Mentoring Program
»» Associate Editor, British Journal of Haematology
»» Senior Editorial Board, American Journal of Blood Research
»» Editorial Board, Leukemia Research
»» Editorial Board, Journal of Clinical Oncology
»» Co-Chair, Tenth International Ultmann Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago and
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Mary 2nd and 3rd, 2014
»» Co-Chair, Tufts Cancer Center Pharmacy and Therapeutics (P&T) Committee, Tufts Medical Center, Boston, MA
»» Invited Speaker – Highlights of ASH in North America. Topic: Hodgkin Lymphoma; Atlanta, GA, January 25th, 2014; and Seattle, WA;
February 1st, 2014
»» Invited Speaker – Lymphoma Research Foundation (LRF) Mentoring Program. Grant opportunities and funding mechanisms for
clinical investigators in the field of lymphoma; Scottsdale, AZ; February 7th, 2014
»» Invited Speaker – St. Luke’s Hospital Oncology Grand Rounds. The Prognosis and Treatment of Hodgkin Lymphoma: Long Term
Considerations (i.e., Survivorship). New Bedford, MA; February 19th, 2014
»» Invited Speaker – Aggressive Non-Hodgkin Lymphoma; New England Lymphoma Workshop (Patient Forum); Boston, MA,
March 22nd, 2014
»» Invited Speaker – Highlights of ASH in Asia. Topic: Hodgkin Lymphoma; Singapore, Asia; March 29th and 30th, 2014
»» Invited Speaker – Controversial Cases in Hematologic Malignancies and Hematology; Prognosis and Treatment of Peripheral T-cell
Lymphoma (Sponsor: Massachusetts General Hospital). Boston, MA; April 12th, 2014
»» Invited Speaker – Hematological malignancies in pregnancy; International Consensus Conference, UZ Louven University, Louven,
Belgium, May 22-23, 2014
»» Invited Speaker – Peripheral T-Cell Lymphomas: Contemporary Prognostic and Therapeutic Approaches; Oncology Grand Rounds;
Lahey Clinic; Burlington, MA; May 29th, 2014
»» Invited Speaker – Arterial Disease, Second Cancers, and Other Aftermath in Hodgkin Lymphoma; Lowell General Hospital Grand
Rounds; Lowell, MA, June 11th, 2014
»» Invited Speaker – Hodgkin Lymphoma in Older (Elderly) Patients, Pathology Working Group and the Subtypes Initiative, Roundtable
discussion on the state-of-the-art pathology and future initiatives; INTERLYMPH 2014 Annual Meeting. UCLA, Los Angeles, CA, June
18th, 2014
»» Invited Speaker – Impact of Lifestyle on Lymphoma Histology and Genetics, Lifestyles and Environment Working Group
INTERLYMPH 2014 Annual Meeting. UCLA, Los Angeles, CA, June 19th, 2014
»» Invited Speaker – Update on Lymphoma; Best of ASCO 2014 (Sponsor: ASCO); Chicago, IL; August 16th, 2014
»» Invited Speaker – The Prognosis and Treatment of Hodgkin Lymphoma: Past, Present, and Future Directions, Lymphoma/Myeloma
Hematology Grand Rounds, MD Anderson Cancer Center; Houston, TX; August 16th, 2014
»» Invited Speaker – Antibody Drug Conjugates in Lymphoma, New Therapeutic Advances in Hematologic Malignancies/Diseases;
Lahey Cancer Center Grand Rounds; Burlington, MA; October 23rd, 2014
»» Invited Speaker – ASH Educational Lecture: The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
56th Annual ASH Meeting, December 2014
»» ASH 2014, Oral Presentation: Rosenberg AS, Klein AK, Ruthazer R, Evens AM. Hodgkin Lymphoma Type Post-Transplant
Lymphoproliferative Disorder (HL-PTLD) after Solid Organ Transplant (SOT): A Comprehensive and Comparative Analysis of Disease
Characteristics, Prognosis, and Survival.
Dr. Klein
»» Top Doctor, Castle Connolly
»» Member, New England Lymphoma Rounds Steering Committee (Sponsor: Lymphoma Research Foundation; www.lymphoma.org/nelr)
»» Member, CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group
»» Host, BMT Online Journal Club
»» Invited Speaker – Massachusetts Association of Blood Banks
»» Invited Speaker – Tufts CTSI Translational Research Day, Regulatory Panel
»» Invited Speaker – Tufts Dental School, Research Ethics
»» Organizer and Invited Speaker – Blood Cancer Symposium, Leukemia & Lymhoma Society, Natick, MA
Dr. Kuliopulos
»» Appointed Director of the Center of Hemostasis and Thrombosis Research, Tufts Medical Center
»» Invited Speaker, Webinar: SMARTT Program, NHLBI; Overcoming Barriers to Early Translation in Therapeutics Development:
Development of PZ-128 for the prevention of Arterial Thrombosis in acute coronary syndromes and percutaneous coronary
»» Invited Speaker, Chemistry Department, UC Santa Cruz, CA; Medicinal Chemistry and Drug Development with Cell-penetrating
Pepducins:, July 25, 2014
»» Invited Speaker, Discovery on Target: Membrane Protein Targets, 2014, ìTargeting Receptors with Cell Penetrating Pepducins: From
Bench to Bedside, Boston, MA, Oct 10, 2014
»» Invited Speaker, Boston Angiogenesis Meeting, ìMatrix Metalloprotease Signaling in Tumor Angiogenesisîs, Boston, MA, Nov 12, 2014
»» Elected member of NIH/NHLBI Scientific Review Board SMARTT Program.
Dr. Levy
»» Lecture and Panel Discussion, May 2014 in Washington D.C.: “Antimicrobial Resistance: a problem without borders” at the Institute
of Medicine-May 2014
»» Participated in the Group Summit Meeting in London on issues of antibiotic resistance in the community Global Respiratory Infection
Partnership(GRIP)- June 2014
»» “Modernizing antibacterial drug development and promoting stewardship” Lecture and discussion at the Brookings institution
Washington DC on the problem of antibiotic resistance and the increasing need for stewardship -February 2014
»» Received lifetime recognition plaque for nine years of support for the National Science Advisory Board for Biosecurity at the National
Institute of Health (2005-2014)
Dr. Matthew
Dr. Miller
»» Boston Magazine Best Doctors, 2014
»» Invited Lecture – Lovering Lecture – Memorial Hospital of Rhode Island
»» Invited – Oncology Tumor Board – Newton Wellesley Hospital
Dr. Parsons
»» Invited Plenary Speaker, “Improving Health in an Urban Asian Population: Patient Navigation for Patients of Chinese Origin with
Newly Diagnosed Breast Cancer”. Avon Foundation for Women Biennial Breast Cancer Forum), Washington, DC.
»» Invited Speaker, Predictors of overweight and obesity in survivors of childhood cancer. American Institute for Cancer Research
Annual Research Conference on Food, Nutrition, Physical Activity, and Cancer (Invited Speaker), Washington, DC.
»» American Cancer Society, Palliative Care and Symptom Management Peer Review Committee, Invited Grant Reviewer
»» Castle Connelly Top Doctor in Pediatric Hematology-Oncology
Dr. Saif
»» America’s Top Doctors
»» America’s Top Doctors for Cancer
»» Compassionate Doctor Recognition
»» Patients' Choice Award
»» AFIP Award
77
intervention, May 28, 2014
»» AFPGMI Award
»» Invited lectures, courses, symposia (national, international, universities, etc)
»» University of Cincinnati
»» AACR workshop focused on the use of metformin in clinical trials
»» King Edward Medical University
»» Armed Forces Post Grad Med. Institute
»» Armed Forces Institute of Pathology
»» Wah Medical College
»» Dana Farber Cancer Institute. Grand Rounds
»» Portsmouth Regional Medical Center
»» Vyas O, Keith L, Saif MW. Clinical Outcomes in Pancreatic Adenocarcinoma Associated with BRCA2 Mutation. Pancreas Club, 2014.
»» Abrahams M, Knisely J, Huber K, Saif MW. Safety and Efficacy of Capecitabine in Adjuvant Treatment of Pancreatic
Cancer. ASTRO. 2014
»» AACR Metformin Symposium, New Oreleans. Oct 2014
Dr. Hedy Smith
»» Boston Magazine, Best Doctors, 2014
»» Cancer Medicine and Hematology DFCI/Cancer Care Course, Boston; September 2014
Dr. Sprague
»» Boston Magazine, Best Doctors, 2014
»» U.S. News & World Report, Top Doctors 2014
»» Advisory Board, OncLive
»» Invited speaker; Current Treatment and Trends in Acute Leukemia, Blood Cancer Conference, Leukemia and
Lymphoma Society, MA, 2014
»» Invited speaker: Current Treatment of Myelodysplastic Syndrome, New Therapeutic Advances in Hematologic
Malignancies, MA. 2014
»» Invited speaker: Case of an Insidous Rash, Medical Grand Rounds. Tufts Medical Center
Dr. Zachary Spigelman
Dr. Strauss
79
DIVISION OF
INTERNAL MEDICINE AND
ADULT PRIMARY CARE
»» DIVISION OF INTERNAL MEDICINE AND ADULT PRIMARY CARE
The Division of Internal Medicine and Adult Primary
Care at Tufts Medical Center is the principal clinical home for adult internal
medicine, family medicine, geriatrics and transitional care medicine. The division contains
six sections, described below.
General Medical Associates (GMA) comprises multiple ambulatory internal medicine
practices and is the primary care teaching practice for the Tufts Internal Medicine Residency.
All of the physicians are internists or family practitioners and many have both a research,
quality or education focus and maintain clinical practices in GMA.
Deborah Blazey-Martin, MD, MPH
The Pratt Diagnostic Center is a concierge model practice. Patients and their families are
able to spend more time with their physician to discuss management of their chronic illnesses and health screening and
prevention. Patients pay an annual fee for this service.
Our Community Practices, strategically located in both South Shore and MetroWest markets, opened in October of
2013. Comprised of internists and family medicine physicians, these practices are dedicated to providing excellent
primary care to our patients in their own neighborhoods. They also host Tufts Medical Center specialists, bringing them
closer to their patients.
The General Medicine Inpatient Service is a hospitalist service caring for a wide range of medical conditions. As the
only non-subspecialty inpatient medical service, it serves as an important component of the resident and medical
student education experience.
The Geriatrics Section offers both inpatient and outpatient geriatric rotations for residents, together with an
educational program for nursing staff at Tufts Medical Center, and a polypharmaceutical and advanced care plan to
address the special needs of elderly patients.
Long-Term Care at Kindred Boston (Boston and Stoughton Locations) is staffed by our hospitalists providing
specialized, long-term acute care to medically complex patients requiring continued care and extended recovery time.
The majority of patients are admitted after a stay in a short-term hospital, often from intensive care and step-down units.
Highlights of 2014
» » Quincy Primary Care Practice received Patient Centered Medical Home Recognition at the highest level; added
two social workers
» » Grant to initiate Point of Care testing for HbA1c
» » Added 3 new primary care physicians
» » •Entered into NEQCA Accountable Care Organization
» » Blue Cross/Blue Shield Depression Emerging measure award
» » Participated in See, Test, and Treat outreach to Chinatown Community in collaboration with Pathology andOB/GYN
Name
Academic Rank
Deborah Blazey-Martin, MD,
MPH, FACP
Assistant Professor
Chief, Internal Medicine and Adult Primary Care
Dineli Ahearn, MD
Assistant Professor
Director, Primary Care Innovation
Yee Chuan Ang, MD
Assistant Professor,
Geriatrician
John Barravecchio, MD
Assistant Professor
Tufts Medical Center Primary Care, Quincy
Michael Cantor, MD
Assistant Professor
Chief Medical Officer , New England Quality Care Alliance
Jeanine Carlson, MD
Associate Clinical Professor
Pratt Diagnostic Center
Steven Carr, MD
Assistant Professor
Daniel Chandler, MD
Assistant Professor
Director of Resident Internal Medicine Education
Elaine Choi, MD
Assistant Professor
Jaclyn Chu, MD
Assistant Professor
Marcie Claybon, MD
Assistant Professor
Brian Cohen, MD
Assistant Professor
Misha Dad, MD
Assistant Professor
Kimberly Dowdell, MD
Assistant Professor
John Doyle, MD,
Assistant Professor
Medical Director of Employee Health Services
Daniel F. Driscoll, MD
Assistant Professor
Medical Director, Tufts Medical Center
Primary Care, Quincy
Paul Duncan, MD
Assistant Professor
Richard Dupee, MD
Geriatrician
Erika Freebern, MD
Assistant Professor
Karen Freund, MD
Professor
Jenny Hong Gao, MD, PhD
Assistant Professor
Renee Goetzler, MD
Assistant Professor
Linda Kaplan, MD
Assistant Professor
David Kent, MD
Professor
Faculty
Medical Director, Pratt Diagnostic Center
Chief of Geriatrics, Pratt Diagnostic Center
Associate Director of Research Collaboration, CTSI
Medical Director, Tufts Medical Center Primary Care,
Framingham
Director, Predictive Analytics and Comparative
Effectiveness (PACE) Center, ICRHPS;
Director, Sackler School of Graduate Biomedical Sciences,
Clinical and Translational Science Program
81
Name
Academic Rank
Richard Kopelman, MD
Professor
Vice-Chair for Education; Program Director, Internal
Medicine Residency Program
Diane Krause, MD, MPH
Assistant Professor
Joan Kross, MD, MPH
Tufts LCO Medical Director
Jae Young Lee, MD
Assistant Professor
Tufts Medical Center Primary Care, Framingham
Mary Lee, MD, MS, FACP
Professor
Special Advisor for Education Innovation
James Mahoney, MD
Assistant Professor
Cinthya Marturano, MD
Assistant Professor
Geriatrician
Associate Chief of Geriatrics
Director of Continuing Medical Education
Catherine Milch, MD
Assistant Professor
Yueling Guo Moran, MD
Assistant Professor
Jana Naef, MD
Assistant Professor
Erin Ney, MD
Assistant Professor
Ann Nguyen-Traxler, MD
Assistant Professor
Marta Onyskiv, MD
Assistant Professor
Judy Pinsker, MD
Karthik Ravindran, MD
Assistant Professor
Tufts Medical Center Primary Care, Framingham
Joseph Rencic, MD
Associate Professor
Associate Program Director of Internal Medicine
Residency Program
Joyce A. Sackey, MD
Associate Professor, Department of
Medicine and Department of Public
Health and Community Medicine
Dean, Multicultural Affairs/Global Health
Kinjalika Sathi, MD
Assistant Professor
Assistant Director of Resident Internal Medicine Education
Kimberly Schelling, MD
Assistant Professor
Harry Selker, MD
Professor
Chief, Institute for Clinical Research and Health Policy
Studies; Pratt Diagnostic Center Staff Physician
Myron Siu, MD
Director Inpatient Services
Laura K. Snydman, MD, FACP
Assistant Professor
Clerkship Director
Steven Spector, MD
Assistant Professor
GMA and Pratt Diagnostic Center
Caitlin Toomey, MD
Assistant Professor
Shirly Tozzi, MD
Assistant Professor
Nancy Tran, MD
Assistant Professor
Yana Urman, MD
Assistant Professor
Michael Wagner, MD
Associate Professor
Wei Wang, MD
Assistant Professor, Geriatrician
Saul Weingart, MD, PhD
Professor
Elisabeth Wilder, MD
Assistant Professor
John B. Wong, MD
Professor
Irina Zilberman, MD
Assistant Professor
Director of Community Primary Care Education, Tufts
Medical Center Primary Care, Quincy
President and CEO, Tufts Medical Center
Chief Medical Officer, Tufts Medical Center
Chief, Clinical Decision Making, Informatics and Telemedicine
The Division of Internal Medicine and Adult Primary Care continues to increase its primary care services at Tufts
Medical Center. In addition to General Medical Associates (GMA), the division has expanded services in Geriatrics,
inpatient medicine and collaborative programs and has extended its services into the community in the spirit of the
distributed academic medical center model.
GMA is also the educational site for 72 internal medicine residents' continuity clinics and their training is provided by
GMA preceptors. Drs. Daniel Chandler (Director of Resident Education) and Kinjalika Sathi (Assistant Director of
Resident Education) coordinate their various clinical, didactic, and administrative responsibilities with a goal to best
maximize their primary care education and experience. GMA has achieved the highest level of NECQA Patient Centered
Medical Home (PCMH) recognition, Level 3 with Distinction, which is uncommon in academic medical centers.
Population based medicine with the patient at the center is the rationale behind this model of care, and promotes the
importance of team-based management of patients. The ability to leverage information technology to achieve these
goals was accomplished by the addition of our Data and Project Manager, Joe Gillis to the administrative leadership
team. Care teams, composed of physicians, nurse practitioners, RNs, medical assistants and practice coordinators care
for all patients in the panel; outreach is facilitated by registries, information technology, health information exchange
and other means to assure that patients receive the indicated care in a culturally and linguistically appropriate manner.
This robust team structure has been developed and rolled out across most of the practice, resulting in increased MHQP
patient satisfaction scores.
The Division's vision for PCMH transformation has the following goals:
»» Emphasize high-quality, team-based preventive care and disease management, with care coordination across the health care
continuum.
»» Invite patients to actively engage in improving their health and well-being.
»» Promote physician, nurse, and staff satisfaction by redesigning the staffing model to allow everyone to work to the top of their
license.
»» Commit to delivering superior customer service.
»» Create and maintain an environment where trainees learn to provide primary care at the highest level and enjoy the practice of
medicine and caring for their patients.
»» Establish a data-driven practice culture of continuous improvement in the quality of care provided and the safety of the
environment of care based on transparency and accountability.
GMA has added more multidisciplinary services over the past years, embedding new specialties and creating new
collaborations. Dr. Lisa Ceglia from Endocrinology provides intensive diabetes consultation, management, and education
within the practice. Andrea Nardini, LICSW and Amanda Weintraub, MSW provide social work services in GMA, and
additional behavioral services are coordinated by Dr. David Adler from Psychiatry. Dr. Ceglia and our social workers are
instrumental in collaborating to lead the team to create and deliver an innovative new Diabetes Education program for the
most complicated and challenging diabetic patients. In 2014 we initiated a collaboration with the Weight and Wellness
Center called "Jumpstart to Wellness," an innovative program to overcome the barriers to obesity counseling in the
primary care setting allowing physicians to fast track their obese patients to the dieticians in the Weight and Wellness
Center without a mandatory entry into the bariatric surgery referral.
83
General Medical Associates (GMA) is the largest ambulatory practice at Tufts Medical Center, located in the Biewend
building. In late 2013 GMA expanded to fill a fifth team and hired 5 new full time physicians whose additional training
includes Nutrition, Geriatrics, and research. Since then 3 additional doctors have joined the practice, including a
geriatrician. GMA cares for more than 34,000 patients resulting in nearly 70,000 primary care office visits per year. The
division also coordinates care and is a major source of referrals to subspecialty colleagues and services within the
organization. GMA consists of about 40 internists, some with careers primarily devoted to clinical care or a combination
of that with medical education and administration. Others have primary appointments in other divisions, mainly
research institutes, but practice clinical medicine in GMA.
As the outpatient practice site for 72 Tufts Internal Medicine Residents, the Division has made significant changes and
innovations over the past year. Under the leadership of Dr. Daniel Chandler, our Director of Residency Education, we have
moved to a "3+1" model for our intern class to increase their primary care continuity. Interns now spend 3 weeks learning
inpatient medicine followed by 1 week of ambulatory care. This allows concentrated times where they are in clinic and are
not interrupted by inpatient demands and can focus on their outpatient responsibilities. In addition, our senior residents
now rotate through our Tufts Medical Center Primary Care-Quincy practice and are exposed to both a community practice
and nursing home care. Dr. Chandler has also added video observations for all residents, a mandatory quality chart review
project, and has created a novel pre-clinic conference structure which uses a smartphone-based audience response system
and stresses feedback on public speaking and teaching skills from the preceptor to the presenting resident.
The GMA Anticoagulation Service continues to monitor patients on warfarin and enoxaparin, and the novel oral
anticoagulants. The service is primarily managed by nurses in consultation with a pharmacist and the primary care
physicians. Patients can have blood drawn in a variety of sites convenient for them including point of care testing in GMA. In
2014 the service managed over 500 patients with excellent results in terms of compliance and time in the therapeutic range.
The general medicine inpatient service continues to be an important clinical and educational program. Under the direction
of Dr. Myron Siu, Director of Inpatient Services, the general medicine ward rotation provides house staff the opportunity to
have intensive exposure to patients with complex illnesses under the care of general internists and to see these physicians
as potential role models for a career in general internal medicine. Dr. Siu is also in charge of the combined inpatient
Geriatric Service and Medical Consultation service, which was added in 2011 to enhance the care of geriatric patients. The
additional service offers geriatric training, promotes education, and offers consultation to other inpatient services.
The community practices in Framingham and Quincy are dedicated primarily to clinical care. From disease prevention to
managing chronic illness to an urgent care appointment, these teams are focused on delivering high-quality, efficient care
to their patients in their local communities. Both Quincy and Framingham are in newly constructed spaces, which were
thoughtfully designed for optimal patient care. Each practice offers same-day appointments, onsite blood drawing stations
and centralized digital medical records that can connect patients to their entire healthcare team, at Tufts Medical Center
or MetroWest Medical Center.
In Quincy, Tufts Medical Center specialists rotate through the practice on a monthly basis making their services
conveniently available to patients locally. Cardiologists and Dermatologists team with their Primary Care Physician
colleagues to provide comprehensive, coordinated care to patients in a patient-friendly environment.
The Pratt Diagnostic Center uses a concierge model to provide a high level of service coupled with expert diagnostic care.
Under the direction of Dr. Brian Cohen, the program continues to thrive since its inception ten years ago. This year we have
added our Geriatric Section Chief, Dr. Richard Dupee, to the PDC where he brings his expertise in caring for the elderly.
The Pratt Diagnostic Center markets its services and clinical practice to members of the Boston business community.
The educational programs of the division consist of the following:
»» Residents’ Ambulatory Medicine in GMA
»» Continuity Clinic
»» Ambulatory Block Rotations
»» Geriatric Block Rotation
»» Primary Care Elective
»» General Medicine Inpatient Service (staffed by a GMA attending and composed of a 3rd year resident, 2 interns, a pharmacist,
and medical students).
»» Third Year Medicine Clerkship for Tufts University School of Medicine
»» General Medicine Consultation Service (staffed by a GMA attending and composed of a 3rd year resident, internal medicine intern,
and a psychiatry intern intermittently)
»» Geriatrics Inpatient Service (staffed by a GMA attending and composed of a 3rd year resident, an internal medicine intern,
a psychiatry intern intermittently, and medical students)
»» Third Year Medicine Clerkship for Tufts University School of Medicine
»» Fourth-year medicine sub-internships for Tufts University School of Medicine
Adult Internal Medicine is an important source of patients for clinical research trials at the medical center. With more
than 34,000 patients in the practice and an electronic medical record which enables researchers to identify patients with
specific diagnoses, the Division is able to work collaboratively with institutionally-sponsored research projects on
identifying patients for research projects.
Dineli Ahearn, MD
Awards
»» Top Doctor 2014, Boston Magazine
Deborah Blazey-Martin, MD MPH
Awards
»» President’s Council of Cornell Women, elected 2014
Committee Assignments
»» NEQCA Board of Trustees
»» Trustee, NEQCA Accountable Care
Invited talks
»» “Jumpstart to Wellness Pilot Program: A collaborative approach to managing morbid obesity” Deborah Blazey-Martin, MD, MPH;
Michael Tarnoff, MD, Jillian Regan, RD; Melissa Page, RD. NEQCA Fall Forum. Norwood, MA. 10/1/2014.
Michael Cantor, MD JD
»» Chair, Physician Council of the Massachusetts Health Quality Partners (MHQP) – the statewide quality measurement collaborative.
»» Vice Chair, Board of Trustees, MHQP.
»» Member, Medical-Scientific Advisory Committee, Mass-New Hampshire Chapter, Alzheimer’s Association
»» Member, Massachusetts Registry of Motor Vehicles, Medical Advisory Board
Daniel Chandler, MD
Awards
»» Excellence in Teaching Award, Tufts Medical School
85
Many of the faculty play pivotal roles in the educational programs, both for the medical school and for the residency
training program. Dr. Richard Kopelman is the Program Director for the internal medicine residency training program
at Tufts Medical Center. Each year, the program recruits 25 new interns and has a total of 72 residents and three chief
medical residents. Dr. Joseph Rencic is the Associate Program Director of the internal medicine residency, with an
additional research focus in clinical decision making and development of expertise. Dr. Laura Snydman provides
oversight for the medical students during their third and fourth year medicine clerkships at Tufts Medical Center. Dr.
Daniel Chandler is Director of Resident Education for Internal Medicine and Adult Primary Care. He sets the overall
education agenda for 72 residents that rotate through GMA for their continuity and primary care experience throughout
their 3 years of training. Dr. Kinjalika Sathi, as the Assistant Director of Residency Education, administers the outpatient
ambulatory curriculum through the primary care clinic, General Medical Associates, and associated outpatient
ambulatory elective clinics. Drs. Laura Snydman, Dan Chandler, Kinjalika Sathi, Caitlin Toomey, and Joe Rencic provide
a “Resident-as-Teacher” program to enhance the skills of residents in teaching medical students. The faculty of the
division are recognized by medical students and residents for their excellence in teaching and their fundamental
contributions to the educational programs of the medical school and medical center.
Kimberly Dowdell, MD
Awards
»» Julius 'Red' Kritzman Award for Primary Care Teaching
Daniel Driscoll, MD
»» NEQCA Board of Trustees
Karen Freund, MD MPH
Awards and Honors
»» Freund KM, Raj A, Terrin N, Kaplan S, Urech T, Carr PL. Progress or Stalemate in Academic Gender Disparities? 15 Year Follow up of
the National Faculty Survey. J Gen Intern Med. 2014:29(1 Suppl):S191. Awarded Best Oral Abstract in Women’s Health, National SGIM
meeting, 2014.
»» Agency for Healthcare Research and Quality (AHRQ), Health Care Research Training (HCRT) Study Section
»» Editor, Editorial Board, Cancer Epidemiology, Biomarkers and Prevention
Invited talks
»» Progress or Stalemate in Academic Gender Disparities? 15 Year Follow up of the National Faculty Survey. National SGIM Meeting, San
Diego CA, April 18, 2014
Jenny Gao, MD PhD
Awards
»» Notable Teaching Award, Tufts Medical School
David Kent, MD
Professional Society Committee Assignments and Leadership
»» Invited Abstract Reviewer, Health Services, Quality Improvement, and Patient-Centered Outcomes Category, International Stroke
Conference 2015
»» Comparative Effectiveness Research, Methods Committee, Society of Clinical and Translational Science
National Panels
»» Ad Hoc Member, National Institute of Neurological Disorders and Stroke Special Emphasis Panel, National Institute of Neurological
Disorders and Stroke PD Planning Grant Review, December 10, 2014 (ZNS1 SRB-J-08)
»» Scientific Advisory Board, Ware Working Group on Neurodegenerative Disease Ethics and Policy, University of Pennsylvania
»» External Advisor, Patient Centered Outcomes Research Institute (PCORI) Methodology Committee Workgroup on Heterogeneity of
Treatment Effect
Invited Lectures & Presentations
»» “Why Risk Based Subgroup Analysis Should be Routine.” Society for Clinical Trials (SCT) 35th Annual Meeting. Philadelphia, PA, USA.
May 18-21, 2014.
»» “Variation in individual treatment effects from repeated period cross-over and multi-person N-of-1 studies.” International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting. May 34 – June 4, 2014. Montreal, Canada.
»» “Using Group Data to Treat Individuals: Understanding the Importance of Heterogeneity of Treatment Effects for Clinical DecisionMaking.” Tufts CTSI Heterogeneity of Treatment Effects in Clinical Trials Seminar: Lahey Clinic. Burlington, MA. June 4, 2014.
»» “Assessing and Reporting Heterogeneity of Treatment Effect in Clinical Trials,” NIH Collaboratory Webinar Grand Rounds, September
12, 2014 Video: https://www.nihcollaboratory.org/Pages/Grand-Rounds-Hub.aspx
»» “Treatment Effect Heterogeneity in Clinical Trials: “An evaluation of 13 large clinical trials using individual patient data.” International
Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress. November 8-12, 2014.
Amsterdam RAI in Amsterdam, The Netherlands. (poster)
»» “Risk modeling and heterogeneity of treatment effect.” International Society for Pharmacoeconomics and Outcomes Research
(ISPOR) 17th Annual European Congress. November 8-12, 2014. Amsterdam RAI in Amsterdam, The Netherlands. (workshop)
Awards
»» Accomplished Teaching Award, Tufts Medical School
»» Publications: Vedula R, Kopelman R, Rencic J. Complementary medicine. J Gen Intern Med. 2014;29:412-416.(Clinical reasoning
series)
Joan Kross, MD MPH
»» Annual LCO Medical Director Leadership Award—Adult Practice
Mary Y Lee, MD
»» Special Advisor for Education Innovation, TMC
»» TMC Board of Governors, member
»» TMC Board of Governors, Quality of Care Committee, member
»» Completed 12 years as Associate Provost, Tufts University
Awards and national/international talks
»» 2014 Tufts University, Distinguished Service Award
»» 2014 Selected as the 2014-2015 International Kimitaka Kaga Visiting Professor, Graduate School of Medicine, The University of Tokyo
(6-month full-time faculty position); provided monthly medical education seminars simulcasted to all major universities in Japan;
assisted The University of Tokyo with their first national medical school accreditation; conducted clinical teaching of residents and
medical students; invited as keynote to several other universities across Japan
»» 2014 Invited Keynote: “Leading Institutional Change: Pearls from Implementing a Flipped Curriculum at Tufts University,” University
of Nebraska Medical Center, Omaha, Nebraska, March 2014
»» 2014 Invited Keynote: “Disruptive Technologies in Education: Maximizing Impact,” Harvard Macy Institute, Boston, MA, June 2014
»» 2014 “Flipping the Curriculum: A Toolkit to Prepare Your Institution for Success” HY Liu, RW Rockhold, LH Fall, MY Lee, LM Love, TA
Birk; AAMC Group on Faculty Affairs (GFA) Professional Development Conference, Boston, MA, July 2014
»» 2014 Invited Keynote: “Flipping an Entire Curriculum, Piece by Piece,” Faculty Scholarship Exchange Seminar Series, University of
Mississippi Medical Center, Jackson, Mississippi, August 2014
»» 2014 Invited Keynote: Curriculum Reform and Accreditation in Medical Education: Lessons from Tufts University, Kyoto University,
November 2014
»» 2014, Board Member, OpenCourseWare Consortium (global consortium, stepped down at end of January 2014)
Grants
»» Aug 2014-Jul 2017 “Capacity Building for Medical Education in Bioethics in India,” Obama-Singh 21st Century Knowledge Initiative,
United States-India Educational Foundation (USIEF/Fulbright), Tufts University School of Medicine and Christian Medical College,
Vellore, India. PIs: Aviva Must (Tufts), Ansu Pulimood (CMC); MY Lee, OSI faculty for faculty development training
»» Nov 2014-Nov 2019 “One Health Work Force,” USAID No: P004721401. $ 8,598,962 subaward to Tufts University; Deputy Director:
Saul Tzipori, Cummings School of Veterinary Medicine; MYLee, expert consultant for faculty development, leadership training,
curriculum development, open educational resources, online learning
87
»» Career Mentorship Award—Spotlight Series on Mentorship—Association of Program Directors in Internal Medicine (ADPIM )
Joseph Rencic, MD
Awards
»» Accomplished Teaching Award, Tufts Medical School
Joyce Sackey, MD
»» Member, President’s Council on Diversity
»» Chair, Group on Graduate and Professional Students’
Kinjalika Sathi, MD
Awards
»» Notable Teaching Award, Tufts Medical School
Harry Selker, MD, MSPH
National Panels:
»» Agency for Healthcare Research and Quality, National Advisory Council Member
»» National Institutes of Health: Directors Pioneer Award Review Committee
Professional Society Committee Assignments and Leadership:
»» Society for General Internal Medicine Conflict of Interest Committee
»» Association for Clinical and Translational Science, Board of Directors, Vice President for Healthcare Implementation,
»» Delivery, and Policy Research, Chair, Public Policy Committee
»» Clinical Research Forum: Public Policy Committee Chair
»» Health Resources in Action: Board of Directors
»» Association for Clinical Research Training: Chair, Advocacy Committee
Editorships:
»» Journal of Investigative Medicine, Associate Editor
»» Clinical and Translational Science, Executive Editor
Laura K. Snydman, MD
Awards
»» 2014 Recognized as a Compassionate Caregiver (part of the Schwartz Center’s Honor Your Caregiver tradition)
Committee Assignments:
»» Elected to Fellowship in the American College of Physicians
»» President, Regional Leadership Board, Society of General Internal Medicine, New England Region
»» Member, Board of Regional Leaders, Society of General Internal Medicine
Undergraduate Medical Education:
»» 2013-present Internal Medicine Site Clerkship Director, Tufts Medical Center
»» 2013-present Learning Community Advisor, TUSM (first and second year medical students)
Saul Weingart, MD, PhD
Awards and Recognition:
»» Promoted to Professor of Medicine at TUSM
»» Promoted to Fellow of ACP
»» Gave Grand Rounds at Tufts MC in anesthesia and pediatrics,
»» Gave Grand Rounds for the 10th Annual Rafael Miara Patient Safety Lecture at Boston Medical Center
Committee Assignments:
»» Completed term as Chair of the Board of Governors of the National Patient Safety Foundation
»» Board Member, NPSF Board of Directors
»» Member, Advisory Board of the Betsy Lehman Center for Patient Safety and Medical Error Reduction
John Wong, MD, FACP
»» Co-chair, American Medical Association/American Gastroenterological Association/Association for the Study of Liver Disease,
Physician Consortium for Performance Improvement. Work Group on Hepatitis C
»» Committee Member, Institute of Medicine (IOM), Diagnostic Error in Health Care
»» Systematic Review Member, American Association for the Study of Liver Disease (AASLD), Hepatitis B Guidelines
»» Discussion Leader, Patient-Centered Outcomes Research Institute, Hepatitis C Workshop (Screening and Diagnostic Tests)
»» Chair, Awards Committee, Society for Medical Decision Making
89
ADULT PRIMARY CARE—
GERIATRICS
»» ADULT PRIMARY CARE GERIATRICS
The Geriatrics section of the Division of Internal
Medicine and Adult Primary Care was established in
the spring of 1998 in order to enhance the training of
students and residents in the subspecialty of geriatrics.
Residents and students receive formal instruction and are assigned clinical experience in
geriatric medicine. Tufts Medical Center provides comprehensive geriatric assessment.
The Geriatrics section welcomed Dr. Richard Dupee to the Pratt Diagnostic Center at Tufts
Richard Dupee, MD
Medical Center in 2014. The section has also recently added another geriatrician, Dr. Yee
Chuan Ang, a Palliative Care physician, will be joining the division shortly and will have a substantial role in geriatrics care.
Geriatrics also plays instrumental role in the NEQCA ACO (Accountable Care Organization) that General Medical
Associates joined in 2014.
Faculty
Name
Academic Rank
Richard Dupee, MD
Chief of Geriatrics
Yee Chuan Ang, MD
Assistant Professor
Geriatrician
Michael Cantor, MD
Assistant Professor
Chief Medical Officer, New England Quality
Care Alliance
Cinthya Marturano, MD
Assistant Professor
Associate Chief of Geriatrics
Wei Wang, MD
Assistant Professor
Geriatrician
Geriatrics Inpatient Service
Older persons are at disproportionate risk of becoming seriously ill and requiring hospital care. The utilization of acute
hospital care by older persons is increasing rapidly with the aging of the population.
Once hospitalized, older patients are at high risk for loss of independence and institutionalization.
»» ADULT PRIMARY CARE GERIATRICS
The inpatient geriatrics service at Tufts Medical Center, comprising a resident team, and led by a geriatrician, is
designed to prevent loss of function and other serious events and conditions common to this age group following
hospitalization.
Geriatrics Consultation Service
The resident team, led by a geriatrician, is available to all medical and surgical services for inpatient consultation
regarding issues and complications that frequently occur when an older patient is hospitalized, guiding the various
subspecialty services In their care of these patients.
MedWest Center for Memory Disorders and Conditions of Older Adults
The MedWest Center for Memory Disorders and Conditions of Older Adults was established in conjunction with Tufts
Medical Center. A team of specialists identifies and treats patients with mild cognitive impairment and with various
stages of Alzheimer’s disease. Specific and sensitive evaluation tools are used to provide early and accurate diagnosis
and treatment, and this approach has given substantial support to patients and families.
Teaching Prog ra m s
The Geriatrics Service is engaged in the teaching of Tufts University medical students and internal medicine residents.
For students at Tufts University School of Medicine, exposure to geriatrics may begin as early as in the first year. Each
year a first-year student with an interest in geriatrics spends one-half day a week in Dr. Dupee’s Wellesley office. The
elective is consistently rated highly by student evaluations.
Third-year clerkship students doing electives in medicine attend conferences on geriatric conditions during each block
at Tufts Medical Center.
Internal medicine residents at Tufts Medical Center are exposed to case-based noon conferences relating to geriatric
conditions. The sessions are highly interactive. In addition, second-year residents have the opportunity to see patients
with Dr. Dupee in his Wellesley office. This format allows residents to have exposure to longitudinal care of the elderly.
The program has been popular with residents, some of whom have chosen second and even third sessions.
Richard Dupee, MD
»» Voted “Top Doctors in Geriatrics” Boston Magazine
»» “Top Doctors in Geriatrics” Castle-Connolly
National Professional Society Committee Appointments
»» Governor, American College of Physicians, Massachusetts Chapter (2010-2014)
»» President, Massachusetts Geriatrics Society (2009-2014)
»» Member, Health and Public Policy Committee, American College of Physicians (2012-2014)
»» Member, Editorial board, “Annals of Long-term Care” (2003-present)
»» Member, Geriatric Task Force Committee. Tufts University School of Medicine & Bay State Medical Center.
91
WILLIAM B. SCHWARTZ DIVISION OF
NEPHROLOGY
»» WILLIAM B. SCHWARTZ DIVISION OF NEPHROLOGY
The William B. Schwartz Division of Nephrology is
internationally known for the quality of patient care,
teaching, research, and public policy contributions. In the
early years of the Division, William B. Schwartz and his colleagues elucidated many basic
principles of acid-base and fluid and electrolyte homeostasis which are used to this day. In
recent years, the Division has carried out seminal studies in the epidemiology, progression,
and treatments of chronic kidney disease and the effects of chronic kidney disease on
cardiovascular disease. Members of the Division have led the development and implementation
Andrew Levey, MD
of clinical guidelines for the identification, classification, and treatment of kidney diseases.
In its research and its clinical programs, the Division has emphasized collaboration with other specialties (metabolism,
neurology, cardiology, infectious disease, urology, and transplantation surgery) and disciplines (epidemiology, statistics).
The Division has established multidisciplinary clinics for polycystic kidney disease and kidney transplantation. The home
dialysis program is growing rapidly.
The teaching programs emphasize basic science-clinical correlations. Fellowships are available in clinical nephrology and
in research. Participants in the research fellowship program undertake formal training in research methods culminating
in a Master of Science degree at the Sackler School of Graduate Biomedical Sciences at Tufts University.
Division members collaborate with methods experts to use the research approaches appropriate for epidemiology,
clinical trials, development of clinical practice guidelines, and outcomes. They also collaborate with domain experts to
focus on the research areas of: chronic kidney disease, assessment of kidney function, aging, nutrition, dialysis and
transplantation, progression, polycystic kidney disease, acute kidney injury, and hypertension. Basic science studies
involve the role of inflammation and oxidative stress in chronic kidney disease and the role of immunosuppressive
regimens in predisposing to infections in dialysis and transplant patients.
Tufts Medical Center is the site of the editorial offices of the American Journal of Kidney Diseases (AJKD), the official
journal of the National Kidney Foundation. The Editor, Deputy Editor, and other Editors are members of the Division.
Highlights of 2014
»» Dr. Levey was recognized by Thomson Reuters as a highly influential researcher.
»» Dr. Meyer received the Distinguished Faculty Award from Tufts University School of Medicine.
»» Dr. Perrone was the PKD Foundation’s Physician of the Year and the recipient of the National Kidney Foundation’s Donald W.
Seldin Distinguished Award recognizing clinical excellence.
»» Drs. Perrone and Miskulin were authors of New England Journal of Medicine articles on the results of the HALT-PKD Study.
»» Dr. Sarnak delivered the Shaul G. Massry Distinguished Lecture at the National Kidney Foundation Spring Clinical Meeting.
Faculty
Academic Rank
Andrew S. Levey, MD
Professor
Division Chief
Editor of the American Journal of Kidney Diseases
Ronald D. Perrone, MD
Professor
Associate Division Chief
Director, Polycystic Kidney Disease Center
Medical Director, Kidney Transplantation
Michael B. Cohen, MD
Assistant Professor
Co-Medical Director, DCI Ball Square
Anthony Z. Dash, MD
Assistant Professor
Co-Medical Director, DCI Ball Square
Meredith C. Foster, ScD, MPH
Research Assistant Professor
Scott J. Gilbert, MD
Associate Professor
Director, Fellowship Training Program
Lesley A. Inker, MD, MS
Associate Professor
Director, Quality Improvement
Medical Director, Kidney and Blood Pressure Center
Bertrand L. Jaber, MD, MS
Associate Professor
Vice Chairman of Medicine for Clinical Affairs, St. Elizabeth’s
Medical Center
Alin A. Joseph, MD, MS*
Clinical Instructor
Amy B. Kuhlik, MD
Assistant Professor
Dean for Student Affairs, TUSM
Nicolaos E. Madias, MD
Maurice S. Segal, MD
Professor of Medicine
Chairman of Medicine, St. Elizabeth’s Medical Center
Klemens B. Meyer, MD
Professor
Director, Dialysis Services Tufts Medical Center
Medical Director, DCI BostonMedical Director, Home Dialysis
Program at DCI Ball Square
Medical Director, DCI Information Systems
Dana C. Miskulin, MD, MS
Associate Professor
Madhumathi Rao, MD, PhD
Assistant Professor
Medical Director, DCI Walden Pond
Michelle M. Richardson, PharmD
Assistant Professor
Director, DCI Outcomes Monitoring Program
Director of Communications
Mark J. Sarnak, MD, MS
Professor
Director of Research
Associate Director, Research Training Program in Nephrology
Daniel E. Weiner, MD, MS
Assistant Professor
Associate Medical Director, DCI Boston
Deputy Editor, American Journal of Kidney Diseases
Name
*New appointment in 2014
M ajor Clinic a l Prog ra m s K i d n ey a n d Blo o d Pressu re C en ter ( K BPC)
Outpatient clinical activities take place primarily in the Center, directed by Dr. Inker. The Center emphasizes a multidisciplinary approach to kidney disease in collaboration with the Division of Transplant Surgery, Department of Urology, the
DCI outpatient dialysis unit and the Frances Stern Nutrition Center. The KBPC specializes in the diagnosis and management
of CKD, hypertension, glomerular diseases, kidney transplantation, and peritoneal dialysis. In 2013, the KBPC began
outpatient measurements of GFR.
93
The Center carries out clinical studies on chronic kidney disease (CKD), including studies of polycystic kidney disease, lupus
nephritis (in conjunction with the Division of Rheumatology), immunosuppression for transplantation, cardiovascular
disease in transplantation, computerized quality of life assessment, and genetic predisposition to progression.
Home Dialysis
The Division has an active home dialysis program at DCI’s Ball Square facility in Somerville, comprising both peritoneal
dialysis and home hemodialysis. Patients are eligible if they are able to perform the required tasks, do not live alone and
have insurance adequate to cover the procedures. Because of its convenience, the program is much appreciated by patients.
Center for Polycystic Kidney Disease
The Center for Polycystic Kidney Disease at Tufts Medical Center was opened in 2006. The physicians are internationally
recognized experts in treating and managing the complications of PKD. On average, 50 new patients are seen each year in
this program. Areas of expertise for patients with PKD include dialysis and transplantation and the evaluation and
management of the complications of liver and kidney cysts including chronic pain, kidney stones, and cardiovascular
issues such as intracranial aneurysms. Care is coordinated with the Departments of Urology, Neurosurgery,
Transplantation Surgery and Genetics.
Kidney Transplantation Program
A weekly Transplant Multidisciplinary clinic is staffed by Dr. Perrone, Medical Director of Kidney Transplantation, together
with a transplantation surgeon. Nurse practitioners serve as transplantation coordinators. The multidisciplinary nature of
the team facilitates consultations for patients who have already received transplants, as well as for patients and donors for
whom transplantation is being considered. Another benefit of this joint activity is the facilitation of dialysis access
planning and interventions.
In-center Dialysis
The DCI Boston in-center hemodialysis unit located at Tufts operates 21 stations. There are two affiliated in-center dialysis
clinics, one at Ball Square in Somerville, the other at Walden Pond in Concord, MA. Both programs are routinely recognized
for high quality clinical care.
Inpatient Programs
The Division provides routine consultation in the diagnosis and management of kidney diseases, as well as expertise for all
forms of renal replacement therapy including hemodialysis, peritoneal dialysis, continuous renal replacement therapy, and
charcoal hemoperfusion.
Under the direction of Dr. Perrone, the Division participates in the Tufts Medical Center Kidney Transplant Program. Many
of the donors in this program are living donors. Tufts Medical Center is a member of the New England Program for Kidney
Exchange (NEPKE) that coordinates sharing by mismatched donor-recipient pairs. Patients who have received transplants
are followed in the KBPC. The transplant team at Tufts Medical Center has carried out more than 1230 kidney transplants.
Inpatient Dialysis
Dialysis Clinic, Inc., the hospital’s dialysis provider, performs pediatric as well as adult hemodialysis at Tufts Medical
Center, with Dr. Meyer as director. Because patients receiving hemodialysis treatment usually are also undergoing many
other tightly scheduled tests and procedures, the program is organized so as to enhance patient flow. Continuous
venovenous hemofiltration (CVVH) and slow continuous ultrafiltration (SCUF) are also available.
Inpatient peritoneal dialysis is performed in intensive care units and on the North 7 inpatient ward, where the nursing staff
are trained to perform peritoneal dialysis. Tufts Medical Center is the only hospital in Greater Boston with a floor on which
the staff nurses are trained to perform peritoneal dialysis.
The Division of Nephrology is committed to education at the national as well as the local level. Division members carry
out clinical and basic research, serve on national boards that establish standards in clinical practice, and lecture at
local, national, and international conferences.
Division members participate extensively in the preclinical years (renal pathophysiology, physical diagnosis) and the
clinical years (ward and consultation services) of the medical school. Dr. Gilbert conducts a series of lectures on core
nephrology topics for 3rd year students during their internal medicine clerkships at Tufts Medical Center. In addition,
Dr. Gilbert offers an elective in evidence-based medicine to 4th year students.
The Division participates in other postgraduate forums. Several Division members serve as research mentors to Masters
of Science candidates in the Sackler School of Graduate Biomedical Sciences. Dr. Gilbert coordinates nephrology
lectures in the Advanced Molecular and Cellular Pharmacology Course at Tufts University School of Medicine, teaches
Renal Pharmacology at the Sackler School of Graduate Biomedical Sciences and leads the Renal Section of the
Nutritional Biochemistry and Physiology at the Friedman School of Nutrition Science and Policy.
Clinical Fellowship Training
Under the direction of Dr. Gilbert, the clinical fellowship program offers training of unusual breadth and depth. Fellows
have clinical rotations both at Tufts Medical Center and at St. Elizabeth’s Hospital. Over the past 14 years, almost half of
the 33 graduates of the fellowship program have continued in full-time academic positions. Another quarter have
become private practitioners with substantial teaching responsibilities, typically in hospitals with university
affiliations. The remainder are engaged in private practice.
Research Fellowship Training
The William B. Schwartz Division of Nephrology offers clinical research training through the NIDDK Institutional
Research Training Award in “Epidemiology, Clinical Trials and Outcomes Research in Nephrology”. This award funds
three research trainees per year. The program is designed for fellows aspiring to a career as an independent investigator
in clinical research in nephrology. The program has been focused primarily on chronic kidney disease, but in recent
years, there has been a growing interest in acute kidney injury.
Policy Initia t i ves
Chronic Kidney Disease in Nicaragua
Dr. Weiner collaborates with public health researchers from Boston University School of Public Health to investigate
chronic kidney disease among workers in rural Nicaragua. The objective is to explore the reported high prevalence of
kidney disease among working age residents in rural northwest Nicaragua to better define prevalence and to develop
hypotheses regarding cause.
DCI Information Systems and Outcomes Monitoring Programs
Dr. Meyer is Medical Director for Information Systems for Dialysis Clinic, Inc., and is a principal architect of DCI’s
information system, which sets an industry standard for quality of care and of information. The team’s current projects
include continued development of decision support tools for treatment of anemia in dialysis patients and the
implementation of an interface between hemodialysis machines and the information system. Dr. Richardson directs the
corporate-wide DCI Outcomes Monitoring Program, which uses patient experience data to improve care.
National Kidney Disease Education Program
Dr. Inker is a member of the National Kidney Disease Education Program (NKDEP) of the NIDDK. She has participated
in the efforts of the NKDEP to recommend reporting GFR estimates by clinical laboratories and to standardize serum
creatinine assays for more accurate GFR estimation.
95
Interns and residents at Tufts Medical Center rotate through the renal ward service and may choose an elective on the
renal consultation service. Senior residents may also choose an elective in the Kidney and Blood Pressure Center. The
senior residents routinely rank this outpatient experience highly.
Res earch Act i v i ty
Research in the Division of Nephrology is focused on solving clinical problems. Each research project has domain
experts, generally a nephrologist, a methods expert, and collaborators from other disciplines. Although the primary
emphasis has been on chronic kidney disease, there are a growing number of projects in acute kidney injury. Some of
the areas of recent emphasis are: chronic kidney disease, assessment of kidney function, aging, nutrition, dialysis and
transplantation, progression, polycystic kidney disease, acute kidney injury, and hypertension.
In 2013, two William B. Schwartz Division of Nephrology members held Career Development (K23) Awards and one
Division member held a prestigious Midcareer Investigator Award in Patient Oriented Research (K24).
C linical Rese a rc h Ac t i v i ty
Recipient
Andrew S. Levey, MD
Funding Source
Purpose of Award
NIH/RI Hospital
Using folic acid for to reduce vascular outcomes in patients
with kidney (FAVORIT)
NIH/NIDDK
Assess aorta, brain, and kidney structure and function in the
AGES-Reykjavik study (with Dr. Inker)
NIH/NIDDK
Seek markers for CKD in a representative multi-ethnic
population with measured GFR (with Dr. Inker)
National Kidney Foundation
Assess GFR Decline as an Outcome for Clinical Trials in CKD
NIH/NIDDK
Estimating GFR from a Panel of Endogenous Filtration Markers
DCI
Monitoring PD adequacy using serum levels of endogenous
filtration markers
NIH*
Chronic Kidney Disease Prognosis Consortium
Pharmalink
Proteinuria Reduction/Primary IGA Nephropathy Patients
NIH/NIDDK
Blood Pressure in Dialysis
DCI
Assessing the accuracies of an autoregulatory adequacy
measure derived from the pulse oximeter pulse waveform
and of the Crit-Line device to predict fluid removal induced
hypotensive events during hemodialysis.s
NIH
Pragmatic trials in maintenance hemodialysis
DCI
Decision support for anemia management in HD
Intelomed*
Measuring cardiovascular stress in hemodialysis patients
Otsuka
A multi-center, longitudinal observational study of patients
with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
to establish the characteristics and determinants of disease
progression.
Otsuka
Determine long-term safety and efficacy of oral tolvaptan in
adults with ADPKD
Otsuka
Investigate modified-release (MR) and immediate-release (IR)
Tolvaptan in subjects with Autosomal Dominant Polycystic
kidney disease (ADPKD)
NIH/NIDDK
PKD Clinical Trials Network
Otsuka*
Compare the efficacy and safety of Tolvaptan in patients with
ADPKD and CKD Stages 2-4
Otsuka*
Evaluate the long-term safety of titrated immediate-release
Tolvaptan in patients with ADPKD
Funding Source
Purpose of Award
Madhumathi Rao, MD, PhD
DCI
Gastrointestinal microbiota, systemic infection, and
inflammation in dialysis patients
NIH/NIDDK
Investigate cognitive function in hemodialysis patients
NIH/NIDDK
Assess relationship among chronic kidney disease, vascular
disease and aging
NIH
The Aging Kidney: Chronic Injury, Impaired Functions and
Clinical Outcomes
NIH*
Kidney tubular damage and dysfunction identify a novel axis of
kidney disease
DCI
Safety and effects of supplementation with ergocalciferol
NIH
Analysis of pulse wave velocity and central aortic pressure
outcomes in SPRINT
NIH/NIDDK
Randomized trial of exercise training on cognitive and physical
functioning in CKD
Keryx
Assess safety and efficacy of ferric citrate in patients on
dialysis
NIH
SPRINT Main Phase II
NIH*
Renal disease, kidney cancer, and metalworking fluid exposure
in autoworkers
NIH*
MIND and the kidneys
Janssen*
Cardiovascular outcomes in subjects with Type 2 DM and
diabetic nephropathy
Evaluate the safety and efficacy of pyridorin in subjects with
nephropathy due to Type 2 DM
* New grant in 2014
Bas ic Res ea rch
Recipient
Funding Source
Purpose of Award
Andrew S. Levey, MD
NIH/NIDDK
Use a proteomic approach to CKD biomarker discovery and
validation
Andrew S. Levey, MD
»» Recognized in Boston Magazine as one of Boston’s best nephrologists
»» Recognized by Thomson Reuters as a highly influential researcher
»» Member, NKF Scientific Advisory Board
»» Invited lecture: Visiting professor at Icahn School of Medicine, NY, NY
»» Invited lecture: ASN Board Review Course, Chicago, IL
»» Major Grant Awards in 2014: Please see Table of Research Activities
97
Recipient
»» Recipient of the Donald W. Seldin award from the National Kidney Foundation
»» Co-executive director, Polycystic Kidney Disease Outcomes Consortium
»» Invited Lecture: New Directions for ADPKD, NKF Spring Clinical Meeting, Las Vegas NV
»» Invited Lecture: Genetics of Non-glomerular disease. NKF Spring Clinical Meeting, Las Vegas NV
»» Invited lecture: Therapeutic intervention in ADPKD: disease mechanisms and pathways to drug development. Quebec Canada
»» Invited lecture: Cardiovascular complications in PKD. Federation of American Societies for Experimental Biology. Lucca, Italy
»» Invited lecture: PKD: from molecular mechanisms to therapy. Federation of American Societies for Experimental Biology. Lucca, Italy
Scott J. Gilbert, MD
»» Member, Medical Advisory Board of the NKF of New England
»» Member, Panel for Accreditation Appeals in Nephrology - Accreditation Council for Graduate Medical Education
»» Member, Executive Committee of the Nephrology Training Program Directors for the American Society of Nephrology
»» Outstanding Attending Teaching Award from House Staff
»» Excellence Teaching Citation from TUSM Clerkship students
»» Outstanding Teaching Award in the Preclinical years from Senior Class of Tufts University School of Medicine
»» Ranked as a top TUSM lecturer by preclinical medical students at TUSM
»» Co-chair, KDOQI Guideline Commentary Workgroup for the new KDIGO Chronic Kidney Disease Guideline Update.
»» Chair, Clinical Oversight Committee of KEEP
»» Member of the National Institute for Diabetes, Digestive and Kidney Disease: United States Renal Data System External Advisory
Committee and Vascular Access Consortium External Advisory Committee
»» Member, National Kidney Disease Education Program Laboratory Work Group.
»» Invited lecture: Invited lecture:
Nicolaos E. Madias, MD
»» Member, Advisory Board for the Hellenic Bioscientific Association in the USA
»» Invited lecture: American College of Physicians Internal Medicine Annual Meeting, Orlando FL
»» Invited lecture: 18th Panhellenic Congress of Nephrology. Alexandroupolis Greece
»» Member, editorial boards of Hippokratia, Hellenic Medicine, International Angiology, Arterial Hypertension and Kidney: A current
survey of world literature
Klemens B. Meyer, MD
»» Recognized as a “Top Doctor” by Boston Magazine
»» Received Distinguished Faculty Award from TUSM
»» Member, Quality Management Committee and Medical Information Steering Committee of Dialysis Clinic Inc
»» Member, Renal Disease and Detoxification Committee of the Association for the Advancement of Medical Instrumentation
»» Member, American Association of Kidney Patients Medical Advisory Board
»» Member, USRDS External Advisory Committee and Fistula First Breakthrough Initiative
»» Invited Lecture: Invited Lecture:
»» Member, Quality Management Committee of Dialysis Clinic Inc
»» Chair, Endpoints Committee for the HALT-PKD Study
»» Michelle M. Richardson, PharmD
»» Invited lecture: Health-related quality of life – It’s not just for social workers anymore. How every member of the IDT can use HRQOL
scores to impact patient care. 34th Annual Dialysis Conference Atlanta GA
»» Invited lecture: Measuring and improving patient experience in dialysis. 34th Annual Dialysis Conference, Atlanta GA
»» Recipient of the Shaul G. Massry Distinguished Lecture award from the National Kidney Foundation
»» Co-chair, Cardiovascular Health Study (CHS) Renal Work Group
»» Co-chair, KDIGO Clinical Practice Guideline for Lipid Management in CKD
»» Member, Steering Committee for CKD Prognosis Consortium
»» Invited lecture: Renal Rounds New York University, NY NY
»» Invited lecture: Hypertension in older CKD patients. NKF Spring Clinical Meeting Las Vegas NV
»» Invited lecture: Visiting professor Drexel University College of Medicine Hahnemann University Hospital
»» Excellence Teaching Citation from TUSM Clerkship students
»» Chair, ASN Quality Metrics Task Force
»» Co-chair, 2015 National Kidney Foundation Spring Clinical Meeting Program Committee
»» Chair designate, 2016 National Kidney Foundation Spring Clinical Meeting Program Committee
»» Grant reviewer, NIA GEMSSTAR review committee
»» Member, ASN Public Policy Board
»» Member, DCI Medical Director Research Committee and Quality Management Committee
»» Invited lecture: How to make real changes in a dialysis facility. NKF Spring Clinical Meeting Las Vegas NV
»» Invited lecture: Eating and enteral therapy during hemodialysis. NKF Spring Clinical Meeting Las Vegas NV
»» Invited lecture: Understanding the readmission problem in dialysis patients. NKF Spring Clinical Meeting Las Vegas NV
»» Invited lecture: Cognitive and psychosocial disorders. NKF Spring Clinical Meeting Las Vegas NV
»» Invited lecture: Literature review, dialysis 2013-2014. NKF Spring Clinical Meeting Las Vegas NV
»» Invited lecture: ESCOs and ACOs: Accountable care in nephrology. NKF Spring Clinical Meeting Las Vegas NV
»» Invited lecture: Fluid management in hemodialysis: what does the future hold? ASN Renal Week Philadelphia PA
»» Invited lecture: How to care for dialysis patients in a world of population quality metrics. ASN Renal Week Philadelphia PA
99
DIVISION OF
»» DIVISION OF PULMONARY, CRITICAL CARE AND SLEEP MEDICINE
PULMONARY, CRITICAL
CARE AND SLEEP
MEDICINE
The Pulmonary Division was established in 1971.
During the 31-year tenure of its first chief, Dr. Fanburg,
the Division grew to comprise ten active MD members
and two full-time PhD members.
Dr. Fanburg established a highly regarded basic research program that focused on metabolic
activities of the lungs including angiotensin converting enzyme activity as well as endothelial
cell biology. His more recent studies have focused on signal transduction pathways related to
Nicholas Hill, MD
serotonin, its transporter and receptors, in the regulation of pulmonary vascular smooth
muscle cell proliferation. Dr. Fanburg has received international recognition and numerous awards for his work.
Dr. Nicholas Hill assumed the directorship in 2002 and has expanded the clinical research activities in the division along
with a doubling in the size of the faculty. Clinical trials are underway on pulmonary hypertension, high flow nasal oxygen
and ventilator management of ARDS. There are also studies in progress to improve ventilator outcomes, especially
through the use of noninvasive ventilation. This modality has gained wide acceptance for its ability to improve outcomes
in patients with certain forms of respiratory failure.
The Division offers a wide array of clinical services. In the early 1990s, it became the Pulmonary and Critical Care Division
when it assumed the medical care of patients in the Medical Intensive Care Unit at Tufts Medical Center. The Center for
Sleep Medicine was incorporated in 2002 under the direction of Dr. Carolyn D’Ambrosio. In addition, specialty clinics in
asthma, pulmonary hypertension, TB, lung cancer and amyotrophic lateral sclerosis are conducted by the Division. The
addition of Dr. Maher Tabba in 2008 brought skills in interventional pulmonology to the Division. The Division also added
coverage of two intensive care units in Lowell, Massachusetts, at Lowell General Hospital and Saints Medical Center in
2013. Dr. Greg Schumaker was appointed to direct this aspect of the Division’s activities.
Highlights of 2014
»» Dr. Nicholas Hill appointed chair of the Steering Committee of the NIH-sponsored Pulmonary Vascular Diseaseomics project
»» Dr. Ioana Preston appointed Chair of the Educational Committee of the Pulmonary Hypertension Association
» » Dr. Kari Roberts serves as Associate Program Director of the Internal Medicine Residency program
» » Dr. Greg Schumaker directs the Lowell General and Saints Medical Center ICUs
»» Dr. Michael McBrine co-directs the ICU at BID-Plymouth Hospital in Plymouth, MA
» » The Division receives major NIH awards (Drs. Fanburg, Hill and Toksoz)
Faculty
Name
Nicholas Hill, MD
Professor
Division Chief
Director, Respiratory Department
Director, Pulmonary Hypertension Center
Christina Anderlind, MD
Assistant Professor
Walter Baigelman, MD
Associate Professor
Medical Director, Managed Care
Amy Chi, MD
Assistant Professor
Associate Director, Winchester Hospital ICU
Coordinator, Winchester Hospital ICU moonlighter program
Carolyn D’Ambrosio, MD
Associate Professor
Director, The Center for Sleep Medicine
John Devlin, Pharm D
Director, ICU Pharmacology Research Program
Special and Scientific staff
Scott Epstein, MD, FACP
Professor
Dean of Educational Affairs, TUSM
Barry Fanburg, MD
Professor
Director, Pulmonary Research
Geraldine Finlay, MD
Erik Garpestad, MD
Associate Professor
Associate Chief
MICU Director
Maher Ghamloush, MD
Assistant Professor
Director, Pathology Conference Series
Khalid Ismail, MD
Assistant Professor
Program Director, Sleep Medicine Fellowship
Usamah Kayyali, PhD, MPH, DPAT
Associate Professor
Sucharita Kher, MD
Assistant Professor
Director, Divisional Outpatient Services
Sebastian Kurz, MD, PhD*
Assistant Professor
Po-Shun Lee, MD
Associate Staff
Michael McBrine, MD
Assistant Professor
ICU Co-director, BIDMC/Jordan Hospital
Ioana Preston, MD
Assistant Professor
Pulmonary Function Lab Director
Co-Director, Pulmonary Hypertension Center
Imrana Qawi, MD
Assistant Professor
Director, Pulmonary/Critical Care Ultrasound Services
Kari Roberts, MD
Associate Professor
Medical Director, Bronchoscopy Service
Associate Program Director, Internal Medicine Residency Program
Russel Roberts, Pharm D*
Senior Clinical Pharmacy Specialist
Greg Schumaker, MD
Assistant Professor
Director, Outpatient Pulmonary Clinic
Director, Lowell General and Saints MC ICUs
Medical Director, Rapid Response Team
Medical Director, Clinical Resource Nurse Program
Amy Simon, MD
Director, Asthma Center
Maher Tabba, MD, FACP
Associate Professor
Program Director, Fellowship Program
Director, Pulmonary Interventional Service
Deniz Toksoz, PhD
Associate Professor
Academic Rank
* New member in 2014
101
The Pulmonary, Critical Care and Sleep Division at Tufts Medical Center offers a broad array of clinical services.
The Critical Care Program, under Dr. Erik Garpestad, oversees the delivery of medical critical care at Tufts Medical
Center. The program provides daytime coverage by a board-certified intensivist seven days a week, as well as nightly
phone coverage by fellows and attendings. Dr. Amy Chi serves as Associate Director of the ICU at Winchester Hospital.
Fellows cover this unit with attending backup for 12 hours, five days a week, and the Division coordinates coverage by
intensivists on evenings and weekends. The Division also provides daytime coverage and overall direction of two ICUs at
Lowell General Hospital and Saints Medical Center, respectively, under the direction of Greg Schumaker, MD.
The Center for Sleep Medicine, under Dr. Carolyn D’Ambrosio, provides diagnostic and therapeutic services for patients
with a variety of sleep-related disorders. It consists of an eight-bed, fully accredited sleep laboratory at Tufts Medical
Center. It serves as an important educational resource for the Pulmonary and Critical Care Fellowship Program.
The Bronchoscopy Service, under Dr. Kari Roberts, offers diagnostic and therapeutic bronchoscopies for inpatients and
outpatients attending Tufts Medical Center.
The Pulmonary Interventional Service, under Dr. Maher Tabba, offers a wide range of advanced pulmonary interventional
procedures that include percutaneous placement of tracheostomy tubes, placement of stents for airway narrowing,
medical thoracoscopy and other pleural procedures including thoracoscopy drainage and pleurodesis. Plans are in place
to obtain fluorescent technology to identify occult airway cancers.
The Division also offers numerous outpatient general and specialty clinics for asthma, sleep disorders and pulmonary
hypertension.
The Division teaches the second-year pathophysiology course at Tufts University School of Medicine, providing didactic
lectures and leading small discussion groups. Third-year clerkships are available on the Pulmonary ward service. A
number of Pulmonary attendings have been recognized by medical students for their teaching.
Fourth-year clerkships are available in the MICU at Tufts Medical Center and at the Winchester Hospital ICU. Electives
are also available on the Pulmonary consultation service, as well as in the Sleep Laboratory and on the Pulmonary
Interventional Service under Maher Tabba. Medical residents experience rotations on the Pulmonary ward and MICU
services, and may choose electives on the Pulmonary consultation service. Division members have received many
teaching awards.
There are ACGME-accredited fellowships in Pulmonary and Critical Care medicine, as well as in Sleep Medicine. The
Division also offers unaccredited fellowships in interventional medicine and pulmonary vascular disease. There are
three fellows in each year of the three-year Pulmonary Critical Care fellowship, and there is an option for additional
years for those wishing a more in-depth research experience. The Sleep Fellowship has one position per year.
Fellows rotate through the ICUs and consultation rotations at Tufts MC during their first year. During the second and
third years, fellows serve as the in-house intensivist at the Winchester Hospital ICU, at the ICUs at Lowell General and
Saints Medical Center, and pursue research interests. These can be in a wide range of areas including basic,
translational and clinical pulmonology. Fellows are encouraged to collaborate with investigators at other institutions if
additional expertise is desired. Most graduates have taken clinical academic positions or have gone into clinical
practice, and some have pursued basic science or clinical research careers
Clinical Research Support
The ongoing clinical research projects within the Division have an annual budget of approximately $480,000.
Recipient
Purpose of Award
Actelion
Phase 3b study of macitentan in patients with pulmonary arterial
hypertension to psychometrically validate the PAH-SYMPACT
instrument
Actelion
Long-term effect of combination therapy with Bosentan and sildenafil
Actelion
Study to assess the safety and tolerabllity of ACT-064992 in patients
with symptomatic pulmonary arterial hypertension (blinded and open
label)
United Therapeutics
A post-marketing observational study to assess respiratory tract
adverse events in pulmonary arterial hypertension patients treated
with Tyvaso (treprostinil) inhalation solution
United Therapeutics
An open-label extension trial of UT-15C SR in subjects with pulmonary
arterial hypertension
United Therapeutics
A phase III, international, multi-center, randomized, double-blind,
placebo-controlled, clinical worsening study of UT-15C in subjects
with pulmonary arterial hypertension receiving background oral
monotherapy
Gilead
Long-term efficacy of Ambrisentan on pulmonary hypertension
patients
Pulmonary Division
Evaluation of endothelial progenitor cells in pulmonary hypertension
Pulmonary Division
Comparison of inhaled nitric oxide versus inhaled epoprostenol as
acute pulmonary vasodilators
Pulmonary Division
Database and DNA tissue bank in pulmonary hypertension
Chest Foundation Respironics
Enhancing utilization of non-invasive ventilation in critical care
Gilead
Assesses the effect of an up- front combination of Tadalafil and
Ambrisentan compared to each drug alone in patients with pulmonary
Pulmonary Division
Sleep during non-invasive ventilation in the ICU
Hospira
Use of dexmetatomidine as sedative agent during non-invasive
ventilation
Hoffman-La Roche
A Phase II, randomized, double-blind, placebo-controlled study
to assess the efficacy and safety of Lebrikizumab in patients with
idiopathic pulmonary fibrosis
Pulmonary Division
Evaluation of total face mask for non-invasive ventilation
INO Therapeutics LLC
Ikaria, Inc.
Determines safety, tolerability and efficacy of pulsed, inhaled nitric
oxide versus placebo as add-on therapy in symptomatic subjects with
pulmonary arterial hypertension
PHAROS
Examines natural history of scleroderma in registry centered at
Georgetown Medical Center
Breathe Technologies
Effect of noninvasive open ventilation (NICU) on work of breathing in
COPD patients
Bayer
An open-label phase IIIb study of riociguat in patients with inoperable
CTEPH or recurrent or persisting PH after surgical treatment who
are not satisfactorily treated and cannot participate in any other
CTEPH trial
Investigator-initiated
Randomized placebo controlled trial of Treprostinil and Tadalafil vs.
Treprostinil alone in patients with pulmonary arterial hypertension.
Centered at RI Hospital
Nicholas Hill, MD
103
Funding Source
Res earch Act i v i t i es (c on t i nu e d )
Recipient
Nicholas Hill, MD (continued)
Sucharita Kher, MD
Ioana Preston, MD
Kari Roberts, MD
Funding Source
Purpose of Award
REATA Pharmaceuticals
A dose-ranging study of the efficacy and safety of bardoxolone
methyl in patients with pulmonary arterial hypertension
Respironics
High intensity non-invasive positive pressure ventilation (NPPV) for
stable hypercapnic COPD patients
Fisher & Paykel Health
Pilot study of optiflow as a NIV rest therapy
Gilead
A Phase 2 randomized, double-blind, placebo-controlled multicenter study to assess the efficacy and safety of GS-6624 in
subjects with idiopathic pulmonary fibrosis
NIH/NHLBI
National biological sample and data repository for pulmonary
Novartis
The Steroid Sparing Effects of Omalizumab in Non-Cystic Fibrosis
ABPA
Gilead
Ambrisentan in portopulmonary hypertension
Actelion
Opus Registry/OPsumit Users Registry
Bayer HealthCare
Motion – a Phase IV, prospective, single arm, open-label study to
measure outcomes in patients with PAH not on active treatment
Bayer HealthCare
Respite – An open-label, international multicenter, single arm,
uncontrolled, phase 3b study of riociguat response to treatment
with phosphosdiesterase-5 inhibitors (PDE-5i)
Brigham and Women’s
The combination Ambrisentan plus Spironolactone in PAH
Gilead
A Phase 2, dose-ranging, randomized, double-blind, placebocontrolled study of GS-4997 in subjects with PAH
George Washington Univ
Pharos – Pulmonary hypertension assessment and recognition of
outcomes in scleroderma
Pulmonary Division
Database and tissue bank for study of pulmonary hypertension
NIH/NHLBI
Estrogen signaling in portopulmonary hypertension
Bas ic Res ea rch Su p p or t
For the past 43 years the Division has been actively involved in NIH-supported research programs that have utilized
biochemical, cell biologic and molecular biologic systems to study pulmonary disease. A variety of investigators from the
Division, including both MDs and PhDs, have performed these studies. Members of the Division regularly participate in
national advisory and grant review committees. The Division has received present research grant support totaling $600,000.
Recipient
Nicholas Hill, MD
Funding Source
Purpose of Award
NIH/NHLBI
Determine the role of endothelial and angiotension receptor
signaling in pulmonary hypertension. (Peter Polgar, PI) (Nicholas
Hill, co-investigator)
NIH/NHLBI
Exploring the trends of use of noninvasive ventilation in COPD
over the past decade using a large multi-hospital database and
to determine barriers to greater use. (Lindenauer, PI; Hill, coinvestigator)
Genzyme
Evaluation of neutral endopeptidase inhibitor + nitric oxide in rates
with pulmonary hypertension induced by monocrotalins
Recipient
Purpose of Award
Barry Fanburg, MD
NIH/NHLBI
Determine the role of the serotonin transporter in serotonylation
of cellular proteins, including fibronectin, that leads to smooth
muscle cell proliferation and migration and development of
pulmonary hypertension
(Hill, collaborator; Toksoz, co-investigator)
Usamah Kayyali, PhD
NIH-NHLBI
Demonstrate how inactivation of p38 MAP kinase signaling by
anthrax lethal toxin leads to the vascular leak associated with
anthrax lethality
Deniz Toksoz, PhD
NIH/NHLBI
Targeted Rho Kinase-1 KO mouse model for vascular smooth
muscle remodeling
Nicholas Hill, MD (selected items)
»» Invited lectures: "NIV: Compare and Contrast Adult and Pediatric Technology and Management Strategy"; "NIV: Noninvasive
Ventilation for Primary Respiratory Failure." 43rd Critical Care Congress, Society of Critical Care Medicine. Post Graduate Course
Speaker. San Francisco, CA
»» Invited lectures: "Molecular Mechanisms and Treatment of Heart and Lung Disease." Joint Symposium, Excellence Cluster
Cardiopulmonary Systems (ECCPS) and Pulmonary Vascular Research Institute (PVRI). Robin Barst Memorial Lecture: "Pulmonary
Vascular Abnormalities in Lung Disease from a Global Perspective." Bad Nauheim, Germany
»» Invited lecture: "High Flow Nasal O2. What is it? How do we use it?" 37th Annual Meeting and Educational Conference, NAMDRC.
Sonoma, CA
»» Invited lecture: "Long-Term Applications of NIV." Pulmonary Grand Rounds. Lahey Hospital and Medical Center, Burlington, MA
»» Invited lecture: "Non-Invasive Ventilation: News, Use and Abuse." 6th Critical Care Symposium; Lead and Improve Outcomes. Long
Beach Memorial Medical Center, Long Beach, CA
»» Invited lectures: "From Bench to Clinic: A Case-Based Approval; Diagnostic Dilemmas Part I". Scientific Symposium: Dispelling
Myths and Promoting Health Research Partnerships between Academia and Industry: "Strategies for Integrating Industry Support
into an Academic Pulmonary and Critical Care Medicine Research Program; Progress or Peril". American Thoracic Society
International Conference, San Diego, CA
»» Invited lecture: "Non-Invasive Ventilation: Use, Abuse and News:. 6th Annual Joseph and Suzanne Seidemann Lectureship in
Pulmonary and Critical Care Medicine, Rutgers Robert Wood Johnson Medical School. New Brunswick, NJ
»» Invited lecture: "Inhaled Drugs for Pulmonary Hypertension." American Association for Respiratory Care, AARC. ACRF for
Conference Drug in PH. St. Petersburg, FL
»» Invited lectures: "Current Management of Pulmonary Hypertension." Simply Speaking, Albany, NY and Miami, FL
»» Chair - Symposium for Fellows. Prime Symposium for PAH. Lecture: Pathophysiology: Prostacyclines for PAH" and "New Directions".
Chicago, IL
»» Invited lectures: "OSA and Cardiovascular Co-Morbidities", "Assessment and Management of Sleep-Disordered Breathing in Chronic
Respiratory Failure" and NIV for Chronic Respiratory Failure." The Alaska Sleep Conference, Anchorage, AK
»» Invited lecture: "An Overall View of Non-Invasive Mechanical Ventilation in ALI/ARDS: Are we Wasting our Time or is There Real
Benefit from this Modality?" The 18th Annual Thomas J. Godar Pulmonary/Critical Care Symposium. Saint Francis Hospital,
Hartford, CT
»» Invited lecture: "NIV; Where have we Been, Where are we Going". Medical Grand Rounds, Weill Cornell Medical Center, New York, NY
»» Faculty, Postgraduate Course. CHEST 2014, the American College of Chest Physicians Annual Meeting. "Leadership Development
Course: A Conversation with Dr. Hill: A Leader's Personal Journey." Non-CME Symposium: The Evolution of Clinical Management in
PAH: Perspectives on Treatment Approaches." Austin, TX
105
Funding Source
»» Invited lectures and Faculty: "Noninvasive Ventilation for Chronic Lung Disease," "What's New in Pulmonary Hypertension,"
"Pulmonary Hypertension - Are we Making Progress?", "Noninvasive Ventilation: The Horizon is Expanding." Bali, Indonesia
»» Moderator: "Mechanical Ventilation and Weaning." Canadian Critical Care Forum. Editorial Comment: "Mechanical Ventilation - Focus
on NIV." Toronto, CA
»» Course Director: 12th Annual Update in Pulmonary Hypertension Symposium. Concurrent Patient Session; Patient Questions &
Answers. "The New Meds: What are they? How are they used?" Plenary Session: "Inhaled Therapies are very much Alive" and
"What's New in Endothelial Receptor Antagonists?" Cambridge, MA
»» Invited lecture: "Diaphragm Paralysis - Diagnosis and Therapy." Medical Grand Rounds, Metrowest Medical Center, Natick, MA
»» Boston Magazine's "Top Doctors"
Christina Anderlind, MD
»» Invited lecture: "Pulmonary Nodules", Lemuel Shattuck Hospital, Boston, MA
»» Invited lecture: "Pulmonary Infiltrates in the Immune Compromised", Lemuel Shattuck Hospital, Boston, MA
Scott Epstein, MD
»» Panel Member, Liberation from Mechanical Ventilation: An Official American College of Chest Physicians/American Thoracic Society
Clinical Practice Guideline
Erik Garpestad, MD
»» American Thoracic Society membership subcommittee
»» Boston Magazine's "Top Doctors"
Usamah Kayyali, PhD
»» Invited lecture: "Targeting Signaling that Regulates the Cytoskeleton in Lung Disease", NIH, National Heart, Lung and Blood Institute,
Lung Division, Bethesda, MD
»» American Thoracic Society International Conference, three presentations; San Diego, CA
»» Grant reviewer for the NIH Respiratory Integrative Biology and Translational Research Study Section
»» Grant reviewer for the NIH-HLBP Program Project Review Workgroup 014
»» Grant reviewer for the NIH-ZHL1 CSR-P (S1) Clinical Centers for Pulmonary Vascular Disease Phenomics
»» Grant reviewer for the State of California Tobacco-Related Disease Research Program
Sucharita Kher, MD
»» Quality Improvement Academy II: Committee on "Moving through your visit". Taskforce focused on improving patient experience
during an outpatient visit.
»» Member, Taskforce on Older Adults with Asthma in Massachusetts. Department of Public Health
»» Women in Medicine Committee, Tufts Medical Center, Department of Medicine
Ioana Preston, MD
»» American Thoracic Society International Conference. Chair of postgraduate course and speaker; "Update in Pulmonary
Hypertension" and "Current Phenotypes in PAH". Research Presentation "Effect of Warfarin Treatment on Survival of Patients with
PAH", REVEAL Registry. San Diego, CA
»» Invited lecture: "Pulmonary Hypertension in Pregnancy". Pulmonary Vascular Research Institute, Giessen, Germany
»» Invited lecture: "Chronic Thromboembolic Pulmonary Hypertension". European Respiratory Society Annual Congress. Munich,
Germany
»» CHEST 2014; the American College of Chest Physicians Annual Meeting. Chair of the Scientific Oral Poster Presentation in
Pulmonary Hypertension. San Antonio, TX
»» Invited lecture: "Diagnosing Chronic Thromboembolic Pulmonary Hypertension". European Pulmonary Hypertension Forum.
Frankfurt, Germany
»» 12th Annual Update in Pulmonary Hypertension Symposium. Co-Director and Discussion leader; "Pulmonary Artery Hypertension:
New Molecules & New Insights" Cambridge, MA
»» Invited lecture: "Pulmonary Hypertension Associated with Sarcoidosis". International Heart and Lung Transplant Society Meeting.
San Diego, CA
»» Invited lecture: "Chronic Thromboembolic Pulmonary Hypertension; an Update". LXXIII Congress of Pneumology and Thoracic
Surgery. Queretaro, Mexico
Indianapolis, IN
»» Invited lecture: "Update on Chronic Thromboembolic Pulmonary Hypertension". Latin American Respiratory Society Meeting.
Medellin, Colombia
»» IRB Committee Member, Tufts Medical Center
»» Research Advocacy Committee member, American Thoracic Society
»» Chair, Educational Committee, Pulmonary Hypertension Association
»» Scientific Leadership Council member, Pulmonary Hypertension Association
»» Grant reviewer for the National Institutes of Health, American Heart Association and Department of Defense
Kari Roberts, MD
»» 12th Annual Update in Pulmonary Hypertension Symposium. Co-Director and Moderator; "Functional Class II, IIIa PAH". Cambridge, MA
»» American Thoracic Society Programming Committee, Pulmonary Circulation Assembly
»» Chair, Networking Subcommittee, Tufts Medical Center
»» American Thoracic Society Members in Transition and Training Committee
»» Pharmacy and Therapeutics Committee Member, Tufts Medical Center
»» TUSM Notable Teaching recognition, Medicine Clerkship, third-year students
»» Boston Magazine's "Top Doctors", Pulmonary Medicine
Greg Schumaker, MD
»» Invited lecture: "Updates on Sepsis", Grand Rounds, Lowell General Hospital, Lowell, MA
»» Invited lecture: "Sepsis Management" Lowell Cardiovascular Conference, Lowell, MA
»» Co-Chair, VAP Prevention Task Force, Tufts Medical Center
»» Co-Chair, Pneumonia Care Committee, Tufts Medical Center
»» Co-Chair, Rapid Response Task Force, Tufts Medical Center
»» UIT Prevention Task Force member, Tufts Medical Center
»» Critical Care Committee member, Tufts Medical Center
107
»» Invited lecture: "Pulmonary Arterial Hypertension; What the Future Holds". Pulmonary Hypertension Association meeting.
DIVISION OF
RHEUMATOLOGY
»» DIVISION OF RHEUMATOLOGY
The Division of Rheumatology offers comprehensive
evaluation, consultation, and management of arthritis
and rheumatic disease. The clinical practice focuses on diagnosis and
treatment of the full spectrum of musculoskeletal and autoimmune rheumatic disorders.
Research in the Division is centered on investigations of the pathogenesis of osteoarthritis,
new quantitative methods to measure its progression, and clinical trials of disease-modifying
investigational treatments. There is an active program in the use of Tai Chi for chronic
Timothy McAlindon, MD
rheumatic diseases such as osteoarthritis, fibromyalgia, and systemic lupus erythematosus.
The Center for Treatment Comparison and Integrative Analysis (CTCIA) generates evidence
reports, health technology assessments, and clinical practice guidelines.
Highlights of 2014
» » Dr. Senada Arabelovic was awarded a Medical Student Clinical Preceptorship Grant
» » Dr. Raveendhara Bannuru obtained a PhD in clinical and translational science from Tufts University
» » Dr. Steven Vlad was appointed to the faculty of the Tufts CTSI (Research Design Center)
» » Dr. Chenchen Wang was promoted to Professor of Medicine at Tufts University of Medicine
Faculty
Academic Rank
Senada Arabelovic, DO
Assistant Professor
Pediatric/Adult Transitional Clinic
Associate Program Director of Fellowship &
Course Director for Medical Student on Electives
Raveendhara Bannuru, MD, PhD
Assistant Professor
Director, Center for Treatment Comparison &
Integrative Analysis
Juan Canoso, MD
Adjunct Professor
Clinical Anatomy
Jeffrey Driban, PhD
Assistant Professor
Research
Aleksander Feoktistov, MD
Adjunct Assistant Professor
Musculoskeletal Ultrasound Program
William Harvey, MD, MSc
Assistant Professor
Clinical Director
Robert Kalish, MD
Associate Professor
Program Director
Grace Lo, MD
Adjunct Assistant Professor
Osteoarticular Research Program
Timothy McAlindon, MD, MPH
Professor
Division Chief
Steven Vlad, MD, PhD
Assistant Professor
Industry Sponsored Clinical Trials
Chenchen Wang, MD, MSc
Professor
Director, Center for Complementary and
Integrative Medicine
Janeth Yinh, MD
Assistant Professor
The Center for Arthritis and Rheumatic Diseases
The Center for Arthritis and Rheumatic Diseases provides ambulatory consultation and follow-up as well as inpatient
consultation services. The spectrum of rheumatic disorders treated by the Rheumatology Division is broad and
encompasses musculoskeletal disorders and complex autoimmune diseases. Areas of expertise include ankylosing
spondylitis, autoimmune rheumatic disorders, bone health, bursitis and tendonitis, gout, inf lammatory muscle
diseases, lupus, Lyme disease, osteoarthritis, psoriatic arthritis, rheumatoid arthritis, and vasculitis. Several members
of the division have expertise in Musculoskeletal Ultrasound. The division also has a newly establish weekly urgent care
clinic to accommodate urgent referrals for diagnosis or treatment of acute or severe presentations in rheumatic disease.
The Division's six faculty and two fellows see approximately 6,000 visits per year.
The Division strives to advance all three aspects of its mission; patient care, education, and research. Emphasis on
achieving these goals include diversifying services, building networks with community physicians and neighborhood
hospitals, offering high quality patient-oriented services, and developing clinically-relevant research programs.
To improve the care of patients, the Division has adopted the use of musculoskeletal ultrasound. This non-invasive
imaging technique provides an enhanced musculoskeletal evaluation that avoids exposure to the ionizing radiation
associated with other imaging techniques. Several of the faculty are skilled in its use and have designed a teaching
series to introduce trainees to this modality. Musculoskeletal ultrasound allows the dynamic assessment of joint and
tendon movements in a manner not possible through other routine imaging modalities. Ultrasound-guidance facilitates
the aspiration and injection of musculoskeletal tissues, improves diagnostic accuracy and therapeutic effectiveness, and
is valuable for research in rheumatology.
109
Name
Pediatric/Adult Transitional Clinic
The clinic is designed to transition pediatric patients with autoimmune disorders who have been followed at the
Floating Hospital for Children into an adult setting. The patients are seen by Dr. Senada Arabelovic.
Lyme Disease Specialty Clinic
Dr. Robert Kalish offers a weekly Lyme disease clinic in which patients are assessed for complex issues regarding the
diagnosis and treatment of Lyme disease. Dr. Kalish has long been involved in Lyme disease research, first studying the
humoral immune response in patients with Lyme arthritis in the 1990’s, and subsequently participating in a long-term
follow-up study of patients with Lyme disease in the Lyme, Connecticut area. He is invited regularly to speak on Lyme
disease for Medical Grand Rounds conferences.
Tufts University medical students from each of the four years rotate through the division. First year students have the
option of a selective with Dr. Kalish or other faculty. Second year students receive lectures by the division’s faculty in the
Musculoskeletal Pathophysiology course that is directed by Dr. Kalish. Fourth year medical students have the option of
completing a one month rotation in Rheumatology.
The Rheumatology Division conducts is involved in teaching medial students, residents, and fellows. Second and third
year residents rotate through the division and participate in the outpatient clinic and inpatient consultation services.
The Rheumatology Fellowship is a two year clinical and research based program that provide training for physicians
interested in specializing in Rheumatology. Each year, the division enrolls one new fellow and graduates physicians into
successful academic and clinical positions. Weekly educational conferences in the division include Rheumatology
Grand Rounds, Rheumatology Case Conference/Journal Club and Rheumatology Radiology Rounds.
Osteoarthritis (OA)
The goals of this program are to advance the
understanding of OA pathophysiology and to seek new
disease-modifying interventions. A critical component
is the development of valid outcome measures for OA
progression that are sensitive to change. Techniques
being explored include quantitative imaging of
articular cartilage, assessment of peri-articular bone
morphology using MRI, dual x-ray absorptiometry, gait
analysis, and the testing of physical function. These
approaches are addressed through epidemiologic
collaborations with the Osteoarthritis Initiative
consortium and through clinical trials. Diseasemodification trials of intra-articular corticosteroids,
vitamin D, collagen hydrolysate, and osteogenic
protein 1 are completed or in progress. The research
program is funded by grants from the NIH, the
American College of Rheumatology Research &
Education Fund, and by sponsorship from industry.
Center for Complementary and Integrative Medicine
The Center for Complementary and Integrative Medicine (CCIM) has been established within the Division of
Rheumatology in the Department of Medicine at Tufts Medical Center.
The primary mission of the CCIM is to improve health outcomes for patients with chronic medical conditions. The CCIM
focuses on the rigorous evaluation and investigation of cost-effective methods of complementary and alternative medicine
therapies. The center strives to integrate evidence-based, multi-disciplinary therapies into conventional care plans for
chronic disease prevention and treatment, providing high-quality clinical care to patients. The CCIM fosters informed and
knowledgeable patients, doctors and researchers through education fueled by national and international collaboration
The CCIM has three major areas of focus:
»» To conduct clinical research projects in therapies, specifically mind-body medicines.
»» To provide ongoing professional development for predoctoral and postdoctoral candidates and related healthcare professionals.
»» To implement and integrate scientific, evidence-based therapies into conventional medical practice, including Tai Chi mind-body
therapy, acupuncture and massage therapy.
Center for Treatment Comparison and Integrative Analysis (CTCIA)
The Center for Treatment Comparison and Integrative Analysis
(CTCIA) has been established within the Division of Rheumatology at
Tufts Medical Center. Using advanced evidence-based
methodologies; the CTCIA helps to answer a host of clinical,
regulatory and health policy questions.
Network of treatment comparisons for pain.
The CTCIA specializes in the development of evidence reports and
utilizes advanced meta-analysis methods to help connect research
with effective practice and guide informed policy decisions. The
center also provides assistance for international panels of experts in
the development of guidelines, supporting the development process
with evidence and methodological support. These evidence reports
have had a significant impact in health policy nationally and
internationally. Using innovative approaches the center has
successfully assisted clients in the regulatory process while securing
FDA approvals and labeling changes. This year the center has
published osteoarthritis guidelines in partnership with
Osteoarthritis Research Society International. The center also
published few other important studies which garnered a significant
amount of national and international media attention.
The CTCIA has three primary areas of focus:
»» To develop state-of-the-art evidence reports and technology assessments
»» To assist expert panels in developing evidence-based clinical practice guidelines.
»» To employ advanced comparative effectiveness research techniques to support FDA approval/regulatory processes.
Industry-Sponsored Trials
The sponsored trial program is supported by a clinical research coordinators and research assistants. The wide range of
pharmaceuticals tested range from new small molecules for fibromyalgia to biologics for immunologic disorders and
osteoarthritis to intra-articular substances for knee osteoarthritis. . The current panel of sponsored trials includes:
»» A multi-center, parallel, couble-blind, randomized, placebo-conrolled study to evaluate the safety and effectiveness of HYMOVIS®,
a new viscoelastic hydrogel, for the streatment of osteoarthritis of the knee
»» A phase 1, placebo-controlled, double-blind, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and
pharmacodynamics of SM04690 injected in the target knee joint of moderately to severe symptomatic osteoarthritis subjects
»» A phase 2a study evaluating the safety, efficacy, and pharmacodynamics effects of ABT-981 in patients with knee osteoarthritis
»» A randomized, double-blind, placebo- and active-controlled study of DS-5565 in subjects with pain associated with fibromyalgia
»» A randomized, double-blind trial assessing the impact of methotrexate discontinuation on the efficacy of subcutaneous tocilizumab
with methotrexate therapy
»» BOTOX® efficacy and safety in the treatment of knee osteoarthritis
111
Res earch S u p p or t H i g h l i g hts
Name
Title
Funding Source
Purpose of Award
Senada Arabelovic, MD
Principal Investigator
Rheumatology Research
Foundation
Medical Student Clinical Preceptorship
Genzyme
Comparative safety profile on Synvisc® for
knee osteoarthritis: a systematic review and
network meta-analysis
Co-Principal
Investigator
ACR
Clinical practice guideline development for
Rheumatoid Arthritis
Investigator
Osteoarthritis Research
Society International
Development of clinical guidelines for
osteoarthritis treatment
Co-Investigator
NIH
Clinical Trial of Tai Chi & Physican Therapy for
Knee Osteoarthritis
Co-Investigator
NIH
Clinical Trial of Tai Chi and Aerobic
Exercise of Fibromyalgia
Co-Investigator
NIH
Rapid Quantitative composite MRI measurement
of Knee OA structural progression
Principal
Investigator
NIH
Characterizaion of Rapidly Progressive
Knee Osteoarthritis
Co-Investigator
NIH
Clinical Trial of Tai Chi & Physical Therapy for
Knee Osteoarthritis
Co-Investigator
Fidia, Samumed,
Allergan, Abbvie
4 Clinical Trials in Knee Osteoarthritis
Co-Investigator
NIH
Effect of intra-articular steroids on structural
progression of knee OA: an RCT
Co-Investigator
NIH
Clinical Trial of Tai Chi and Aerobic Exercise for
Fibromyalgia
Gilead
Research Contract
Rheumatology Research
Foundation
Amgen/Wyeth Rheumatology Fellowship Training
Award
NIH/NIAMS
Effect of intra-articular steroids on structural
progression of knee OA: an RCT
NIH/NIAMS
Periarticular Bone Density as Biomarker for
early Knee OA
Co-Investigator
NIH/NIAMS
Efficacy of CAM on Patient Centered Outcomes
NIH/NIAMS
Rapid quantitative composite MRI measurement
of Knee OA structural progression
Co-Principal
Investigator
ACR
Clinical practice guideline development for
Rheumatoid Arthritis
NIH/NIAMS
Constitutional and Metabolic Factors associated
with the development of Hand OA
Co-Principal
Investigator
NIH/NIAMS
Characterization of Rapidly Progressive Knee
Osteoarthritis
Co-Principal
Investigator
PCORI
A Method for Patient-Centered Enrollment in
Comparative Effectiveness Trials: Mathematical
Equipoise
Co-Principal
Investigator
NIH/NCCAM
Tai Chi and Knee Osteoarthritis
Raveendhara Bannuru, MD,
PhD, FAGE
Jeffrey B. Driban, PhD,
ATC, CSCS
Robert Kalish, MD
Name
Funding Source
Purpose of Award
Co-Principal
Investigator
NIH/NCCAM
Tai Chi and Fibromyalgia
Osteoarthritis Research
Society International
Prevention and Treatment of Osteoarthritis
through the Promotion and Presentation
of Research, Education, and the Worldwide
Dissemination of New Knowledge.
Site Principal
Investigator
Genentech, DaiichiSankyo
Clinical trials of drugs for rheumatoid arthritis
and fibromyalgia
NIH/NCCAM
Clinical Trial of Tai Chi and Aerobic Exercise for
Fibromyalgia
NIH/NCCAM
Midcareer Investigator Award in Patient-Oriented
Research
NCCAM
Clinical Trial of Tai Chi and Physical Therapy for
Knee Osteoarthritis
NCCAM/NIH
Mentoring & Research in Patient-Oriented
Integrative Medicine
NIH/NCCAM
Clinical Trial of Tai Chi Mind-Body for the
Treatment of Post-Traumatic Stress Disorder
Primary Mentor
Donaldson Charitable
Trust Foundation
A Randomized Controlled Trial of Tai Chi for
Breast Cancer Survivors with Aromatase Inhibitor
associated Arthralgias
Primary Mentor
2014 Tufts Summer
Medical Student
Research Fellowship
Functional Balance and Well-being among
Patients with Fibromyalgia
Primary Mentor
Traditional Chinese
Medicine Universities
Mentoring and Clinical Research Training in
Chinese Investigators
Steven Vlad, MD, PhD
Chenchen Wang, MD
Raveendhara Bannuru, MD, PhD
»» Faculty of 1000 international award for excellent research presented at the Osteoarthritis Research Society International 2014 World
Congress, Paris, France
»» Plenary keynote speaker at the Mexican Federation of Orthopedic and Traumatology College (FEMECOT) 25th Congress (annual
meeting) held on October 21-25, 2014 in Leon, Guanajuato, Mexico
»» Session moderator: Annual Scientific Meeting of American College of Rheumatology, Boston, MA, USA, November 2014
»» Appeared in interviews with WBZ Channel 4/ CBS Boston, Boston Globe, and Reuters on the shockwave therapy article published in
Annals of Internal Medicine
»» Advisory Committee: Postdoctoral Affairs Office for Tufts University School of Medicine
»» Clinical and Translational Science Curriculum Committee for MS/PhD Graduate Program of the Tufts Clinical and Translational
Science Institute and the Sackler School of Graduate Biomedical Sciences, Tufts University
»» Core Expert Panel Member and Evidence Synthesis Team Leader: Osteoarthritis Treatment Guideline Development Group (OAGDG)
for Osteoarthritis Research Society International
»» Guidelines Core Oversight Team: American College of Rheumatology Committee on ACR Guidelines for the Treatment of
»» Rheumatoid Arthritis
113
Title
Jeffrey Driban, MD
»» Research Travel Award, Tufts Medical Center
»» NATA Representative to the Osteoarthritis Action Alliance
»» Committee Member, National Athletic Trainers’ Association Research and Education Foundation Free Communications
Subcommittee
»» Associate Editor, BMC Musculoskeletal Disorders
»» Committee Member, Eastern Athletic Trainers’ Association Research Committee
»» Physician Liaison for Ambulatory EHR, Tufts Medical Center
»» Clinical Director, Division or Rheumatology, Tufts Medical Center
»» ICD-10 Clinical Liaison, Tufts Medical Center
»» Care Improvement Council, Tufts Medical Center
»» Chair, Committee on Government Affairs, American College of Rheumatology
»» Invited Witness, US House of Representatives Energy & Commerce Committee Hearing, June 12, 2014, Barriers to Specialty Care
and Treatment
Robert Kalish, MD
»» Boston Magazine. “Top Doctors”
»» Tufts University School of Medicine Award for Excellence in Teaching, 2014
»» American College of Rheumatology Educational Grant Study Section
»» American College of Rheumatology – State of the Art Meeting Planning Committee
Timothy McAlindon, MD MPH
»» Boston Magazine. “Top Doctors”
»» Co-Editor, Arthritis and Rheumatism
»» Board of Directors, OARSI
»» Committee Chair, OARSI OA Treatment Guidelines
»» ACR RA Clinical Treatment Guidelines, literature Review Team Leader
Steven Vlad, MD PhD
»» Tufts University School of Medicine Curriculum Committee
Chenchen Wang MD, MSc
»» Excellence Presentation Award in 2014 Beijing International Acupuncture and Neurology Seminar, Beijing, China
»» Excellence Presentation Award in 2014 International Congress of Oriental Medicine in Taipei, Taiwan.
»» Outstanding Research Award, the 2014 International Tai Chi Symposium, Las Vegas, US
»» Dr. Chenchen Wang was promoted as Professor of Medicine at Tufts University of Medicine
115
THE INSTITUTES
Tufts Me di ca l Cen ter h a s th re e I n st i t u tes w h i ch a re n a t i on a l l y kn ow n fo r
thei r bas i c a n d c l i ni ca l resea rch a ct i v i t i es. T h e I n st i t u tes d o n ot re p o rt
di re c tl y to the Depa rtment of M e d i ci n e b u t m a ny of t h e i r m e m b e rs carry
out c l i ni ca l a c ti v i ti es w i thi n t h e va r i ou s d i v i si on s.
INSTITUTE FOR
CLINICAL RESEARCH AND
HEALTH POLICY STUDIES
»» INSTITUTE FOR CLINICAL RESEARCH AND HEALTH POLICY STUDIES
The Institute for Clinical Research and Health Policy Studies (ICRHPS)
is a hospital-wide enterprise that includes members of many clinical
departments of Tufts Medical Center. Academic appointments and clinical activities of
Institute members are conducted through the Division of Clinical Care Research (CCR) of the Department of Medicine. In
addition, some faculty members have clinical appointments in departments other than the Department of Medicine.
These cross-appointments enhance research and the leadership role of the Institute in the broader Tufts campus.
About half of the Institute’s research is federally supported, primarily by the National Institutes of Health (NIH) and the
Patient Care Outcomes Research Institute (PCORI). The Institute’s research involves the study of clinical features of
disease; the optimal use of treatments and of evidence; measurement of the outcomes of healthcare interventions; and
the influence of socioeconomic, organizational, and policy factors on healthcare. Over the past 20 years, as a result of
ICRHPS/CCR-based research, Tufts Medical Center has had the world’s highest average ISI citation index in health care
research, and has been most often ranked first of any institution. In addition to its research portfolio, ICRHPS has an
AHRQ-funded T32 Training Program.
Through the efforts of the ICRHPS faculty, and faculty throughout the Department of Medicine and the Tufts campus, the
Tufts Clinical and Translational Science Institute (Tufts CTSI) was established in August 2008 with a grant from the NIH.
The CTSI’s promotion of collaborative, full-spectrum translational research has a substantial impact on the conduct of
research at Tufts and at affiliated hospitals across Massachusetts and Maine. The Tufts CTSI includes the Research
Design Center-Biostatistics Research Center (RDC-BRC), the Clinical and Translational Science Center (formerly the
Tufts GCRC), and the Clinical and Translational Research Graduate Program of the Tufts Sackler School. The Graduate
Program provides research training to ICRHPS fellows and to trainees throughout many Tufts Medical Center clinical
departments and divisions. The RDC-BRC provides support to all Tufts departments and divisions in biostatistics, study
design, data collection, budgetary planning, writing, and related project development.
Highlights of 2014
» » Receipt of $6,162,235 in new funding for 25 new research projects in 2014
» » 72 different research projects
» » Authorship by faculty of 120 articles in over 90 different journals
» » Recognition of faculty by participation in many national panels
Name
Academic Rank
Professor
Division Chief
Executive Director, Institute for Clinical Research and Health
Policy Studies
Dean, Tufts Clinical and Translational Science Institute
Director, CCHSR
David Adler, MD
Professor, Psychiatry and Medicine
Clinician-Researcher, CHS
Ethan Balk, MD, MPH
Associate Professor
Director, CCES
Joni Beshansky, RN, MPH
Associate Professor (left in 4/14)
Assistant Director, CCHSR
Janis Breeze, MPH
Instructor
Epidemiologist, RDC-BRC
James Chambers, PhD
Assistant Professor
CEVR
Hong Chang, PhD
Assistant Professor
CHS
Biostatistician, RDC-BRC
Joshua Cohen, PhD
Research Associate Professor
CEVR
Denise Daudelin, RN, MPH
Assistant Professor
Project Director, CCHSR
Karen Freund, MD
Professor
Co-PI, Tufts CTSI
Director, Program on Equity in Health and Science
Richard Hermann, MD
Associate Professor of Medicine and
Psychiatry
CHS
David Kent, MD, MS
Professor
Director, Clinical and Translational Research Graduate
Program, Sackler School
Director, PACE
CCHSR
Manlik Kwong, BS
Adjunct Instructor
Software Engineer, CCHSR
Deborah Lerner, MS, PhD
Professor of Medicine and Psychiatry
Director, Program on Health, Work and Productivity, CHS
Laurel Leslie, MD
Professor, Medicine and Pediatrics
THI
Tufts CTSI
Pei-Jung Lin, PhD, MS
Assistant Professor
CEVR
Thomas Mackie, PhD
Assistant Professor
CHS
Jason Nelson, MPH
Instructor
PACE
Peter Neumann, ScD
Professor
Director, CEVR
Professor of Medicine and Pediatrics
Director, CHS
Director, Center for Child and Family Outcomes
119
Faculty
Name
Academic Rank
Jessica Paulus, ScD
Assistant Professor
Associate Director and Epidemiologist RDC-BRC
Associate Director, Sackler Graduate Program
Lori Lyn Price, MAS
Instructor
Gowri Raman, MD, MS
Assistant Professor
CCES
Angie Mae Rodday, MS
Assistant Professor
CHS
William Rogers, PhD
Research Assistant Professor
CHS
Carolyn Rubin, EdD
Assistant Professor (left 7/1/14)
CHS
Tufts CTSI
Robin Ruthazer, MPH
Assistant Professor
Associate Director and Biostatistician, RDC-BRC
CCHSR
PACE
Dana Gelb Safran, ScD
Associate Professor
CHS
Saeid Shahraz, PhD
Assistant Professor-pending
PACE
Djora Soeteman, PhD
Assistant Professor
PACE
Norma Terrin, PhD
Associate Professor
Director and Biostatistician, RDC-BRC
CHS
Hocine Tighiouart, MS
Instructor
Lisa Welch, PhD
Assistant Professor
Evaluation Manager, Tufts CTSI
Research center abbreviations:
RDC-BRC = Research Design Center-Biostatistics Research Center
CCES = Center for Clinical Evidence Synthesis
CCHSR = Center for Cardiovascular Health Services Research
CEVR = Center for Evaluation and Risk in Health
PACE = Predictive Analytics and Comparative Effectiveness Center
CHS = Center for Health Solutions (formerly The Health Institute)
Ass ociate a n d Ad j u n c t St a ff Aff ilia t io n s
Alawi Alsheikh-Ali, MD, MS
Sheikh Khalifa Medical City, Abu Dhabi, UAE
Mohan Bala, PhD, MBA
Sanofi-Aventis
Peter Bonis, MD
Kathleen Bungay, PharmD
Northeastern University
Joseph Cappelleri, PhD
Pfizer, Inc
Ralph D’Agostino, Sr., PhD
Boston University
Issa Dahabreh, MD, MS
Brown University
Olaf Damman, MD
Jonathan Davis, MD
Roger Fielding, MD
Tufts HNRC
Frederick Frankhauser, JD
Gary Freeman, MD
Zoll Medical
Seyyed Nassir Ghaemi, MD, MPH
Alexandra Glazier, JD, MPH
New England Organ Bank
Baystate Medical Center
Elizabeth Goodman, MD
Massachusetts General Hospital
Alice Gottlieb, MD
William Gouveia, PharmD
Daniel Greenberg, PhD
Ben Gurion University of the Negev, Israel
David Greenblatt, MD
Tufts University
Judy Hinchey, MD
Caritas St. Elizabeth’s Medical Center
Gordon Huggins, MD
John Ioannidis, MD
Stanford University
Bertrand Jaber, MD
Caritas St. Elizabeth’s Medical Center
Jeroen Jansen, PhD
MAPI Group
Howard Jen, MD
Georgios Kitsios, MD, MS, PhD
Lahey Clinic
Jeffrey Lasker, MD
NEQCA
Mary Lee, MD
Tufts University
Andrew Levey, MD
Peter Lindenauer, MD, MSc
Alice Lichtenstein, DSc
Tufts Friedman School/HNRC
John Mason, PhD
Blue Cross Blue Shield of Massachusetts
Kimberley McGuigan, PhD, MBA
Pfizer, Inc
Sandeep Menon, BHMS, MPH, PhD
Pfizer, Inc
Vandana Menon, MD, PhD, MPH, MS
Outcome Sciences, Inc.
Catherine Milch, MD, PhD
Millenium Pharmaceuticals
Stephen Pauker, MD
Brian Pereira, MD
AMAG Pharmaceuticals, Inc.
Inga Peter, PhD
Mount Sinai Medical Center
Thomas Pfeiffer, DNS
Harvard University
Rosalie Phillips, MPH
Tufts Public Health
Anastassio Pittas, MD
Douglas J. Reichgott
Michael Rothberg, MD
Mark Sarnak, MD, MS
Caroline Schwartz, ScD
DeltaQuest Foundation
Joanna Seddon, MD
Robert Sege, MD
Boston Medical Center
Radley Sheldrick, MD
David Snydman, MD
Paul Stark, ScD
Tufts School of Dental Medicine
Gary Strauss, MD
Teruhiko Terasawa, MD
Fujita Health Univ School of Medicine, Japan
James Udelson, MD
Katrin Ulhig, MD, MS
Chenchen Wang, PhD
Christine Wanke, MD
John Ware, PhD
University of Massachusetts Medical School
Elias Zintzaras, MD, PhD
Univ of Thessaly School of Medicine, Greece
Deborah R. Zucker, MD
American Federation of Medical Research
Robert Goldberg, PhD
121
The Division of Clinical Care Research/ICRHPS has no clinical programs of its own. Physician-Researcher Division
members have appointments in Internal Medicine and Adult Primary Care, Neurology, Pediatrics, and Psychiatry where
they are active participants in clinical activities. Among those with primary appointments in the Division, clinical
activities are as listed below:
» » Harry Selker, MD
Internal Medicine and Adult Primary Care/Pratt Diagnostic Clinic
» » David Adler, MD»
Psychiatry
» » Karen Freund, MD»
» » Howard Jen, MD»
Pediatric Surgery
» » David Kent, MD»
» » Laurel Leslie, MD»
General Pediatrics
» » Susan Parsons, MD»
Adult and Pediatric Hematology- Oncology
Faculty in the Division of CCR/ICRHPS teach courses and seminars in clinical research methods to faculty, fellows,
residents, and administrative staff. In addition to teaching at Tufts Medical Center and other Boston institutions,
ICRHPS faculty have given courses around the world. Primarily, however, faculty members of the Institute are involved
with the teaching activities in the Tufts Clinical and Translational Science (Tufts CTSI) Clinical Research Curriculum,
MS/PhD Clinical Research Graduate Program of the Tufts Sackler School of Biomedical Sciences.
The CTS graduate program, under the direction of Dr. David Kent, aims to train the next generation of leaders and
innovators in the application of methods of health services research, especially to direct improvement of clinical
practice. By teaching core clinical research skills and facilitating the completion of an independent research project, the
program aims to help self-motivated trainees embark on careers as clinical and health services researchers.
The CTS graduate program, the first in the nation linking an MS/PhD program in a biomedical graduate school with an
academic medical center for clinical research training, has emerged as a national model. The program is designed for
individuals who have completed training in the medical sciences (MD, DO, DDS, DVM, etc.), or in another advanced
biomedical degree program; the majority of students are postdoctoral clinical fellows or faculty at Tufts Medical Center and
other Tufts-affiliated hospitals. The program confers an MS and a PhD in Clinical Research and also provides individual
courses to other non-matriculated students. Students select one of the three following concentrations which choice allows
them to develop more extensive competency in their chosen area: Evidence-based Clinical Effectiveness Research, Clinical
Investigation, and, Health Services and Outcomes Research. Additionally, in order to promote better interdisciplinary
research education through increased comprehensiveness of the program content, the program provides students with the
option of choosing a focus in another discipline, which would typically represent the content area of their thesis.
The Program has a formal mentoring system to facilitate fellows’ development and execution of independent research
projects. All students enrolled in this program must complete an independent research project thesis. Visiting fellows,
special fellows, and fellows from a variety of Tufts Medical Center Departments and Divisions also participate in
fellowship offerings. Nearly all of the fellows who have trained in this Program are currently active faculty at medical
schools or the NIH, and the rest serve as senior staff or consultants in health services delivery and policy.
Post-doctoral training is provided by the CCR federally-sponsored T32 training grant in Clinical Care and Health
Services Research; A KM1 Career Development Award (KM1) Program in Comparative Effectiveness Research (CER);
and, KL2 Junior Faculty Career Development Award Program faculty.
The seven primary research programs of the Division of Clinical Care Research are listed below, followed by short
descriptions of their activities.
»» Research Design Center/Biostatistics Research Center
»» Center for Cardiovascular Health Services Research
»» Center for Clinical Evidence Synthesis
»» Center for Evaluation of Value and Risk in Health
−− Program for Child and Family Outcomes
−− Program on Health, Work, and Productivity
−− Program on Innovation in Pediatric Policy and Practice
»» Predictive Analytics and Comparative Effectiveness Center
»» Program on Equity in Science and Health
Research Design Center/Biostatistics Research Center
(Dr. Norma Terrin, Director; Faculty: Drs. Hong Chang, Farzad Noubary, Jessica Paulus, Ms. Janis Breeze, Ms.
Lori Lyn Price, Ms. Robin Ruthazer, Mr. Hocine Tighiouart)
The Research Design Center/Biostatistics Research Center (RDC-BRC), a joint program between ICRHPS/CCR and the
Tufts CTSI, seeks to promote innovation and excellence across the spectrum of patient-oriented research through
development of new statistical and study design methods and provision of training, education and support in applying
standard and cutting-edge design and analytic techniques. The RDC-BRC serves as the academic center for biostatistics
at Tufts University and its affiliated teaching hospitals. It provides a forum to develop new methods, consulting
strategies, and solutions to problems through internal meetings and seminars as well as through attendance at local and
national meetings. BRC faculty are involved as investigators on their own investigator-initiated research as well as on
projects throughout Tufts Medical Center, Tufts University, and other Tufts affiliates. RDC-BRC staff serve nationally as
consultants to institutions, federal agencies, corporations and grant proposal review panels, and as members of Data
Safety and Monitoring (DSMB) boards. In addition, the faculty in the RDC-BRC is responsible for statistical and
computational instruction and mentoring to students in the Sackler Clinical Research Program.
Center for Cardiovascular Health Services Research
(Dr. Harry Selker, Director; Ms. Joni Beshansky, Associate Director; Faculty: Dr. David Kent, Ms. Denise
Daudelin, Mr. Manlik Kwong, Ms. Robin Ruthazer)
For over 25 years, the Center for Cardiovascular Health Services Research (CCHSR) has focused on the development of
treatment strategies, decision aids, methods, and systems aimed at improving medical care, especially emergency and
cardiac care. It is particularly known for a series of studies of factors influencing cardiac care, and for the development of
clinical predictive instrument decision aids which provide diagnostic predictions for emergency physicians and
paramedics in the emergency clinical care setting. These instruments can also be used retrospectively to determine the
appropriateness of care. Related work has included conduct of multiple larger national clinical effectiveness trials,
including demonstrating better treatment and clinical outcomes for patients with acute coronary syndromes and acute
myocardial infarction.
Electrocardiographs now in common use include predictive instruments developed by Dr. Selker for cardiac ischemia
and the outcomes of reperfusion therapy for ST elevation myocardial infarction (STEMI) that are printed on patients'
electrocardiograms; these instruments have been shown in large trials to improve emergency care. Building on this,
more recently CCHSR ran a national randomized placebo controlled trial to determine If a long-neglected treatment for
AMU, an Intravenous solution of glucose, insulin, and potassium (GIK) if given very early in the course of ACS and AMI
could reduce cardiac arrest and death. The results of this 871-participant study showed that although progression to
AMI was not significantly reduced, the odds of having cardiac arrest or dying were reduced by half, and the size of the
AMI was reduced by 80%. A second trial is planned to confirm this result, which, if true, could potentially save the lives
of tens of thousands of patients in the US, each year.
123
»» Center for Health Solutions (formerly The Health Institute)
Predictive Analytics and Comparative Effectiveness Center
(Dr. David Kent, Director; Dr. Jessica Paulus, Dr. Djora Soeteman, Dr. Saied Shahraz, Ms. Robin Ruthazer, Dr.
Issa Dahabreh),
The Predictive Analytics and Comparative Effectiveness Center (PACE) studies the limitations of using group-derived
evidence as the basis for decision making in individual patients. The approach is based on the close integration of
clinical and statistical reasoning and the goal is to provide clinicians and patients with evidence better tailored to their
particular circumstances. PACE has expertise in clinical medicine, risk modeling, individual patient meta-analysis, and
observational comparative effectiveness studies. Among other projects, Dr. Kent is the Principal Investigator of several
federally-funded research grants related to this theme, including the Risk of Paradoxical Embolism (RoPE) study, an
international multi-site study to determine which patients are most likely to benefit from the closure of a patent
foramen-ovale (compared with medical therapy) in the setting of cryptogenic stroke. A related study examines
anticoagulant compared with antiplatelet therapy in the same population. A PCORI-sponsored methods project is
evaluating a framework to examine heterogeneity of treatment effect across a large set of clinical trial and an NIH
Common Fund to develop a framework to assess the value of providing risk information for decision making. The PACE
Center also addresses fundamental analytic issues in how to employ a risk-modeling approach to clinical trial analysis.
Center for Clinical Evidence Synthesis
(Dr. Ethan Balk, Director; Faculty: Dr. Gowri Raman, Dr. Norma Terrin)
The Center for Clinical Evidence Synthesis (CCES) promotes the application of evidence-based methods to healthcare and
biomedical topics and the development of methodologies in evidence synthesis. CCES has become an internationally
recognized leader in meta-analysis and evidence-based practice. Members are experts in the fields of meta-analysis,
clinical data-synthesis, decision, and cost-effectiveness analysis, clinical guideline creation and evaluation and health
services and outcomes research. CCES was an AHRQ-designated Evidence-based Practice Center for 15 years and
continues to collaborate on these projects nation-wide. In addition, CCES members have done consulting and conducted
evidence reviews under contracts from government agencies, pharmaceutical companies, and other organizations. CCES
faculty are experienced teachers in critical literature appraisal and have trained multidisciplinary audiences in the
conduct of evidence based reviews through curricula and programs in national and international settings. They serve as
mentors to trainees and as consultants to academic and private entities in evidence appraisal.
Center for the Evaluation of Value and Risk in Health
(Dr. Peter Neumann, Director; Faculty: Drs. Joshua Cohen, James Chambers, Pei Jung Lin)
The Center for the Evaluation of Value and Risk in Health (CEVR) was established in December 2005 by Peter Neumann,
ScD (Director) and Joshua Cohen, PhD (Deputy Director) to focus on issues pertaining to value, cost-effectiveness, and
risk tradeoffs in healthcare decisions. The mission of CEVR is to analyze the benefits, risks, and costs of strategies to
improve health and health care and to communicate the findings to clinicians and policymakers. CEVR researchers
undertake scientific research projects, advance methods development for the field, train the next generation of
practitioners and users, and work with policymakers worldwide to develop reasoned policy solutions.
CEVR researchers bring experience in economics and decision analysis to a host of clinical and public health policy issues.
Research at CEVR focuses on: 1) evaluating and comparing diverse benefit-risk tradeoffs that are central to a multitude of
healthcare decisions; 2) understanding the attitudes and perceptions of value from the perspective of patients, physicians,
and policymakers, and 3) applying cost-effectiveness analyses in medical and public health interventions such as
preventive measures, screening and treatment for Alzheimer’s disease, cancer, and other diseases and conditions.
CEVR has developed two unique databases to help measure and communicate the clinical and economic value of health
care strategies. CEVR is the home of The Tufts Cost-Effectiveness Analysis Registry, an internationally known resource
containing detailed information on more than 1,700 standardized cost-effectiveness analyses published in the peerreviewed literature (w w w.cearegistry.org). In addition, CEVR has developed and maintains The Tufts Medical Center
Medicare National Coverage Decisions (NCDs) Database, a first of its kind that documents decisions made by the
Centers for Medicare and Medicaid Services (CMS). Recent projects include a CMS Innovation Award to evaluate cloudbased technology in the critical care setting, analysis of the costs and benefits of treatments for leukemia, lymphoma,
and myeloma; multiple unmanaged co-morbidities in diabetes patients; factors inf luencing Medicare coverage of new
technologies; modeling the impact of early Alzheimer's disease detection, and understanding the inf luence of
comparative effectiveness research on coverage and reimbursement.
Center for Health Solutions
(Dr. Susan Parsons, Director; Faculty: Drs. David Adler, Hong Chang, Richard Hermann, Debra Lerner, Laurel
Leslie, William Rogers, Angie Mae Rodday, Carolyn Rubin)
The principal program areas of research encompassed by CHS’s work are the following: 1) Program on Child and Family
Outcomes, led by Susan Parsons, MD, MRP, studying the quality of life of families coping with a chronic illness (such as
cancer or mental health disorders); 2) Program on Health, Work, and Productivity, led by Debra Lerner, MS, PhD, addresses
the burgeoning need to improve the health of working people and reduce the human and economic burden of health
problems on them, their families, employers, and the nation, and 3) the Program on Innovation in Pediatric Policy and
Practice, led by Dr. Laurel Leslie, addresses the effective development and implementation of evidence-informed care of
children and adolescents with health, developmental, and behavioral concerns cared for in community settings such as
schools, pediatric clinics, and child welfare/protective services. Faculty members within CHS receive research support from a
variety of sources, including federal funders (NIH, AHRQ, VA, and CDC), pharmaceutical companies, and foundations.
Program on Equity in Science and Health
(Dr. Karen Freund, Director)
The Program on Equity in Science and Health addresses diversity in the biomedical workforce and disparities In
healthcare delivery. The mission of the program is to address two separate but related aspects of equity through
research, 1) equity in science and biomedical careers, including understanding the factors associated with recruitment,
promotion, and retention of women and minority faculty in academic biomedical careers and 2) disparities in the
delivery of healthcare, especially to women and minority communities. The program focuses on interventions to reduce
and eliminate these disparities.Research Support
125
The Center for Health Solutions, first founded In 1988 as The Health Institute (THI) at Tufts MC was home to the Medical
Outcomes Study (MOS)—a landmark study designed to measure the relationship between the organization and delivery of
medical care and the functional health outcomes of patients. The Center for Health Solutions' overall mission is to improve
health by advancing measurement of, and knowledge about, the social, behavioral, medical and biological factors that
influence individual and population health. To accomplish this goal, CHS develops tools to advance the science of
outcomes measurement from the patient’s point of view; engages in large-scale research projects to examine the links
between structure, process and outcomes of health care; conducts multidisciplinary research into the complex pathways
linking health and its social, behavioral, medical and biological determinants; and works with clinicians, government,
employers, health plans and other public and private sector organizations to translate research into practice and policy.
Recipient
Ethan Balk, MD
James Chambers, PhD
Karen Freund, MD
Richard Hermann, MD
David Kent, MD
Funding Source
Purpose of Award
CDC
Updates to Existing Systematic Reviews on Diabetes Prevention
and Control for the Guide to Community Preventive Services
Plastic Surgery Foundation
A Systematic Review of Selected Outcomes in Women with
Silicone Breast Implants
AHRQ EPC
Methods Research and Support in Decision Simulation Modeling
AdvaMed
Update of a Predictive Model (1999-2013) and Evaluation of
Consistency with Private Payers Coverage Determination
Millennium, Medtronic, and
Genentech
Pharma Consortium: Use of CER by Medicare for National
Coverage
MDMA
Determining the Consistency and Transparency of Private Payer
Coverage Determination for Medical Devices
Bayer
Is Coverage Policy for MS Treatment Consistent with the
Evidence?
Pfizer
Estimating the Population Health Benefits of new
Pharmaceuticals
Pfizer
Disinvestment in US healthcare: Opportunities and Challenges
Genentech
Is Coverage Policy for Rheumatoid Arthritis Treatment
Consistent with the Evidence?
MITA
PET: A Review of the Cost Effectiveness Evidence Base
NIH/NIMH
Insurance Instability and Disparities in Chronic Disease
Outcomes
NIH/NIGMS
Longitudinal Follow up to the National Faculty Survey
PCORI via Lahey Clinic
Cervical Spondolytic Myelopathy Surgical Trial
NIH via Ohio State
OSU Cancer Center Support Grant
American Cancer Society
Patient Navigation to Eliminate Cancer Disparities
AHRQ via ECRI
National Quality Measures Clearinghouse Project
NIH/NIMH via UPenn
Patient Safety in Inpatient Psychiatry
PCORI via Brown University
Evaluating Observational Data Analyses: Confounding Control
and Treatment
NIH
Value of Personalized Risk Information (Dual PI: Peter Neumann)
NIH/NINDS
Targeted Antithrombotic Therapy in Cryptogenic Stroke with
Patent Foramen
NPC
Variation in individual treatment effects from repeated period
cross-over studies
NIH/NINDS
The Risk of Paradoxical Embolism Study (RoPE)
NIH/NINDS
A field synopsis of sex in cardiovascular and cerebrovascular
disease prediction
PCORI
Assessing and Reporting Heterogeneity of Treatment Effects in
Clinical Trials
Recipient
Debra Lerner, ScD
Purpose of Award
NIH/NIMH
Preventing Mid and Later Life Work Limitations: Communitybased Depression Care
Info Tech
Development and Implementation of a Sleep Module for the
Wellness Checkpoint
VA via UPenn
RD Merit Award
Employer’s Health
Right Direction for Addressing Workplace Depression
Aetna
Applied Research Services
Janssen
Caregivers of Individuals Diagnosed with Schizophrenia: Impact
on Employment and Unmet Needs
PCORI
Comparative Effectiveness of Adolescent Lipid Screening and
Treatment Strategies
American Academy of Pediatrics
Pediatric Research in Office Settings
ADDF
The Potential Economic Impact of Chronic Disease Management
in Alzheimer's Disease Prevention
Alzheimer’s Foundation
Nationwide Frequency and Cost of Preventable Hospitalizations
in Alzheimer’s Disease
Genentech
Healthcare Utilization, Expenditures, and Quality of Care of
Alzheimer’s Disease
NIH via MGH
BADERC: Estimating Costs of Multiple Chronic Conditions
among Adults with Diabetes
CDC
Cost Effectiveness of Cancer Interventions
West Health Policy Center
Economic Discontinuities in Health Care Delivery
Shire Dev, Inc
Systematic Literature Review of Adjunct Pharmacotherapy in
Children and Adolescents with ADHD
Pfizer
A Catalog of Alzheimer’s Disease Data Resources
Bayer
Bayer Fellowship
LLS
Understanding the Value of Interventions for Leukemia,
Lymphoma and Myeloma
Sanofi
Economics of Added Life Years
Sanofi
When a Life Extending Technology is not Cost-Effective, Even if
Offered for Free
Medtronic
Review of Degenerative Back and Leg Pain Models
CMS-Medicare via BIDMC
Cloud AWARE Program: Patient Centric Electronic Environment
for Improving Acute Care Hospital
Pei Jung Lin, PhD
Peter Neumann, ScD
Performance
Abbott
Analyze the health economic outcome variables to determine
health care costs
Amgen
Heart Failure Module 3: Financial Impact of Reducing
Hospitalization
Trinity Partners
The Value of Specialty Biopharmaceuticals
Novartis
Burden of Condition Analysis for Acute Spinal Cord Injury
GE (UK)
Economic Modeling of Amyloid Imaging Tests for Alzheimer’s
Disease
127
Laurel Leslie, MD
Funding Source
Res earch S u p p or t (con t i nu e d )
Recipient
Peter Neumann, ScD (continued)
Susan Parsons, MD
Inga Peter, MD
Gowri Raman, PhD
Angie Mae Rodday, MS
Funding Source
Purpose of Award
Novartis
University of Eastern Finland ALSOVA Dataset Review and
Analysis
Biogen IDEC
WTP for Newborn Screening Tests for Rare Diseases
Biogen IDEC
Assessment of Value to Mitigate Mobility and other Neurological
Symptoms Associated with MS
BCBSMA
2013 Cost and Affordability Research Grant (Natalia Olchanski,
CEVR PI)
NPC
FDAMA Section 114 Case Studies and Policy Implications
Merck
Understanding Communications between Surgeons and
Anesthesiologists: Relaxant Use
Robert Wood Johnson
Foundation
Updating the Panel on Cost-Effectiveness in Health and
Medicine
Bill and Melinda Gates
Foundation
Registry on Cost per Disability Adjusted Life Years
(DALY) Studies
NIH via NYMC
Familial T-Cell Depleted Stem Cell Transplant in High Risk Sickle
Cell Anemia
Avon Foundation
Patient Navigation for Medically Underserved Breast Cancer
Patients
NIH via Johns Hopkins
Family Self Management during the Transition from Acute Care
to Home after Pediatric Bone Marrow Transplantation
Children's Hospital
Children's Hospital Collaborative Clinical Effectiveness Fund on
Home Vent Use
Leukemia and Lymphoma
Society
Proof of Paradigm in Cost-Effectiveness Analysis with Novel
Therapeutics
Yawkey Foundation
Patient Navigation Program
NIH/NHLBI
Genetic Markers of GIK Effect in Acute Coronary Syndrome in
the IMMEDIATE Trial
Cubist Pharmaceuticals
Inappropriate Therapy Systematic Reviews
AHRQ via Brown U
Renal Artery Stenosis Update
PhRMA Foundation
Predoctoral Fellowship in Health Outcomes
NIH/NIMH via Brown U
Aging, comorbid conditions, and health care utilization in
persons with HIV
NIH via Brown U
Health Literacy Explanatory Models and Medication Adherence
in HIV Disease
AHRQ
Postdoctoral Training Grant in Health Services Research
William Rogers, PhD
PCORI
NIH/NCCATS
Clinical and Translational Science Award
David Adler, MD
»» Chair Publications Board, Group for Advancement of Psychiatry
Honors and Awards:
»» 2010-2014 – Best Doctors in America
»» 2010-2014 – Best of Boston Physicians, Boston Magazine
Editorships:
»» Editorial Board, Comparative Effectiveness Reviews
National Panels:
»» National Guidelines Clearinghouse
James Chambers, PhD, MPharm, MSc
»» Research Review Committee Co-Chair, International Society for Pharmacoeconomics and Outcomes Research
New Grant Funding:
»» Industry Funding for various projects from Bayer, Biogen, Genentech, Pfizer, and MDMA totaling $519,106
Invited Lectures & Presentations:
»» A Delicate Balance: How Can We Rightsize Treatment Costs? TedMed Great Challenges Live Event. December 11th, 2014. Recording
available here: http://www.tedmed.com/greatchallenges/liveevent/499614
Karen Freund, MD
»» Member, Agency for Healthcare Research and Quality (AHRQ), Health Care Research Training (HCRT) Study Section
Editorships:
»» Editorial Board, Cancer Epidemiology, Biomarkers and Prevention
New Grant Funding
»» NIH Funding “Insurance Instability and Disparities in Chronic Disease Outcomes”, $1,686,021
»» Ohio State Subcontract, “Cancer Center Support Grant”, $23,925
Richard Hermann, MD, MS
Editorships:
»» Associate Editor, BMC Health Services Research 2012-present
National Panels:
»» Member, National Committee for Quality Assurance (NCQA): Behavioral Health Measurement Advisory Panel
David Kent, MD
»» Invited Abstract Reviewer, Health Services, Quality Improvement, and Patient-Centered Outcomes Category, International Stroke
Conference 2015
»» Comparative Effectiveness Research, Methods Committee, Society of Clinical and Translational Science
National Panels:
»» Ad Hoc Member, National Institute of Neurological Disorders and Stroke Special Emphasis Panel, National Institute of Neurological
Disorders and Stroke PD Planning Grant Review, December 10, 2014 (ZNS1 SRB-J-08)
»» Scientific Advisory Board, Ware Working Group on Neurodegenerative Disease Ethics and Policy, University of Pennsylvania
»» External Advisor, Patient Centered Outcomes Research Institute (PCORI) Methodology Committee Workgroup on Heterogeneity of
Treatment Effect
129
Ethan Balk, MD, MPH
»» “Why Risk Based Subgroup Analysis Should be Routine.” Society for Clinical Trials (SCT) 35th Annual Meeting. Philadelphia, PA,
USA. May 18-21, 2014.
»» “Variation in individual treatment effects from repeated period cross-over and multi-person N-of-1 studies.” International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting. May 34 – June 4, 2014. Montreal, Canada.
»» “Using Group Data to Treat Individuals: Understanding the Importance of Heterogeneity of Treatment Effects for Clinical DecisionMaking.” Tufts CTSI Heterogeneity of Treatment Effects in Clinical Trials Seminar: Lahey Clinic. Burlington, MA. June 4, 2014.
»» “Assessing and Reporting Heterogeneity of Treatment Effect in Clinical Trials,” NIH Collaboratory Webinar Grand Rounds, September
12, 2014 Video: https://www.nihcollaboratory.org/Pages/Grand-Rounds-Hub.aspx
»» “Treatment Effect Heterogeneity in Clinical Trials: “An evaluation of 13 large clinical trials using individual patient data.” International
Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress. November 8-12, 2014.
Amsterdam RAI in Amsterdam, The Netherlands. (poster)
»» “Risk modeling and heterogeneity of treatment effect.” International Society for Pharmacoeconomics and Outcomes Research
(ISPOR) 17th Annual European Congress. November 8-12, 2014. Amsterdam RAI in Amsterdam, The Netherlands. (workshop)
New Grant Awards:
»» NIH/NINDS supplement, “A field synopsis of sex in cardiovascular and cerebrovascular disease prediction” $71,000
»» NPC, “Variation in individual treatment effects from repeated period cross-over studies” $150,000
»» PCORI via Brown U, “Evaluating Observational Data Analysis: Confounding Control and Treatment” $521,526
Debra Lerner, MS, PhD
»» Scientific Advisory Board, Boeringher Ingelheim, Inc
Invited Lectures:
»» Biogen Idec. “The Work Limitations Questionnaire (WLQ): Development and Applications,” March 27, 2014 (Cambridge, MA)
»» Employee Assistance Roundtable. “Tufts Depression Study Results and Work Limitations Questionnaire (WLQ),” April 28, 2014
(Chicago, IL)
»» NEEBC Wellness Program. “Be Well at Work: Employee-Centered Care for Depression,” October 15, 2014 (Waltham, MA)
New Grant Awards:
»» Janssen, “Caregivers of Individuals Diagnosed with Schizophrenia: Impact on Employment and Unmet Needs”, $80,000
»» UPenn via Veterans Administration “VA R&D Merit Award”, $162,953
Laurel Leslie, MD, MPH
»» Secretary/Treasurer, American Board of Pediatrics
»» Associate Director, Pediatric Research in Office Settings, American Academy of Pediatrics
National Panels:
»» Member, Administration on Children and Families: Developing and Implementing State Psychotropic Medication Systems across
Child Welfare, Mental Health, and Medicaid
»» Member, Institute of Medicine Forum on Promoting Children’s Cognitive, Affective, and Behavioral Health
»» Member, National Scientific Panel , California Evidence-Based Clearinghouse for Child Welfare, San Diego, CA
»» Member, Institute of Medicine, Forum on Promoting Children's Cognitive, Affective, and Behavioral Health, Washington DC
»» “Quality improvement applications to tertiary integration. New England Quality Care Alliance. Norwood, MA. April 2014.
»» “Why do we use medications for young children in the CWS population: Reflections from psychiatry and pediatrics.” Annual San
Diego International Conference on Child & Family Maltreatment. San Diego, CA, January 2014.
»» “Community engagement in comparative effectiveness research.” Translational Science 2014. Washington, DC, April 2014.
»» “Research capacity-building in diverse communities.” Baystate Medical Center. Springfield, MA, May 2014.
»» “Community and stakeholder engagement in PBRNs.” Pediatric Clinical Research Networks Special Interest Group. Pediatric
Academic Societies Annual Meeting. Vancouver, BC, May 2014.
Pei Jung Lin, PhD
New Grant Awards:
»» Nationwide Frequency and Costs of Preventable , Alzheimer’s Foundation, $49,921
»» Healthcare Utilization, expenditures, and quality of care, Boston Area Diabetes Research Center $210,000
Peter Neumann, ScD
Journal Editorships:
»» Editorial advisory panel, Expert Reviews in Pharmacoeconomics and Outcomes Research
»» Editorial board, Health Affairs
»» Editorial board, Value in Health
National Panels:
»» Co-Chair, Panel on Cost-Effectiveness in Health and Medicare
»» Robert Wood Johnson Foundation Health Policy Fellows Advisory Board
New Grant Funding:
»» Industry Funded Projects from Abbott, Amgen, Biogen, and NPC totaling $367,250
»» Centers for Disease Control $39,324
Invited Lectures:
»» Improving Health in an Urban Asian Population: Patient Navigation for Patients of Chinese Origin with Newly Diagnosed Breast
Cancer. Avon Foundation for Women Biennial Breast Cancer Forum (Invited Plenary Speaker).
»» Predictors of overweight and obesity in survivors of childhood cancer. American Institute for Cancer Research Annual Research
Conference on Food, Nutrition, Physical Activity, and Cancer (Invited Speaker).
National Panels:
»» NIH Population Science and Epidemiology Integrated Review Group, Cardiovascular and Sleep Epidemiology Study Section
»» American Cancer Society, Palliative Care and Symptom Management Peer Review Committee – Grant Reviewer
»» Professional Society Committee Assignments and Leadership:
»» Member, CTSA Consortium Child Health Oversight Committee Pediatric-Adult Lifespan Working Group
Awards/Honors:
»» Castle Connolly Top Doctor in Pediatric Hematology-Oncology
New Grant Funding:
»» Avon Foundation $100,000
»» Leukemia and Lymphoma Society “Proof of Paradigm in Cost Effectiveness Analysis with Novel Therapeutics”, $599,936
Gowri Raman, MD, MS
New Grant Funding:
»» AHRQ via Brown University, “ Renal Artery Stenosis EPC Update”
Angie Mae Rodday, MPH
»» Rodday AM, Paulus JK. Developing a case-based curriculum to teach biostatistics and epidemiology to clinicians. Oral Presentation
at the 2014 Annual Joint Statistical Meeting, August 2014, Boston, MA.
131
William Rogers, ScD
New Grant Awards
»» NIH via Brown University, “Aging, Comorbid Conditions, and Health Care Utilization in Persons with HIV”, $166,022
National Panels:
»» Agency for Healthcare Research and Quality, National Advisory Council Member
»» National Institutes of Health: Directors Pioneer Award Review Committee
»» Professional Society Committee Assignments and Leadership:
»» Society for General Internal Medicine Conflict of Interest Committee
»» Association for Clinical and Translational Science, Board of Directors, Vice President for Healthcare Implementation,
»» Delivery, and Policy Research, Chair, Public Policy Committee
»» Clinical Research Forum: Public Policy Committee Chair
»» Health Resources in Action: Board of Directors
»» Association for Clinical Research Training: Chair, Advocacy Committee
Editorships:
»» Journal of Investigative Medicine, Associate Editor
»» Clinical and Translational Science, Executive Editor
Honors and Awards:
»» Barry Coller Excellence in Service Award , Association for Clinical and Translational Science
New Grant Funding:
»» PCORI, “A method for Patient-Centered Enrollment in Comparative Effectiveness Trials: Mathematical Equipoise “, $1,055,452
Norma Terrin, PhD
Editorships:
»» Statistics Editor, Clinical Infectious Diseases
»» Associate Editor, Quality of Life Research
»» Editorial Board, Research Synthesis Methods
Invited Talks:
»» Marginal Structural Models to Estimate the Effect of Food Insecurity on Depression in Injection Drug Users, New England Statistics
Symposium, Harvard School of Public Health, Boston, April 2014
INSTITUTE FOR
MOLECULAR CARDIOLOGY
RESEARCH (MCRI)
The MCRI has as its mission the study of molecular mechanisms of human cardiovascular disease; translation of bench
findings to new bedside strategies for diagnosis and therapy; and the mentoring of MD and PhD trainees committed to a
career in academic cardiovascular research. The MCRI programmatic areas of focus include vascular biology,
cardiomyocyte biology, electrophysiology, human genetics and genomics, immunology, inflammation, molecular
pharmacology, signal transduction and transplantation biology. Members of the MCRI work collaboratively with clinical
cardiologists and cardiovascular surgeons, biochemists, neuroscientists, pharmacologists, geneticists, immunologists,
and epidemiologists to further research in all facets of cardiovascular diseases. Pre-doctoral, graduate, and
post-graduate training are high priorities of the Institute, with numerous trainees, including students from the Sackler
School of Graduate Biomedical Sciences at Tufts and post-doctoral fellows from all over the world conducting their
research in MCRI labs. The MCRI is the home of an NIH-funded Training Program in Cardiovascular Research, which
offers nine training positions annually to promising new investigators. In addition, the Institute sponsors a Molecular
Medicine Seminar Series throughout the academic year and an Annual MCRI Retreat with nationally and internationally
recognized guest speakers participating. The intellectual environment is highly regarded with an outstanding group
of investigators.
Highlights of 2014
» » Identification of a critical predictor of clinical risk for sudden death and heart disease in the diabetic population
» » Establishment of a novel role of gamma delta T cells in early atherosclerosis
» » Dr. Gordon Huggins named Principal Investigator of the Tufts Medical Center NE Regional Heart Failure Network
» » Dr. Iris Jaffe received a prestigious Established Investigator Award from the American Heart Association
133
»» INSTITUTE FOR MOLECULAR CARDIOLOGY RESEARCH (MCRI)
Established in 1997, the Molecular Cardiology Research Institute at
Tufts Medical Center is comprised of seventeen principal investigators
and physician-scientists working with over seventy staff and trainees.
Faculty
Name
Academic Rank
Elisa Kent Mendelsohn
Professor of Molecular
Cardiology and Medicine
Executive Director, MCRI
Chief Scientific Officer, Tufts Medical Center
Vice-Chairman of Research, Department of Medicine
Co-Director, Women’s Heart Center
Maria Pilar AlcaideAlonso, PhD
Assistant Professor
Debbie Beasley, PhD
Associate Research Professor
Martin Beinborn, MD
Assistant Professor
Robert Blanton, MD
Assistant Professor
Tinatin Chabrashvili, MD, PhD
Associate Professor (Neurology)
Isabelle Draper, PhD
Assistant Professor
Professor
Assistant Program Director, Cardiology Fellowship
Director, Center for Translational Genomics; Vice-Chair, IRB;
Chair, SRC
Co-Director, MD PhD Program, Tufts University School of
Medicine
Gordon Huggins, MD
Associate Professor
Lakshmanan Iyer, PhD
Assistant Research Professor
(Neuroscience)
Iris Jaffe, MD, PhD
Associate Professor
Co-Director, MCRC
Navin Kapur, MD
Assistant Professor
Director, Interventional Research Division of the Surgical
Research Laboratories
Director, Acute Circulatory Support Program
Alan Kopin, MD
Professor
Director, Molecular Pharmacology Research Center
Janis Lem, PhD
Associate Research Professor
(Ophthalmology)
Director, Transgenic Core Facility
Sami Noujaim, PhD
Assistant Professor
Ho-Jin Park, PhD
Assistant Professor
Gavin Schnitzler, PhD
Assistant Professor
The Molecular Cardiology Research Institute has a close relationship with the Division of Cardiology. Six members of the MCRI are
active clinicians within the Division of Cardiology and several serve in leadership roles in the Preventive Cardiology Center, Heart
Failure and Transplant Program, and the Women’s Heart Center. Please refer to the Division of Cardiology for specific information
regarding major clinical programs.
Recognized nationally and internationally as a leader in cardiovascular research, the Molecular Cardiology Research
Institute is training a new generation of investigators in the state-of-the-art technologies necessary to translate bench
findings to the bedside and to develop new diagnostic and therapeutic strategies to fight cardiovascular disease. The
MCRI has a robust fellowship program funded in part by a National Institutes of Health T32 training grant with nine
training positions. Fellows are engaged in basic, translational and clinical research throughout the Institute and the
Cardiology Division.
Graduates of the MCRI fellowship program typically pursue careers in academic medicine (MD graduates) or research
departments (PhDs) as independent investigators, with the occasional fellow pursuing an opportunity in industry.
Research in the MCRI is funded by the NIH (primarily through the NHLBI), the American Heart Association, the
Juvenile Diabetes Research Foundation, private philanthropic foundations and Industry sponsors including
pharmaceutical, biotech and medical device companies. The major programs of the Molecular Cardiology Research
Institute are described below.
»» Richard Karas, MD, PhD, Director
»» Iris Jaffe, MD, PhD, Co-Director
»» Pilar Alcaide Alonso, PhD
»» Robert Blanton, MD
»» Navin Kapur, MD
»» Gavin Schnitzler, PhD
The Molecular Cardiology Research Center, a group of closely aligned laboratories, is the founding group of investigators
that formed the MCRI. The six laboratories of the Molecular Cardiology Research Center work closely with one another
to explore themes of common interest in heart and blood vessel diseases.
The Karas Laboratory is focused in four primary areas: improving understanding of the effects of estrogen on the
cardiovascular system; investigating the extent to which abnormalities of blood vessel function contribute to both
atherosclerosis and high blood pressure, examining the importance of low levels of the “good cholesterol” HDL in
contributing to heart disease and stroke, and studying the role of protein kinase G (the main effector of nitric oxide) on
vascular health. The laboratory studies the molecular pathways within cells of the heart and blood vessels that mediate
responses to estrogen. Heart and blood vessel diseases are by far the leading causes of death for women in this country,
and patient-based studies have shown that hormone replacement therapies in postmenopausal women can alter the risk
of heart and blood vessel diseases. Dr. Karas’ work is aimed at learning more about how estrogen and nitric oxide
regulates the development of heart and blood vessel diseases. The laboratory also has an active research program in
studying the adverse events that can result from the use of cholesterol altering medications.
135
MCRI Investigators provide extensive mentoring and financial support to students at Tufts University School of
Medicine and the Sackler School of Graduate Biomedical Sciences. Currently, five graduate students from Tufts are
mentored by MCRI faculty and many of the MCRI investigators direct and lecture in graduate courses. The clinicianscientists within the MCRI participate in the teaching of medical students through the Patient-Doctor II course and the
Integrating Biomedical Research and Clinical Medicine course, as well as teaching students, house officers and clinical
cardiology fellows while attending in the ambulatory clinics and the inpatient services.
The Jaffe Laboratory is investigating the role of aldosterone, a hormone that regulates blood pressure, in the
development of hardening of the arteries, the blood vessel disease that causes heart attacks. Aldosterone works by
entering cells and binding to the mineralocorticoid receptor (MR) resulting in changes in the genes that are turned on in
that cell. Human clinical trials of drugs that block aldosterone binding to MR demonstrate that these drugs decrease
mortality and prevent heart attacks. However, the mechanism of protection from heart attack by these drugs is not
known. The Jaffe laboratory has demonstrated that MR is located in the cells of the human blood vessel and MR controls
the pattern of genes turned on in the vessel. The Jaffe Lab recently found that aldosterone promotes hardening of the
arteries by activating the immune system resulting in inf lamed arteries. In addition, the lab determined that MR in the
blood vessel plays a direct role in aging-associated high blood pressure. More recently the lab has become interested in
exploring new ways in which the hormone aldosterone might interact with the sex hormone estrogen and also in
determining why woman exposed to pregnancy complications have a much higher risk of heart disease later in life.
These studies will continue provide new insights into the causes of common cardiovascular diseases and identify new
drug targets for prevention and treatment of heart attacks, strokes, and high blood pressure.
The Alcaide Alonso Laboratory aims to find specific ways to prevent and/or treat inflammation, a condition negatively
affecting health in a variety of diseases ranging from autoimmune disease to cardiovascular disease. Inflammation is in
part mediated by infiltration of immune cells such us T cells into tissues and organs. The lab's research studies combine in
vitro and in vivo vascular immunology and cardiac physiology approaches to identify basic mechanisms that mediate T
cell infiltration in tissues, with a focus on the heart in the context of heart failure. A better understanding of these basic
mechanisms may result in the development of new therapeutic interventions that target T cell infiltration in the heart as a
way to reduce inflammation and potentially heart failure, a syndrome affecting nearly 25 million people worldwide.
The Blanton Laboratory seeks to understand how the heart protects itself from a process called “pathologic cardiac
hypertrophy”. Pathologic hypertrophy commonly occurs in patients’ hearts with medical conditions like hypertension,
heart valve disease (such as aortic stenosis), and myocardial infarction, and it often leads to congestive heart failure. The
laboratory is studying how pathologic hypertrophy develops in order to determine which molecules in the heart help
prevent pathologic remodeling. These molecules may turn out to be good targets to try to target with drugs. The laboratory
discovered that a protein called “PKGIα” helps keep the heart from developing pathologic hypertrophy. Now it is using
animal models to try to identify how PKGIα protects the heart from pathologic hypertrophy, in particular, with which other
molecules in the heart PKGIα cooperates to determine if these other molecules may serve as new drug targets.
The Kapur Laboratory’s translational research focuses on large animal models of acute and chronic heart failure, circulatory
support device development, and cardioprotective mechanisms in the setting of acute myocardial infarction. The laboratory’s
basic research focuses on molecular mechanisms governing maladaptive cardiac remodeling in heart failure, in particular, In
signaling via the transforming growth factor beta (TGFb) system. Over the past 6 years, the laboratory has published several
key papers focused on a TGFb co-receptor known as endoglin and was the first to establish that reduced endoglin activity
improves survival and limits maladaptive cardiac remodeling in heart failure. More recently, the laboratory has
demonstrated that targeting endoglin using an antibody-mediated approach not only limits the development of cardiac
fibrosis, but can reverse established cardiac fibrosis in preclinical models of heart failure.
The Schnitzler Laboratory is studying the roles of chromatin changes in the regulation of transcription by nuclear
hormone receptors, including estrogen receptor and glucocorticoid receptor. The laboratory uses a combination of
standard and high-throughput techniques to understand how the genetic and epigenetic factors that modulate
chromatin structure give rise to tissue-specific transcriptional responses to glucocorticoids or estrogen.
Laboratory of Vascular Myocyte Biology
Debbie Beasley, PhD
The Beasley Laboratory seeks to understand the early events that promote arterial inf lammation, the predecessor of
vascular diseases that can lead to heart attack or stroke. There has been an explosion in recent years in the
understanding of “innate immunity” (i.e. immunity that is present at birth). Notably, cells of the immune system have
been shown to express various members of a family of receptors (Toll-like receptors) that sense unique molecular
patterns associated with viruses, bacteria and other microorganisms, and thereby notify host cells about the presence of
microorganisms, and elicit an immune response. The laboratory is testing the novel idea that a specific type of white
blood cell that is normally involved in fighting infections and not previously suspected of promoting atherosclerosis,
leads to early atherosclerotic lesions. The results will provide new avenues for treating and/or preventing vascular
disease by modulating these specific immune responses. Further, the laboratory is studying whether intestinal bacteria
inf luences the progression of vascular disease in mouse models via mechanisms that involve a novel immune cell type.
The results may provide new avenues for treating or preventing vascular disease by modulating intestinal bacteria.
Neurovascular Laboratory
Tinatin Chabrashvili, MD, PhD
Laboratory of Lipid Metabolism and Cardiovascular Signaling
Ho-Jin Park, PhD
Autonomic neuropathy is a major complication of diabetes and has been associated with a marked increase in the
incidence of sudden death in the diabetic population. The Galper Laboratory has demonstrated a new relationship
between the development of this complication of diabetes and the regulation of cholesterol. The laboratory has
identified several new candidate molecules that might be involved in this process and might serve as new targets in the
treatment and prevention of this complication of diabetes and the associated abnormal heart beats and sudden death.
Abdominal aortic aneurysm is a disease that affects more than 10% of men above the age 65. Currently, its life
threatening complications can only be treated surgically. Using a mouse model for this disease, the Galper Laboratory
has data which suggest that a new drug that was developed for the treatment of life threatening infections might be used
to decrease the incidence and severity of aneurysms. The laboratory is also testing the possibility that a low dose of a
drug that causes inf lammation might actually protect the aorta from the development of this disease. These
experiments may support the use of these agents as a kind of immunization against this devastating disease.
Recently the Galper laboratory has extended its work on abnormal heart rhythm to similar mechanisms that might lead
to death of nerve cells that cause Parkinson’s disease. A protein that is in excess in the diabetic mouse and in the
diabetic patient is also in excess in Parkinson’s disease. The lab has established data supporting the conclusion that this
excess protein may be involved in accelerating the death of nerve cells in the brain that cause Parkinson’s disease.
Center for Translational Genomics
Gordon Huggins, MD
Research in the MCRI Center for Translational Genomics (CTG) is focused on understanding how genetic factors
contribute to diseases involving the heart muscle, heart valves as well as risk factors for heart diseases including obesity
and adult-onset diabetes. The goals of the CTG include identifying disease-causing genes and mutations, developing
diagnostic and prognostic markers and drug targets, and creating new therapeutic strategies for those most likely to
develop disease. Through a predictive and personalized approach, treatments can be tailored for those predisposed to
disease based upon the anticipated severity of the disease. The Center is currently studying the genetics of common
diseases such as hypertension and obesity, as well as hypertrophic cardiomyopathy (an abnormal enlargement of the
heart that can cause heart failure and sudden death), bicuspid aortic valve and aortic aneurysm.
Molecular Pharmacology Research Center
Alan Kopin, MD, Director
Martin Beinborn, MD
Isabelle Draper, PhD
The Kopin Laboratory studies G protein-coupled receptors (GPCRs), a family of more than 300 proteins which modulate
a wide variety of physiological functions. These receptors are among the most important targets for drug discovery. The
laboratory is developing tools to modulate selected receptors (e.g. CCR6) which play an important role in causing
inf lammation (e.g. atherosclerosis, asthma). The modulators that are generated will provide novel tools to enable better
137
Dr. Chabrashvili is a clinician-scientist in the Department of Neurology who specializes in movement disorders. The
Chabrashvili laboratory is located in the MCRI and studies cerebral microvascular inf lammation and blood-brain
barrier permeability.
understanding of disease mechanisms as well as provide a first step toward developing a new class of therapeutics. The
lab also studies how genetic variation in GPCRs inf luences receptor and/or drug activity. These investigations may
provide hints regarding the role of receptors in health and in disease as well as preview how inter-individual differences
may alter drug response. The Kopin Laboratory is also investigating a subset of GPCRs which are both unique to insects
(vs. mammals) and which modulate functions critical for insect survival. These receptors provide promising insecticide
targets. Screening for corresponding compounds is part of the ongoing effort in the lab.
The Beinborn Laboratory focuses primarily on receptors that are relevant for the treatment of diabetes, obesity, and
bone disease. Recently, the lab's efforts have helped to launch approaches for discovering two new types of diabetes
drugs that hold the promise of being superior to currently available medications. A major drug screening program in
collaboration with the National Institutes of Health based on some of these findings is currently underway. In a second
initiative, also in collaboration with the NIH, the lab has begun to identify novel blockers of the parathyroid hormone
receptor. Such compounds are anticipated to be useful for the treatment of a rare form of hereditary bone disease, but
may also provide future therapies for much more prevalent conditions including life-threatening forms of
hypercalcemia and the formation of cancer metastases in the bone.
The Draper Laboratory is a Drosophila laboratory which focuses on expediting the characterization of genes relevant to
human physiology. Dr. Draper pioneered the introduction of mammalian genes in the f ly system as a means to expedite
the exploration of conserved protein function in vivo. Her current research focuses on the investigation of muscle
physiology and disease, motor function and RNA processing. Collaborative efforts led to the establishment of a research
pipeline, enabling rapid translation of findings from Drosophila melanogaster to human myoblast cell lines (healthy,
diseased; differentiated from primary cultures or from iPSCs). Conversely, the functional characterization of novel
modifiers of muscle disease that are identified in mammalian systems can be expedited in the Drosophila model
organism. Using proprietary technology in conjunction with this multisystem approach the Draper Laboratory is
assessing the effects of candidate drugs as potential therapeutics for human muscle/heart disease.
Noujaim Research Laboratory
Sami Noujaim, PhD
Dr. Noujaim’s research focuses on the study of cardiac fibrillation mechanisms. Specifically, he is interested in the role
that inward rectifiers play in atrial fibrillation (AF). AF is the most common heart rhythm disturbance, and a major
cause of morbidity and mortality. Pharmacological treatment of AF is inadequate. This is in part due to the relatively
poor understanding of AF mechanisms and of the structural and molecular bases of drug-ion channel interactions. The
Noujaim laboratory uses technological, and conceptual advances from the fields of structural biology and ion channel
trafficking in order to explore the electrophysiological details of the contribution of inward rectifiers, and specifically
the acetylcholine sensitive potassium current (IKACh) to arrhythmogenesis in the atria. The laboratory also studies
functional and trafficking aspects of drug-ion channels interactions. Atrial fibrillation (AF) is the most common heart
rhythm disturbance.
Retina Research Laboratory
Janis Lem, PhD
Opsin mutations cause ~25% of blinding dominant retinal degenerations. Twenty-two years after the identification of the
first rhodopsin mutation, effective therapies to slow or prevent degeneration have yet to be developed, most likely
because the mechanism of degeneration differs for the 75+ different rhodopsin mutations. The Lem laboratory has
identified a subset of opsin mutants that share properties that suggest they have a shared mechanism of degeneration
and, hence, a shared therapy. This could lead to development of diagnostic methods to identify other rhodopsin mutants
that fall in this subclass and identify the population of patients that will respond well to approaches that are specific to
this mechanism of degeneration.
In 2014, the Institute engaged in the following funded research projects:
PI
Funding Source
Title of Project
NIH
Endothelial regulation of IL17 producing T effector cell
migration
NIH
T Cell Mediated Immune Responses as a Regulator of Heart
Failure
American Heart Association
The Role of Inflammation and Leukocyte Recruitment in
Heart Failure
Pilar Alcaide Alonso/Iris Jaffe
Tufts University
Aldosterone Regulation of Transendothelial Migration: A
Potential Novel Target for Heart Attack Prevention
Kathleen Barrett
Pre-Doctoral Fellowship
Debbie Beasley
NIH
Atherogenic role of T cell modulation by intestinal bacteria
Martin Beinborn
NIH
Development of a Novel Screen for Inhibitors of PTH
Receptor-Mediated Signaling
NIH
Cardiac Myocycte-Role of PKG I Alpha in Aging-Dependent
Cardiac Remodeling
American College of Cardiology
GEMSTAR Matching Grant
Jamie Doyle
Charles A. King Trust
Generation of Novel Probes to Explore the Role of MRGPRS
Isabelle Draper
U of Florida
Gene Discovery in Muscular Dystrophy
Juvenile Diabetes Research Foundation
Sudden Death in Type 1 Diabetes: A Mouse Model for Dead
in Bed Syndrome
NIH
Role of Sterols and Insulin in Cardiac Autonomic Response
JT Babbitt Foundation
Genes that Modify Hypertrophic Cardiomyopathy
Miriam Hospital
Gene and Behavioral Effects on High-Density Lipoprotein
Miriam Hospital
GENE X Behavior Interaction in the LOOK AHEAD Study
Miriam Hospital
Gene X Environmental Interaction in Diabetic Nephropathy
NIH
Basic Mechanisms of Human Calcific Aortic Valve Disease
The Role of Smooth Muscle Cell Mineralocorticoid
Receptors
Extra-Renal Mineralocorticoid Receptors in Hypertension
NIH
The Role of Vascular MR-Regulated Genes in Vascular
Function and Disease
NIH
Smooth Muscle Mineralocorticoid Receptors in Vascular
Aging and Hypertension
Iris Jaffe/Robert Blanton
Novartis
Acute and Sustained Cardiac and Vascular Effects of
Serelaxin in the Angiotensin II/L-NAME Heart Failure Model
Hongwei Jin
A new animal model for the study of the mechanism of
ventricular arrhythmias in type I diabetes
Pilar Alcaide Alonso
Robert Blanton
Jonas Galper
Gordon Huggins
Iris Jaffe
139
PI
Funding Source
Title of Project
Abiomed
Impella CP: Door to Unload Study
Cardiac Assist
TandemHeart RV Phase One Preclinical Study
MD Start
Mechanical Pre-Load Reduction via Vena-Caval Occlusion
for Decompensated Heart Failure
Maquet
Clinical Hemodynamic Study of MEGA-IABP Function
NIH
Cardiac Fibrosis in Progressive Heart Failure:
The Role of Endoglin
Tracon Pharmaceuticals
Endoglin: A Novel Therapeutic Target for Fibroproliferative Diseases
Merck
The Role of PKG-1a in cGMP Signaling Mechanisms through
the Evaluation of the Effects of cGMP Modulations in
Normal and Disease Studies in the PKG1-LZM Mouse
Merck
TAC LKR140269
NIH
Vascular Surgery - Estrogen and the Injury Response
NIH
Training Program in Cardiovascular Research
Alan Kopin
NIH
Bursicon Receptor Antagonists: Templates for Developing
Novel Insecticides
Kevin Morine
Heart Failure Society of America
Transient Receptor Potential Channel Transcriptional Profile
in Advanced Heart Failure
Sami Noujaim
NIH
Structural and molecular basis of drug-induced
IKACh reduction
Yali Zhang
Tufts University
Zucker Award
Navin Kapur
Richard Karas/Robert Blanton
Richard Karas
Pilar Alcaide, PhD
»» Abstract entitled “T Cell Mediated Immune Responses Regulate Cardiac Remodeling and Survival in Pressure Overload Induced Heart
Failure” selected as Best of AHA specialty conferences, Basic Cardiovascular Sciences annual meeting July 2014
Robert Blanton, MD
»» Received award for top 10% of abstracts at AHA Basic Cardiovascular Sciences Meeting. Abstract entitled “Identification of Novel
Protein Kinase G I Alpha Antiremodeling Substrates in the Myocardium”
Iris Jaffe, MD, PhD
»» Recipient, Established Investigator Award, American Heart Association
»» Recipient, AHA High Blood Pressure Research Council Mid-Career Award for Research Excellence
Navin Kapur, MD
»» Named Director, Acute Circulatory Support Program; Tufts Medical Center
»» Elected Member, Program Planning Committee, American College of Cardiology
»» Named to the Editorial Board: Frontiers in Cardiac Electrophysiology
Sami Noujaim, PhD
»» Named to the Editorial Board: Frontiers in Cardiac Electrophysiology
INSTITUTE FOR
MOLECULAR ONCOLOGY
RESEARCH (MORI)
promote the translation of basic research findings into the clinic. To achieve this goal, MORI scientists carry out research
that spans the spectrum from gene discovery to target validation for drug development. MORI functions independently
of the Department of Medicine and reports to a Board of Advisors comprised of senior Tufts Medical Cente and TUSM
executives and the Chairman of the Department of Medicine.
Highlights of 2014
» » Institute investigators gave 30 Invited Lectures
» » MORI faculty produced 55 publications
» » Faculty received 7 new research awards totaling $1.23M
141
»» INSTITUTE FOR MOLECULAR ONCOLOGY RESEARCH (MORI)
The Molecular Oncology Research Institute (MORI), a core component
of the Tufts Medical Center Cancer Center, has 17 faculty members
and occupies over 44,000 square feet in the 75 Kneeland Street
research building. Its mission is to explore the molecular mechanisms of neoplastic transformation and to
Faculty
Name
Academic Rank
Philip Tsichlis, MD
Executive Director, MORI
Jane F. Desforges Professor
Anika Agarwal, MD, MPhil
Assistant Professor
Associate Professor
Alain Charest, PhD
Associate Professor
Lidija Covic, PhD
Assistant Professor
Keyong Du, PhD
Assistant Professor
Andrew Evens, DO
Professor
Mark Ewen, PhD
Associate Professor
Ole Gjoerup, PhD
Assistant Professor
Philip Hinds, PhD
Professor
Guo-fu Hu, PhD
Associate Professor
Miaofen Hu, PhD
Assistant Professor
Athan Kuliopulos, MD, PhD
Professor
Charlotte Kuperwasser, PhD
Associate Professor
Paul Mathew, MD
Associate Professor
Elizabeth McNiel, DVM, PhD
Assistant Professor
James Yoo, MD
Assistant Professor
Seminars
The Institute has a biweekly seminar program for intramural research at MORI at which graduate students and postdoctoral fellows
present their work.
MORI holds a monthly faculty seminar program where principal investigators present their work to the MORI faculty. These
seminars encourage the sharing of ideas and prompt collaborations between laboratories.
The Institute sponsors a campus-wide seminar series in which invited speakers from other institutions present their research to
Tufts MC and TUSM faculty. These seminars encourage the sharing of ideas and foster collaborations between laboratories.
Research Support
In 2014, the Institute received new, peer-reviewed research awards in the amount of $1.23 million.
Funding Source
Title of Project
Tufts CTSI
Finding the X Factor: how breast cancers conscript the tumor
microenvironment
Lidija Covic, PhD
NIH
Development of PAR2 Inhibitors for the Treatment of
Nonalcoholic steatohepatitis (NASH)
Andrew Evens, D.O., MS
NIH
EMR Adverse Drug Event Detection for Pharmacovigilance
(subcontract)
Miaofen Hu, MD, PhD
Tufts CTSI
The role of Cdk6 in Adipogenesis, Obesity, and Diabetes
BCRF
Understanding the link between cellular reprogramming and
early pre-malignant changes in human breast epithelial cells
(continuation)
NIH/NCI
Mechanisms of Breast Cancer Associated with Obesity –
supplement
Animal Cancer Foundation
EZH2: A new target for canine bladder cancer
Charlotte Kuperwasser, PhD
Elizabeth McNiel, DVM
PI
Dr. Rachel Buchsbaum
Invited lectures:
»» Invited speaker, AACR Meeting, April 2014. Tiam1 and the Breast Cancer Microenvironment
Honors and Awards:
»» Tufts University School of Medicine Outstanding Lecturer
»» Tufts University School of Medicine Accomplished Teaching
Dr. Andrew Evens
Invited Lectures:
»» Center of Cancer Systems Biology (CCSB) Grand Rounds. Translational Analyses of Novel Targeted Agents for the Treatment of
Lymphoma (Sponsor: GeneSys Research Institute (GRI)). Boston, MA; January 7th, 2014.
»» 2014 Highlights of ASH in North America. Topic: Hodgkin Lymphoma (Sponsor: ASH). Atlanta, GA; January 25th, 2014.
»» 2014 Highlights of ASH in North America. Topic: Hodgkin Lymphoma (Sponsor: ASH). Seattle, WA; February 1st, 2014.
»» Lymphoma Research Foundation (LRF) Mentoring Program. Grant opportunities and funding mechanisms for clinical investigators
in the field of lymphoma (Sponsor: LRF). Scottsdale, AZ; February 7th, 2014.
»» St. Luke’s Hospital Oncology Grand Rounds. The Prognosis and Treatment of Hodgkin Lymphoma: Long Term Considerations (i.e.,
Survivorship). New Bedford, MA; February 19th, 2014.
»» Aggressive Non-Hodgkin Lymphoma; New England Lymphoma Workshop (Patient Forum); March 22nd, 2014.
»» 2014 Highlights of ASH in Asia. Topic: Hodgkin Lymphoma (Sponsor: ASH). Singapore, Asia; March 29th and 30th, 2014.
»» Controversial Cases in Hematologic Malignancies and Hematology 2014. Topic: Prognosis and Treatment of Peripheral T-cell
Lymphoma (Sponsor: Massachusetts General Hospital). Boston, MA; April 12th, 2014.
»» Peripheral T-Cell Lymphomas: Contemporary Prognostic and Therapeutic Approaches. Oncology Grand Rounds; Lahey Clinic.
Burlington, MA; May 29th, 2014.
»» Arterial Disease, Second Cancers, and Other Aftermath in Hodgkin Lymphoma; Lowell General Hospital Grand Rounds; Lowell, MA,
June 11th, 2014.
»» Hodgkin Lymphoma in Older (Elderly) Patients, Pathology Working Group and the Subtypes Initiative, Roundtable discussion on the
state-of-the-art pathology and future initiatives; INTERLYMPH 2014 Annual Meeting. UCLA, Los Angeles, CA, June 18th, 2014.
»» Impact of Lifestyle on Lymphoma Histology and Genetics, Lifestyles and Environment Working Group INTERLYMPH 2014 Annual
Meeting. UCLA, Los Angeles, CA, June 19th, 2014.
143
»» The Prognosis and Treatment of Hodgkin Lymphoma: Past, Present, and Future Directions, Lymphoma/Myeloma Hematology Grand
Rounds, MD Anderson Cancer Center; Houston, TX; August 16th, 2014.
»» Antibody Drug Conjugates in Lymphoma, New Therapeutic Advances in Hematologic Malignancies/Diseases; Burlington, MA;
October 23rd, 2014.
Honors and Awards:
»» 2014 Scientific Advisory Board (SAB), Lymphoma Research Foundation (LRF)
Dr. Philip Hinds
Invited Lectures:
»» 2014 National Health Research Institutes, Taipei, Taiwan
»» 2014 Department of Pharmacology, Rush University
Dr. Athan Kuliopulos
Invited Lectures:
»» Delivered Webinar for the NHLBI SMARTT Program 5 year renewal: “Overcoming Barriers to Early Translation in Therapeutics
Development: Development of PZ-128 for the Prevention of Arterial Thrombosis in Acute Coronary Syndromes and Percutaneous
Coronary Intervention, May 28, 2014.
»» Chemistry Department, UC Santa Cruz, CA; Medicinal Chemistry and Drug Development with Cell-penetrating Pepducins, July 25,
2014
»» Discovery on Target; Membrane Protein Targets, 2014, ITargeting Receptors wit Cell Penetrating Pepducins; From Bench to Bedside,
Boston, MA October 10, 2014
»» Boston Angiogenesis Meeting, IMatrix Metalloprotease Signaling in Tumor Angiogenesis, Boston, MA, November 12, 2014
Honors and Awards:
»» Elected member of NIH/NHLBI Scientific Review Board SMARTT Program
Dr. Paul Mathew
Honors and Awards:
Dr. Elizabeth McNiel
Honors and Awards:
»» 2014 Comparative Oncology Award, Animal Cancer Foundation
Dr. Philip Tsichlis
Invited Lectures
»» March 25, 2014: Invited presentation at Astrazeneca in Waltham, MA
»» April 6, 2014: AACR Meeting, San Diego, CA; Chaired and presented a lecture in the session on “Modulation of Micro RNA Expression”
»» April 22, 2014: Invited presentation at ArQule, a biotechnology company in Boston, MA
»» May 22, 2014: Invited presentation in the Clinical Immunology Lecture Series at the Beth Israel-Deaconess, Boston, MA
»» October 2014: European meeting on Inflammation and Cancer. “Akt and Regulatory Tcells”
Honors and Awards
»» “Taxiarchis of Phoenix” Medal awarded by the President of the Hellenic Republic for major contributions to science, the arts, culture
and society (2014).
»»
Honorary degree, University of Crete, (2014).
Dr. James Yoo
Honors and Awards
»» 2011-2014 Chair, ASCRS Awards Committee
PUBLICATIONS
145
Abstracts, letters to editor and presentations excluded from listings.
Divis ion of C a rd i ol og y
»» PUBLICATIONS
1.
Bader Y, Link M, Estes NAM. The Athlete’s Electrocardiogram in Shenasa M, Josephson ME, Estes NAM ECG
Handbook of Contemporary Cardiotext, Minneapolis, MN (2014).
2.
Barrett Mueller K, Lu Q, Mohammed NN, Luu V, McCurley A, Williams GH, Adler GK, Karas RH, Jaffe IZ. Estrogen
receptor inhibits mineralcortocoid receptor transcriptional regulatory function. Endocrinology. 2014;
155(11):4461-4472. PMID: 25051445.
3.
Bene NC, Alcaide P, Wortis HH, Jaffe IZ. Mineralcortocoid Receptors in Immune Cells; Emerging Role in
Cardiovascular Disease. Steroids, 2014 April 21 pii: S0039-128Z(14)00076-2. Doi:10.1016/j. PMCID: PMC4205205.
4.
Blankstein R, Rowin EJ. What is the best imaging test for patients with hypertrophic cardiomyopathy? It depends
on the clinical question! J Cardiovasc comput Tomogr. 2014 Nov-Dec;8(6):438-41.
5.
Boumil MM and Salem DN. In…and out: open access publishing in scientific journals. Quality Management in
Health Care 23(3):133-7, 2014.
6.
Caselli S, Maron M, Urbano-Moral, Pandian NG, Maron B, Pellicca A. Differentiating left ventricular hypertrophy
in athletes from that in patients with hypertrophic cardiomyopathy. Am J Cardiol 2014; 114:1383-1389.
7.
Caselli S, Montesanti D, Aurore C, Di Paolo D, Pisicchio C, Squeo MR, Musumeci B, Spataro A, Pandian NG,
Pelliccia A. Patterns of left ventricular strain and strain-rate in Olympic athletes. J Am Soc Echocardiogr. 2014
Nov 20. pii: S0894-7317(14)00752-4, doi: 10.1016/J.echo.2014.10.010.
8.
Chan RH, Maron BJ, Olivotto I, Assenza G, Lesser JR, Haas T, Gruner C, Crean A, Rakowski H, Udelson JE, Rowin
E, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson
CM, Manning WJ, Appelbaum E, Maron MS. Prognostic Utility of Contrast-Enhanced Cardiovascular Magnetic
Resonance Imaging in Hypertrophic Cardiomyopathy: An International Multicenter Study. Circulation
2014:130:484-95.
9.
Chen CW, Jaffe IZ, and Karumanchi SA. Preeclampsia and Cardiovascular Disease. Cardiovasc Res,
2014:101(4):579-86. PMID: PMC3941598.
10.
Dohadwala M, Link MS. Implantable defibrillators in Long QT Syndrome, Brugada Syndrome, Hypertrophic
Cardiomyopathy, and Arrhythmogenic Right Ventricular Cardiomyopathy. Cardiology Clinics-Pacemakers and
Implantable Cardioverter Defibrillators, edited by Theofanie Mela, 2014; 305-318.
11.
Douglas PS, Hoffmann U, Lee KL, Mark DB, Al-Khalidi HR, Anstrom K, Dolor RJ, Kosinski A, Krucoff MW,
Mudrick DW, Patel MR, Picard MH, Udelson JE, Velasquez EJ, Cooper L; PROMISE investigators. PROspective
Multicenter Imaging Study for Evaluation of chest pain: Rational and design of the PROMISE trial. Am Heart J.
2014:167:796-803.
12.
DuPont JJ, Hill MA, Bender SB, Jaisser F, and Jaffe IZ. Aldosterone and Mineralocortocoid Receptors: Regulators
of Ion Channels Beyond the Kidney. Hypertension, 2014:63(4):632-7. PMCID: PMC3954941.
13.
Ellis KL, Zhou Y, Beshansky JR, Ainehsazan E, Yang Y, Selker HR, Huggins GS, Cupples LA, Peter I. Genetic
variation at glucose and insulin trait loci and response to glucose-insulin-potassium (GIK) therapy: the
IMMEDIATE trail. The pharmacogenomics journal 2014.
14.
Esposito M, Shah NN, Korabathina R, Pan C, Paruchuri V, Finley J, Shah A, Boyle A, Vaillant R, Kimmelstiel CD,
Kapur NK. Quantitative assessment of myocardial perfusion using time-density curve analysis after elective
percutaneous coronary intervention. J Invasiv Cardiol. 2014 Feb;26(2):60-3. PubMed PMID: 24486662.
15.
Estes NA. Controversies in Cardiovascular Medicine Revisited Circulation. 2014 Oct 28;130(18):1561.doi:10.1161/
CIRCULATIONAHA.114.013338.
Estes Nam. Examining Achilles Heel: Improving responses t CRT Therapy J Am Coll Cardiol Img. 2014;7(12)
1249-1250.
17.
Estes NA 3rd. Is it Time for a New Approach to Implantable Cardioverter-Defibrillator Replacement? J Am Coll
Cardiol. 2014 Jun 10,63(22):22395-7.
18.
Faletra F, Pedrazzini G, Pasotti E, Pandian NG. Mitral insufficiency, Book Chapter in book, Echocardiography in
Mitral Valve Disease Editor: Francesco Faletra. 2014 Publ: Springer(In Press).
19.
Faletra FF, Ramamurthi A, Dequarti MC, Leo LA, Moccetti T, Pandian NG. Artifacts in three-dimensional
echocardiography. J Am Soc Echocardiogr 2014:27:453-62.
20.
Fleming LM. Subspecialis Scholarship In Quality Improvement (2014) JACC.64(10):1064-5.
21.
Fleming LM, Gavin M, Piatkowski G, Chang J, Mukamal K. Derivation and Validation of a 30-day Heart Failure
Readmission Model (2014) American Journal of Cardiology. In Press.
22.
Fleming LM, Kociol R. Interventions for Heart Failure Readmissions: Successes and Failures. (2014) Current
Heart Failure Reports. Epub March 1, 2014.
23.
Fleming LM, Manning WJ. Extracardiac Findings on Echocardiography: Blissful Ignorance or a Call to Improve
our Training? (2014) J Am Soc Echocardiography. 27(5):547-8.
24.
Fogel R, Epstein AE, Estes NAM, Lindsay BD, Kremers MS, Kapa S, Brindis R, and Russo AE. The disconnect
between the guidelines, the appropriate use criteria, and reimbursement coverage decisions: the ultimate
dilemma. J Am Coll Cardiol. 2014 Jan 7;63(1):12-14.
25.
Galmiche G, Pizard A, Gueret A, El Moghrabi S, Berger S, Labat C, Jaffe IZ, Lacolley P, and Jaisser F. Smooth
Muscle Cell Mineralocorticoid Receptors are Mandatory for Aldosterone-salt to Induce Vascular Stiffness.
Hypertension. 2014; 63(3):520-526. PMID:24296280.
26.
Goldenberg I, Kutyifa V, Klein HU, Cannom DS, Brown MW, Dan A, Daubert JP, Estes NA 3rd, Foster E, Greenberg
H, Kautzner J, Klempfner R, Kuniss M, Merkely B, Pfeffer MA, Quesada A, Viskin S, McNitt S, Polonsky B, Ghanem
A, Solomon SD, Wilber D, Areba W, Moss AJ. Survival with cardiac-resynchronization therapy in mild heart
failure. N Engl J Med. 2014 May 1;370(18):1694-70.
27.
Gruner C, Chan RH, Crean A, Rakowski H, Rowin EJ, Care M, Deva D, Williams L, Appelbaum E, Gibson CM,
Lesser JR, Haas TS, Udelson JE, Manning WJ, Siminovitch K, Ralph-Edwards AS, Rastegar H, Maron BJ, Maron
MS. Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance
imaging in patients with hypertrophic cardiomyopathy. Eur Heart J 2014 Oct; 35(39):2706-13.
28.
Holwerda KM, Burke SD, Faas MM, Zsengeller Z, Stillman IE, van Goor H, McCurley A, Jaffe IZ, Karumanchi SA,
and Lely AT. Hydrogen Sulfide Attenuates SFlt1-Induced Hypertension and Renal Damage by Upregulating
Vascular Endothelial Growth Factor. J Am Soc. Nephrol. 2014; 25(4):717-725. PMCID:PMC3968492.
29.
Jaffe IZ, Jaisser F. Endothelial Mineralocorticoid Receptors: turning cardiovascular risk factors into cardiovascular
dysfunction. Invited Editorial. Hypertension, 2014;63(5):915-917. PMCID: PMC3984296.
30.
Javed A, Jumean M, Murad MH, et al. Dignostic performance of body mass index to identify obesity as defined by
body adiposity in children and adolescents: a systematic review and meta-analysis. Pediatr Obes. 2014 Jun 25.
31.
Jumean MF, Kiernan MS. Determinants of survival following hospitalization for acute heart failure. Curr Heart
Fail Rep. 2014 Jun;11(2):201-11. Doi:10.1007/s11897-014-0190-z. Review. PMID: 24477905.
32.
Jumean M, Pham DT, Kapur NK. Percutaneous bi-atrial extracorporeal membrane oxygen for acute circulatory
support in advanced heart failure. Catheter Cardiovasc Interv. 2014 Dec 22. Doi:10.1002/ccd.25791. PubMed
PMID: 25535957.
»» PUBLICATIONS
16.
147
»» PUBLICATIONS
33.
Kalin JA, Madias C, Link MS. Prevention of sudden cardiac death: Commotio cordis. In Emergency Management
for Sport and Physical Activity. Edited by Casa and Stearns. Jones and Bartlett. 2014; 53-60.
34.
Kapur NK, Paruchuri V. Interventions for failing vessels, valves, and now…ventricles: the parachute device.
Catheter Cardiovasc Interv. 2014 Mar 1;83(4):631-2. doi:10.1002/ccd.25398. PubMed PMID: 24532330.
35.
Kapur NK, Paruchuri V, Thinh D, Reyelt L, Murphy B, Beale C, Bogins C, Wiener D, Nilson J, Esposito M, Perkins
S, Perides G, Karas RH. Hemodynamic Effects of Left Atrial or Left Ventricular Cannulation for Acute Circulatory
Support in a Bovine Model of Left Heart Injury. ASAIO J. 2014 Dec 5. PubMed PMID:25485565.
36.
Kapur NK, Qiao X, Paruchuri V, Mackey EE, Daly GH, Ughreja K, Morine KJ, Levine J, Aronovitz MJ, Hill NS, Jaffe
IZ, Letarte M, Karas RH. Reducing endoglin activity limits calcineurin and TRPC-6 expression and omproves
survival in a mouse model of right ventricular pressure overload. J Am Heart Assoc. 2014 Jul 11;3(4). pii: e000965.
doi: 10.1161/JAHA.114.000965. PubMed PMID: 25015075.
37.
Kapur NK, Upshaw J, Kiernan MS, Pham DT. Left ventricular assist device thrombosis presenting as an acute
coronary syndrome. J Thorac Cardivasc Surg. 2014 June;147(6):e72-3. doi: 10.1016/j.jtcvs.2014.02.037. PubMed
PMID: 24642558.
38.
Kiernan MS, French AL, DeNofrio D, Parmar YJ, Pham DT, Kapur NK, Pandian NG, Patel AR. Preoperative Three
Dimensional Echocardiography to Assess Risk of Right Ventricular Failure Following Left Ventricular Assist
Device Surgery. J Card Fail. 2014 Dec 20. pii. S1071-9164(14)01351-7. doi. 10.1016/j,carfail.2014.12.009. PubMed
PMID: 25535957.
39.
Kim J, Parikh P, Mahboob M, Arrighi JA, Atalay MK, Rowin EJ, Maron MS. Asymptomatic young man with Danon
Disease. Tex Heart Inst J 2014 Jun 14 (3):332-4.
40.
Kimmelstiel C, Kapur NK. Low alcohol tolerance – a blessing for septal ablation. Catheter Cardiovasc Interv. 2014
Jul 1;8(1):108-9. doi: 10.1002/ccd.25537. PubMed PMID: 24975263.
41.
Klejn S, Pandian NG, Thomas J, Perez de Isla L, Kamp O, Zuber M, Nihoyannopoulos, Forster T, Nesser HJ, Geibel
A, Gorrissen W, Zamorano J. Normal reference values of left ventricular strain using three-dimensional speckle
tracking echocardiography: results from a multicenter study. Eur Heart J CV Imaging 2014 Oct 26. pii: jeu213.
42.
Koenig, Jaffe IZ. Direct Role for Smooth Muscle Cell Mineralocorticoid Receptor in Vascular Remodeling: Novel
Mechanisms and Clinical Implications. Invited Review. Curr Hypertens Rep, 2014; 16(5):427. doi:10.1007/s11906014-0427-y. PMCID: PMC3951242.
43.
Lassnce-Soares RM, Sood S, Chakraborty N, Jhamnani S, Aghili N, Nashin H, Hammamieh R, Jett M, Epstein SE,
Burnett MS. Chronic stress impairs collateral blood flow recovery in aged mice. Journal of Cardiovascular
Translational Research. 2014 Nov;7(8):749-55.
44.
Lawless CE, Asplund C, Asif IM, Courson R, Emery MS, Fuisz A, Kovacs RJ, Lawrence SM, Levine BD, Link MS,
Martinez MW, Matherne GP, Olshansky B, Roberts WO, Salberg L, Vetter VL, Vogel RA, Whitehead J. Protecting
the Heart of the American Athlete: Proceedings of the American College of Cardiology Sports and Exercise
Cardiology Think Tank October 18, 2012, Washington DC. J Am Coll Cardiol. 2014;64:2146-2171.
45.
Levine YC, Rosenberg MA, Mittleman M, Samuel M, Methachittiphan N, Link MS, Josephson ME, Buxton AE.
B-type natriuretic peptide is a major predictor of ventricular arrhythmias. Heart Rhythm. 2014; 11: 1109-1116.
46.
Link MS, Estes NAM 3rd. Sudden Cardiac Deaths in Athletes, Including Commotio Cordis in Zipes D, Clinical
Electrophysiology, 2014; 1061-1072.
47.
Link MS, Laidlaw D, Polonsky B, Zareba W, McNitt S, Gear K, Marcus F, Estes NAM 3rd. Effectiveness of
antitachycardia packing for recurrent ventricular tachycardia… J Am Coll Cardiol. 2014; 64: 2560.
Link MS, Laidlaw D, Polonsky B, Zareba W, McNitt S, Gear K, Marcus F, Estes NA 3rd. Ventricular Arrhythmias in
the North Americal Multidisciplinary Study of ARVC: Predictors, Characteristics, and Treatment. J Am Coll
Cardiol. 2014 Jul 15;64(2):19-25.
49.
Link MS, Luttmann-Gibson H, Schwartz J, et al. Reply: Triggering of cardiac arrhythmias: the proglem of
multicollinearity among air pollution and meteorological factors. J Am Coll Cardiol 2014;63(12):1227-8.
50.
Love C, Estes NAM 3rd. Following leads to improve patient outcomes: It’s about time Vol. 11, Issue 12,
p2163-2164.
51.
Majithia A, Estes NAM 3rd, Weinstock J. Advances in sudden death prevention: the emerging role of the fully
subcutaneous defibrillator. Am J Med. 2014 Mar;127(3):188-94.
52.
Malik R, Maron M, Rastegar H, Pandian NG. Hypertrophic cardiomyopathy with right ventricular outflow tract
left ventricular intracavitary obstruction. Echocardiography 2014;31:682-685.
53.
Malik R, Zilberman M, Tang L, Miller S, Pandian NG. Ectopia cordis with a double outlet right ventricle, large
ventricular septal defect, malposed great arteries and left ventricular hypoplasia. Echocardiography 2014.
54.
Mangili A, Ahmad R, Wolfert RL, Kuvin J, Polak J, Karas RH, Wanke CA. Lipoprotein-associated phospholipase A2
(Lp-PLA2), A novel cardiovascular inflammatory marker, in HIV-infected patients. Clin Infect Dis, 2014; 58:893900. PMCID:PMC3935500.
55.
Maron BJ, Haas TS, Maron MS, Lesser JR, Browning JA, Chan RH, Olivotto I, Garberich RF, Schwartz RS. Left atrial
remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by
cardiovascular magnetic resonance. Am J Cardiol 2014:113:1394-400.
56.
Maron BJ, Maron MS. The 25-year genetic era in hypertrophic cardiomyopathy: revisited. Circ Cardiovasc Genet
2014;7:401-4.
57.
Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and
future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 2014;64:83-99.
58.
Maron MS. My approach to the clinical management of hypertrophic cardiomyopathy. Trends Cardiovasc Med
2014;24:314-5.
59.
Methachittiphan N, Deeprasertkul P, Link MS. Electrocardiographic characteristics of ventricular arrhythmias in
inherited channelopathies. In Electrocardiography of Complex Arrhythmias. Cardiac Electrophysiology Clincs.
Sep 2014, p 419-432.
60.
Meyer TE, Kiernan MS, McManus DD, Shih J. Decision-making under uncertainty in advanced heart failure. Curr
Heart Fail Rep. 2014 Jun;11(2):188-96. doi:10.1007/s11897-014-0195-7. Review. PMID: 24691659.
61.
Morris AA, Butler J, Konstam MA. Heart Failure with normal ejection fraction, heart failure with preserved
ejection fraction, diastolic heart failure, or huff-puff: time for a new taxonomy for hypertensive-metabolic heart
failure. J Card Fail. 2014 Oct;20(10):779-81.
62.
Pandian NG. 3-Dimensional echocardiography – History and Technical Developments, in book “ThreeDimensional Echocardiography. Ed: Ricardo Ronderos (In Press) 2014.
63.
Pandian NG, Ramamurthi A, Applebaum S. Role of echocardiography in arotic stenosis. Prog CV Disease 2014;
57:47-54.
64.
Paranandi A, Asztalos BF, Mangili A, Kuvin JT, Gerrior J, Sheehan H, Tang AM, Skinner S, Wanke C. Effects of
omega-3 fatty acids on triglycerides and HDL sub-profiles in HIV-infected persons with hypertriglyceridemia.
AIDS Res Hum Retroviruses. 2014;30:800-805.
65.
Patel AR. “Diastology for the Echo Boards”. In Questions, Tricks, and Tips for the Echocardiography Boards. Eds:
Sorrell VS and Jayasuriya S. Wolters Kluwer 2014.
149
»» PUBLICATIONS
48.
»» PUBLICATIONS
66.
Peter I, Papandonatos GD, Belalcazar LM, Yang Y, Erar B, Jakicic JM, Unick JL, Balasubramanyam A, Lipkin EW,
Delahanty LM, Wagenknecht LE, Wing RR, McCaffery JM, Huggins GS, Look ARG. Genetic modifiers of
cardiorespiratory fitness response to lifestyle interventions. Med Sci Sports Exerc 2014;46:302-11.
67.
Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi SA and Jaffe IZ. Aldosterone promotes vascular
remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Athero Thromb Vasc Biol,
2014;34(2):355-364. PMCID: PMC3951242.
68.
Puchner SB, Liu T, Mayrhofer T, Truong QA, Lee H, Fleg JL, Nagurney JT, Udelson JE, Hoffmann U, Ferencik M.
High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of
significant stenosis in acute chest pain: results from the ROMICAT-II trial. J Am Coll Cardiol. 2014;64:684-92.
69.
Rock M, Karas AZ, Rodriguez K, Gallo M, Pritchett-Corning K, Karas RH, Aronovitz M, Gaskill B. The time-tointegrate-to-nest as a indicator of wellbeing in laboratory mice. J Am Assoc Lab Anim Sci, 2014; 53:24-28. PMCID:
PMC3894644.
70.
Rossignol P, Dobre D, Gregory D, Massaro J, Kiernan M, Konstam MA, Zannad F. Incident hyperkalemia may be
an independent therapeutic target in low ejection fraction heart failure patients: insight from the HEAL study. Int
J Cardiol. 2014 May 15;173(3):380-7. Epub 2014 Feb 28. PMID:24726210.
71.
Rowin EJ, Maron BJ, Kiernan MS, Casey SA, Feldman DS, Hryniewicz KM, Chan RH, Harris KM, Udelson JE,
DeNofrio D, Roberts WC, Maron MS. Advanced heart failure with preserved systolic function in nonobstructive
hypertrophic cardiomyopathy: under-recognized subset of candidates for heart trainsplant. Circ Heart Fail.
2014;7:967-75. PMID:25239116.
72.
Ruwald AC, Schuger C, Moss AJ, Kutyifa V, Olshansky B, Greenberg H, Cannom DS, Estes NA, Ruwald MH, Huang
DT, Klein H, McNitt S, Beck CA, Goldstein R, Brown MW, Kautzner J, Shoda M, Wilber D, Zareba W, Daubert JP.
Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter
Automatic Defibrillatory Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circ Arrhythm
Electrophysiol. 2014 Oct;7(5):785-92.
73.
Saksena S, Marchlinski F, Dimiano R, Estes NAM Interventional Cariac Electrophysiology Cardiotext, Mineapolis,
MN, 2014.
74.
Sasaki H, Nagayama T, Zhu G, Zhang M, Lee Dong I, Seo K, Bedja D, Hsu S, Tsukamoto O, Takashima S, Kitakaze
M, Blanton RM, Karas RH, Mendelsohn ME, Kass DA, Takimoto E. PDE5 inhibitor efficacy is estrogen dependent
in female heart disease. J Clin Invest. 2014; 124:2464-2471. PMCID: PMC4089449.
75.
Selan J, Michaelson M, Fanburg B, Estes NAM. Evaluation and Management of Heart Rhythm, Disturbances Due
to Cardiac Sarcoidosis, Circulation Heart and Lunch JACC Cardiovasc Imaging. 2014 Dec;7(12):1249-50.
76.
Selker HP, Udelson JE, Massaro JM, Ruthazer R, D’Agostino RB, Griffith JL, Sheehan PR, Desvigne-Nickens P,
Rosenberg Y, Tian X, Vickery EM, Atkins JM, Aufderheide TP, Sayah AJ, Pirrallo RG, Levy MK, Richards ME,
Braude DA, Doyle DD, Frascone RJ, Kosiak DJ, Leaming JM, Van Gelder CM, Walter GP, Wayne MA, Woolard RH,
Beshansky JR. One-Year Outcomes of Out-of-Hospital Administration of Intravenous Glucose, Insulin, and
Potassium (GIK) in Patients With Suspected Acute Coronary Syndromes (from the IMMEDIATE [Immediate
Myocardial Metabolic Enhancement During Initial Assesment and Treatment in Emergency Care] Trial). Am J
Cardiol. 2014;113:1599-605.
77.
Shenoy C, Maron M, Pandian NG. Cardiovascular magnetic resonance imaging for bicuspid aprtic valve
syndrome. Editorial commentary. European Heart J, Cardiovascular Imaging 2014;15:612-614.
78.
Shenoy C, Pandian NG. Invasive Echocardiography for the Boards, in book chapter in “Tricks, Tips and Questions
for the Echocardiography Boards, Ed: Sorrell VL and Jauasuria S. Publisher. Walters Kluwer 2014.
Shenoy C, Salehi HR, Faletra F, Pandian NG. Echocardiography in Ischemic Heart Disease, book chapter, in
Textbook of Echocardiography Editor: Navin Nanda. 2014 Publ: Jaypee.
80.
Sylvia LM, Ordway L, Pham DT, DeNofrio D, Kiernan M. Bivalrudin for treatment of LVAD thrombosis – a case
series. ASAIO J Nov-Dec 60(6):744-7. 2014. PMID:25072553.
81.
Thomas SS, Kimmelstiel C. Alcohol Septal Ablation vs Surgical Myectomy for HCM- the Controversy Continues.
Catheter Cardiovasc Interv. 2014; 83:278-9.
82.
Torromeo C, Evangelista A, Schiatiti M, Puddu P, Pandian NG, Nardinocchi P, Varano V, Gabriele S, Teresi, Piras P.
Torsional correlaties for end systolic volume index in adult healthy subjects. International J Applied Science and
Technology. 2014: 4:11-21.
83.
Urbano-Moral JA, Gangadharamurthy D, Comenzo RL, Pandian NG, Patel AR. Three-dimensional Speckle
Tracking Echocardiography in Light Chain Cardiac Amyloidosis: Examination of Left and Right Ventricular
Myocardial Mechanics Parameters. Rev Esp Cardiol (In Press) 2014.
84.
Urbano-Moral JA, Rowin EJ, Maron MS, Crean A, Pandian NG. Investigation of global and regional myocardial
mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in
hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2014 Jan 7(1):11-9.
85.
Vaduganathan M, Dei Cas A, Mentz RJ, Greene SJ, Khan S, Subacius HP, Chioncel O, Maggioni AP, Konstam MA,
Senni M, Fonarow GC, Butler J, Gheorghiade M; EVEREST Trial Investigators. Mineralocortidoid receptor
antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from
the EVEREST Trial). Am J Cardiol. 2014 Sep 1;114(5):743-50.
86.
Vaduganathan M, Green SJ, Ambrosy AP, Mentz RJ, Subacius HP, Chioncel O, Maggiono AP, Swedberg K, Zannad
F, Konstam MA, Senni M, Givertz MM, Butler J, Gheorghiade M; EVEREST trial inestigators. Relation of serum
uric acid levels and outcomes amoung patient hospitalized for worsening heart failure with reduced ejection
fraction (from the efficacy of vasopressin antiagonism in heart failure outcome study with tolvaptan tiral). Am J
Cardiol. 2014 Dec 1;114(11):1713-21.
87.
Vest AR, Cho LS. Hypertension in pregnancy. Curr Artheroscler Rep. 2014 Mar;16(3):395.
88.
Vest AR, Young JB. Should we target obesity in advanced heart failure? Curr Treat Options Cardio Med. 2014
Feb;16(2):284.
89.
Volpe G, Wanke G, Imai C, Heffernan K, Kuvin J, Mangili A. High-fat meals do not impair postprandial
endothelial function in HIV-infected and uninfected men. AIDS Res Hum Retroviruses. AIDS Res Hum
Retroviruses. 2014;30:881-887.
90.
Vu DM, Tai A, Tatro JB, Karas RH, Huber BT, Beasley D. T cells are prevalent in proximal aorta and drive nascent
atherosclerotic lesion progression and neutrophilia in hypercholesterolemic mice. PLoS One 2014;
9(10):e109416. PMCID:PMC4196850.
91.
Weinstock J, Estes NAM. Cardiac Resynchronization Therapy: Extending Current Responses to Phrenic Nerve
Stimulation, J Cardiovascular Electrophysiology, 2014, J Cardiovasc Electrophysiol. 2014 May;255):491-3.
92.
Wessler BS, Thaler DE, Ruthazer R, et al. Response to letter regarding article, “Transesophageal
echocardiography in cryptogenic stroke and patent foramen ovale analysis of putative high-risk features from the
risk of paradoxical embolism database”. Circ Cardiovasc Imaging 2014;7(3):573.
93.
Wessler BS, Thaler DE, Ruthazer R, et al. Transesophageal echocardiography in cryptogenic stroke and patent
foramen ovale: analysis of putative high-risk features from the risk of paradoxical embolism database. Circ
Cardiovasc Imaging 2014;7(1):125-31.
151
»» PUBLICATIONS
79.
»» PUBLICATIONS
94.
Yoneyama S, Guo Y, Lanktree MB, Barnes MR, Elbers CC, Karczewski KJ, Padmanabhan S, Bauer F, Baumert J,
Beitelshees A, Berenson GS, Boer JM, Burke G, Cade B, Chen W, cooper-Dehoff RM, Gaunt TR, Gieger C, Gong Y,
Gorski M, Heard-Costa N, Johnson T, Lamonte MJ, McDonough C, Monda KL, Onland-Moret NC, Nelson CP,
O’Connell JR, Ordovas J, Peter I, Peters A, Shaffer J, Shen H, Smith E, Speilotes L, Thomas F, Thorand B, Monique
Verschuren WM, Anand SS, Dominiczak A, Davidson KW, Hegele RA, Heid I, Hofker MH, Huggins GS, Illig T,
Johnson JA, Kirkland S, Look ARG, Konig W, Langaee TY, McCaffery J, Melander O, Mitchell BD, Munroe P,
Murray SS, Papanicolaou G, Redline S, Reilly M, Samani NJ, Schork NJ, Van Der Schouw YT, Shimbo D, Shuldiner
AR, Tobin MD, Wijmenga C, Yusuf S, Consortium G, Consortium CAI, Hakonarson H, Lange LA, Demerath EW,
Fox CS, North KE, Reiner AP, Keating B, Taylor KC. Gene-centric meta-analyses for central adiposity traits in up
to 57,412 individuals of European descent confirm known loci and reveal several novel associations. Hum Mol
Genet 2014;23:2498-510.
95.
Yutzey KE, Demer LL, Body SC, Huggins GS, Towler DA, Giachelli CM, Hofmann-Bowman MA, Mortlock DP,
Rogers MB, Sadeghi MM, Aikawa E. Calcific Aortic Valve Disease: A Consensus Summary From the Alliance of
Investigators on Calcific Aortic Valve Disease. Arteriosclerosis, thrombosis, and vascular biology 2014.
96.
Zhang Y, Welzig CM, Picard K, Du C, Wang B, Kyriakis J, Aronovitz M, Claycomb W, Blanton R, Park H-J, Galper
JB. Glycogen Synthase Kinase-3βInhibition Amerliorates Cardiac Parasympathetic Dysfunction in Type 1
Diabetic Akita Mice. Diabetes 2014 Jun;63(6):2097-113. PMCID:PMC4030105.
Divis ion of C l i ni ca l De c i s i on Ma k in g
97.
Choi H, Hamberger MJ, Munger Clary H, et al. Seizure frequency and patient-centered outcome assessment in
epilepsy. Epilepsia 2014;55:1205-12.
98.
Concannon TW, Fuster M, Saunders T, et al. A systematic review of stakeholder engagement in comparative
effectiveness and patient-centered outcomes research. J Gen Intern Med 2014;29:1692-701.
99.
Han PK, Joekes K, Elwyn G, et al. Development and evaluation of a risk communication curriculum for medical
students. Patient Educ Couns 2014;94:43-9.
100. Hunink M, Glasziou P, Pliskin J, Weinstein M, Wittenberg E, Drummond M, Wong JB. Decision Making in Health
and Medicine, 2nd Ed., Cambridge University Press. 2014.
101. Kassirer JP. Arnold S. Relman, MD, 1923-2014. Am J Kidney Dis 2014;64:A15-6.
102. Kho AN, Hynes DM, Goel S, et al. CAPriCORN: Chicago Area Patient-Centered Outcomes Research Network. J
Am Med Inform Assn 2014;21:607-11. Multimodality Writing Group for Stable Ischemic Heart Disease, Wolk MJ,
Bailey SR, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use
criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of
Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of
Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm
Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed
Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Card Fail
2014;20:65-90.
103. Pauker SG. Moments when utilities are functional. Med Decis Making 2014;34:4-7.
104. Pauker SG, Alseiari M. How big is big enough? Thinking about contralateral prophylactic mastectomy. J Natl
Cancer I 2014;106.
105. Roman G, Wolk MJ, Bailey SR, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013
multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a
report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart
Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure
Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of
Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic
Surgeons. J Nucl Cardiol 2014;21:192-220.
106. Rubin CL, Allukian N, Wang X, et al. "We make the path by walking it": building an academic community
partnership with Boston Chinatown. Progn Community Health Partnersh 2014;8:353-63.
107. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid
arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis
2014;73:492-509.
109. Wedzicha JA, Steinbrook R, Kassirer JP. Should medical journals publish sponsored content? BMJ 2014;348:g352.
110. Wong JB. Evidence-based medicine, pharmacogenetics, and antiplatelet therapy decision making for acute
coronary syndrome. Ann Intern Med 2014;160:284-5.
111. Wong JB. Principles of health economics and application to rheumatic disorders. In Hochberg MC, Silman AJ,
Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. 6th Ed., Elsevier, 2014; pp 20-6.
Divis ion of C l i ni ca l N ut r i t i on
112. Au LE, Harris SS, Dwyer JT, Jacques PF, Sacheck JM. Association of serum 25-hydroxyvitamin D with race/
ethnicity and constitutive skin color in urban schoolchildren. J Pediatr Endocrinol Metab 2014;27:1095-100.
113. Au LE, Harris SS, Jacques PF, Dwyer JT, Sacheck JM. Adherence to a vitamin D supplement intervention in urban
schoolchildren. J Acad Nutr Diet 2014;114:86-90.
114. Bailey RL, Saldanha LG, Gahche JJ, Dwyer JT. Estimating caffeine intake from energy drinks and dietary
supplements in the United States. Nutr Rev 2014;72 Suppl 1:9-13.
115. Berner LA, Keast DR, Bailey RL, Dwyer JT. Fortified foods are major contributors to nutrient intakes in diets of US
children and adolescents. J Acad Nutr Diet 2014;114:1009-22 e8.
116. Byun AJ, Hung KE, Fleet JC, et al. Colon-specific tumorigenesis in mice driven by Cre-mediated inactivation of
Apc and activation of mutant Kras. Cancer Lett 2014;347:191-5.
117. Davidoff F, Rosenberg IH. Association of dietary, circulating, and supplement fatty acids with coronary risk. Ann
Intern Med 2014;161:454.
118. Davis CD, Bailey RL, Dwyer JT, Coates PM. John Austin Milner, PhD (1947-2013). J Nutr 2014;144:411-3.
119. Dwyer J. Defining nutritious breakfasts and their benefits. J Acad Nutr Diet 2014;114:S5-7.
120. Dwyer JT, Saldanha LG, Bailen RA, et al. A free new dietary supplement label database for registered dietitian
nutritionists. J Acad Nutr Diet 2014;114:1512-7.
121. Dwyer JT, Woteki C, Bailey R, et al. Fortification: new findings and implications. Nutr Rev 2014;72:127-41.
122. Ellwood K, Balentine DA, Dwyer JT, Erdman JW, Jr., Gaine PC, Kwik-Uribe CL. Considerations on an approach for
establishing a framework for bioactive food components. Adv Nutr 2014;5:693-701.
123. Feeney MJ, Dwyer J, Hasler-Lewis CM, et al. Mushrooms and Health Summit proceedings. J Nutr
2014;144:1128S-36S.
153
»» PUBLICATIONS
108. Wang C, Iversen MD, McAlindon T, et al. Assessing the comparative effectiveness of Tai Chi versus physical
therapy for knee osteoarthritis: design and rationale for a randomized trial. BMC Complem Altern M
2014;14:333.
124. Harshman SG, Saltzman E, Booth SL. Vitamin K: dietary intake and requirements in different clinical conditions.
Curr Opin Clin Nutr Metab Care 2014;17:531-8.
125. Karl JP, Cheatham RA, Das SK, et al. Effect of glycemic load on eating behavior self-efficacy during weight loss.
Appetite 2014;80:204-11.
126. Karl JP, Fu X, Dolnikowski GG, Saltzman E, Booth SL. Quantification of phylloquinone and menaquinones in
feces, serum, and food by high-performance liquid chromatography-mass spectrometry. J Chromatogr B Analyt
Technol Biomed Life Sci 2014;963:128-33.
»» PUBLICATIONS
127. Keusch GT, Denno DM, Black RE, et al. Environmental enteric dysfunction: pathogenesis, diagnosis, and clinical
consequences. Clin Infect Dis 2014;59 Suppl 4:S207-12.
128. Kris-Etherton PM, Akabas SR, Bales CW, et al. The need to advance nutrition education in the training of health
care professionals and recommended research to evaluate implementation and effectiveness. Am J Clin Nutr
2014;99:1153S-66S.
129. Kris-Etherton PM, Pratt CA, Saltzman E, Van Horn L. Introduction to nutrition education in training medical and
other health care professionals. Am J Clin Nutr 2014;99:1151S-2S.
130. Ma J, Sloan M, Fox CS, et al. Sugar-sweetened beverage consumption is associated with abdominal fat
partitioning in healthy adults. J Nutr 2014;144:1283-90.
131. Shaul ME, Hallacoglu B, Sassaroli A, et al. Cerebral blood volume and vasodilation are independently diminished
by aging and hypertension: a near infrared spectroscopy study. J Alzheimers Dis 2014;42 Suppl 3:S189-98.
132. Sun L, Dwyer J. Dietetics in China at the crossroads. Asia Pac J Clin Nutr 2014;23:16-26.
133. Urban LE, McCrory MA, Rasmussen H, et al. Independent, additive effects of five dietary variables on ad libitum
energy intake in a residential study. Obesity (Silver Spring) 2014;22:2018-25.
134. Wang Y, Gapstur SM, Gaudet MM, Peterson JJ, Dwyer JT, McCullough ML. Evidence for an association of dietary
flavonoid intake with breast cancer risk by estrogen receptor status is limited. J Nutr 2014;144:1603-11.
135. Wang Y, Stevens VL, Shah R, et al. Dietary flavonoid and proanthocyanidin intakes and prostate cancer risk in a
prospective cohort of US men. Am J Epidemiol 2014;179:974-86.
136. Weaver CM, Dwyer J, Fulgoni VL, 3rd, et al. Processed foods: contributions to nutrition. Am J Clin Nutr
2014;99:1525-42.
137. Zhang FF, Kelly MJ, Saltzman E, Must A, Roberts SB, Parsons SK. Obesity in pediatric ALL survivors: a metaanalysis. Pediatrics 2014;133:e704-15.
138. Zhang FF, Roberts SB, Parsons SK, et al. Low Levels of Energy Expenditure in Childhood Cancer Survivors:
Implications for Obesity Prevention. J Pediatr Hematol Oncol 2014.
139. Zhang FF, Rodday AM, Kelly MJ, et al. Predictors of being overweight or obese in survivors of pediatric acute
lymphoblastic leukemia (ALL). Pediatr Blood Cancer 2014;61:1263-9.
Divis ion of End ocr i n ol og y
140. Akmal A, Kung J. “Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity.” Expert Opin
Drug Saf. 2014; 13(10):1397-406.
141. Aulet RM, Wein RO, Siegel RD. Surgical management of an atypical presentation of a thyroid storm. Int J
Endocrinol Metab. 2014; 1;12(2):e13539.
143. Dawson-Hughes B, Harris SS, Ceglia L, Palmero NJ. Effect of supplemental vitamin D and calcium on serum
sclerostin levels. Eur J Endocrinol. 2014; 13;170(4):645-50.
144. Dawson-Hughes B, Harris SS, Lichtenstein AH, Dolnikowski G, Palermo NJ, Rasmussen H. Dietary Fat Increases
Vitamin D-3 Absorption. J Acad Nutr Diet. 2014; S2212-2672(14):01468-3.
145. Dawson-Hughes B, Harris SS, Ceglia L, Palermo NJ. Serum sclerostin levels vary with season. J Clin Endocrinol
Metab. 2014; 99(1):E149-52
146. Fekete Cs and Lechan RM, Central Regulation of the Hypothalalmic-Pituitary-Thyroid Axis Under Physiological
and Pathophysiological Conditions, Endocrine Rev 2014: 35: 159-194.
147. Harris SS, Dawson-Hughes B. Effects of hydration and calcium supplementation on urine calcium concentration
in healthy postmenopausal women. J Am Coll Nutr. 2014.
148. Karl JP, Cheatham RA, Das SK, Hyatt RR, Gilhooly CH, Pittas AG, Lieberman HR, Lerner D, Roberts SB and
Saltzman E. Effect of glycemic load on eating behavior self-efficacy during weight loss. Appetite 2104
Sep;80:204-11.
149. Mitri J, Nelson J, Ruthazer R, Garganta C, Nathan DM, Hu FB, Dawson-Hughes B and Pittas AG. Plasma
25-hydroxyvitamin D and risk of metabolic syndrome: an ancillary analysis in the Diabetes Prevention Program.
EJCN 2014 Mar;68(3):376-83
150. Mitri J and Pittas AG. Vitamin D and diabetes. Endocrinol Metab Clin N Am 2014: Mar;43(1):205-32
151. Muscogiuri G, Mitri J, Mathieu C, Badenhoop K, Tamer G, Orio F, Mezza T, Vieth R, Colao AA, Pittas A.
Mechanisms in endocrinology: vitamin D as a potential contributor in endocrine health and disease. Eur J
Endocrinol. 2014 Sep;171(3):R101-10.
152. Pittas AG, Dawson-Hughes B, Sheehan, P, Rosen C, Ware JH, Knowler WC, Staten M. Rationale and design of the
Vitamin D and Type 2 Diabetes (D2d) Study: A Diabetes Prevention Trial. Diabetes Care. 2014; 37:1-8.
153. Pittas AG. Inhaled Insulin. In: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA 2007-2014
154. Pojednic RM, Ceglia L.The Emerging Biomolecular Role of Vitamin D in Skeletal Muscle. Exerc Sport Sci Rev.
2014; 42(2):76-81.
155. Pojednic RM, Ceglia L, Olsson K, Gustafsson T, Lichtenstein AH, Dawson-Hughes B, Fielding RA. Effects of
1,25-Dihydroxyvitamin D3 and Vitamin D 3 on the Expression of the Vitamin D Receptor in Human Skeletal
Muscle Cells. Calcif Tissue Int. 2014 Dec 6. [Epub ahead of print]
155
»» PUBLICATIONS
142. Bassoli E, L. Denti & A. Gatto, G. Spaletta, M. Sofroniou, A. Parrilli, M. Fini, R. Giardino, A. Zamparelli, N. Zini, F.
Barbaro, E. Bassi, S. Mosca, D. Dallatana, R. Toni. A planar fractal analysis of the arterial tree of the human
thyroid gland: implications for additive manufacturing of 3D ramified scaffolds. In: Bartolo PS. et al (Eds). High
Value Manufacturing: Advanced Research in Virtual and Rapid Prototyping, CRC Press, Taylor & Francis group,
London, 2014, pp. 423-429.
156. Pojednic RM, Ceglia L, Lichtenstein AH, Dawson-Hughes B, Fielding RA. Vitamin D receptor protein is
associated with interleukin-6 in human skeletal muscle. Endocrine. 2014 Dec 16. [Epub ahead of print]
157. Rizzoli R, Bischoff-Ferrari H, Dawson-Hughes B, Weaver C. Nutrition and Bone Health in Women after the
Menopause. Womens Health, 2014; 10(6): 599-608.
158. Rizzoli R, Dawson-Hughes B, Kaufman JM, Fardellone P, Brandi ML, Vellas B, Collette J, Regnister JY, Correction
of vitamin D insufficiency with combined strontium renalate and vitamin D3 in osteoporotic patients, Eu J
Endocrinol, 2014; 170(3): 441-50.
»» PUBLICATIONS
159. Seida JC, Mitri J, Colmers I, Majumdar SR, Davidson MB, Edwards AL, Hanley DA, Pittas AG, Tjosvold L, Johnson
JA. Clinical review: Effect of Vitamin D Supplementation on Improving Glucose Homeostasis and Preventing
Diabetes: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2014 Oct;99(10):3551-60. doi:
10.1210/jc.2014-2136. Epub 2014 Jul 25.
160. Siris E S, Adler R, Bilezikian J, Bolonese M, Dawson-Hughes B, Favus MJ, Harris ST, Jan de Beur SM, Knosla S,
Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB. Clinical diagnosis of osteoporosis: A
Consensus Report from the National Bone Health Alliance Working Group. Osteoporosis Int 2014; 25(5): 1439-43.
PMID 24577348.
161. Spartano NL, Lamon-Fava S, Matthan NR, Ronxhi J, Greenberg AS, Obin MS, Lichtenstein AH. Regulation of
ATP-binding cassette transporters and cholesterol efflux by glucose in primary human monoyctes and bone
marrow derived macrophages. Exp Clin Endocrinol Diabetes 2014; 122(8):463-8.
162. Toni R, Taddeo Alderotti e le radici medioevali della terapia steroidea, L’Endocrinologo 2014; 15; 135-138.
163. Toni R, La sindrome di Maestre di San Juan-Kallman- De Morsier, L’Endocrinologo 2014; 15; 82-85.
164. Toni R, I segni di Graefe e Stellwag nell’ipertioidismo, L’Endocrinologo 2014; 15; 186-189.
165. Toni R, La sindrome da inappropriate antidiuresi, L’Endocrinologo 2014; 15; 234-237.
166. Toni R, Cellule da castrazione, castrati e gonadotropinoma, L’Endocrinologo 2014; 15; 36-39.
167. Toni R, Il feocromocitoma e il paraganglioma, ’Endocrinologo 2014; 15: 286-289.
168. Tripathy S, Lytle KA, Stevens RD, Bain JR, Newgard CB, Greenberg AS, Huang LS, Jump DB. Fatty acid elongase-5
(Elovl5) regulates hepatic triglyceride catabolism in obese C57BL6J mice. J. Lipid Res. 2014; 9;55(7): 1448-1464.
169. Vu DM, Tai A, Tatro JB, Karas RH, Huber BT, Beasley D. γδT cells are prevalent in the proximal aorta and drive
nascent atherosclerotic lesion progression and neutrophilia in hypercholesterolemic mice. PLoS One. 2014 Oct
14;9(10):e109416.
170. Wittmann G, Singru PS, Nouriel SS, Harney JW, Larsen PR, Lechan RM, Inflammation-inducible type 2
deiodinase expression in the leptomeninges, choroid plexus and at brain blood vessels: a study in male rats, mice
and Syrian hamsters, Endocrinology, 2014; 155: 2009-1019.
171. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall, S, Dawson-Hughes B. The recent prevalence of
osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or
lumbar spine. J Bone Miner Res. 2014; 29(11):2520-6.
172. Zamparelli A, Zini N, Cattin Li, Spaletta G, Dallatana D, Bassi E, Barbaro F, Iafisco M, Mosca S, Parrill Ai, Fin Mi,
Giardino R, Sandri M, Sprio S, Tampieri A, Maraldi NM, Toni R. Growth on poly-l-lactic acid porous scaffold
preserves CD73 and CD90 immunophenotype markers of rat bone marrow stromal cells. J.Mat. Sci. Mat. Med.
2014; 25: 2421- 2436.
173. Zanetti M, Harris SS, Dawson-Hughes B, Ability of Vitamin D to reduce inflammation in adults without acute
illness, Nutr Rev 2014; 72(2): 95-8.
Divis ion of G a st roe nte rol og y
174. Bonis PA, The epidemiology and characteristics of eosinophilic esophagitis. Gastroenterol Hepatol (N Y). 2014
Jan;10(1):56-8. PubMed PMID: 24799841; PubMed Central PMCID: PMC4008961.
175. Bonis, PA, Gonzalez A, Sullivan MF, Bonder A, Allison HV, Bonis PA, Guelrud M. Obliteration of symptomatic
Schatzki rings with jumbo biopsy forceps (with video). Dis Esophagus. 2014 Sep-Oct;27(7):607-10. doi: 10.1111/
dote.12167. Epub 2014 Feb 19. PubMed PMID: 24552567.
177. Guelrud, M, Winston D, Guelrud M. Gastric cardia intestinal metaplasia is common in Schatzki’s ring: Study of
resection specimens. Presented at the 79th Meeting of the American College of Gastroenterology 10/20/2014.
178. Leung, J, Schoepfer AM, Straumann A, Panczak R, Kuehni CE, Romero Y, Maurer E, Alexander JA, Hirano I,
Gonsalves N, MD, Furuta GT, Dellon ES, Moawad FJ, Collins MH, Bussmann C, Netzer P, Zwahlen M, Safroneeva
E. International EEsAI Study Group. Dysphagia, behavioral changes, and thoracic pain predict adult patientreported eosinophilic esophagitis severity. Gastroenterology 2014: 147(6): 1255–1266.e21
179. Leung, J, Kang D, Schlachter SC, Carruth RW, Kim M, Wu T, Tabatabaei N, Vacas-Jacques P, Shishkov M, Woods
K, Sauk JS, Nishioka NS, Tearney GJ. Comprehensive confocal endomicroscopy of the esophagus in vivo. Endosc
Int. Open 2014. Available at: https://www.thieme-connect.com/products/ejournals/
abstract/10.1055/s-0034-1377177 [Accessed August 30, 2014]
180. Leung, J, Tabatabaei N, Kang D, Wu T, Kim M, Carruth RW, Sauk J, Shreffler W, Yuan Q, Katz A, Nishioka NS,
Tearney GJ. Tethered confocal endomicroscopy capsule for diagnosis and monitoring of eosinophilic esophagitis.
Biomed. Opt. Express 2014;5:197.
181. Weinstock, J.V., Elliot, D.E. Helminth infections decrease host susceptibility to immune-mediated diseases. J.
Immunol. 193: 3239-3247, 2014.
182. Weinstock, J.V., Khumbatta, M, Firozgary, B, Tweardy, D. J.,.Firozgarv, G., Bhatena, Z., Bulsara, T., Siller, R., and
Robinson, P. Somatostatin negatively regulates parasite burden and granulomatous responses in cysticercosis.
BioMed Research International: 1-6, 2014. ID 247182.
183. Weinstock, J.V., Oxenkrug, G.F., Turski, W.A., Zgrajka, W., Ruthazer, R. and Summergrad, P.: Disturbances of
tryptophan metabolism and risk of depression in HCV patients treated with IFN-alpha. J. Infect. Dis. Ther. 2: 131.
doi:10.4172/2332-0877, 2014. 1000131
184. Weinstock, J.V. Do we still need worms to promote immune health? Clinical Reviews in Allergy & Immunology
2014. (DOI) 10.1007/s12016-014-8458-3: “Parasites and us. Sampan Newspaper, Boston, MA 2014.
185. Weinstock, J.V., Keo, T., Leung, J.: Helminthic Infections of the Gastrointestinal Tract and Liver. Yamada Textbook
of Gastroenterology. 2014
186. Weinstock, J.V., Keo, T., Leung, J..: Atlas Helminthic Infections of the Gastrointestinal Tract and Liver. Yamada
Textbook of Gastroenterology. 2014
187. Weinstock, J.V., Elliott, D.E., Sultan, S.: Innate Immunity in Disease. Clinical Gastroenterology and Hepatology.
2014 NIHMS576900
188. Weinstock, J.V.: Substance P and the regulation of inflammation in intestinal infections and inflammatory bowel
disease. Acta Physiologica, 2014.
157
»» PUBLICATIONS
176. Guelrud M, Gonzalez A, Sullivan MF, Bonder A, Allison HV, Bonis PA, Guelrud M. Obliteration of symptomatic
Schatzki rings with jumbo biopsy forceps (with video). Dis Esophagus. 2014;27:607-610
Divis ion of G e og ra p h i c Me d i ci ne a n d I n fec t io n s D isea ses
189. Allison GM, Muldoon EG, Kent DM, Paulus JK, Ruthazer R, Ren A, Snydman DR. Prediction model for 30-day
hospital readmissions among patients discharged receiving outpatient parenteral antibiotic therapy. Clin Infect
Dis. 2014 Mar;58(6):812-9. PubMed PMID: 24357220; PubMed Central PMCID: PMC3935501.
»» PUBLICATIONS
190. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, Puri P, Sterling RK, Luketic V, Stravitz RT, Siddiqui MS, Fuchs M,
Thacker LR, Wade JB, Daita K, Sistrun S, White MB, Noble NA, Thorpe C, Kakiyama G, Pandak WM, Sikaroodi M,
Gillevet PM. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and
endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther. 2014 May;39(10):1113-25. doi: 10.1111/
apt.12695. Epub 2014 Mar 16.
191. Bertagnolio S, Barcarolo JH and Jordan MR. Surveillance of HIV Drug Resistance in Adults Receiving ART
(Acquired HIV Drug Resistance - Concept Note. World Health Organization, Geneva, Switzerland. July 2014.
ISBN 978 92 4 150707 3. Available at: http://www.who.int/hiv/topics/drugresistance/protocols/en/ (56 pages).
192. Bertagnolio S, Barcarolo JH, and Jordan MR. Surveillance of HIV Drug Resistance in Adults Initiating
Antiretroviral Therapy (Pre-treatment HIV Drug Resistance) – Concept Note. World Health Organization,
Geneva, Switzerland. July 2014. ISBN 978 92 4 150719 6 Available at: http://www.who.int/hiv/topics/
drugresistance/protocols/en/ (40 pages).
193. Boucher HW, Talbot GH, Dunne MW. Dalbavancin or oritavancin for skin infections. N Engl J Med. 2014 Sep
18;371(12):1161-2. PubMed PMID: 25229922.
194. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily
conventional therapy for skin infection. N Engl J Med. 2014 Jun 5;370(23):2169-79. PubMed PMID: 24897082.
195. Boucher HW. A tribute to Dr Robert C. Moellering Jr (1937-2014). Infect Dis Clin North Am. 2014 Sep;28(3):xiiixiv. PubMed PMID: 25151569.
196. Cambiano V, Bertagnolio S, Jordan MR, Pillay D, Perriëns JH, Venter F, Lundgren J, Phillips A. Predicted levels of
HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral
therapy initiation. AIDS. 2014 Jan;28 Suppl 1:S15-23. PubMed PMID: 24468943.
197. Daoud Z, Sokhn ES, Azar E, Masri K, Doron S. Mutant prevention concentrations of ciprofloxacin against urinary
isolates of Escherichia coli and Klebsiella pneumoniae. J Infect Dev Ctries. 2014 Feb 13;8(2):154-9. PubMed
PMID: 24518624.
198. Dinh, D., Volpe, G., Duffalo, C., Bhalchandra, S., Tai, AK, Kane, AV, Wanke, CA and Ward, HD The Intestinal
Microbiota, Microbial Translocation and Systemic Inflammation in Chronic HIV Infection. J Infect Dis 2015
211:19-27. doi: 10.1093/infdis/jiu409. Epub 2014 Jul 23.
199. S. Doron and A. Bisno. Evaluation of acute pharyngitis in adults. UpToDate 2012 to present.
200. S. Doron and J. Ruiz. Tonsillectomy in adults: indications. UpToDate 2012 to present.
201. Doron S, Boucher HW. Editorial commentary: the Department of Defense fights the battle against antimicrobial
resistance: can the United States win the war? Clin Infect Dis. 2014 Aug;59(3):398-400. PubMed PMID: 24795326.
202. Dunn JM, Krause PJ, Davis S, Vannier EG, Fitzpatrick MC, Rollend L, Belperron AA, States SL, Stacey A,
Bockenstedt LK, Fish D, Diuk-Wasser MA. Borrelia burgdorferi Promotes the Establishment of Babesia microti in
the Northeastern United States. PLoS One. 2014 Dec 29;9(12):e115494. PubMed PMID: 25545393; PubMed
Central PMCID: PMC4278703.
203. Esposito DH, Stich A, Epelboin L, Malvy D, Han PV, Bottieau E, da Silva A, Zanger P, Slesak G, van Genderen PJ,
Rosenthal BM, Cramer JP, Visser LG, Muñoz J, Drew CP, Goldsmith CS, Steiner F, Wagner N, Grobusch MP, Plier
DA, Tappe D, Sotir MJ, Brown C, Brunette GW, Fayer R, von Sonnenburg F, Neumayr A, Kozarsky PE; Tioman
Island Sarcocystosis Investigation Team. Acute muscular sarcocystosis: an international investigation among ill
travelers returning from Tioman Island, Malaysia, 2011-2012. Clin Infect Dis. 2014 Nov 15;59(10):1401-10.
PubMed PMID: 25091309.
204. Gelfand JA, Vannier E. Babesia species. In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious
Diseases, 8th edition. GL Mandell, JE Bennett, R Dolin, eds. Churchill Livingstone. 3165-3172, 2014.
206. Hadley S. Resistant gram-positive infections: where have we been, where are we now, and where are we going?
Clin Ther. 2014 Oct 1;36(10):1298-302. PubMed PMID: 25287699.
207. Hibberd PL, Kleimola L, Fiorino AM, Botelho C, Haverkamp M, Andreyeva I, Poutsiaka D, Fraser C, SolanoAguilar G, Snydman DR. No Evidence of Harms of Probiotic Lactobacillus rhamnosus GG ATCC 53103 in Healthy
Elderly-A Phase I Open Label Study to Assess Safety, Tolerability and Cytokine Responses. PLoS One. 2014 Dec
1;9(12):e113456. PubMed PMID: 25438151; PubMed Central PMCID: PMC4249962.
208. Hong SY, Fanelli TJ, Jonas A, Gweshe J, Tjituka F, Sheehan HM, Wanke C, Terrin N, Jordan MR, Tang AM.
Household food insecurity associated with antiretroviral therapy adherence among HIV-infected patients in
Windhoek, Namibia. J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):e115-22. PubMed PMID: 25356779;
PubMed Central PMCID: PMC4215168.
209. Hulgan T, Boger MS, Liao DH, McComsey GA, Wanke CA, Mangili A, Walmsley SL, McCreath H, Milne GL,
Sanchez SC, Currier JS, Lake JE. Urinary eicosanoid metabolites in HIV-infected women with central obesity
switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial. Mediators Inflamm.
2014;2014:803095. PubMed PMID: 24991090; PubMed Central PMCID: PMC4058804.
210. Johnson K, Boucher HW. Editorial commentary: imminent challenges: carbapenem-resistant enterobacteriaceae
in transplant recipients and patients with hematologic malignancy. Clin Infect Dis. 2014 May;58(9):1284-6.
211. Jonas A, Sumbi V, Mwinga S, DeKlerk M, Tjituka F, Penney S, Jordan MR, Desta T, Tang AM, Hong SY. HIV drug
resistance early warning indicators in namibia with updated World Health Organization guidance. PLoS One.
2014 Jul 2;9(7):e100539. PubMed PMID: 24988387; PubMed Central PMCID: PMC4079656.
212. Kane AV, DM. Dinh, HD Ward, Childhood Malnutrition and the Intestinal Microbiome Pediatrics Research 2014
Oct 30. doi: 10.1038/pr.2014.179. [Epub ahead of print]
213. Kattula D, Sarkar R, Sivarathinaswamy P, Velusamy, V, Venugopal,S, Naumova, EN, Muliyil,JP, Ward, HD, Kang, G.
The first 1000 days of life: Pre- and post-natal risk factors for morbidity and growth in a birth cohort in southern
India. BMJ Open 2014;4:e005404
214. Keusch GT, Rosenberg IH, Denno DM, Duggan C, Guerrant RL, Lavery JV, Tarr PI, Ward HD, Black RE, Nataro JP,
Ryan ET, Bhutta ZA, Coovadia H, Lima A, Ramakrishna B, Zaidi AK, Burgess DC, Brewer T. Environmental Enteric
Dysfunction: Pathogenesis, Diagnosis, and Clinical Consequences. Clin Infect Dis 59 (suppl 4):S207-S212 2014
215. Kogelman L, Barnett ED, Chen LH, Quinn E, Yanni E, Wilson ME, Benoit C, Karchmer AW, Ooi WW, Jentes ES,
Hamer DH. Knowledge, attitudes, and practices of US practitioners who provide pre-travel advice. J Travel Med.
2014 Mar-Apr;21(2):104-14. PubMed PMID: 24593023.
159
»» PUBLICATIONS
205. Griffiths JK, Barza M. Editorial commentary: What happens in hospitals should stay in hospitals. Clin Infect Dis.
2014 Jun;58(12):1666-7. PubMed PMID: 24795327.
216. Kuriyan R, Griffiths JK, Finkelstein JL, Thomas T, Raj T, Bosch RJ, Kurpad AV, Duggan C. Innovations in nutrition
education and global health: the Bangalore Boston nutrition collaborative. BMC Med Educ. 2014 Jan 8;14:5.
PubMed PMID: 24400811; PubMed Central PMCID: PMC3897915.
217. Laws MB, Danielewicz M, Rana A, Kogelman L, Wilson IB. Health Literacy in HIV Treatment: Accurate
Understanding of Key Biological Treatment Principles is Not Required for Good ART Adherence. AIDS Behav.
2014 Oct 30. PubMed PMID: 25354736.
»» PUBLICATIONS
218. Lin T, Troy EB, Hu LT, Gao L, Norris SJ. Transposon mutagenesis as an approach to improved understanding of
Borrelia pathogenesis and biology. Front Cell Infect Microbiol. 2014 May 20;4:63. PubMed PMID: 24904839;
219. Lynch K, Agarwal P, Paranandi A, Hadley S, Vullaganti M. Extensive VZV Encephalomyelitis without Rash in an
Elderly Man. Case Rep Neurol Med. 2014;2014:694750. PubMed PMID: 24864218; PubMed Central PMCID:
PMC4017713.
220. Mangili A, Ahmad R, Wolfert RL, Kuvin J, Polak JF, Karas RH, Wanke CA. Lipoprotein-associated phospholipase
A2, a novel cardiovascular inflammatory marker, in HIV-infected patients. Clin Infect Dis. 2014 Mar;58(6):893900. PubMed PMID: 24336757; PubMed Central PMCID: PMC3935500.
221. Marques A, Telford SR 3rd, Turk SP, Chung E, Williams C, Dardick K, Krause PJ, Brandeburg C, Crowder CD,
Carolan HE, Eshoo MW, Shaw PA, Hu LT. Xenodiagnosis to detect Borrelia burgdorferi infection: a first-in-human
study. Clin Infect Dis. 2014 Apr;58(7):937-45. PubMed PMID: 24523212; PubMed Central PMCID: PMC3952603.
222. Masters WA, Webb P, Griffiths JK, Deckelbaum RJ. Agriculture, nutrition, and health in global development:
typology and metrics for integrated interventions and research. Ann N Y Acad Sci. 2014 Dec;1331(1):258-69.
223. McMahon JH, Manoharan A, Wanke C, Mammen S, Jose H, Malini T, Kadavanu T, Jordan MR, Elliott JH, Lewin
SR, Mathai D. Targets for intervention to improve virological outcomes for patients receiving free antiretroviral
therapy in Tamil Nadu, India. AIDS Care. 2014;26(5):559-66. PubMed PMID: 24125035.
224. Mehrzad R, Barza M. Are physician pagers an outmoded technology? Technol Health Care. 2014 Oct 28. PubMed
PMID: 25351275.
225. Muldoon EG, Switkowski K, Tice A, Snydman DR, Allison GM. A national survey of infectious disease
practitioners on their use of outpatient parenteral antimicrobial therapy (OPAT). Scand J Infect Dis. 2014 Nov
21:1-7. PubMed PMID: 25415655.
226. Natamba BK, Achan J, Arbach A, Oyok TO, Ghosh S, Mehta S, Stoltzfus RJ, Griffiths JK, Young SL. Reliability and
validity of the center for epidemiologic studies-depression scale in screening for depression among HIV-infected
and -uninfected pregnant women attending antenatal services in northern Uganda: a cross-sectional study. BMC
Psychiatry. 2014 Nov 22;14(1):303. PubMed PMID: 25416286; PubMed Central PMCID: PMC4260190.
227. Natamba BK, Kilama H, Arbach A, Achan J, Griffiths JK, Young SL. Reliability and validity of an individually
focused food insecurity access scale for assessing inadequate access to food among pregnant Ugandan women of
mixed HIV status. Public Health Nutr. 2014 Aug 29:1-11. PubMed PMID: 25171462.
228. Nichols BE, Sigaloff KC, Kityo C, Hamers RL, Baltussen R, Bertagnolio S, Jordan MR, Hallett TB, Boucher CA, de
Wit TF, van de Vijver DA. Increasing the use of second-line therapy is a cost-effective approach to prevent the
spread of drug-resistant HIV: a mathematical modelling study. J Int AIDS Soc. 2014 Dec 5;17:19164. PubMed
PMID: 25491351; PubMed Central PMCID: PMC4260459.
229. Nierenberg NE, Poutsiaka DD, Chow JK, Cooper J, Price LL, Freeman RB, Rohrer R, Snydman DR. Pretransplant
lymphopenia is a novel prognostic factor in cytomegalovirus and noncytomegalovirus invasive infections after
liver transplantation. Liver Transpl. 2014 Dec;20(12):1497-507. PubMed PMID: 25205044.
230. O'Connor RM, Fung JM, Sharp KH, Benner JS, McClung C, Cushing S, Lamkin ER, Fomenkov AI, Henrissat B,
Londer YY, Scholz MB, Posfai J, Malfatti S, Tringe SG, Woyke T, Malmstrom RR, Coleman-Derr D, Altamia MA,
Dedrick S, Kaluziak ST, Haygood MG, Distel DL. Gill bacteria enable a novel digestive strategy in a wood-feeding
mollusk. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):E5096-104. PubMed PMID: 25385629; PubMed Central
PMCID: PMC4250168.
232. Paranandi A, Asztalos BF, Mangili A, Kuvin J, Gerrior J, Sheehan H, Skinner SC, Tang AM, Wanke CA. Short
communication: effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIVinfected persons with hypertriglyceridemia. AIDS Res Hum Retroviruses. 2014 Aug;30(8):800-5. PubMed PMID:
24988179; PubMed Central PMCID: PMC4118719.
233. Phillips AN, Cambiano V, Miners A, Revill P, Pillay D, Lundgren JD, Bennett D, Raizes E, Nakagawa F, DeLuca A,
Vitoria M, Barcarolo J, Perriens J, Jordan MR, Bertagnolio S.
234. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug
resistance in antiretroviral drug-naïve populations beginning treatment: modeling study and economic analysis.
The Lancet HIV 2014;1(2):e85-e93.
235. Safren SA, Biello KB, Smeaton L, Mimiaga MJ, Walawander A, Lama JR, Rana A, Nyirenda M, Kayoyo VM,
Samaneka W, Joglekar A, Celentano D, Martinez A, Remmert JE, Nair A, Lalloo UG, Kumarasamy N, Hakim J,
Campbell TB; PEARLS (ACTG A5175) Study Team. Psychosocial predictors of non-adherence and treatment
failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS
trial. PLoS One. 2014 Aug 25;9(8):e104178. PubMed PMID: 25153084; PubMed Central PMCID: PMC4143224.
236. Sarkar R, Kattula D, Francis MR, Ajjampur SS, Prabakaran AD, Jayavelu N, Muliyil J, Balraj V, Naumova EN, Ward
HD, Kang G. Risk factors for cryptosporidiosis among children in a semi urban slum in southern India: a nested
case-control study. Am J Trop Med Hyg. 2014 Dec 3;91(6):1128-37. PubMed PMID: 25331810; PubMed Central
PMCID: PMC4257634.
237. Sarkar R, Tate JE, Ajjampur SS, Kattula D, John J, Ward HD, Kang G. Burden of diarrhea, hospitalization and
mortality due to cryptosporidial infections in Indian children. PLoS Negl Trop Dis. 2014 Jul 24;8(7):e3042.
238. Severa M, Islam SA, Waggoner SN, Jiang Z, Kim ND, Ryan G, Kurt-Jones E, Charo I, Caffrey DR, Boyartchuk VL,
Luster AD, Fitzgerald KA. The transcriptional repressor BLIMP1 curbs host defenses by suppressing expression of
the chemokine CCL8. J Immunol. 2014 Mar 1;192(5):2291-304. PubMed PMID: 24477914; PubMed Central
PMCID: PMC3943885.
239. Shi Y, Dadhwal P, Li X, Liang FT. BosR functions as a repressor of the ospAB operon in Borrelia burgdorferi. PLoS
One. 2014 Oct 1;9(10):e109307. doi: 10.1371/journal.pone.0109307. eCollection 2014. PubMed PMID: 25271631;
240. Sindhu KN, Sowmyanarayanan TV, Paul A, Babji S, Ajjampur SS, Priyadarshini S, Sarkar R, Balasubramanian KA,
Wanke CA, Ward HD, Kang G. Immune response and intestinal permeability in children with acute
gastroenteritis treated with Lactobacillus rhamnosus GG: a randomized, double-blind, placebo-controlled trial.
Clin Infect Dis. 2014 Apr;58(8):1107-15. PubMed PMID: 24501384; PubMed Central PMCID: PMC3967829.
161
»» PUBLICATIONS
231. Paluszynski J, Monahan Z, Williams M, Lai O, Morris C, Burns P, O'Connor R. Biochemical and functional
characterization of CpMuc4, a Cryptosporidium surface antigen that binds to host epithelial cells. Mol Biochem
Parasitol. 2014 Feb;193(2):114-21. PubMed PMID: 24690740; PubMed Central PMCID: PMC4073680.
241. Sluis-Cremer N, Jordan MR, Huber K, Wallis CL, Bertagnolio S, Mellors JW, Parkin NT, Harrigan PR. E138A in
HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resourcelimited settings. Antiviral Res. 2014 Jul;107:31-4. PubMed PMID: 24746459; PubMed Central PMCID:
PMC4089891.
242. Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane-tazobactam against a broad spectrum of recent
clinical anaerobic isolates. Antimicrob Agents Chemother. 2014;58(2):1218-23. PubMed PMID: 24277025;
»» PUBLICATIONS
243. Snydman DR. Editorial commentary: the complexity of latent cytomegalovirus infection in stem cell donors. Clin
Infect Dis. 2014 Aug 15;59(4):482-3. PubMed PMID: 24850803.
244. Sponseller JK, Griffiths JK, Tzipori S. The evolution of respiratory Cryptosporidiosis: evidence for transmission by
inhalation. Clin Microbiol Rev. 2014 Jul;27(3):575-86. PubMed PMID: 24982322; PubMed Central PMCID:
PMC4135895.
245. Taylor LE, Foont JA, DeLong AK, Wurcel A, Linas BP, Chapman S, Maynard MA, Cu-Uvin S, Mayer KH. The
spectrum of undiagnosed hepatitis C virus infection in a US HIV clinic. AIDS Patient Care STDS. 2014 Jan;28(1):49. PubMed PMID: 24428794; PubMed Central PMCID: PMC3894677.
246. Telford SR 3rd, Hu LT, Marques A. Is there a place for xenodiagnosis in the clinic? Expert Rev Anti Infect Ther.
2014 Nov;12(11):1307-10. PubMed PMID: 25301228.
247. Thibodeau E, Doron S, Iacoviello V, Schimmel J, Snydman DR. Carbapenem-resistant enterobacteriaceae:
analyzing knowledge and practice in healthcare providers. Peer J. 2014 May 22;2:e405. PubMed PMID: 24883259;
248. Traa MX, Barboza L, Doron S, Snydman DR, Noubary F, Nasraway SA Jr. Horizontal infection control strategy
decreases methicillin-resistant Staphylococcus aureus infection and eliminates bacteremia in a surgical ICU
without active surveillance. Crit Care Med. 2014 Oct;42(10):2151-7. PubMed PMID: 24979485.
249. Vannier E, Krause PJ. Babesiosis in China, an emerging threat. Lancet Infect Dis. 2014 Dec 19. pii: S14733099(14)71062-X. PubMed PMID: 25539585.
250. Volpe GE, Wanke CA, Imai CM, Heffernan KS, Kuvin JT, Mangili A. High-fat meals do not impair postprandial
endothelial function in HIV-infected and uninfected men. AIDS Res Hum Retroviruses. 2014 Sep;30(9):881-7.
doi: 10.1089/AID.2013.0272. Epub 2014 Jun 26. PubMed PMID: 24892462; PubMed Central PMCID:
PMC4151053.
251. Volpe GE, Ward H, Mwamburi M, Dinh D, Bhalchandra S, Wanke C, Kane AV. Associations of cocaine use and
HIV infection with the intestinal microbiota, microbial translocation, and inflammation. J Stud Alcohol Drugs.
2014 Mar;75(2):347-57. PubMed PMID: 24650829; PubMed Central PMCID: PMC3965688.
252. Wang P, Glowacki MN, Hoet AE, Needham GR, Smith KA, Gary RE, Li X. Emergence of Ixodes scapularis and
Borrelia burgdorferi, the Lyme disease vector and agent, in Ohio. Frontiers in Cellular and Infection Microbiology
2014 Jun 4;4:70. doi: 10.3389/fcimb.2014.00070. eCollection 2014. PubMed PMID: 24926441; PubMed Central
PMCID: PMC4044495
253. Wanyiri JW, Kanyi H, Maina S, Wang DE, Steen A, Ngugi P, Kamau T, Waithera T, O'Connor R, Gachuhi K, Wamae
CN, Mwamburi M, Ward HD. Cryptosporidiosis in HIV/AIDS patients in Kenya: clinical features, epidemiology,
molecular characterization and antibody responses. Am J Trop Med Hyg. 2014 Aug;91(2):319-28. PubMed
254. Weston A, Golan Y, Holcroft C, Snydman DR. The efficacy of daptomycin versus vancomycin for methicillinresistant Staphylococcus aureus bloodstream infection in patients with impaired renal function. Clin Infect Dis.
2014 Jun;58(11):1533-9. PubMed PMID: 24642554; PubMed Central PMCID: PMC4017894.
Divis ion of H e m a tol og y/Onc ol o gy
255. Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Evens, AM Peripheral T-cell lymphomas in a large US
multicenter cohort: prognostication in the modern era including impact of frontline therapy. Annals of oncology
: official journal of the European Society for Medical Oncology / ESMO 2014;25:2211-7.
256. Agarwal A, Saif MW KRAS in pancreatic cancer. JOP. 2014 Jul 28;15(4):303-5. doi: 10.6092/1590-8577/2660. PMID:
25076326 [PubMed - in process] Free Article
258. Arendt LM, Keller PJ, Skibinski A, Goncalves K, Naber SP, Buchsbaum RJ, Gilmore H, Come SE, and Kuperwasser
C. Anatomical localization of progenitor cells in human breast tissue reveals enrichment of uncommitted cells
within immature lobules. Breast Cancer Research 2014;16:453
259. Ballen KK, Joffe S, Brazauskas R, Wang Z, Alijurf MD, Akpek G, Dandoy C, Frangoul HA, Freytes CO, Khera N,
Lazarus HM, LeMaistre CF, Mehta P, Parsons SK, Szwajcer D, Ustun C, Wood WA, Majahil NS. Hospital Length of
Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission:
Comparison among Alternative Graft Sources. Biol Blood Marrow Transplant 2014 Jul 23; 20 (11): 1819-1827. doi:
10.1016/j.bbmt.2014.07.021. [Epub ahead of print]. PMID: 25064747
260. Bhalla A, Saif MW. PARP-inhibitors in BRCA-associated pancreatic cancer. JOP. 2014 Jul 28;15(4):340-3. doi:
10.6092/1590-8577/2690. PMID: 25076338 [PubMed - in process] Free Article
261. Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H. Longitudinal DSCMRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma. Am J
Clin Oncol. 2014 Nov 26. [Epub ahead of print] PMID: 25436828
262. Burney S, Khawaja KI, Saif MW, Masud F. Chemotherapy and metformin in pancreatic adenocarcinoma and
neuroendocrine tumors. JOP. 2014 Jul 28;15(4):313-6. doi: 10.6092/1590-8577/2677. PMID: 25076330 [PubMed
- in process] Free Article
263. Burney S, Irfan K, Saif MW, Masud F. Diabetes and pancreatic cancer. JOP. 2014 Jul 28;15(4):319-21. doi:
264. Caprario, LC Strauss, GM, The benefit of chemotherapy in elderly patients with small cell lung cancer, Expert
Review of Anticancer Therapy, 2014.
265. Casavant D, McManus M, Parsons S, Zurakowski D, Graham R. Trial of telemedicine for patients on home
ventilator support: Feasibility, confidence in clinical management and use in medical decision-making. J
Telemed Telecare 2014 October 14. DOI: 10.1177/ 1357633X14555620.
266. Cerulli RS, Dashnamoorthy R, Evens AM. The Bruton’s Tyrosine Kinase Inhibitor CC-292 in Diffuse Large B-Cell
Lymphoma (DLBCL), T-Cell Lymphoma (TCL), and Hodgkin Lymphoma (HL): Induction of Cell Death and
Examination of Rational Novel/Novel Therapeutic Combinations. Blood (ASH): 2014; 124 (21): 1772.
267. Chandhok NS, Saif MW. Updates on the use of neoadjuvant therapy in borderline resectable pancreatic cancer.
JOP. 2014 Mar 10;15(2):91-4. doi: 10.6092/1590-8577/2303. PMID: 24618425 [PubMed - indexed for MEDLINE]
Free Article
268. Chaulagain C, Pilichowska M, Brinckerhoff M, Tabba M, and Erban J. Secondary Pulmonary Alveolar Proteinosis
in Hematologic Malignancies. Hematology and Stem Cell Therapy 2014. Hematol Oncol Stem Cell Ther. 2014:
7(4):127-35
163
»» PUBLICATIONS
257. Agarwal A, Daly KP, Butler-Bowen H, Saif MW. Safety and efficacy of radiofrequency ablation with aflibercept
and FOLFIRI in a patient with metastatic colorectal cancer. Anticancer Res. 2014 Nov;34(11):6775-8. PMID:
25368290 [PubMed - indexed for MEDLINE]
269. Chen J, Elfiky A, Han M, Chen C, Saif MW. The role of Src in colon cancer and its therapeutic implications. Clin
Colorectal Cancer. 2014 Mar;13(1):5-13. doi: 10.1016/j.clcc.2013.10.003. Epub 2013 Nov 13. Review. PMID:
270. Christopoulos A, Saif MW, Sarris EG, Syrigos KN. Epidemiology of active tuberculosis in lung cancer patients: a
systematic review. Clin Respir J. 2014 Oct;8(4):375-81. doi: 10.1111/crj.12094. Epub 2014 Mar 5. PMID: 24345074
[PubMed - in process]
271. Choi M, Saif MW, Kim R. Is there a role for second line therapy in advanced pancreatic cancer? JOP. 2014 Mar
10;15(2):106-9. doi: 10.6092/1590-8577/2325. PMID: 24618429 [PubMed - indexed for MEDLINE] Free Article
»» PUBLICATIONS
272. Chu E, Haller D, Cartwright T, Twelves C, Cassidy J, Sun W, Saif MW, McKenna E, Lee S, Schmoll HJ.
Epidemiology and natural history of central venous access device use and infusion pump function in the
NO16966 trial. Br J Cancer. 2014 Mar 18;110(6):1438-45. doi: 10.1038/bjc.2014.74. Epub 2014 Feb 18. PMID:
273. Cohen JT, Lin P and Parsons SK: Economic issues in pediatric cancer. In: Pizzo PA and Poplack DG, eds.
Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott Williams and Wilkins, 2014; Seventh
edition; in press.
274. Comenzo RL. LECT2 makes the amyloid list. Blood 2014;123:1436.
275. Comenzo RL. Plasma Cell Neoplasms, Their Precursor States and Their Prediction of Organ Damage. J Clin Oncol
2014;32:2679-82.
276. Cunningham J, Kantekure K, Saif MW. Medullary carcinoma of the colon: a case series and review of the
literature. In Vivo. 2014 May-Jun;28(3):311-4. Review. PMID: 24815832 [PubMed - indexed for MEDLINE]
277. Daoud V, Saif MW, Goodman M. Adjuvant treatment for pancreatic cancer. JOP. 2014 Jul 28;15(4):348-50. doi:
278. Dashnamoorthy R, Abermil N, Behesti A, Kozlowski P, Lansigan F, Kinlaw W, Gartenhaus R, Jones G, Hlatky L,
Evens AM. The Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL) and Potential Treatment Strategies
with Novel Fatty Acid Synthase (FASN) Small Molecule Inhibitors. Blood (ASH): 2014; 124 (21): 4490.
279. Dashnamoorthy R, Behesti A, Abermil N, Sharma J, Coyle M, Kandela I, Mazar A, Hlatky L, Evens AM. GenomeWide Analysis Reveals MYC-Dependent Cell Death and Identifies Predictive Biomarkers of Ixazomib Sensitivity
in Preclinical Models of T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL). Blood (ASH): 2014; 124 (21):
3120.
280. Dashnamoorthy, R, Bhalla S, Gartenhaus RB, Evens AM. Et al. The novel organic arsenical darinaparsin induces
MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human
xenograft models Clinical cancer research: an official journal of the American Association for Cancer Research
2014;20:6023-33.
281. De Souza AL, Saif MW. Platinum-based therapy in adenosquamous pancreatic cancer: experience at two
institutions. JOP. 2014 Mar 10;15(2):144-6. doi: 10.6092/1590-8577/2358. PMID: 24618440 [PubMed - indexed for
MEDLINE] Free Article
282. De Souza AL, Saif MW. Diabetes and pancreatic cancer. JOP. 2014 Mar 10;15(2):118-20. doi: 10.6092/15908577/2286. PMID: 24618432 [PubMed - indexed for MEDLINE] Free Article
283. De Souza AL, Saif MW. Thromboembolism and pancreatic cancer. JOP. 2014 Jul 28;15(4):292-4. doi:
284. De Souza AL, Saif MW. Squamous cell carcinoma of the pancreas. JOP. 2014 Nov 28;15(6):630-1. doi:
10.6092/1590-8577/2718. No abstract available. PMID: 25435587 [PubMed - in process] Free Article
285. DeVita MD, Evens AM, Rosen ST, Greenberger PA, Petrich AM. Multiple successful desensitizations to
brentuximab vedotin: a case report and literature review. Journal of the National Comprehensive Cancer
Network : JNCCN 2014;12:465-71.
286. El-Jurdi NH, Saif MW. Should ageism be a stratification factor in patients with pancreatic cancer? JOP. 2014 Mar
287. El-Jurdi NH, Saif MW. Pancreatic cancer: new hopes for early detection and a future screening tool? JOP. 2014 Jul
28;15(4):358-9. doi: 10.6092/1590-8577/2696. PMID: 25076343 [PubMed - in process] Free Article
289. Evens AM, Kostakoglu L The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage
disease. Blood 2014;124:3356-64.
290. Evens AM. Non Hodgkin’s Lymphoma. Section 13, Hematology. In: Bope & Kellerman, eds. Conn's Current
Therapy, 66th edition, 2014.
291. Evens AM, Winter JN, Gordon LI, Chiu Brian C.-H.,Tsang R, Rosen ST. Non-Hodgkin lymphoma. In: Haller D,
Wagman LD, Camphausen KA, Hoskins WJ, eds. A Multidisciplinary Approach, 17th edition, 2014.
292. Evens AM, Smith MR, Lossos IS, et al. Frontline bortezomib and rituximab for the treatment of newly diagnosed
high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. British journal of
haematology 2014;166:514-20.
293. Foley, C.J., Fanjul-Fernandez, M., Bohm, A., Agarwal, A., Koukos, G., Covic, L., Lopez-Otin, C. & Kuliopulos, A.
Matrix Metalloprotease-1a Deficiency Suppresses Tumor Growth and Angiogenesis. (2014) Oncogene
33:2264-72.
294. Foley, C.J. & Kuliopulos, A. Mouse Matrix Metalloprotease-1a (Mmp1a) Gives New Insight into MMP1 Function.
(2014) J. Cellular Physiol. 229:1875-80
295. Flores JP, Saif MW. Chapter –Pancreatic Cancer. Prof. S, Eds. In: Clinical Oncology for Tablets 2014
296. Gandhi M, Ma S, Smith SM, Nabhan C, Evens AM, JN Winter, Gordon LI, Petrich AM. Brentuximab Vedotin (BV)
Plus Rituximab (R) As Frontline Therapy for Patients (Pts) with Epstein Barr Virus (EBV)+ and/or CD30+
Lymphoma: Phase I Results of an Ongoing Phase I-II Study. Blood (ASH): 2014; 124 (21): 3096.
297. Gandhi MD, Evens AM, Fenske TS, et al. Pancreatitis in patients treated with brentuximab vedotin: a previously
unrecognized serious adverse event. Blood 2014;123:2895-7.
298. Gentzler RD, Evens AM, Rademaker AW, et al. F-18 FDG-PET predicts outcomes for patients receiving total
lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin
lymphoma. British journal of haematology 2014;165:793-800.
299. Goodman MD, Saif MW. Adjuvant therapy for pancreatic cancer. JOP. 2014 Mar 10;15(2):87-90. doi:
10.6092/1590-8577/2324. PMID: 24618424 [PubMed - indexed for MEDLINE] Free Article
300. Gorovets D, Saif MW, Huber K. Novel treatment approaches for locally advanced pancreatic cancer. JOP. 2014
Mar 10;15(2):95-8. doi: 10.6092/1590-8577/2284. PMID: 24618426 [PubMed - indexed for MEDLINE] Free Article
301. Graham RJ, Rodday AM, Parsons SK. Family-Centered Assessment and Function for Children with Chronic
Mechanical Respiratory Support. J Pediatr Health Care 2014, Jul-Aug; 28(4):295-304. doi: 10.1016/j.
pedhc.2013.06.006. 2013 Aug 12.[Epub ahead of print]. PMID: 23942254
165
»» PUBLICATIONS
288. Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI. Frontline
bortezomib and rituximab for the treatment of newly diagnosed high tumor burden (HTB) indolent nonHodgkin lymphoma (iNHL): A multicenter phase II study. J Clin Oncol (ASCO) 32:5s, 2014 (suppl; abstr 8545).
302. Grapsa D, Dokou A, Tsokanou-Kouli V, Kaltsas S, Dalakou E, Trigidou R, Saif MW, Politi E. Immunohistochemical
expression of p53, p63, c-myc, p21(WAF1/cip1) and p27(kip1) proteins in urothelial bladder carcinoma:
correlation with clinicopathological parameters. J BUON. 2014 Oct-Dec;19(4):1121-4.PMID: 25536625 [PubMed
- in process]
303. Graziani C, Hegde S, Saif MW. Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer.
Anticancer Res. 2014 Dec;34(12):7339-43. PMID: 25503169 [PubMed - in process]
»» PUBLICATIONS
304. Greenough A, Moffitt A, Healy J, Patel A, Richards KL, Fedoriw YD, Dunphy C, Choi WWL, Srivastava G Czader
M, Mann KP, Flowers CR, Bernal-Mizrachi L, Naresh K, Chadburn A, Gordon LI, Evens AM, Gill J, Collie AMB,
Hsi ED, Love CL, Dave SS. Strand-Specific Total RNA Sequencing Establishes the Complete Transcriptome and
Alternative Splicing Repertoire in Diffuse Large B Cell Lymphoma. Blood (ASH): 2014; 124 (21): 864.
305. H Toki MI, Saif MW, Syrigos KN ypersensitivity reactions associated with oxaliplatin and their clinical
management. Expert Opin Drug Saf. 2014 Nov;13(11):1545-54. doi: 10.1517/14740338.2014.963551. Epub 2014
Oct 11. PMID: 25307143 [PubMed - in process]
306. Ho VT, Kim HT, Kao G, Cutler C, Levine J, Rosenblatt J, Joyce R, Antin JH, Soiffer RJ, Ritz J, Avigan D, Alyea EP .
Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic
cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014 Dec;89(12):1092-6.
307. Hosein PJ, Maragulia JC, Salzberg MP, et al. A multicentre study of primary breast diffuse large B-cell lymphoma
in the rituximab era. British journal of haematology 2014;165:358-63.
308. Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in
treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica.
2014;99:1479-85.
309. Jeyapalan S, Boxerman J, Donahue J, Goldman M, Kinsella T, Dipetrillo T, Evans D, Elinzano H, Constantinou M,
Stopa E, Puthawala Y, Cielo D, Santaniello A, Oyelese A, Mantripragada K, Rosati K, Isdale D, Safran H; Brown
University Oncology Group Study. Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed
high-grade glioma: a Brown University Oncology Group Study. Am J Clin Oncol. 2014 Oct;37(5):444-9. doi:
10.1097/COC.0b013e31827de92b. PMID: 23388562
310. John PK, Kougioumtzopoulou AS, Syrigos KN, Saif MW. Updates in management of ampullary carcinomas. JOP.
2014 Mar 10;15(2):140-3. doi: 10.6092/1590-8577/2283.
311. PMID: 24618439 [PubMed - indexed for MEDLINE] Free Article John PK, Saif MW. Radioembolization in the
treatment of neuroendocrine tumors of the pancreas. JOP. 2014 Jul 28;15(4):332-4. doi: 10.6092/1590-8577/2688.
PMID: 25076336 [PubMed - in process] Free Article
312. John P, Butler H, Saif MW. Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with
pancreatic cancer. Anticancer Res. 2014 Dec;34(12):7267-70. PMID: 25503159 [PubMed - in process]
313. Johung KL, Saif MW, Chang BW. Locally advanced unresectable pancreatic cancer. JOP. 2014 Jul 28;15(4):329-31.
doi: 10.6092/1590-8577/2684. PMID: 25076335 [PubMed - in process] Free Article
314. Joza N, Saif MW. Biomarkers in pancreatic adenocarcinoma. JOP. 2014 Jul 28;15(4):308-9. doi: 10.6092/15908577/2675. PMID: 25076328 [PubMed - in process] Free Article
315. Kaddis N, Saif MW. Second-line treatment for pancreatic cancer. JOP. 2014 Jul 28;15(4):344-7. doi: 10.6092/15908577/2691. PMID: 25076339 [PubMed - in process] Free Article
316. Kaltsas S, Syrigos KN, Saif MW. Pancreatic cancer in 2014. JOP. 2014 Mar 10;15(2):84-6. doi: 10.6092/15908577/2403. No abstract available. PMID: 24618423 [PubMed - indexed for MEDLINE] Free Article
317. Karampelas IN, Syrigos KN, Saif MW. Targeted agents in treatment of neuroendocrine tumors of pancreas. JOP.
2014 Jul 28;15(4):351-3. doi: 10.6092/1590-8577/2694. PMID: 25076341 [PubMed - in process] Free Article
318. Kaul E, Shah G, Chaulagain C, Comenzo RL. Plerixafor and G-CSF for Autologous Stem Cell Mobilization in AL
Amyloidosis. Bone Marrow Transplant 2014;49:1233.
319. Kelly MJ, Horan JT, Alonzo TA, Eapen M, Gerbing RB, He W, Lange BJ, Parsons SK, Woods WG. Comparable
survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched
related donor, or unrelated donor transplantation. Pediatr Blood Cancer 2014 , 61 (2): 269-75. 2013 Aug 19 [Epub
ahead of print]. doi: 10.1002/pbc.24739. PMID: 23955900, PMCID: PMC3919967
320. Khagi S, Saif MW. Gastroenteropancreatic neuroendocrine tumors: hormonal treatment updates. JOP. 2014 Mar
322. Khouri J, Saif MW. Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): new insights on clinical
outcomes and malignant progression. JOP. 2014 Jul 28;15(4):310-2. doi: 10.6092/1590-8577/2676. PMID:
25076329 [PubMed - in process] Free Article
323. Kiagia M, Syrigos KN, Saif MW. Quality of life in patients with pancreatic cancer. JOP. 2014 Jul 28;15(4):317-8. doi:
324. Kim HT1, Frederick D, Armand P, Andler E, Kao G, Cutler C, Koreth J, Alyea EP 3rd, Antin JH, Soiffer RJ, Ritz J, Ho
VT. White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J
Hematol. 2014 Jun;89(6):591-7.
325. Knopf K, Duh MS, Lafeuille MH, et al. Meta-Analysis Of The Efficacy And Safety Of Bortezomib Retreatment In
Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia 2014;14:380-8.
326. Kougioumtzopoulou AS, Syrigos KN, Saif MW. Elderly patients with pancreatic cancer. JOP. 2014 Jul 28;15(4):3225. doi: 10.6092/1590-8577/2682. PMID: 25076333 [PubMed - in process] Free Article
327. Kostakoglu L, Evens, AM. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
Clinical advances in hematology & oncology : H&O 2014;12:20-35.
328. Krishnamoorthy SK, Jambawaliker S, Saif MW. Positron emission tomography imaging of pancreatic cancer. JOP.
2014 Mar 10;15(2):124-7. doi: 10.6092/1590-8577/2326. PMID: 24618434 [PubMed - indexed for MEDLINE] Free
Article
329. Krishnamoorthy SK, Saif MW. PET scanning: worth the cost in cancer? Not for all cancers--it's not reliable
enough yet. Oncology (Williston Park). 2014 May;28(5):391-2. No abstract available. PMID: 25004652 [PubMed indexed for MEDLINE] Free Article
330. Kritharis A, Kanakry JA, Sehn LH, Feldman T, Kroll A, Gascoyne RD, Petrich AM, Abramson JS, HernandezIlizaliturri F, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato AR, Caimi P, Advani R, Klein AK, Lossos
IS, Press OW, Smith SM, Fabregas JC, Nabhan C, Fenske TS, Friedberg JW, Vose JM, Blum KA, Evens AM. Gray
Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse
Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of
Therapy with Associated Impact on Outcome. Blood (ASH): 2014; 124 (21): 1703.
331. Kritharis A, Fowler T, Dashnamoorthy R, Burgess KE, Beheshti A Abermil N, Roy A, Hlatky L, Pilichowska M,
McNiel E, Evens AM. A Comparative Oncology Study of Canine and Human Genomics and Proteomics in
Peripheral T-Cell Lymphoma (PTCL): Examination of Shared Oncogenic Signaling for Biomarker and
Therapeutic Target Discovery. Blood (ASH): 2014; 124 (21): 3019.
167
»» PUBLICATIONS
321. Khagi S, Saif MW. The management of gastroenteropancreatic neuroendocrine tumors with somatostatin
analogues. JOP. 2014 Jul 28;15(4):295-8. doi: 10.6092/1590-8577/2619. PMID: 25076324 [PubMed - in process]
Free Article
332. Li J, Saif MW. Role of neoadjuvant therapy in management of pancreatic cancer. JOP. 2014 Jul 28;15(4):354-7. doi:
333. Li D, Pant S, Ryan DP, Laheru D, Bahary N, Dragovich T, Hosein PJ, Rolfe L, Saif MW, LaValle J, Yu KH, Lowery
MA, Allen A, O'Reilly EM. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01
as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and
negative tumor hENT1 expression. Pancreatology. 2014 Sep-Oct;14(5):398-402. doi: 10.1016/j.pan.2014.07.003.
Epub 2014 Jul 18. PMID: 25278310 [PubMed - in process]
»» PUBLICATIONS
334. Loughran TP, Jr., Zickl L, Olson TL, et al..Evens, AM Immunosuppressive therapy of LGL leukemia: prospective
multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 2014
335. Macone AB, Caruso BK, Levy SB, et al. In Vitro and In Vivo Antibacterial Activities of Omadacycline, a Novel
Aminomethylcycline. Antimicrobial Agents and Chemotherapy 2014;58(2):1127-1135. doi:10.1128/
AAC.01242-13
336. Marks E, Saif MW, Jia Y. Updates on first-line therapy for metastatic pancreatic adenocarcinoma. JOP. 2014 Mar
337. Mathew P. The bifunctional role of steroid hormones: implications for therapy in prostate cancer. Oncology
(Williston Park). 2014 May;28(5):397-404. Review. PMID: 25004653
338. Mathew P.The hemostatic system as a therapeutic target in urothelial carcinoma. Oncology (Williston Park). 2014
Oct;28(10):816, 830. PMID: 25323606
339. Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA. Immunoglobulin light chain amyloidosis. Expert
Rev Hematol 2014;7:143-56.
340. N Brennan GT, Relias V, Saif MW. Novel agents for the treatment of pancreatic cancer. JOP. 2014 Mar
341. Nabhan C, Aschebrook-Kilfoy B, Chiu BC, Kruczek K, Smith SM, Evens AM. The impact of race, age, and sex in
follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras. American journal of
hematology 2014;89:633-8.
342. Nabhan C, Aschebrook-Kilfoy B, Chiu BC, et al. The impact of race, ethnicity, age and sex on clinical outcome in
chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the
modern era. Leukemia & lymphoma 2014;55:2778-84.
343. Niazi AK, Kaley K, Saif MW. Gastrointestinal stromal tumor of colon: a case report and review of literature.
Anticancer Res. 2014 May;34(5):2547-50. PMID: 24778074 [PubMed - indexed for MEDLINE]
344. Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in
2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014;28:525-42.
345. Oh SY, Cunningham J, Saif MW. Colonic metastasis from gastric cancer.
346. Clin Colorectal Cancer. 2014 Dec;13(4):255-6. doi: 10.1016/j.clcc.2014.09.009. Epub 2014 Sep 21. No abstract
available. PMID: 25442816 [PubMed - in process]
347. Oikonomopoulos GM, Syrigos KN, Skoura E, Saif MW. FOLFIRINOX: from the ACCORD study to 2014. JOP. 2014
Mar 10;15(2):103-5. doi: 10.6092/1590-8577/2278. PMID: 24618428 [PubMed - indexed for MEDLINE] Free Article
348. Pennarola BW, Rodday AM, Davies SM, Syrjala KL, Patel S, Bingen K, Kupst MJ, Schwartz L, Guinan EC, Mayer
DK, Ratichek SJ, Hibbard JH, Parsons SK. Changing Factors Associated with Parent Activation in Pediatric
Hematopoietic Stem Cell Transplant. Support Care Cancer 2014 (in press).
349. Puri A, Saif MW. Pharmacogenomics update in pancreatic cancer. JOP. 2014 Mar 10;15(2):114-7. doi:
10.6092/1590-8577/2285. PMID: 24618431 [PubMed - indexed for MEDLINE] Free Article
350. Puri A, Stevenson RL, Khouri J, Comenzo RL, Kao GSH, Klein AK, Miller KB, Rosenberg A, Smith H, Sprague KA,
Relias V, Evens AM. Hepatitis B (HBV) Screening in Patients Receiving Rituximab: A Comprehensive Analysis
Including Comparison of Adherence By Oncologists and Non-Oncologists. Blood (ASH): 2014; 124 (21): 2595.
351. Puzanov I, Sosman J, Santoro A, Saif MW, Goff L, Dy GK, Zucali P, Means-Powell JA, Ma WW, Simonelli M,
Martell R, Chai F, Lamar M, Savage RE, Schwartz B, Adjei AA. Phase 1 trial of tivantinib in combination with
sorafenib in adult patients with advanced solid tumors. Invest New Drugs. 2015 Feb;33(1):159-68. doi: 10.1007/
s10637-014-0167-5. Epub 2014 Oct 8. PMID: 25294187 [PubMed - in process] Free PMC Article
»» PUBLICATIONS
352. Puzanov I, Sosman J, Santoro A, Saif MW, Goff L, Dy GK, Zucali P, Means-Powell JA, Ma WW, Simonelli M,
Martell R, Chai F, Lamar M, Savage RE, Schwartz B, Adjei AA., Phase 1 trial of tivantinib in combination with
sorafenib in adult patients with advanced solid tumors. Invest New Drugs. 2014.
353. Ramfidis VS, Psyrri A, Syrigos KN, Saif MW. First line treatment for metastatic pancreatic adenocarcinoma:
looking for the step forward. JOP. 2014 Jul 28;15(4):286-8. doi: 10.6092/1590-8577/2622. PMID: 25076321
[PubMed - in process] Free Article
354. Reddy NM, Evens AM. Chemotherapeutic advancements in peripheral T-cell lymphoma. Seminars in
355. Reece DE, Hegenbart U, Sanchorawala V, et al. Long-term follow-up from a phase 1/2 study of single-agent
bortezomib in relapsed systemic AL amyloidosis. Blood. 2014;124:2498-506.
356. Relias V, Saif MW. Biological identification of ampullary adenocarcinomas. JOP. 2014 Jul 28;15(4):306-7. doi:
357. Rizvi SM, Wong J, Saif MW, Jia Y. Pharmacogenetics in neuroendocrine tumors of the pancreas. JOP. 2014 Jul
358. Rodday AM, Parsons SK, Correll CU, Robb AS, Zima BT, Saunders TS, Leslie LK. Child and Adolescent
Psychiatrists’ Attitudes and Practices Prescribing Second Generation Antipsychotics. J Child Adolesc
Psychopharmacol. 2014 Mar; 24(2):90-3. doi: 10.1089. PMID: 24679174, PMCID: PMC3967387
359. Saif MW, Lee AM, Offer SM, McConnell K, Relias V, Diasio RB. A DPYD variant (Y186C) specific to individuals of
African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine
approach. Mayo Clin Proc. 2014 Jan;89(1):131-6. doi: 0.1016/j.mayocp.2013.09.008. PMID: 24388031 [PubMed indexed for MEDLINE] Free PMC Article
360. Rubin CL, Allukian N, Wang X, Ghosh S, Huang CC, Wang J, Brugge D, Wong JB, Mark S, Dong S, Koch-Weser S,
Parsons SK, Leslie LK, Freud KM. We make the path by walking it: Building an academic community partnership
with Boston’s Chinatown. Progress in Community Health Partnership 2014 January; 8(3): 353-63. DOI: 10.1353/
cpr.2014.0046.
361. Saif MW, Kaley K, Rodriguez T, Garcon MC. Gemcitabine as salvage treatment in patients with poorly
differentiated pancreatic neuroendocrine tumors: a case series. JOP. 2014 Jan 10;15(1):38-41. doi: 10.6092/15908577/1628. PMID: 24413782 [PubMed - indexed for MEDLINE] Free Article
362. Saif MW. Management of a patient with metastatic colorectal cancer and liver metastases. Case Rep Oncol Med.
2014;2014:790192. doi: 10.1155/2014/790192. Epub 2014 Mar 12. PMID: 24744930 [PubMed] Free PMC Article
363. Saif MW. MM-398 achieves primary endpoint of overall survival in phase III study in patients with gemcitabine
refractory metastatic pancreatic cancer. JOP. 2014 May 27;15(3):278-9. doi: 10.6092/1590-8577/2507. No abstract
available. PMID: 24865544 [PubMed - indexed for MEDLINE] Free Article
364. Saif MW, Ledbetter L, Kaley K, Garcon MC, Rodriguez T, Syrigos KN. Maintenance therapy with capecitabine in
patients with locally advanced unresectable pancreatic adenocarcinoma. Oncol Lett. 2014 Sep;8(3):1302-1306.
Epub 2014 Jun 11. PMID: 25120712 [PubMed] Free PMC Article
169
365. Saif MW. Advanced stage pancreatic cancer: novel therapeutic options. Expert Rev Clin Pharmacol. 2014
Jul;7(4):487-98. doi: 10.1586/17512433.2014.910451. PMID: 24939470 [PubMed - indexed for MEDLINE]
366. Saif MW. Antimetabolites. DeVita V, Hellman, Rosenberg S, Eds. In: Principles of Medical Oncology. Edition 10,
2014.
367. Saif MW, Relias V, Syrigos K, Gunturu KS. Incidence and management of ZIv-aflibercept related toxicities in
colorectal cancer. World J Clin Oncol. 2014 Dec 10;5(5):1028-35. doi: 10.5306/wjco.v5.i5.1028. Review. PMID:
25493238 [PubMed] Free PMC Article
»» PUBLICATIONS
368. Salahuddin A, Saif MW. Pancreatic tuberculosis or autoimmune pancreatitis. Case Rep Med. 2014;2014:410142.
doi: 10.1155/2014/410142. Epub 2014 Apr 15. PMID: 24839445 [PubMed] Free PMC Article
369. Saret CJ, Winn A, Shah G, Parsons SK, Lin PJ, Cohen JT, Neumann PJ. Value of Innovation in Leukemia,
Lymphoma, and Myeloma: A Systematic Review. Blood 2014 (in press).
370. Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D. Effect
of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon
cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four
randomised controlled trials. Lancet Oncol. 2014 Dec;15(13):1481-92. doi: 10.1016/S1470-2045(14)70486-3. Epub
2014 Nov 12. PMID: 25456367 [PubMed - indexed for MEDLINE]
371. Selker H, Oye K, Eichler, H, Stockbridge, N, Mehta, C, Kaitin, K,McElwee, N, Honig, P, Erban, J, D’Agostino, R. A
Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials. Nature Clinical Pharmacology &
Therapeutics 2014: 95 (2): 147–153.
372. Shah U, Kritharis A, Evens AM Paraneoplastic pyoderma gangrenosum with posttransplant lymphoproliferative
disorder Annals of hematology2014
373. Stevenson R, Saif MW. Chapter – Immuntherapy for Pancreatic Cancer Prof. Nima Rezaei, Eds. In: Cancer
Immunology: A Translational Medicine Context, Volume 3. 2014. Springer, Powell, WY, USA
374. Tejani MA, Saif MW. Pancreatic neuroendocrine tumors: does chemotherapy work? JOP. 2014 Mar 10;15(2):1324. doi: 10.6092/1590-8577/2301. PMID: 24618436 [PubMed - indexed for MEDLINE] Free Article
375. Terrin N, Rodday AM, Parsons SK. Joint Models for Predicting Transplant-Related Mortality from Quality of Life
Data. Qual Life Res 2015; 24:31-39. doi: 10.1007/s11136-013-0550-2 [Epub ahead of print]. PMID: 24129669,
PMCID: PMC3989470
376. Theochari MS, Syrigos KN, Saif MW. Biomarkers in pancreatic neuroendocrine tumors. JOP. 2014 Mar
377. Toki MI, Syrigos KN, Saif MW. The role of biliary drainage in patients with pancreatic adenocarcinoma. JOP. 2014
Mar 10;15(2):128-31. doi: 10.6092/1590-8577/2292. PMID: 24618435 [PubMed - indexed for MEDLINE] Free
Article
378. Toki MI, Syrigos KN, Saif MW. Risk determination for pancreatic cancer. JOP. 2014 Jul 28;15(4):289-91. doi:
379. Tourkantonis IS, Peponi E, Syrigos KN, Saif MW. Pharmacogenetics in pancreatic cancer. JOP. 2014 Jul
380. Valencia E, Saif MW. Neurofibromatosis type 1 and GIST: is there a correlation? Anticancer Res. 2014
Oct;34(10):5609-12. PMID: 25275063 [PubMed - indexed for MEDLINE]
381. Vyas OH, Kaul E, Rosenberg AS, Shah GL, Shah UA, Comenzo RL, Kao GSH, Evens AM, Smith H, Klein AK, Miller
KB, Sprague KA. Splenic Irradiation and a Reduced-Intensity Conditioning Regimen Prior to Allogeneic StemCell Transplantation for Myelofibrosis. Blood (ASH): 2014; 124 (21): 3170.
382. Yu E, Saif MW, Huber K. Phase 1 trials in pancreatic cancer. JOP. 2014 Jul 28;15(4):326-8. doi: 10.6092/15908577/2683. PMID: 25076334 [PubMed - in process] Free Article
383. Zhang FF, Rodday AM, Kelly MJ, Must A, MacPherson C, Roberts SB, Saltzman E, Parsons SK. Predictors of Being
Overweight or Obese in Survivors of Pediatric Acute Lymphoblastic Leukemia (ALL). Pediatr Blood Cancer 2014
Jul; 61(7):1263-9. doi: 10.1002/pbc.24960. 2014 Jan 30. [Epub ahead of print]. PMID: 24482072
385. Zhang FF, Roberts SB, Parsons SK, Must A, Kelly MJ, Wong WW, Saltzman E. Low Levels of Energy Expenditure in
Childhood Cancer Survivors: Implications for Obesity Prevention. J Pediatr Hematol Oncol 2014 Sep 5. [Epub
ahead of print]. PMID: 25197775
386. Zhang, P., Covic, L. & Kuliopulos, A. Platelet receptors and drug targets: PAR-1, collagen, vWF, thromboxane, and
other novel targets. (2014) Antiplatelet Therapy and Cardiovascular Disease. 29-44. Ed. Ron Waksman. WileyBlackwell. Ch. 5.
387. Zhou P, Ma X, Iyer L, Chaulagain C, Comenzo RL. One siRNA pool targeting the λ constant region stops λ light
chain production and causes terminal endoplasmic reticulum stress. Blood 2014;123:3440-51.
Divis ion of In te r n a l Me d i ci ne a n d Adu lt Prim a r y C a re
388. Brown RT, Miao Y, Mitchell SL, Bharel M, Patel M, Ard KL, Grande LJ, Blazey-Martin D, Floru D, Steinman MA.
Health outcomes of obtaining housing among older homeless adults. Am J Public Health. In press 2014.
389. Ramachandran A, Freund KM, Bak S, Heeren T, Chen C, Battaglia TA. Multiple Barriers Delay Care Among
Women with Abnormal Cancer Screening Despite Patient Navigation. J Women’s Health. 2014 Dec 16. [Epub
ahead of print] PMID: 25513858
390. Cheng T, Freund KM, Winter M, Orlander J. Limited Adoption of Current Guidelines for Clinical Breast
Examination by Primary Care Physician Educators. J Women’s Health. 2014 Nov 18. [Epub ahead of print] PMID:
25405388
391. Zoher G, Benzel EC, Heary RF, Riew KD, Albert TJ, Butler WE, Barker II FG, Heller JG, McCormick PC, Whitmore
RG, Freund KM, Schwartz JS. Cervical Spondylotic Myelopathy Surgical (CSM-S) Trial: Study Design and
Rationale. Neurosurgery 2014 Jul. PMID: 24991714
392. Ko N, Darnell J, Calhoun E, Freund KM, Wells K, Shapiro C, Dudley D, Patierno S, Fiscella K, Raich P, Battaglia T;
PNRP investigators. Can Patient Navigation Improve Receipt of Recommended Breast Cancer Care? Evidence
from the National Patient Navigation Research Program. J Clin Oncol. 2014 Jul. PMID: 25071111 PMCID:
PMC4145185
393. Freund KM, Battaglia TA, Calhoun E, Darnell JS, Dudley DJ, Fiscella K, Hare ML, LaVerda N, Lee JH, Levine P,
Murray DM, Patierno SR, Raich PC, Roetzheim RG, Simon M, Snyder FR, Warren-Mears V, Whitley EM, Winters P,
Young GS, Paskett ED, and the Writing Group of the Patient Navigation Research Program. The Impact of Patient
Navigation on Timely Cancer Care: The Patient Navigation Research Program. J Natl Cancer Inst. 2014 Jun;106(6).
PMID: 24938303 PMCID: PMC4072900
171
»» PUBLICATIONS
384. Zhang FF, Kelly MJ, Saltzman E, Must A, Roberts SB, Parsons SK. Obesity in Pediatric ALL Survivors: A MetaAnalysis. Pediatrics 2014; Mar;133(3):e704-15. doi: 10.1542/peds.2013-3332. 2014 Feb 17 [Epub ahead of print].
PMID: 24534408, PMCID: PMC3934345
Parsons SK, Leslie LK, Freund KM. “We make the path by walking it:” Building an academic community
partnership with Boston Chinatown. Prog Community Health Partnersh. 2014 Fall;8(3):353-63. PMID: 25435562
395. Clark JA, Parker VA, Battaglia TA, Freund KM. Patterns of Task and Network Actions Performed by Navigators to
Facilitate Cancer Care. Health Care Manage Rev. 2014 Apr-Jun; 39(2):90-101. PMID: 23478753
396. Wilkinson J, Lauer E, Greenwood NW, Freund KM, Rosen AK. Evaluating Representativeness and Cancer
Screening Outcomes in a State Department of Developmental Services Database. Intellect Dev Disabil. 2014 Apr;
52(2):136-46. PMID: 24725112
»» PUBLICATIONS
397. Carle AC, Jean-Pierre P, Winters PC, Van Dyun MAS, Valverde P, Warren-Mears V, Wells K, Simon MA, Raich PC,
Post D, Patierno SR, Katz M, Freund KM, Dudley DJ, Darnell J, Fiscella K. Psychometric Evaluation of the Patient
Satisfaction with Logistical Aspects of Navigation (PSN-L) Scale Using Item Response Theory. Med Care. 2014
Apr; 52(4):354-61. PMID: 24848207
398. Gunn CM, Clark JA, Battaglia TA, Freund KM, Parker VA. An Assessment of Patient Navigator Activities in Breast
Cancer Patient Navigation Programs Using a Nine-Principle Framework. Health Serv Res. 2014 May 13. PMID:
24820445
399. Gunn CM, Freund KM, Kaplan SA, Raj A, Carr PL. Knowledge and Perceptions of Family Leave Policies Among
Female Faculty in Academic Medicine. Womens Health Issues. 2014 Mar-April; 24(2):e205-10. PMID: 24533979
PMCID: PMC3994529
400. Kapoor A, Battaglia TA, Isabelle AP, Hanchate A, Kalish RL, Bak S, Mishuris RG, Shroff S, Freund KM. The Impact
of Health Insurance Coverage during Insurance Reform on Diagnostic Resolution of Cancer Screening
Abnormalities. J Health Care Poor Underserved. 2014 Feb; 25(Suppl 1):109-21. PMID: 24583491
401. Freund KM, Isabelle AP, Hanchate A, Kalish RL, Kapoor A, Bak S, Mishuris RG, Shroff S, Battaglia TA. The Impact
of Health Insurance Reform on Insurance Instability. J Health Care Poor Underserved. 2014 Feb; 25(Suppl 1):95108. PMID: 24583490 NIHMS ID: NIHMS623536
402. De La Cruz I, Freund KM, Battaglia TA, Chen CA, Bak S, Kalish R, Lottero B, Egan P, Heeren T, Kronman AC.
Impact of Depression on the Intensity of Patient Navigation for Women with Abnormal Cancer Screenings. J
Health Care Poor Underserved. 2014 Feb; 25(1):383-95. PMID: 24509033 PMCID: PMC4184058
403. Primeau SW, Freund KM, Ramachandran A, Bak SM, Heeren T, Chen CA, Morton S, Battaglia TA. Social Service
Barriers Delay Care among Women with A normal Cancer Screening. J Gen Intern Med. 2014 Jan; 29(1):169-75.
PMID: 24197626 PMCID: PMC3889949
404. Vedula R, Kopelman R, Rencic J. Complementary medicine. J Gen Intern Med. 2014;29:412-416.(Clinical
reasoning series)
405. Yu EA, Snydman LK, Rencic J. Ramsay Hunt syndrome presenting with ataxia and syndrome of inappropriate
antidiuretic hormone secretion. Am J Med 2014;127(12):e9-10. PMID: 25132348.
406. Botros J, Rencic J, Centor RM, Henderson M. Anchors away. J Gen Intern Med. 2014;29:1414-1418. (Clinical
reasoning series)
407. Vedula R, Kopelman R, Rencic J. Complementary medicine. J Gen Intern Med. 2014;29:412-416.(Clinical
reasoning series)
408. Yu EA, Snydman LK, Rencic J. Ramsay Hunt syndrome presenting with ataxia and syndrome of inappropriate
antidiuretic hormone secretion. Am J Med 2014;127(12):e9-10. PMID: 25132348.
409. Shields HM, Stoffel EM, Chung DC, Sequist TD, Li JW, Pelletier SR, Spencer J, Silk JM, Austin BL, Diguette S,
Furbish JE, Lederman R, Weingart SN. Disparities in evaluation of patients with rectal bleeding 40 years and
older. Clin Gastroenterol Hepatol 2014; 12:669-75.
410. Weingart SN, Zhu J, Young-Hong J, Barr Vermilya H, Hassett M. Do drug interaction alerts between a
chemotherapy order-entry system and an electronic medical record affect clinician behavior? J Oncol Pharm
Pract 2014;20:163-71.
411. Weissman JS, Lopez L, Schneider EC, Epstein AM, Lipsitz S, Weingart SN. The association of hospital quality
ratings with adverse events. Int J Qual Health Care 2014; 26:129-35.
413. Zhu J, Li L, Zhao H, Han G, Wu AW, Weingart SN. Development of a patient safety climate for Chinese hospitals:
cross-national adaptation and psychometric evaluation. BMJ Qual Saf 2014;23:847-56.
414. Weingart SN, Hsieh C, Lane S, Cleary A. Standardizing central venous catheter care by using observations from
patients with cancer. Clin J Oncol Nurs 2014;18:321-6.
415. Okoroh JS, Uribe EF, Weingart SN. Racial and ethnic disparities in patient safety. J Patient Safe 2014 Aug 12. [Epub
ahead of print]
416. Abookire SA, Gandhi TK, Kachalia A, Sands K, Mort E, Bommarito G, Gagne J, Sato L, Weingart SN. Creating a
fellowship curriculum in patient safety and quality. Am J Med Qual 2014 Sept 2. [Epub ahead of print]
417. Gandhi TK, Abookire SA, Kachalia A, Sands K, Mort E, Bommarito G, Gagne J, Sato L, Weingart SN. Design and
implementation of the Harvard fellowship in patient safety and quality. Am J Med Qual, 2014 Sept 2. [Epub ahead
of print]
418. Golshan M, Losk K, Camuso K, Hirshfield-Bartek J, Cutone L, Lin N, Sagara Y, Aydogan F, Kadish S, Weingart SN,
Bunnell C. Understanding process-of-care delays in surgical treatment of breast cancer at a comprehensive
cancer center. Breast Cancer Res Treat 2014;148:125-33.
419. Weingart SN. Implementing practice guidelines: easier said than done [commentary]. Isr J Health Policy Res 2014
3:20.
Divis ion of N e p h rol og y
420. Adrogue HJ, Madias NE. The impact of sodium and potassium on hypertension risk. Semin Nephrol 2014;34:25772. Epub 2014 Apr 8;PMID:25016398.
421. Adrogue HJ, Madias NE. Diagnosis and treatment of hyponatremia. Am J Kidney Dis 2014;64:681-4. Epub 2014 Jul
2;PMID:24996937.
173
»» PUBLICATIONS
412. Bunnell C, Losk K, Kadish S, Lin N, Hirshfield-Bartek J, Cutone L, Camuso K, Golshan M, Weingart S. Measuring
opportunities to improve the timeliness of breast cancer care at Dana-Farber/Brigham and Women’s Cancer
Center. J Natl Compr Canc Netw 2014;12:S-5-S-9.
422. Adrogue HJ, Madias NE. Sodium surfeit and potassium deficit: keys to the pathogenesis of hypertension: J Am
Soc Nephrol 2014;8:203-13. Epub 2013 Nov 4;PMID:24200471.
423. Alqahtani F, Koulouridis I, Susantitaphong P, Dahal K, Jaber BL. A meta-analysis of continuous vs intermittent
infusion of loop diuretics in hospitalized patients. J Crit Care 2014;29:10-7. Epub 2013 May 14;PMID:23683555.
424. Brown JR, Katz R, Ix JH, de Boer IH, Siscovick DS, Grams ME, Shlipak M, Sarnak MJ. Fibroblast growth factor-23
and the long-term risk of hospital-associated AKI among community-dwelling older individuals. Clin J Am Soc
Nephrol 2014;9:239-46. Epub 2013 Nov 21;PMID:24262510.
»» PUBLICATIONS
425. Brown JR, Solomon RJ, Sarnak MJ, McCullough PA, Splaine ME, Davies L, Ross CS, Dauerman HL, Stender JL,
Conley SM, Robb JF, Chaisson K, Boss R, Lambert P, Goldberg DJ, Lucier D, Fedele FA, Kellett MA, Horton S,
Phillips WJ, Downs C, Wiseman A, MacKenzie TA, Malenka DJ;Northern New England Cardiovascular Disease
Study Group. Reducing contrast-induced acute kidney injury using a regional multicenter quality improvement
intervention. Circ Cardiovasc Qual Outcomes 2014;7:693-700. Epub 2014 Jul 29;PMID:25074372..
426. Cohen-Bucay A, Garimella P, Ezeokonkwo C, Bijol V, Strom JA, Jaber BL. Acute oxalate nephropathy associated
with Clostridium difficile colitis. Am J Kidney Dis 2014;63:113-8. Epub 2013 Oct 30;PMID:24183111.
427. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green
JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de
Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS; CKD Prognosis Consortium. Decline in estimated
glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014;311:2518-31.
PMID:24892770.
428. Crews DC, Scialla JJ, Boulware LE, Navaneethan SD, Nally JV Jr, Liu X, Arrigain S, Schold JD, Ephraim PL, Jolly SE,
Sozio SM, Michels WM, Miskulin DC, Tangri N, Shafi T, Wu AW, Bandeen-Roche K; DEcIDE Network Patient
Outcomes in End Stage Renal Disease Study Investigators. Comparative effectiveness of early versus
conventional timing of dialysis initiation in advanced CKD. Am J Kidney Dis 2014;63:805-15. Epub 2014 Feb
6;PMID:24508475.
429. Crews DC, Scialla JJ, Liu J, Guo H, Bandeen-Roche K, Ephraim PL, Jaar BG, Sozio SM, Miskulin DC, Tangri N,
Shafi T, Meyer KB, Wu AW, Powe NR, Boulware LE; for the Developing Evidence to Inform Decisions about
Effectiveness (DEcIDE) Patient Outcomes in End Stage Renal Disease Study Investigators. Predialysis health,
dialysis timing, and outcomes among older United States adults. J Am Soc Nephrol 2014;25:370-9. Epub 2013 Oct
24;PMID:24158988.
430. Darsie B, Shlipak MG, Sarnak MJ, Katz R, Fitzpatrick AL, Odden MC. Kidney function and cognitive health in
older adults: the Cardiovascular Health Study. Am J Epidemiol 2014;180:68-75. Epub 2014 May 20;doi:10.1093/
aje/kwu102;PMID:24844846.
431. Drew DA, Sarnak MJ. Ischemic and hemorrhagic stroke: high incidence in hemodialysis and peritoneal dialysis
patients. Am J Kidney Dis 2014;63:547-8. doi:10.1053/j.ajkd.2014.01.009;PMID:24670482.
432. Drew DA, Tighiouart H, Scott T, Kantor A, Fan L, Artusi C, Plebani M, Weiner DE, Sarnak MJ. Asymmetric
dimethylarginine, race, and mortality in hemodialysis patients. Clin J Am Soc Nephrol 2014;9:1426-33. Epub 2014
Jun 26;PMID:24970872.
433. Drew DA, Tighiouart H, Scott TM, Lou KV, Fan L, Shaffi K, Weiner DE, Sarnak MJ. FGF-23 and cognitive
performance in hemodialysis patients. Hemodial Int 2014;18:78-86. Epub 2013 Oct 24;PMID:24164913.
434. Drew DA, Weiner DE. Cognitive impairment in chronic kidney disease: keep vascular disease in mind. Kidney Int
2014;85:505-7. PMID:24583984.
435. Driver TH, Katz R, Ix JH, Magnani JW, Peralta CA, Parikh CR, Fried L, Newman AB, Kritchevsky SB, Sarnak MJ,
Shlipak MG; Health ABC Study. Urinary kidney injury molecule 1 (KM-1) and interleukin 18 (IL-18) as risk
markers for heart failure in older adults: the Health, Aging, and Body Composition (Health ABC) Study. Am J
Kidney Dis 2014;64:49-56. Epub 2014 Mar 18;doi:10.1053/j.ajkd.2014.01.432;PMID:24656453.
436. Driver TH, Shlipak MG, Katz R, Goldenstein L, Sarnak MJ, Hoofnagle AN, Siscovick DS, Kestenbaum B, de Boer
IH, Ix JH. Low serum bicarbonate and kidney function decline: the Multi-Ethnic Study of Atherosclerosis
(MESA). Am J Kidney Dis 2014;64:534-41. Epub 2014 Jun 18;PMID:24953891.
438. Fan L, Sarnak MJ, Tighiouart H, Drew DA, Kantor AL, Lou KV, Sharri K, Scott TM, Weiner DE. Depression and
all-cause mortality in hemodialysis patients. Am J Nephrol 2014;40:12-8. Epub 2014 Jun 24;PMID:24969267.
439. Fan L, Tighiouart H, Levey AS, Beck GJ, Sarnak MJ. Urinary sodium excretion and kidney failure in nondiabetic
chronic kidney disease. Kidney Int 2014;86:582-8. Epub 2014 Mar 9;doi:10.1038/ki.2014.59;PMID:24646858.
440. Foster MC, Rawlings AM, Marrett E, Neff D, Grams ME, Kasiske BL, Willis K, Inker LA, Coresh J, Selvin E.
Potential effects of reclassifying CKD as coronary heart disease risk equivalent in the US population. Am J Kidney
Dis 2014;63:753-60. Epub 2013 Dec 23;PMID:24369751.
441. Garimella PS, Ix JH, Katz R, Chonchol MB, Kestenbaum BR, de Boer IH, Siscovick DS, Shastri S, Hiramoto JS,
Shlipak MG, Sarnak MJ. Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery
disease in the Cardiovascular Health Study. Atherosclerosis 2014;233:91-6. Epub 2014 Jun 4;PMID:2459128.
442. Garimella PS, Hirsch AT. Peripheral artery disease and chronic kidney disease. Adv Chronic Kidney Dis 2014;
21:460-71.
443. Gilbert SJ and Weiner DE (Eds). National Kidney Foundations Primer on Kidney Disease. 6th Edition, Elsevier,
Philadelphia, 2014.
444. Goldstein L, Driver TH, Fried LF, Rifkin DE, Patel KV, Yenchek RH, Harris TB, Kritchevsky SB, Newman AB,
Sarnak MJ, Shlipak MG, Ix JH; Health ABC Study Investigators. Serum bicarbonate concentrations and kidney
disease progression in community-living elders: the Health, Aging and Body Composition (Health ABC) Study.
Am J Kidney Dis 2014;64:542-9. Epub 2014 Jun 18;doi:10.1053/j.ajkd.2014.05.009;PMID:24953890.
445. Greene T, Teng CC, Inker LA, Redd A, Ying J, Woodard M, Coresh J, Levey AS. Utility and validity of estimated
GFR-based surrogate time-to-event points in CKD: a simulation study. Am J Kidney Dis 2014;64:867-79. Epub
2014 Oct 31;PMID:25441440.
446. Grubbs V, Moss AH, Cohen LM, Fischer MJ, Germain MJ, Jassal SW, Perl J, Weiner DE, Mehrotra R; on behalf of
the Dialysis Advisory Group of the American Society of Nephrology. A palliative approach to dialysis care: a
patient-centered transition to the end of life. Clin J Am Soc Nephrol 2014; 9:2203-9. Epub 2014 Aug 7;
pii:CJN.006550114; PMID:24104274.
447. Guay-Woodfod LM, Henske E, Igarshi P, Perrone RD, Reed-Gitomer B, Somlo S, Torres VE, Ketchum CJ, Star RA,
Flessner MF, Rasooly RS. Filling the holes in cystic kidney disease research. Clin J Am Soc Nephrol 2014;9:17991801. Epub 2014 Jun 5;PMID:24903391.
448. Inker LA. Albuminuria: time to focus on accuracy. Am J Kidney Dis 2014;63:378-81. PMID:24560154.
175
»» PUBLICATIONS
437. Fan L, Inker LA, Rossert J, Froissart M, Rossing P, Mauer M, Levey AS. Glomerular filtration rate estimation using
cystatin C alone or combine with creatinine as a confirmatory test. Neph Dial Transplant 2014;29:1195-1203.
Epub 2014 Jan 20;PMID:24449101.
449. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI. KDOQI US
commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J
Kidney Dis 2014;63:713-35. Epub 2014 Mar 16;PMID:24647050.
450. Inker LA, Lambers Heerspink HJ, Mondal H, Schmid CH, Tighiouart H, Noubary F, Coresh J, Greene T, Levey AS.
GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects
from 37 randomized trials. Am J Kidney Dis 2014;64:848-59. Epub 2014 Oct 16;PMID:25441437.
»» PUBLICATIONS
451. Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T; Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI). Early change in proteinuria as a surrogate end point for kidney disease progression: an
individual patient meta-analysis. Am J Kidney Dis 2014;64:74-85. Epub 2014 Apr 29;PMID:24787763.
452. Jessani S, Levey AS, Box R, Inker LA, Islam M, Chaturvedi N, Mariat C, Schmid CH, Jafar TH. Estimation of GFR in
South Asians: a study from the general population in Pakistan. Am J Kidney Dis 2014;63:49-58. Epub 2013 Sept
26;PMID:24074822.
453. Kanbay M, Solak Y, Gaipov A, Takir M, Weiner DE. Allopurinol as a kidney-protective, cardioprotective, and
antihypertensive agent: hype or reality. Blood Purif 2014;37:172-8. Epub 2014 May 27;PMID:24903910.
454. Kim DH, Grodstein F, Newman AB, Chaves PH, Odden MC, Klein R, Sarnak MJ, Patel KV, Lipsitz LA. Prognostic
implications of microvascular and macrovascular abnormalities in older adults: cardiovascular health study. J
Gerontol A Biol Sci Med 2014;69:1495-502. Epub 2014 May 25;doi:10.1093/Gerona/glu074;PMID:2484308.
455. Koyner JL, Cerda J, Goldstein SL, Jaber BL, Liu KD, Shea JA, Faubel S; Acute Kidney Injury Advisory Group of the
American Society of Nephrology. The daily burden of acute kidney injury: a survey of the US nephrologists on
World Kidney Day. Am J Kidney Dis 2014;64:394-401. Epub 2014 May 9;PMID: 24815216.
456. Kraut JA, Madias NE. Lactic acidosis. N Engl J Med 2014;371:2309-19. PMID:25494270.
457. Lambers Heerspink HJ, Tighiouart H, Sang Y, Ballew S, Mondal H, Matsushita K, Coresh J, Levey AS, Inker LA.
GFR decline and subsequent risk of established kidney outcomes: a meta-analusis of 37 randomized controlled
trials. Am J Kidney Dis 2014;64:860-6. Epub 2014 Oct 16;PMID:25441439.
458. Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J,
Greene T, Levey AS, de Zeeuw D. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc
analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes with the Angiotension II
Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis
2014;63:244-50. Epub 2013 Nov 6;PMID:24210590.
459. Levey AS, Fan L, Eckfeldt JH, Inker LA. Cystatin C for glomerular filtration rate estimation: coming of age. Clin
Chem 2014;60:916-9. Epub 2014 May 28;PMID:24871681.
460. Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis 2014;63:820-34.
Epub Jan 28;PMID:24485147.
461. Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J. GFR decline as
an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and
the US Food and Drug Administration. Am J Kidney Dis 2014;64:821-35. Epub 2014 Oct 16;PMID:25441437.
462. Levey AS, Shaffi K, Inker LA. In reply to “Creatinine-based GFR estimating equations in kidney transplant
recipients” and “Assessing kidney function in transplant recipients: time to work together and address the most
relevant questions.” Am J Kidney Dis 2014;64:819. PMID:25344002.
463. Menon V, Rao M. Interactions of a low molecular weight inhibitor from Streptomyces sp. MBR04 with human
cathepsin D: implications in mechanism of inactivation. Appl Biochem Biotechnol 2014;174:1705-23. Epub 2014
Aug 21;PMID:25141983.
464. Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, Bae KT, Braun W, Winklhofer FT,
Hogan MC, Rahbari-Oskoui F, Moore CG, Flessner MF, Schrier RW;HALT-PKD Study. Health-related quality of
life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
Am J Kidney Dis 2014;63:214-26. Epub 2013 Oct 31;PMID:24183837.
466. Odden MC, Shlipak MG, Whitson HE, Katz R, Kearney PM, Defilippi C, Shastri S, Sarnak MJ, Siscovick DS,
Cushman M, Psaty BM, Newman AB. Risk factors for cardiovascular disease across the spectrum of older age: The
Cardiovascular Health Study. Atherosclerosis 2014;237:336-42. Epub 2014 Sep 30;PMID:25303772.
467. Pierro ML, Kainerstorfer JM, Civiletto A, Weiner DE, Sassaroli A, Hallacoglu B, Fantini S. Reduced speed of
microvascular blood flow in hemodialysis patients versus healthy controls: a coherent hemodynamics
spectroscopy study. J Biomed Opt 2014;19:026005. doi: 10.1117/1.JBO.19.2.026005.
468. Samaniego M, Perrone RD. Living donor transplantation: should we advocate for it? Nephrol News Issues
2014;28:22-3;PMID:24649751.
469. Sarnak MJ. A patient with heart failure and worsening kidney function. Clin J Am Soc Nephrol 2014;9:1790-8.
Epub 2014 Apr 24;doi:10.2215/CJN.11601113;PMID:24763864.
470. Sarnak MJ, Katz R, Newman A, Harris T, Peralta CA, Devarajan P, Bennett MR, Fried L, Ix JH, Satterfield S,.
Siomnsick EM, Parikh CR, Shlipak MG; Health ABC Study. Association of urinary injury biomarkers with
mortality and cardiovascular events. J Am Soc Nephrol 2014;25:1545-53. Epub 2013 Feb 7;PMID:24511130.
471. Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czamecki
PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG,
Chapman AB; the HALT-PKD Trial Investigators. Blood pressure in early autosomal dominant polycystic kidney
disease. N Engl J Med 2014; 371:2255-66. Epub 2014 Nov 15; PMID:25399733.
472. Scialla JJ, Liu J, Crews DC, Guo H, Bandeen-Roche K, Ephraim PL, Tangri N, Sozio SM, Shafi T, Miskulin DC,
Michels WM, Jaar BG, Wu AW, Powe NR, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal
Disease Study Investigators. An instrumental variable approach finds no associated harm or benefit with early
dialysis initiation in the United States. Kidney Int 2014;86:798-809. Epub 2014 Apr 30;PMID:24786707.
473. Shaffi K, Uhlig K, Perrone RD, Ruthazer R, Rule A, Lieske JC, Navis G, Poggio ED, Inker LA, Levey AS.
Performance of creatinine-based GFR estimating equations in solid-organ transplant recipients. Am J Kidney Dis
2014;63:1007-18. Epub 2014 Apr 2;PMID:24703720.
474. Shafi T, Sozio SM, Bandeen-Roche KJ, Ephraim PL, McDermott A, Scialla JJ, Crews DC, Tangri N, Miskulin DC,
Michels WM, Jaar BG, Herzog CA, Zager PG, Meyer KB, Wu AW, Boulware LE; DEcIDE Network Patient
Outcomes in End Stage Renal Disease Study Investigators. Predialysis systolic BP variability and outcomes in
hemodialysis patients. J Am Soc Nephrol 2014;25:799-809. Epub 2014 Jan 2;PMID:24385593.
177
»» PUBLICATIONS
465. Miskulin DC, Tangri N, Bandeen-Roche K, Zhou J, McDermott A, Meyer KB, Ephraim PL, Michels WM, Jaar BG,
Crews DC, Scialla JJ, Sozio SM, Shafi T, Wu AW, Cook C, Boulware LE; Developing Evidence to Inform Decisions
about Effectiveness (DEcIDE) Network Patient Outcomes in End Stage Renal Disease Study Investigators.
Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol 2014;9:1930-9. Epub
2014 Oct 15;PMID:25318751.
Performance of creatinine-based GFR estimating equations in solid-organ transplant recipients. Am J Kidney Dis
2014;63:1007-18. Epub 2014 Apr 2;PMID:24703720.
476. Sud M, Tangri N, Pintilie M, Levey AS, Naimark DM. Risk of end-stage renal disease and death after
cardiovascular events in chronic kidney disease. Circulation 2014;130:450-65. Epub 2014 Jun 4;PMID:24899688.
477. Sud M, Tangri N, Levin A, Pintilie M, Levey AS, Naimark DM. CKD stage at nephrology referral and factors
influencing the risks of ESRD and death. Am J Kidney Dis 2014;63:928-36. Epub 2014 Jan 28;PMID:24485146.
»» PUBLICATIONS
478. Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron
deficiency anemia in hemodialysis patients: a meta-analysis. Am J Kidney Dis 2014;39:130-41. Epub 2014 Feb
7;PMID:24513913.
479. Susantitaphong P, Jaber BL. Understanding discordant meta-analysis of convective dialytic therapies for chronic
kidney failure. Am J Kidney Dis 2014;63:888-91. PMID:24856616.
480. Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czamecki
PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD;
the HALT-PKD Trial Investigators. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N
Engl J Med 2014; 371:2267-2276. Epub 2014 15 Nov; PMID:25399731.
481. Tsai CW, Grams ME, Inker LA, Coresh J, Selvin E. Cystatin C- and creatinine-based estimated glomerular
filtration rate, vascular disease, and mortality in persons with diabetes in the United States. Diabetes Care
2014;37:1002-8. Epub 2013 Nov 22;PMID:24271191.
482. Weiner DE, Brunelli SM, Hunt A, Schiller B, Glassock R, Maddux FW, Johnson D, Parker T, Nissenson A.
Improving clinical outcomes among hemodialysis patients: a proposal for “Volume First” approach from the
Chief Medical Officers of US Dialysis Providers. Am J Kidney Dis 2014;64:685-95. Epub 2014 Aug
22;PMID:25156305.
483. Weiner DE, Seliger SL. Cognitive and physical function in chronic kidney disease. Curr Opin Nephrol Hypertens
2014;23:291-7. PMID:24638060.
484. Weiner DE, Tighiouart H. In reply to “Etiological versus prognostic models in cohort studies” and “Nutritional
supplement use in hemodialysis patients”. Am J Kidney Dis 2014;63:1068. PMID:24856621.
485. Weiner DE, Tighiouart H, Ladik V, Meyer KB, Zager PG, Johnson DS. Oral intradialytic nutritional supplement
use and mortality in hemodialysis patients. Am J Kidney Dis 2014;63:276-85. Epub 2013 Oct 3;PMID:24094606.
486. Weiner DE, Winkelmayer WC. Commentary on “The DOPPS practice monitor for US dialysis care: potential
impact of recent guidelines and regulatory changes on management of mineral and bone disorder among US
hemodialysis patient”: the calm before the 2016 storm? Am J Kidney Dis 2014;63:854-8. PMID:24725918.
487. Weiner D E and Sarnak M J: Cardiovascular Considerations in Dialysis, in Daugirdas JT, Blake PG and Ing TS (ed):
Handbook of Dialysis (ed 5), chap 33. Philadelphia, PA, Lippencott Williams & Wilkins, 2014.
488. Wen CP, Matsushita K, Coresh J, Iseki K, Islam M, Katz R, McClellan W, Peralta CA, Wang H, de Zeeuw D, Astor
BC, Gansevoort RT, Levey AS, Levin A; Chronic Kidney Disease Prognosis Consortium. Relative risks of chronic
kidney disease for mortality and end-stage renal disease across races are similar. Kidney Int 2014;86:819-27. Epub
2014 Jan 28;PMID:24522492.
Divis ion of Pul m on a r y, C r i t i ca l C a re a n d S leep M edic in e
489. Al-Naamani N, Roberts KE, Hill NS, Preston IR. Imatinib as rescue therapy in a patient with pulmonary
hypertension associated with Gaucher disease. Chest 2014;146:e81-3.
490. Al-Qadheeb NS, Balk EM, Fraser GL, Skrobik Y, Riker RR, Kress JP, Whitehead S, Devlin JW. Randomized ICU
trials do not demonstrate an association between interventions that reduce delirium duration and short-term
mortality: a systematic review and meta-analysis. Crit Care Med 2014;42:1442-54.
491. Angus DC, Deutschman CS, Hall JB, Wilson KC, Munro CL, Hill NS. Choosing wisely® in critical care: maximizing
value in the intensive care unit. Am J Crit Care 2014;23:444-5.
492. Batra S, Machicaso VI, Bynon JS, Mehta S, Tanikella R, Krowka MJ, Zacks S, Trotter J, Roberts KE, et al. Pulmonary
vascular complications of liver disease group; the impact of left ventricular hypertrophy on survival in candidates
for liver transplantation. Liver Transpl 2014;20:705-12.
494. Blanco MA, Maderer A, Oriel A, Epstein SK. How we launched a developmental student-as-teacher (SAT)
program for all medical students. Med Teach 2014;36:385-9.
495. Budhiraja R, Siddiqi TA, Quan SF. Sleep disorders in chronic obstructive pulmonary disease: etiology, impact and
management. J Clin Sleep Med 2014 (in press)
496. Chaulagain CP, Pilichowska M, Brinckerhoff L, Tabba M, Erban JK. Secondary pulmonary alveolar proteinosis in
hematologic malignancies. Hematol Oncol Stem Cell Ther 2014;7:127-35.
497. Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, Derk C, Fischer A, Frech T, Furst DE, GombergMaitland M, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA, Molitor JA, Preston IR et al. Survival and
predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the
pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res
2014;66:489-95.
498. D’Ambrosio CM. The multifaceted origins of sleep-disordered breathing. Clin Chest Med 2014;35:xiii-xiv.
499. Devlin JW, Al-Qadheeb NS, Chi A, Roberts R, Qawi I, Garpestad E, Hill NS. Efficacy and safety of early
dexmedetomidine during noninvasive ventilation for patients with acute respiratory failure: a randomized,
double-blind, placebo-controlled pilot study. Chest 2014;145:1204-12.
500. Devlin JW. The author replies. Crit Care Med 2014;42:e810.
501. Devlin JW, Pohlman AS. Everbody, every day: an “awakening and breathing coordination, delirium monitoring/
management, and early exercise/mobility” culture is feasible in your ICU. Crit Care Med 2014;42:1280-1.
502. Devlin JW, Zaal IJ, Slooter AJ. Clarifying the confusion surrounding drug-associated delirium in the ICU. Crit
Care Med 2014;42:1565-6.
503. DiRaimondo TR, Klock C, Warburton R, Herrera Z, Penumatsa K, Toksoz D, Hill N, Khosla C, Fanburg B. Elevated
transglutaminase 2 activity is associated with hypoxia-induced experimental pulmonary hypertension in mice.
ACS Chem Biol 2014;9:266-75.
504. Dweik RA, Rounds S, Erzurum SC, Archer S, Fagan K, Hassoun PM, Hill NS et al. ATS Committee on Pulmonary
Hypertension Phenotypes. An official American Thoracic Society Statement: pulmonary hypertension
phenotypes. Chest 2014;145:1204-12.
505. Gagnon DJ, Roberts R, Sylvia L. Implementation of the systems approach to improve a pharmacist-managed
vancomycin dosing service. 2014;71:2080-4.
506. Galie N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR et
al. Updated treatment algorithm of pulmonary arterial hypertension. Turk Kardiyol Dern Ars 2014;42 Suppl
1:78-94.
179
»» PUBLICATIONS
493. Bioc JJ, Magee C, Cucchi J, Fraser GL, Dasta JF, Edwards RA, Devlin JW. Cost effectiveness of a benzodiazepine vs.
a nonbenzodiazepine-based sedation regimen for mechanically ventilated, critically ill adults. J Crit Care
2014;29:753-7.
507. Kaput NK, Qiao X, Paruchuri V, Mackey EE, Daly GH, Ughreja K, Morine KJ, Levine J, Aronovitz MJ, Hill NS et al.
Reducing endoglin activity limits calcineurin and TRPC-6 expression and improves survival in a mouse model of
right ventricular pressure overload. J Am Heart Assoc 2014;229:1484-93.
508. Khan WH, Mohsenin V, D’Ambrosio CM. Sleep in asthma. Clin Chest Med 2014;35:483-93.
509. Liesching T, Nelson DL, Cormier KL, Sucov A, Short K, Warburton R, Hill NS. Randomized trial of bilevel versus
continuous positive airway pressure for acute pulmonary edema. J Emerg Med 2014;46(1):130-40.
»» PUBLICATIONS
510. Lindenauer PK, Stefan MS, Shieh MS, Pekow PS, Rothberg MC, Hill NS. Outcomes associated with invasive and
noninvasive ventilation among patients hospitalized with exacerbations of chronic obstructive pulmonary
disease. JAMA Intern Med 2014;174:1982-93.
511. Liu T, Ghamloush MM, Aldawood A, Warburton R, Toksoz D, Hill NS, Tang DD, Kayyali US. Modulating
endothelial barrier function by targeting vimentin phosphorylation. J Cell Physiol 2014;229:1484-93.
512. Matura L, Ventetuolo CE, Palevsky HI, Lederer DJ, Horn EM, Mathai SC, Pinder D, Archer-Chicko C, Bagiella E,
Roberts KE, Tracy RP, Hassoun PM et al. Interleukin-6 and tumor necrosis factor-alpha are associated with
quality of life-related symptoms in pulmonary arterial hypertension. Annals ATS 2014.
513. Ozsancak Ugurlu A, Sidhom SS, Khodabandeh A, Leong M, Mohr C, Lin DY, Buchwald I, Bahhady I, Wengryn J,
Maheshwari V, Hill NS. Use and outcomes of noninvasive positive pressure ventilation in acute care hospitals in
Masachusetts. Chest 2014;145:964-71.
514. Penumatsa K, Abualkhair S, Wei L, Warburton R, Preston I, Hill NS, Watts W, Fanburg BL, Toksoz D. Tissue
transglutaminase promotes serotonin-induced AKT signaling and mitogenesis in pulmonary vascular smooth
muscle cells. Cell Signal 2014;26(12):2818-26.
515. Penumatsa KC, Toksoz D, Warburton RR, Hilmer AJ, Liu T, Khosla C, Comhair SA, Fanburg BL. Role of hypoxiainduced transglutaminase 2 in pulmonary artery smooth muscle cell proliferation. Am J Physiol Lung Cell Mol
Physiol 2014;307:L576-85.
516. Preston IR, Feldman J, White J, Franco V, Ishizawar D, Burger C, Waxman AB, Hill NS. Safety and efficacy of
transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial
hypertension. Pulm Circ 2014;4:456-61.
517. Quan SF, Budhiraja R, Clarke DP et al. You still need more than CPAP for OSA patients to lose weight. J Clin Sleep
Med 2014;10:349.
518. Quan SF, Budhiraja R, Batool-Anwar S et al. Lack of impact of mild obstructive sleep apnea on sleepiness, mood
and quality of life. Southwest J Pulm Crit Care. 2014;9:44-56.
519. Sauer AM, Slooter AJ, Veldhuijzen DS, van Eijk MM, Devlin JW, van Dijk D. Intraoperative dexamethasone and
delirium after cardiac surgery: a randomized clinical trial. Anesth Analg 2014;119:1046-52.
520. Selan JC, Michaelson M, Fanburg BL, Estes NA. Evaluation and management of heart rhythm disturbances due
to cardiac sarcoidosis. Heart Lung Circ 2014;23:1100-9.
521. Sprung CL, Truog RD, Curtis JR, Joynt GM, Baras M, Michalsen A, Briegel J, Kesecioglu J, Efferen L, De Robertis E,
Bulpa P, Metnitz P, Patil N, Hawryluck L, Manthous C, Moreno R, Leonard S, Hill NS, et al. Seeking worldwide
professional consensus on the principles of end-of-life care for the critically ill. The consensus for worldwide
end-of-life practice for patients in intensive care units (WELPICUS) study. Am J Respir Crit Care Med
2014;190:855-66.
522. Tanios M, Epstein S, Grzeskowiak M et al. Influence of sedation strategies on unplanned extubation in a mixed
intensive care unit. Am J Crit Care 2014 23:30614.
Divis ion of R h e um a tol og y
523. Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efficacy of hyaluronic acid
in comparison with NSAIDs for knee osteoarthritis. A systematic review and meta-analysis.
Seminars in Arthritis and Rheumatism 2014; 43(5):593:9. [PMID: 24216297]
524. Bannuru RR, Vaysbrot EE, McIntyre LF. Did the American Academy of Orthopedic Surgeons osteoarthritis
guidelines miss the mark? Arthroscopy: The Journal of Arthroscopic & Related Surgery 2014; 30(1):86-9. [PMID:
24384274]
526. Bannuru RR, Sullivan MC, Manning E. Yoga for Rheumatic Conditions: Potential Physical, Cognitive and
Affective Advantages. J Yoga Phys Ther 2014; 4: 160.
527. Bannuru RR, Flavin NE, Vaysbrot EE, Harvey W, McAlindon TE. High-energy extracorporeal shock wave therapy
for treating chronic calcific tendonitis of the shoulder: a systematic review. Annals of Internal Medicine 2014;
160(8):542-9. [PMID: 24733195].
528. Driban JB, Zhang FF, Lo GH, Price LL, Booth S, Eaton CB, Lu B, Nevitt M, Jackson B, Garganta C, Hochberg MC,
Kwoh K, McAlindon TE. Vitamin D deficiency is associated with progression of knee osteoarthritis. J Nutr. 2014
Dec;144(12):2002-8. doi: 10.3945/jn.114.193227.
529. Driban JB, Wang C, Iversen MD, McAlindon T, Harvey WF, Wong JB, Fielding RA, Price LL, Rones R, Gamache T,
Schmid CH. Assessing the comparative effectiveness of Tai Chi versus physical therapyfor knee osteoarthritis:
design and rationale for a randomized trial. BMC Complement Altern Med. 2014 Sep 8;14:333. doi:
10.1186/1472-6882-14-333.
530. Driban JB, Zhang M, Price LL, Harper D, Lo GH, Miller E, Ward RJ, McAlindon TE. Development of a rapid knee
cartilage damage quantification method using magnetic resonance images. BMC Musculoskelet Disord. 2014
Aug 6;15:264. doi: 10.1186/1471-2474-15-264.
531. Driban J, Pang J, McAlindon T, Tamez-Pena J, Fripp J, Miller E. On the use of coupled shape priors for
segmentation of magnetic resonance images of the knee. IEEE J Biomed Health Inform. 2014 Jun 30. [Epub ahead
of print]
532. Driban JB, Eaton CB, Lo GH, Ward RJ, Lu B, McAlindon TE. Association of knee injuries with accelerated knee
osteoarthritis progression: data from the Osteoarthritis Initiative. Arthritis Care Res (Hoboken). 2014
Nov;66(11):1673-9. doi: 10.1002/acr.22359.
533. Driban JB, Barbe MF, Amin M, Kalariya NS, Zhang M, Lo GH, Tassinari AM, Harper D, Price LL, Eaton CB,
Schneider E, McAlindon TE. Validation of quantitative magnetic resonance imaging-based apparent bone
volume fraction in peri-articular tibial bone of cadaveric knees. BMC Musculoskelet Disord. 2014 Apr 29;15:143.
doi: 10.1186/1471-2474-15-143.
534. Driban JB, Lu B, Duryea J, McAlindon T, Lapane KL, Eaton CB. Milk consumption and progression of medial
tibiofemoral knee osteoarthritis: data from the Osteoarthritis Initiative. Arthritis Care Res (Hoboken). 2014
Jun;66(6):802-9. doi: 10.1002/acr.22297.
181
»» PUBLICATIONS
525. Bannuru RR, McAlindon TE, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin
Y, Hunter DJ, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos EM, Underwood M. OARSI Guidelines for the
Non-Surgical Management of Knee Osteoarthritis. Osteoarthritis and Cartilage 2014; 22(3):363-88. [PMID:
24462672].
535. Kalish RA, Navarro-Zarza JE, Hernandez-Díaz C, Saavedra MA, Alvarez-Nemegyei J, Canoso JJ, Villaseñor-Ovies
P. Pre-workshop knowledge of musculoskeletal anatomy of rheumatology fellows and rheumatologists of seven
North, Central and South American Countries. Arthritis Care Res, 2014; 66 (2):270-276
536. Kalish R, McDonald G, Vannier A, Weinkauf C, Danic I, Pilichowska-Roehling M, Shinkura R, Selsing E, ImanishiKari T. Anti-DNA and RNA autoantibodies in the etiopathogenesis of SLE; (Abstract #2023). Presented at the
Keystone Symposia on Autoimmunity and Tolerance, February 5, 2014, Keystone, CO.
»» PUBLICATIONS
537. McAlindon TE, Zhang FF, Driban JB, Lo GH, Price LL, Booth S, Eaton CB, Lu B, Nevitt M, Jackson B, Garganta C,
Hochberg MC, Kwoh K. Vitamin D deficiency is associated with progression of knee osteoarthritis. J Nutr. 2014
Dec;144(12):2002-8. doi: 10.3945/jn.114.193227.
538. McAlindon T, Wang C, Iversen MD, Harvey WF, Wong JB, Fielding RA, Driban JB, Price LL, Rones R, Gamache T,
Schmid CH. Assessing the comparative effectiveness of Tai Chi versus physical therapy for knee osteoarthritis:
design and rationale for a randomized trial. BMC Complement Altern Med. 2014 Sep 8;14:333. doi:
10.1186/1472-6882-14-333.
539. McAlindon T, Zhang M, Driban JB, Price LL, Harper D, Lo GH, Miller E, Ward RJ. Development of a rapid knee
Aug 6;15:264. doi: 10.1186/1471-2474-15-264.
540. McAlindon T, Pang J, Driban J, Tamez-Pena J, Fripp J, Miller E. On the use of coupled shape priors for
segmentation of magnetic resonance images of the knee. IEEE J Biomed Health Inform. 2014 Jun 30. [Epub ahead
of print]
541. McAlindon TE, Driban JB, Eaton CB, Lo GH, Ward RJ, Lu B. Association of knee injuries with accelerated knee
osteoarthritis progression: data from the Osteoarthritis Initiative. Arthritis Care Res (Hoboken). 2014
Nov;66(11):1673-9. doi: 10.1002/acr.22359.
542. McAlindon TE, Driban JB, Barbe MF, Amin M, Kalariya NS, Zhang M, Lo GH, Tassinari AM, Harper D, Price LL,
Eaton CB, Schneider E. Validation of quantitative magnetic resonance imaging-based apparent bone volume
fraction in peri-articular tibial bone of cadaveric knees. BMC Musculoskelet Disord. 2014 Apr 29;15:143. doi:
10.1186/1471-2474-15-143.
543. McAlindon T, Lu B, Driban JB, Duryea J, Lapane KL, Eaton CB. Milk consumption and progression of medial
tibiofemoral knee osteoarthritis: data from the Osteoarthritis Initiative. Arthritis Care Res (Hoboken). 2014
Jun;66(6):802-9. doi: 10.1002/acr.22297.
544. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin
Y, Hunter DJ, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos EM, Underwood M. Response to Letter to the
Editor entitled "Comments on 'OARSI guidelines for the non-surgical management of knee osteoarthritis'".
Osteoarthritis Cartilage. 2014 Jun;22(6):890-1. doi: 10.1016/j.joca.2014.04.001. Epub 2014 Apr 15. No abstract
available.
545. McAlindon T, Bannuru RR, Flavin NE, Vaysbrot E, Harvey W,. High-energy extracorporeal shock-wave therapy for
treating chronic calcific tendinitis of the shoulder: a systematic review. Ann Intern Med. 2014 Apr 15;160(8):5429. doi: 10.7326/M13-1982. Review.
546. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin
Y, Hunter DJ, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos EM, Underwood M. OARSI guidelines for the
non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi: 10.1016/j.
joca.2014.01.003. Epub 2014 Jan 24.
547. McAlindon TE, Bannuru RR, Vaysbrot EE, Sullivan MC,. Relative efficacy of hyaluronic acid in comparison with
NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014
Apr;43(5):593-9. doi: 10.1016/j.semarthrit.2013.10.002.
548. Vlad S, Kim C, Linsenmeyer KD, Guermazi A, Clancy MM, Niu J, Felson DT. Prevalence of Radiographic and
Symptomatic Hip Osteoarthritis in an urban US Community: the Framingham Osteoarthritis Study. Arthritis
Rheumatol. 2014 Nov;66(11):3013-7. doi: 10.1002/art.38795. PubMed PMID: 25103598.
Institute fo r C l i n i ca l Res e a rch a n d Hea lt h Po lic y S t u dies
550. Allison GM, Muldoon EG, Kent DM, Paulus JK, Ruthazer R, Ren A, Snydman DR. Prediction Model for 30-Day
Hospital Readmissions Among Patients Discharged Receiving Outpatient Parenteral Antibiotic Therapy. Clin
Infect Dis. 2014 Mar;58(6):812-9. PMID: 24357220; PMCID: PMC3935501.
551. Al-Qadheeb NS, Balk EM, Fraser GL, Skrobik Y, Riker RR, Kress JP, Whitehead S, Devlin JW. Randomized ICU
Trials Do Not Demonstrate an Association Between Interventions That Reduce Delirium Duration and ShortTerm Mortality: A Systematic Review and Meta-Analysis. Crit Care Med. 2014 Jun;42(6):1442-54. PMID:
24557420.
552. Balk EM, Earley A, Hadar N, Shah N, Trikalinos TA. Benefits and Harms of Routine Preoperative Testing:
Comparative Effectiveness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014
Jan. Available from http://www.ncbi.nlm.nih.gov/books/NBK184821/ PMID: 24555204.
553. Ballen KK, Joffe S, Brazauskas R, Wang Z, Aljurf MD, Akpek G, Dandoy C, Frangoul HA, Freytes CO, Khera N,
Lazarus HM, LeMaistre CF, Mehta P, Parsons SK, Szwajcer D, Ustun C, Wood WA, Majhail NS. Hospital Length of
Stay in the First 100 Days After Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission:
Comparison among Alternative Graft Sources. Biol Blood Marrow Transplant. Epub 2014 Jul 23. PMID: 25064747.
554. Bassett IV, Govindasamy D, Erlwanger AS, Hyle EP, Kranzer K, van Schaik N, Noubary F, Paltiel AD, Wood R,
Walensky RP, Losina E, Bekker LG, Freedberg KA. Mobile HIV Screening in Cape Town, South Africa: Clinical
Impact, Cost and Cost-Effectiveness. PLoS One. 2014 Jan 22;9(1):e85197. PMID: 24465503; PMCID: PMC3898963.
555. Benedict LA, Paulus JK, Rideout L, Chwals WJ. Are CT scans obtained at referring institutions justified prior to
transfer to a pediatric trauma center? J Pediatr Surg. 2014 Jan;49(1):184-7; discussion 187-8. PMID: 24439606.
556. Berkman ND, Lohr KN, Ansari MT, Balk EM, Kane R, McDonagh M, Morton SC, Viswanathan M, Bass EB, Butler
M, Gartlehner G, Hartling L, McPheeters M, Morgan LC, Reston J, Sista P, Whitlock E, Chang S. Grading the
strength of a body of evidence when assessing health care interventions: an EPC update. J Clin Epidemiol. 2014
Dec 20. pii: S0895-4356(14)00536-8. [Epub ahead of print] PubMed PMID: 25721570.
557. Beshansky JR, Sheehan PR, Klima KJ, Hadar N, Vickery EM, Selker HP. A community consultation survey to
evaluate support for and success of the IMMEDIATE trial. Clin Trials. 2014 Apr;11(2):178-86. PMID: 24686107;
PMCID: PMC4025913.
558. Blaha GR, Brooks NO, Mackel CE, Pani A, Stewart AP, Price LL, Barouch FC, Chang J, Marx JL. Changes in flare
after intravitreal injection of three different anti-vascular endothelial growth factor medications. Retina. 2014 Aug
25. [Epub ahead of print]. PMID: 25158942
183
»» PUBLICATIONS
549. Vlad S, Axe JM, Osbourne Paull J, Richmond J. Does Insurance Type, Private Versus Public, Have a Correlation
with MRSA Carrier Status In a Population Undergoing Orthopedic Surgery? J Infect Dis Ther 2014:2(5);164. doi:
10.4172/2332-0877.1000164
559. Boyd CM, Kent DM. Evidence-Based Medicine and the Hard Problem of Multimorbidity, Journal of General
Internal Medicine. JGIM. J Gen Intern Med. 2014 Apr; 29(4):552-3. PMID: 24442331. PubMed Central PMCID:
PMC3965745
560. Bugaev N, Breeze JL, Daoud V, Arabian SS, Rabinovici R. Management and outcome of patients with blunt
splenic injury and preexisting liver cirrhosis. J Trauma Acute Care Surg. 2014 Jun;76(6):1354-61. PubMed PMID:
24854300.
»» PUBLICATIONS
561. Burke JF, Hayward RA, Nelson JP, Kent DM. Using internally developed risk models to assess heterogeneity in
treatment effects in clinical trials. Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):163-9. Epub 2014 Jan 14.
562. Cai X, Razmara A, Paulus JK, Switkowski K, Fariborz PJ, Goryachev SD, D'Avolio L, Feldmann E, Thaler DE. Case
Misclassification in Studies of Spinal Manipulation and Arterial Dissection. J Stroke Cerebrovasc Dis. Epub 2014
Jul 29. PMID: 25085345
563. Cangelosi MJ, Rodday AM, Saunders T, Cohen JT. Evaluation of the economic burden of diseases associated with
poor nutrition status. JPEN J Parenter Enteral Nutr. 2014 Nov;38(2 Suppl):35S-41S. Epub 2013 Dec 6. PubMed
PMID: 24316964.
564. Carle AC, Jean-Pierre P, Winters P, Valverde P, Wells K, Simon M, Raich P, Patierno S, Katz M, Freund KM, Dudley
D, Fiscella K. Psychometric evaluation of the patient satisfaction with logistical aspects of navigation (PSN-L)
scale using item response theory. Med Care. 2014 Apr;52(4):354-61. PubMed PMID: 24848207; PubMed Central
PMCID: PMC4149289.
565. Casavant DW, McManus ML, Parsons SK, Zurakowski D, Graham RJ. Trial of telemedicine for patients on home
ventilator support: feasibility, confidence in clinical management and use in medical decision-making. J
Telemed Telecare. 2014 Oct 14. PMID: 25316042.
566. Chambers JD. Do Changes in Drug Coverage Policy Point to an Increased Role for Cost-Effectiveness Analysis in
the USA? Pharmacoeconomics. Epub 2014 May 24. PMID: 24859242
567. Chambers JD, Cangelosi MJ, Neumann PJ. Medicare's use of cost-effectiveness analysis for prevention (but not
for treatment). Health Policy. 2014 Nov 22. [Epub ahead of print]
568. Chambers JD, Thorat T, Pyo J, Chenoweth M, Neumann PJ. Despite high costs, specialty drugs may offer value for
money comparable to that of traditional drugs. Health Aff (Millwood). 2014 Oct;33(10):1751-60. PubMed PMID:
25288419.
569. Chambers JD, Winn A, Zhong Y, Olchanski N, Cangelosi MJ. Potential role of network meta-analysis in valuebased insurance design. Am J Manag Care. 2014 Aug;20(8):641-8. PubMed PMID: 25295678.
570. Chambers JD. Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care? Office of Health
Economics Seminar Briefing. March 2014.
571. Cheng TM, Freund KM, Winter M, Orlander JD. Limited adoption of current guidelines for clinical breast
examination by primary care physician educators. J Womens Health (Larchmt). 2015 Jan;24(1):11-7. Epub 2014
Nov 18. PubMed PMID: 25405388.
572. Chung M, Ma J, Patel K, Berger S, Lau J, Lichtenstein AH. Fructose, high-fructose corn syrup, sucrose, and
nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr.
2014 Sep; 100(3):833-49. Epub 2014 Aug 6. PubMed PMID: 25099546; PubMed Central PMCID: PMC4135494.
573. Clark JA, Parker VA, Battaglia TA, Freund KM. Patterns of task and network actions performed by navigators to
facilitate cancer care. Health Care Manage Rev. 2014 Apr-Jun;39(2):90-101. PubMed PMID: 23478753.
574. Cohen JT. FDA's proposed ban on trans fats: How do the costs and benefits stack up? Clin Ther. 2014 Mar 1;
36(3):322-7. PMID: 24636817.
575. Cohen GM, Drain PK, Noubary F, Cloete C, Bassett IV. Diagnostic Delays and Clinical Decision Making With
Centralized Xpert MTB/RIF Testing in Durban, South Africa. J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):e8893. PMID: 25314255.
576. Concannon TW, Fuster M, Saunders T, Patel K, Wong JB, Leslie LK, Lau J. A Systematic Review of Stakeholder
Engagement in Comparative Effectiveness and Patient-Centered Outcomes Research. J Gen Intern Med. Epub
2014 Jun 4. PMID: 24893581.
578. Dacks PA, Andrieu S, Blacker D, Carman AJ, Green AM, Grodstein F, Henderson VW, James BD, Lane RF, Lau J,
Lin PJ, Reeves BC, Shah RC, Vellas B, Yaffe K, Yurko-Mauro K, Shineman DW, Bennett DA, Fillit HM. Dementia
Prevention: Optimizing the Use of Observational Data for Personal, Clinical, and Public Health Decision-making.
Journal of Prevention of Alzheimer’s Disease 2014;1(2):117-23.
579. Dahabreh IJ, Kent DM. Can the learning health care system be educated with observational data? JAMA. 2014
Jul;312(2):129-30. PubMed PMID: 25005647.
580. De La Cruz II, Freund KM, Battaglia TA, Chen CA, Bak S, Kalish R, Lottero B, Egan P, Heeren T, Kronman AC.
Impact of depression on the intensity of patient navigation for women with abnormal cancer screenings. J Health
Care Poor Underserved. 2014 Feb; 25(1):383-95. PMID: 24509033.
581. Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai WR, Rodriguez W, Bassett IV. Diagnostic point-ofcare tests in resource-limited settings. Lancet Infect Dis. 2014 Mar;14(3):239-49. Epub 2013 Dec 10. Review.
582. Drew DA, Lok CE, Cohen JT, Wagner M, Tangri N, Weiner DE. Vascular Access Choice in Incident Hemodialysis
Patients: A Decision Analysis. J Am Soc Nephrol. Epub 2014 Jul 25. PMID: 25240262
583. Drew DA, Tighiouart H, Scott T, Kantor A, Fan L, Artusi C, Plebani M, Weiner DE, Sarnak MJ. Asymmetric
Dimethylarginine, Race, and Mortality in Hemodialysis Patients. Clin J Am Soc Nephrol. Epub 2014 Jun 26.
PMID: 24970872.
584. Drew DA, Tighiouart H, Scott TM, Lou KV, Fan L, Shaffi K, Weiner DE, Sarnak MJ. FGF-23 and cognitive
performance in hemodialysis patients. Hemodial Int. 2014 Jan;18(1):78-86. Epub 2013 Oct 24. PubMed PMID:
24164913.
585. Drew DA, Weiner DE, Tighiouart H, Scott T, Lou K, Kantor A, Fan L, Strom JA, Singh AK, Sarnak MJ. Cognitive
Function and All-Cause Mortality in Maintenance Hemodialysis Patients. Am J Kidney Dis. Epub 2014 Sep 17.
PMID: 25240262
586. Driban JB, Barbe MF, Amin M, Kalariya NS, Zhang M, Lo GH, Tassinari AM, Harper D, Price LL, Eaton CB,
Schneider E, McAlindon TE. Validation of quantitative magnetic resonance imaging-based apparent bone
volume fraction in peri-articular tibial bone of cadaveric knees. BMC Musculoskelet Disord. 2014 Apr 29;
15(1):143. PMID: 24779374; PMCID: PMC4021054
587. Earley A, Persson R, Garlitski AC, Balk EM, Uhlig K. Effectiveness of implantable cardioverter defibrillators for
primary prevention of sudden cardiac death in subgroups a systematic review. Ann Intern Med. 2014 Jan
21;160(2):111-21. Review. PubMed PMID: 24592496.
185
»» PUBLICATIONS
577. Concannon TW, Guise JM, Dolor RJ, Meissner P, Tunis S, Krishnan JA, Pace WD, Saltz J, Hersh WR, Michener L,
Carey TS. A national strategy to develop pragmatic clinical trials infrastructure. Clin Transl Sci. 2014
Apr;7(2):164-71. Epub 2014 Jan 28. PubMed PMID: 24472114; PubMed Central PMCID: PMC4126802.
588. Ellis KL, Zhou Y, Beshansky JR, Ainehsazan E, Yang Y, Selker HP, Huggins GS, Cupples LA, Peter I. Genetic
IMMEDIATE trial. Pharmacogenomics J. Epub 2014 Aug 19. PMID: 25135348.
589. Elmariah S, Furlan AJ, Reisman M, Burke D, Vardi M, Wimmer NJ, Ling S, Chen X, Kent DM, Massaro J, Mauri L.
Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE
I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack
Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial. JACC Cardiovasc Interv. 2014
Aug;7(8):913-20. PMID: 25147037.
»» PUBLICATIONS
590. Fan L, Sarnak MJ, Tighiouart H, Drew DA, Kantor AL, Lou KV, Shaffi K, Scott TM, Weiner DE. Depression and
all-cause mortality in hemodialysis patients. Am J Nephrol. 2014;40(1):12-8. Epub 2014 Jun 24. PubMed PMID:
591. Fan L, Tighiouart H, Levey AS, Beck GJ, Sarnak MJ. Urinary sodium excretion and kidney failure in nondiabetic
chronic kidney disease. Kidney Int. Epub 2014 Mar 19. PMID: 24646858. First MB, Bhat V, Adler D, Dixon
L,Goldman B, Koh S, Levine B, Oslin D, Siris S. How Do Clinicians Actually Use the in Clinical Practice and Why
We Need to Know More. Journal of Nervous and Mental Disease, 202(12): 1-4, 2014.
592. Freund KM, Battaglia TA, Calhoun E, Darnell JS, Dudley DJ, Fiscella K, Hare ML, LaVerda N, Lee JH, Levine P,
Murray DM, Patierno SR, Raich PC, Roetzheim RG, Simon M, Snyder FR, Warren-Mears V, Whitley EM, Winters P,
Young GS, Paskett ED; Writing Group of the Patient Navigation Research Program. Impact of patient navigation
on timely cancer care: the Patient Navigation Research Program. J Natl Cancer Inst. 2014 Jun 17;106(6):dju115.
Print 2014 Jun. PubMed PMID: 24938303; PubMed Central PMCID: PMC4072900.
593. Freund KM, Isabelle AP, Hanchate AD, Kalish RL, Kapoor A, Bak S, Mishuris RG, Shroff SM, Battaglia TA. The
impact of health insurance reform on insurance instability. J Health Care Poor Underserved. 2014 Feb;25(1
Suppl):95-108. PubMed PMID: 24583490.
594. Gala RB, Margulies R, Steinberg A, Murphy M, Lukban J, Jeppson P, Aschkenazi S, Olivera C, South M,
Lowenstein L, Schaffer J, Balk EM, Sung V; Society of Gynecologic Surgeons Systematic Review Group. Systematic
review of robotic surgery in gynecology: robotic techniques compared with laparoscopy and laparotomy. J Minim
Invasive Gynecol. 2014 May-Jun;21(3):353-61. Epub 2013 Dec 1. PubMed PMID: 24295923.
595. Garneau MS, Price LL, Withrow SJ, Boston SE, Ewing PJ, McClaran JK, Liptak JM, Berg J. Perioperative Mortality
and Long-Term Survival in 80 Dogs and 32 Cats Undergoing Excision of Thymic Epithelial Tumors. Vet Surg. 2014
Nov 3. [Epub ahead of print] PubMed PMID: 25367336.
596. Genberg BL, Lee Y, Rogers WH, Wilson IB. Four Types of Barriers to Adherence of Antiretroviral Therapy are
Associated with Decreased Adherence Over Time. AIDS Behav. Epub 2014 Apr 20. PMID: 24748240.
597. Ghogawala Z, Benzel EC, Heary RF, Riew KD, Albert TJ, Butler WE, Barker FG 2nd, Heller JG, McCormick PC,
Whitmore RG, Freund KM, Schwartz JS. Cervical Spondylotic Myelopathy Surgical (CSM-S) Trial: Randomized
Controlled Trial Design and Rationale. Neurosurgery. Epub 2014 Jul 2. PMID: 24991714.
598. Graham RJ, Rodday AM, Parsons SK. Family-centered assessment and function for children with chronic
mechanical respiratory support. J Pediatr Health Care. 2014 Jul-Aug;28(4):295-304. Epub 2013 Aug 12. PubMed
PMID: 23942254.
599. Gunn CM, Clark JA, Battaglia TA, Freund KM, Parker VA. An assessment of patient navigator activities in breast
cancer patient navigation programs using a nine-principle framework. Health Serv Res. 2014 Oct;49(5):1555-77.
Epub 2014 May 13. PubMed PMID: 24820445.
600. Gunn CM, Freund KM, Kaplan SA, Raj A, Carr PL. Knowledge and Perceptions of Family Leave Policies Among
Female Faculty in Academic Medicine. Womens Health Issues. 2014 Mar-Apr;24(2):e205-10. Epub 2014 Feb 14.
PMID: 24533979; PMCID: PMC3994529.
601. Hadar N, Raman G, Moorthy D, O'Donnell TF, Thaler DE, Feldmann E, Lau J, Kitsios GD, Dahabreh IJ.
Asymptomatic carotid artery stenosis treated with medical therapy alone: temporal trends and implications for
risk assessment and the design of future studies. Cerebrovasc Dis. 2014;38(3):163-73. Epub 2014 Oct 9. PubMed
PMID: 25300534.
603. Hayek M, Mackie TI, Mulé CM, Bellonci C, Hyde J, Bakan JS, Leslie LK. A multi-state study on mental health
evaluation for children entering foster care. Adm Policy Ment Health. 2014 Jul;41(4):552-67. PubMed PMID:
23709285.
604. Hodgkin D, Horgan CM, Quinn AE, Merrick EL, Stewart MT, Leslie LK. Management of newer medications for
attention-deficit/hyperactivity disorder in commercial health plans. Clin Ther. 2014 Dec 1;36(12):2034-46. Epub
2014 Nov 14. PMID: 25450473
605. Hong SY, Fanelli TJ, Jonas A, Gweshe J, Tjituka F, Sheehan HM, Wanke C, Terrin N, Jordan MR, Tang AM.
Household food insecurity associated with antiretroviral therapy adherence among HIV-infected patients in
Windhoek, Namibia. J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):e115-22. PubMed PMID: 25356779;
606. Hudcova J, Ruthazer R, Bonney I, Schumann R. Sodium homeostasis during liver transplantation and correlation
with outcomes. Anesth Analg. 2014 Dec;119(6):1420-8. PubMed PMID: 25211389.
607. Huefner JC, Griffith AK, Smith GL, Vollmer DG, Leslie LK. Reducing psychotropic medication in an intensive
residential treatment center. J Child Fam Stud. 2014 May; 23(4): 675-685.
608. Inker LA, Lambers Heerspink HJ, Mondal H, Schmid CH, Tighiouart H, Noubary F, Coresh J, Greene T, Levey AS.
GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects
from 37 randomized trials. Am J Kidney Dis. 2014 Dec;64(6):848-59. Epub 2014 Oct 16. PubMed PMID: 25441438.
609. Iyengar A, Paulus JK, Gerlanc DJ, Maron JL. Detection and potential utility of C-reactive protein in saliva of
neonates. Front Pediatr. 2014 Nov 21;2:131. eCollection 2014. PubMed PMID: 25485262; PubMed Central PMCID:
PMC4239436.
610. Jordan M, Obeng-Aduasare Y, Sheehan H, Hong S, Terrin N, Duong D, Trung N, Wanke C, Kinh N, Tang A.
Correlates of non-adherence to antiretroviral therapy in a cohort of HIV-positive drug users receiving
antiretroviral therapy in Hanoi, Vietnam. Int J STD AIDS August 2014 vol. 25 no. 9 662-668.
611. Kapoor A, Battaglia TA, Isabelle AP, Hanchate AD, Kalish RL, Bak S, Mishuris RG, Shroff SM, Freund KM. The
impact of insurance coverage during insurance reform on diagnostic resolution of cancer screening
abnormalities. J Health Care Poor Underserved. 2014 Feb;25(1 Suppl):109-21. PubMed PMID: 24583491; PubMed
612. Karl JP, Cheatham RA, Das SK, Hyatt RR, Gilhooly CH, Pittas AG, Lieberman HR, Lerner D, Roberts SB, Saltzman
E. Effect of glycemic load on eating behavior self-efficacy during weight loss. Appetite. 2014 Sep 1;80C:204-211.
Epub 2014 May 21. PMID: 24859114.
187
»» PUBLICATIONS
602. Hallikainen I, Martikainen J, Lin PJ, Cohen JT, Lahoz R, Välimäki T, Hongisto K, Väätäinen S, Vanhanen M,
Neumann PJ, Hänninen T, Koivisto AM. The Progression of Alzheimer's Disease Can Be Assessed with a Short
Version of the CERAD Neuropsychological Battery: The Kuopio ALSOVA Study. Dement Geriatr Cogn Dis Extra.
2014 Dec 11;4(3):494-508. eCollection 2014 Sep-Dec. PubMed PMID: 25685140; PubMed Central PMCID:
PMC4296232
613. Kelly MJ, Horan JT, Alonzo TA, Eapen M, Gerbing RB, He W, Lange BJ, Parsons SK, Woods WG. Comparable
survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched
related donor, or unrelated donor transplantation. Pediatr Blood Cancer. 2014 Feb; 61(2):269-75. Epub 2013 Aug
19. PMID: 23955900; PMCID: PMC3919967.
614. Kelly MJ, Trikalinos TA, Dahabreh IJ, Gianferante M, Parsons SK. Cranial radiation for pediatric T-lineage acute
lymphoblastic leukemia: a systematic review and meta-analysis. Am J Hematol. 2014 Oct;89(10):992-7. Epub
2014 Jul 22. Review. PubMed PMID: 24912665; PubMed Central PMCID: PMC4167220.
»» PUBLICATIONS
615. Ko NY, Darnell JS, Calhoun E, Freund KM, Wells KJ, Shapiro CL, Dudley DJ, Patierno SR, Fiscella K, Raich P,
Battaglia TA. Can patient navigation improve receipt of recommended breast cancer care? Evidence from the
National Patient Navigation Research Program. J Clin Oncol. 2014 Sep 1;32(25):2758-64. Epub 2014 Jul 28.
616. Koulouridis I, Price LL, Madias NE, Jaber BL. Hospital-acquired kidney injury and hospital readmission: a cohort
study. Am J Kidney Dis. 2015 Feb;65(2):275-82. Epub 2014 Oct 22. PMID:25446018.
617. Kozminski MA, Wei JT, Nelson J, Kent DM. Baseline characteristics predict risk of progression and response to
combination medical therapy for benign prostatic hyperplasia. British Journal of Urology. 2014 May 13. [Epub
ahead of print] .
618. Ku E, Glidden DV, Johansen KL, Sarnak M, Tighiouart H, Grimes B, Hsu CY. Association between strict blood
pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease. Kidney
Int. 2014 Dec 10. [Epub ahead of print] PubMed PMID: 25493952.
619. Lambers Heerspink HJ, Tighiouart H, Sang Y, Ballew S, Mondal H, Matsushita K, Coresh J, Levey AS, Inker LA.
GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled
trials. Am J Kidney Dis. 2014 Dec;64(6):860-6. Epub 2014 Oct 16. PubMed PMID: 25441439.
620. Laws MB, Lee Y, Rogers WH, Beach MC, Saha S, Korthuis PT, Sharp V, Cohn J, Moore R, Wilson IB. Providerpatient communication about adherence to anti-retroviral regimens differs by patient race and ethnicity. AIDS
Behav. 2014 Jul;18(7):1279-87. PubMed PMID: 24464408; PubMed Central PMCID: PMC4047172.
621. Leslie LK, Maciolek S, Biebel K, Debordes-Jackson G, Nicholson J. Exploring Knowledge Exchange at the
Research-Policy-Practice Interface in Children's Behavioral Health Services. Adm Policy Ment Health. Epub 2014
Jan 25. PMID: 24464480.
622. Leyenaar JK, Capra LA, O'Brien ER, Leslie LK, Mackie TI. Determinants of career satisfaction among pediatric
hospitalists: a qualitative exploration. Acad Pediatr. 2014 Jul-Aug;14(4):361-8. PMID: 24976348.
623. Lin PJ, Yang Z, Fillit HM, Cohen JT, Neumann PJ. Unintended benefits: the potential economic impact of
addressing risk factors to prevent Alzheimer's disease. Health Aff (Millwood). 2014 Apr;33(4):547-54. PMID:
24711313.
624. Lustgarten MS, Price LL, Chale A, Phillips EM, Fielding RA. Branched chain amino acids are associated with
muscle mass in functionally limited older adults. J Gerontol A Biol Sci Med Sci. 2014 Jun;69(6):717-24. Epub 2013
Oct 1. PubMed PMID: 24085401; PubMed Central PMCID: PMC4073623.
625. Lustgarten MS, Price LL, Fielding RA. Analytes and Metabolites Associated With Muscle Quality in Young,
Healthy Adults. Med Sci Sports Exerc. 2014 Nov 19. [Epub ahead of print] PubMed PMID: 25412292.
626. Lustgarten MS, Price LL, Chalé A, Fielding RA. Metabolites related to gut bacterial metabolism, peroxisome
proliferator-activated receptor-alpha activation, and insulin sensitivity are associated with physical function in
functionally-limited older adults. Aging Cell. 2014 Oct;13(5):918-25. Epub 2014 Jul 18. PubMed PMID: 25041144;
627. Mitri J, Nelson J, Ruthazer R, Garganta C, Nathan DM, Hu FB, Dawson-Hughes B, Pittas AG; Diabetes Prevention
Program Research Group. Plasma 25-hydroxyvitamin D and risk of metabolic syndrome: an ancillary analysis in
the Diabetes Prevention Program. Eur J Clin Nutr. 2014 Mar;68(3):376-83. Epub 2014 Jan 22. PubMed PMID:
628. Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V. Clinical and economic consequences of hospitalacquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and metaanalysis. Antimicrob Resist Infect Control. 2014 Oct 20;3(1):32. eCollection 2014. PubMed PMID: 25371812;
630. Neumann PJ, Saret CJ. Is the US "leading from behind" on health policy? Eur J Health Econ. 2014 Mar;15(2):1136. Epub 2013 Dec 10. PubMed PMID: 24323196.
631. Nierenberg NE, Poutsiaka DD, Chow JK, Cooper J, Price LL, Freeman RB, Rohrer R, Snydman DR. Pretransplant
Lymphopenia is a Novel Prognostic Factor in CMV and Non-CMV Invasive Infection After Liver Transplantation.
Liver Transpl. Epub 2014 Sep 10. PMID: 25205044.
632. Olchanski N, Winn A, Cohen JT, Neumann PJ. Abdominal aortic aneurysm screening: how many life years lost
from underuse of the medicare screening benefit? J Gen Intern Med. 2014 Aug;29(8):1155-61. Epub 2014 Apr 9.
633. Oxenkrug G, Turski W, Zgrajka W, Weinstock J, Ruthazer R, Summergrad P. Disturbances of Tryptophan
Metabolism and Risk of Depression in HCV Patients Treated with IFN-Alpha. J Infect Dis Ther. 2014 Feb 25;2(2).
pii: 131. PubMed PMID: 25346938; PubMed Central PMCID: PMC4206908.
634. Paulus JK, Dahabreh IJ, Balk EM, Avendano EE, Lau J, Ip S. (2014), Opportunities and challenges in using studies
without a control group in comparative effectiveness reviews. Res Synth Method, 5: 152–161.
635. Palinkas LA, Garcia AR, Aarons GA, Finno-Velasquez M, Holloway IW, Mackie TI, Leslie LK, Chamberlain P.
Measuring use of research evidence: The structured interview for evidence use. Research on Social Work
Practice, December 1, 2014
636. Pennarola BW, Rodday AM, Bingen K, Schwartz LA, Patel SK, Syrjala KL, Mayer DK, Ratichek SJ, Guinan EC,
Kupst MJ, Hibbard JH, Parsons SK. Changing factors associated with parent activation after pediatric
hematopoietic stem cell transplant. Support Care Cancer. Epub 2014 Dec 18. PMID: 25519755.
637. Persson R, Earley A, Garlitski AC, Balk EM, Uhlig K. Adverse events following implantable cardioverter
defibrillator implantation: a systematic review. J Interv Card Electrophysiol. 2014 Aug;40(2):191-205. doi:
10.1007/s10840-014-9913-z. Epub 2014 Jun 20. PMID: 24948126.
638. Primeau SW, Freund KM, Ramachandran A, Bak SM, Heeren T, Chen CA, Morton S, Battaglia TA. Social service
barriers delay care among women with abnormal cancer screening. J Gen Intern Med. 2014 Jan;29(1):169-75.
Epub 2013 Oct 3. PMID: 24197626; PMCID: PMC3889949.
639. Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, Olivera CK, Abed H, Balk EM, Murphy
M; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of
menopause: a systematic review. Obstet Gynecol. 2014 Dec;124(6):1147-56. PMID: 25415166.
640. Ramachandran A, Freund KM, Bak SM, Heeren TC, Chen CA, Battaglia TA. Multiple Barriers Delay Care Among
Women with Abnormal Cancer Screening Despite Patient Navigation. J Womens Health (Larchmt). Epub 2014
Dec 16. PMID: 25513858.
641. Raval AB, Salluzzo J, Dvorak T, Price LL, Mignano JE, Wu JK. Salvage Gamma Knife Radiosurgery after failed
management of bilateral trigeminal neuralgia. Surg Neurol Int. 2014 Nov 21;5:160. PMID: 25525553.
189
»» PUBLICATIONS
629. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness--the curious resilience of the $50,000-perQALY threshold. N Engl J Med. 2014 Aug 28;371(9):796-7. PMID: 25162885
642. Rodday AM, Parsons SK, Correll CU, Robb AS, Zima BT, Saunders TS, Leslie LK. Child and adolescent
psychiatrists' attitudes and practices prescribing second generation antipsychotics. J Child Adolesc
Psychopharmacol. 2014 Mar; 24(2):90-3. PMID: 24679174; PMCID:PMC3967387.
643. Rogers WH, Thornton K, von Glahn T. Blending group and practice site scores to increase the reliability of
physician quality information. Health Serv Res. 2014 Feb;49(1):113-26. Epub 2013 Jul 5. PubMed PMID:
23829352.
»» PUBLICATIONS
Parsons SK, Leslie LK, Freund KM. "We make the path by walking it": building an academic community
partnership with Boston Chinatown. Prog Community Health Partnersh. 2014 Autumn;8(3):353-63. PubMed
PMID: 25435562.
645. Sakai C, Mackie TI, Shetgiri R, Franzen S, Partap A, Flores G, Leslie LK. Mental health beliefs and barriers to
accessing mental health services in youth aging out of foster care. Acad Pediatr. 2014 Nov-Dec;14(6):565-73. Epub
2014 Oct 30. PubMed PMID: 25439155.
646. Schimpf MO, Rahn DD, Wheeler TL, Patel M, White AB, Orejuela FJ, El-Nashar SA, Margulies RU, Gleason JL,
Aschkenazi SO, Mamik MM, Ward RM, Balk EM, Sung VW; Society of Gynecologic Surgeons Systematic Review
Group. Sling surgery for stress urinary incontinence in women: a systematic review and metaanalysis. Am J
Obstet Gynecol. 2014 Jul;211(1):71.e1-71.e27. Epub 2014 Jan 30. Review. PubMed PMID: 24487005.
647. Selker HP, Udelson JE, Massaro JM, Ruthazer R, D'Agostino RB, Griffith JL, Sheehan PR, Desvigne-Nickens P,
Rosenberg Y, Tian X, Vickery EM, Atkins JM, Aufderheide TP, Sayah AJ, Pirrallo RG, Levy MK, Richards ME,
Braude DA, Doyle DD, Frascone RJ, Kosiak DJ, Leaming JM, Van Gelder CM, Walter GP, Wayne MA, Woolard RH,
Beshansky JR. One-Year Outcomes of Out-of-Hospital Administration of Intravenous Glucose, Insulin, and
Potassium (GIK) in Patients With Suspected Acute Coronary Syndromes (from the IMMEDIATE [Immediate
Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial). Am J
Cardiol. 2014 May 15;113(10):1599-605. Epub 2014 Mar 1. PMID: 24792735; PMCID: PMC4043184
648. Selker HP, Oye KA, Eichler HG, Stockbridge NL, Mehta CR, Kaitin KI, McElwee NE, Honig PK, Erban JK,
D'Agostino RB. A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials. Clin Pharmacol Ther.
2014 Feb;95(2):147-53. Epub 2013 Sep 23. PMID: 24060819; PMCID: PMC3904553.
649. Selker HP, Kravitz RL, Gallagher TH. The National Physician Payment Commission Recommendation to
Eliminate Fee-for-Service Payment: Balancing Risk, Benefit, and Efficiency in Bundling Payment for Care. J Gen
Intern Med. 2014 May;29(5):698-9. Epub 2014 Feb 27. PMID: 24573713; PMCID: PMC4000325.
Performance of creatinine-based GFR estimating equations in solid-organ transplant recipients. Am J Kidney
Dis. 2014 Jun;63(6):1007-18. Epub 2014 Apr 2. PubMed PMID: 24703720; PubMed Central PMCID: PMC4113340.
651. Shenoy ES, Noubary F, Kim J, Rosenberg ES, Cotter JA, Lee H, Walensky RP, Hooper DC. Concordance of PCR and
culture from nasal swabs for MRSA in setting of concurrent anti-staphylococcal antibiotics. J Clin Microbiol. 2014
Apr;52(4):1235-7. Epub 2014 Jan 22. PMID: 24452168; PMCID: PMC3993487.
652. Shenoy ES, Paras ML, Noubary F, Walensky RP, Hooper DC. Natural history of colonization with methicillinresistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE): a systematic review.
BMC Infect Dis. 2014 Mar 31;14:177. Review. PubMed PMID: 24678646; PubMed Central PMCID: PMC4230428.
653. Silberman EK, Summergrad P, Price LL. Parameters of Training, Academic Involvement, and Practice Setting
Predictive of Retention in Combined Medical-Psychiatric Practice. Academic Psychiatry. Epub 2014 Mar 25.
PMID: 24664599
654. Sorita A, Ahmed A, Starr SR, Thompson KM, Reed DA, Dabrh AM, Prokop L, Kent DM, Shah ND, Murad MH,
Ting HH. Off-hour presentation and outcomes in patients with acute ischemic stroke: A systematic reviewand
meta-analysis. Eur J Intern Med. 2014 Apr;25(4):394-400. Epub 2014 Apr 12. PMID: 24721584.
655. Sullivan AL, Beshansky JR, Ruthazer R, Murman DH, Mader TJ, Selker HP. Factors associated with longer time to
treatment for patients with suspected acutecoronary syndromes: a cohort study. Circ Cardiovasc Qual Outcomes.
2014 Jan 1; 7(1):86-94. Epub 2014 Jan 14. PMID: 24425697; PMCID: PMC3985420.
657. Thaler DE, Ruthazer R, Weimar C, Mas JL, Serena J, Di Angelantonio E, Papetti F, Homma S, Mattle HP,
Nedeltchev K, Mono ML, Jaigobin C, Michel P, Elkind MS, Di Tullio MR, Lutz JS, Griffith J, Kent DM. Recurrent
stroke predictors differ in medically treated patients with pathogenic vs. other PFOs. Neurology. 2014 Jul
15;83(3):221-6. Epub 2014 Jun 13. PubMed PMID: 24928123; PubMed Central PMCID: PMC4117365.
658. Thaler DE, Ruthazer R, Weimar C, Serena J, Mattle HP, Nedeltchev K, Mono ML, Di Angelantonio E, Elkind MS,
Di Tullio MR, Homma S, Michel P, Meier B, Furlan AJ, Lutz JS, Kent DM. Determinants of antithrombotic choice
for patent foramen ovale in cryptogenic stroke. Neurology. Epub 2014 Oct 22. PMID: 25339209.
659. Tickle-Degnen L, Saint-Hilaire M, Thomas CA, Habermann B, Martinez LS, Terrin N, Noubary F, Naumova EN.
Emergence and evolution of social self-management of Parkinson's disease: study protocol for a 3-year
prospective cohort study. BMC Neurol. 2014 May 2;14(1):95. PMID: 24885181; PMCID: PMC4016672.
660. Traa MX, Barboza L, Doron S, Snydman DR, Noubary F, Nasraway SA Jr. Horizontal Infection Control Strategy
Decreases Methicillin-Resistant Staphylococcus aureus Infection and Eliminates Bacteremia in a Surgical ICU
Without Active Surveillance. Crit Care Med. Epub 2014 Jun 27.PMID: 24979485.
661. Trikalinos T. A., Hoaglin D. C., Small K. M., Terrin N. and Schmid C. H. (2014), Methods for the joint metaanalysis of multiple tests, Research Synthesis Methods, 5, pages 294–312.
662. Uhlig K, Leff B, Kent DM, Dy S, Brunnhuber K, Burgers JS, Greenfield S , Guyatt G , High K, Leipzig R , Mulrow C,
Schmader K, Schunemann H, Walter LC, Woodcock J, Boyd CM. A framework for crafting clinical practice
guidelines those are relevant to the care and management of people with multimorbidity J Gen Intern Med 2014
Apr;29(4):670-679.
663. Wachman EM, Hayes MJ, Lester BM, Terrin N, Brown MS, Nielsen DA, Davis JM. Epigenetic variation in the
mu-opioid receptor gene in infants with neonatal abstinence syndrome. J Pediatr. 2014 Sep;165(3):472-8. Epub
2014 Jul 1. PubMed PMID: 24996986; PubMed Central PMCID: PMC4145036.
664. Wang C, Iversen MD, McAlindon T, Harvey WF, Wong JB, Fielding RA, Driban JB, Price LL, Rones R, Gamache T,
Schmid CH. Assessing the comparative effectiveness of Tai Chi versus physical therapy for knee osteoarthritis:
design and rationale for a randomized trial. BMC Complement Altern Med. 2014 Sep 8;14:333. PubMed PMID:
665. Weiner DE, Tighiouart H, Ladik V, Meyer KB, Zager PG, Johnson DS. Oral intradialytic nutritional supplement
use and mortality in hemodialysis patients. Am J Kidney Dis. 2014 Feb;63(2):276-85. Epub 2013 Oct 3. PubMed
PMID: 24094606.
666. Weiss CO, Varadhan R, Puhan MA, Vickers A, Bandeen-Roche K, Boyd CM, Kent DM. Multimorbidity and
evidence generation. J Gen Intern Med. 2014 Apr;29(4):653-60. Epub 2014 Jan 18. Review. PubMed PMID:
191
»» PUBLICATIONS
656. Terrin N, Rodday AM, Parsons SK. Joint Models for Predicting Transplant-Related Mortality from Quality of Life
Data. Qual Life Res 2015; 24:31-39. doi: 10.1007/s11136-013-0550-2 [Epub ahead of print]. PMID: 24129669,
PMCID: PMC3989470.
667. Welch LC, Litman HJ, Borba CP, Vincenzi B, Henderson DC. Does a Physician's Attitude toward a Patient with
Mental Illness Affect Clinical Management of Diabetes? Results from a Mixed-Method Study. Health Serv Res.
2014 Dec 9. [Epub ahead of print] PubMed PMID: 25487069.
668. Wendelburg KM, O'Toole TE, McCobb E, Price LL, Lyons JA, Berg J. Risk factors for perioperative death in dogs
undergoing splenectomy for splenic masses: 539 cases (2001-2012). J Am Vet Med Assoc. 2014 Dec
15;245(12):1382-90. PMID: 25459483 .
»» PUBLICATIONS
669. Wessler B, Thaler DE, Ruthazer R, Weimar C, Di Tullio MR, Elkind MS, Homma S, Lutz JS, Mas JL, Mattle HP,
Meier B, Nedeltchev K, Papetti F, Di Angelantonio E, Reisman M, Serena J, Kent DM. Transesophageal
Echocardiography in Cryptogenic Stroke and PFO: The Analysis of Putative High Risk Features from the Risk of
Paradoxical Embolism (RoPE) Database. Circ Cardiovasc Imaging. 7(1):125-31, 2014. PMID: 24214884; PMCID:
PMC3934652.
670. Wilkinson J, Lauer E, Greenwood NW, Freund KM, Rosen AK. Evaluating representativeness and cancer
screening outcomes in a state department of developmental services database. Intellect Dev Disabil. 2014
Apr;52(2):136-46. PubMed PMID: 24725112.
671. Wilson IB, Fowler FJ Jr, Cosenza CA, Michaud J, Bentkover J, Rana A, Kogelman L, Rogers WH. Cognitive and
field testing of a new set of medication adherence self-report items for HIV care. AIDS Behav. 2014
Dec;18(12):2349-58. PubMed PMID: 24077970; PubMed Central PMCID: PMC4000749.
672. Wuerz TH, Kent DM, Malchau H, Rubash HE. A nomogram to predict major complications after hip and knee
arthroplasty. J Arthroplasty. 2014 Jul;29(7):1457-62. Epub 2014 May 1. PubMed PMID: 24793891.
673. Yeh M, Aarons GA, Ho J, Leslie LK, McCabe K, & Hough RL. Parental etiological explanations and longitudinal
medication use for youths with Attention Deficit Hyperactivity Disorder. Administration and Policy in Mental
Health. 2014: 41(3): 401-409. PMID: 23504264
674. Zalesak M, Greenbaum JS, Cohen JT, Kokkotos F, Lustig A, Neumann PJ, Pritchard D, Stewart J, Dubois RW. The
value of specialty pharmaceuticals - a systematic review. Am J Manag Care. 2014 Jun;20(6):461-72. PMID:
25180434.
675. Zhang FF, Driban JB, Lo GH, Price LL, Booth S, Eaton CB, Lu B, Nevitt M, Jackson B, Garganta C, Hochberg MC,
Kwoh K, McAlindon TE. Vitamin D deficiency is associated with progression of knee osteoarthritis. J Nutr. 2014
Dec;144(12):2002-8. Epub 2014 Oct 1. PubMed PMID: 25411034; PubMed Central PMCID: PMC4230211.
676. Zhang M, Driban JB, Price LL, Harper D, Lo GH, Miller E, Ward RJ, McAlindon TE. Development of a rapid knee
Aug 6;15:264. PubMed PMID: 25098589; PubMed Central PMCID: PMC4126278.
677. Zhang FF, Roberts SB, Parsons SK, Must A, Kelly MJ, Wong WW, Saltzman E. Low Levels of Energy Expenditure in
Childhood Cancer Survivors: Implications for Obesity Prevention. J Pediatr Hematol Oncol. Epub 2014 Sep 5.
PMID: 25197775
678. Zhang FF, Rodday AM, Kelly MJ, Must A, Macpherson C, Roberts SB, Saltzman E, Parsons SK. Predictors of being
overweight or obese in survivors of pediatric acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2014
Jul;61(7):1263-9. Epub 2014 Jan 30. PMID: 24482072.
679. Zhang FF, Kelly MJ, Saltzman E, Must A, Roberts SB, Parsons SK. Obesity in Pediatric ALL Survivors: A MetaAnalysis. Pediatrics. 2014 Mar;133(3):e704-15. Epub 2014 Feb 17. PMID: 24534408; PMCID: PMC3934345.
680. Zintzaras E, Miligkos M, Ziakas P, Balk EM, Mademtzoglou D, Doxani C, Mprotsis T, Gowri R, Xanthopoulou P,
Mpoulimari I, Kokkali C, Dimoulou G, Rodopolou P, Stefanidis I, Kent DM, Hadjigeorgiou GM. Assessment of the
Relative Effectiveness and Tolerability of Treatments of Type 2 Diabetes Mellitus: A Network Meta-analysis. Clin
Ther. 2014 Aug 7. pii: S0149-2918(14)00430-5. doi:10.1016/j.clinthera.2014.06.035. [Epub ahead of print] Review.
681. Zoher G, Benzel EC, Heary RF, Riew KD, Albert TJ, Butler WE, Barker II FG, Heller JG, McCormick PC, Whitmore
RG, Freund KM, Schwartz JS. Cervical Spondylotic Myelopathy Surgical (CSM-S) Trial: Study Design and
Rationale. Neurosurgery 2014 Jul. PMID: 24991714.
682. Kiernan MS, French AL, DeNofrio D, Parmar YJ, Pham DT, Kapur NK, Pandian NG, Patel AR. Preoperative Three
Dimensional Echocardiography to Assess Risk of Right Ventricular Failure Following Left Ventricular Assist
Device Surgery. J Card Fail. 2014 Dec 20. [Epub ahead of print]. Pubmed Abstract
683. Jumean M, Pham DT, Kapur NK. Percutaneous Bi-atrial extracorporeal membrane oxygenation for acute
circulatory support in advanced heart failure. Catheter Cardiovasc Interv. 2014 Dec 22. [Epub ahead of print].
Pubmed Abstract
684. Kapur NK, Paruchuri V, Thinh D, Reyelt L, Murphy B, Beale C, Bogins C, Wiener D, Nilson J, Esposito M, Perkins
S, Perides G, Karas RH. Hemodynamic Effects of Left Atrial or Left Ventricular Cannulation for Acute Circulatory
Support in a Bovine Model of Left Heart Injury. ASAIO J. 2014 Dec 5. [Epub ahead of print]. Pubmed Abstract
685. Lane JM, Doyle JR, Fortin JP, Kopin AS, Ordovás JM. Development of an OP9 derived cell line as a robust model to
rapidly study adipocyte differentiation. PLoS One. 2014 Nov 19;9(11):e112123. Pubmed Abstract
686. Doyle JR, Harwood BN, Krishnaji ST, Krishnamurthy VM, Lin WE, Fortin JP, Kumar K, Kopin AS. A two-step
strategy to enhance activity of low potency peptides. PLoS One. 2014 Nov 12;9(11):e110502. Pubmed Abstract
687. Harwood BN, Draper I, Kopin AS. Targeted inactivation of the rickets receptor in muscle compromises
Drosophila viability. J Exp Biol. 2014 Nov 15;217(Pt 22):4091-8. Pubmed Abstract Vu DM, Tai A, Tatro JB, Karas
RH, Huber BT, Beasley D. γδT cells are prevalent in the proximal aorta and drive nascent atherosclerotic lesion
progression and neutrophilia in hypercholesterolemic mice. PLoS One. 2014 Oct 14;9(10):e109416. Pubmed
Abstract
688. Massaad MJ, Oyoshi MK, Kane J, Koduru S, Alcaide P, Nakamura F, Ramesh N, Luscinskas FW, Hartwig J, Geha
RS. Binding of WIP to actin is essential for T cell actin cytoskeleton integrity and tissue homing. Mol Cell Biol.
2014 Sep 22; 34(23):4343-54. Pubmed Abstract
689. Yutzey KE, Demer LL, Body SC, Huggins GS, Towler DA, Giachelli CM, Hofmann-Bowman MA, Mortlock DP,
Rogers MB, Sadeghi MM, Aikawa E. Calcific Aortic Valve Disease: A Consensus Summary From the Alliance of
Investigators on Calcific Aortic Valve Disease. Arterioscler Thromb Vasc Biol. 2014 Sep 4. pii:
ATVBAHA.114.302523. Pubmed Abstract
690. Gordon FK, Vallaster CS, Westerling T, Iyer LK, Brown M, Schnitzler GR. Research Resource: Aorta- and LiverSpecific ER?-Binding Patterns and Gene Regulation by Estrogen. Mol Endocrinol. 2014 Aug;28(8):1337-51.
Pubmed Abstract
691. Ellis KL, Zhou Y, Beshansky JR, Ainehsazan E, Yang Y, Selker HP, Huggins GS, Cupples LA, Peter I. Genetic
IMMEDIATE trial. Pharmacogenomics J. 2014 Aug 19. doi: 10.1038/tpj.2014.41. Pubmed Abstract
692. Draper I, Mahoney LJ, Mitsuhashi S, Pacak CA, Salomon RN, Kang PB. Silencing of Drpr Leads to Muscle and
Brain Degeneration in Adult Drosophila. Am J Pathol. 2014 Aug 8. pii: S0002-9440(14)00374-5. Pubmed Abstract
193
»» PUBLICATIONS
M olecular C a rd i ol og y Res e a rch I n st it u te
693. Barrett Mueller K, Lu Q, Mohammad NN, Luu V, McCurley A, Williams GH, Adler GK, Karas RH, Jaffe IZ. Estrogen
Receptor Inhibits Mineralocorticoid Receptor Transcriptional Regulatory Function. Endocrinology. 2014 Jul
22:en20141270. Pubmed Abstract
694. Kapur NK, Qiao X, Paruchuri V, Mackey EE, Daly GH, Ughreja K, Morine KJ, Levine J, Aronovitz MJ, Hill NS, Jaffe
IZ, Letarte M, Karas RH. Reducing endoglin activity limits calcineurin and TRPC-6 expression and improves
survival in a mouse model of right ventricular pressure overload. J Am Heart Assoc. 2014 Jul 11;3(4). Pubmed
Abstract
»» PUBLICATIONS
695. Zhang Y, Welzig CM, Picard KL, Du C, Wang B, Pan JQ, Kyriakis JM, Aronovitz MJ, Claycomb WC, Blanton RM,
Park HJ, Galper JB. Glycogen synthase kinase-3β inhibition ameliorates cardiac parasympathetic dysfunction in
type 1 diabetic Akita mice. Diabetes. 2014 Jun;63(6):2097-113. Pubmed Abstract
696. Sasaki H, Nagayama T, Blanton RM, Seo K, Zhang M, Zhu G, Lee DI, Bedja D, Hsu S, Tsukamoto O, Takashima S,
Kitakaze M, Mendelsohn ME, Karas RH, Kass DA, Takimoto E. PDE5 inhibitor efficacy is estrogen dependent in
female heart disease. J Clin Invest. 2014 Jun 2;124(6):2464-71. Pubmed Abstract
697. Koenig JB, Jaffe IZ. Direct role for smooth muscle cell mineralocorticoid receptors in vascular remodeling: novel
mechanisms and clinical implications. Curr Hypertens Rep. 2014 May;16(5):427. Pubmed Abstract
698. Jaffe IZ, Jaisser F. Endothelial cell mineralocorticoid receptors: turning cardiovascular risk factors into
cardiovascular dysfunction. Hypertension. 2014 May;63(5):915-7. Pubmed Abstract
699. Doyle JR, Krishnaji ST, Zhu G, Xu ZZ, Heller D, Ji RR, Levy BD, Kumar K, Kopin AS. Development of a membraneanchored chemerin receptor agonist as a novel modulator of allergic airway inflammation and neuropathic pain.
J Biol Chem. 2014 May 9;289(19):13385-96. doi: 10.1074/jbc.M113.522680. Pubmed Abstract
700. Bene NC, Alcaide P, Wortis HH, Jaffe IZ. Mineralocorticoid receptors in immune cells: Emerging role in
cardiovascular disease. Steroids. 2014 Apr 21. Pubmed Abstract
701. Chen CW, Jaffe IZ, Karumanchi SA. Pre-eclampsia and cardiovascular disease. Cardiovasc Res. 2014 Mar
15;101(4):579-86. Pubmed Abstract
702. Kapur NK, Paruchuri V. Interventions for failing vessels, valves, and now . ventricles: the parachute device.
Catheter Cardiovasc Interv. 2014 Mar 1;83(4):631-2. Pubmed Abstract
703. Hayden RS, Fortin JP, Harwood B, Subramanian B, Quinn KP, Georgakoudi I, Kopin AS, Kaplan DL. Cell-tethered
ligands modulate bone remodeling by osteoblasts and osteoclasts. Adv Funct Mater. 2014 Jan 29;24(4):472-479.
Pubmed Abstract
704. Yoneyama S, Guo Y, Lanktree MB, Barnes MR, Elbers CC, Karczewski KJ, ... Huggins GS, ... Taylor KC. Genecentric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known
loci and reveal several novel associations. Hum Mol Genet. 2014 Jan 6. [Epub ahead of print]. Pubmed Abstract
705. Mangili A, Ahmad R, Wolfert RL, Kuvin J, Polak JF, Karas RH, Wanke CA. Lipoprotein-Associated Phospholipase
A2, a Novel Cardiovascular Inflammatory Marker, in HIV-Infected Patients. Clin Infect Dis. 2014 Jan 2. [Epub
ahead of print]. Pubmed Abstract
706. Rock ML, Karas AZ, Rodriguez KB, Gallo MS, Pritchett-Corning K, Karas RH, Aronovitz M, Gaskill BN. The timeto-integrate-to-nest test as an indicator of wellbeing in laboratory mice. J Am Assoc Lab Anim Sci. 2014
Jan;53(1):24-8. Pubmed Abstract
M olecular Onc ol og y Res e a rch In st it u te
707. Arendt L, Keller P, Skibinski A, Goncalves K, Naber S, Buchsbaum RJ, Gilmore H, Come S, Kuperwasser C.
Anatomical localization of progenitor cells in human breast tissue reveals enrichment of uncommitted cells
within immature lobules. Breast cancer research: BCR 2014;16:453.
708. Jun HJ, Roy J, Smith TB, Wood LB, Lane k, Woolfenden S, Punko D, Bronson RT, Haigis KM, Breton S, Charest A.
ROS1 signaling regulates epithelial differentiation in the epididymis. Endocrinology 2014;155:3661-73.
710. Jun HJ, Bronson RT, Charest A. Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma.
Stem cells 2014;32:338-48.
711. Foley, C.J.,Fanjul-Fernandez, R., Bohm, A., Nguyen, N., Agarwal, A., Austin, K., Koukos, G., Covic, L., Lopez-Otin,
C., Kuliopulos, A. Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis. (2014)
Oncogene. 33(17):2264-72.
712. Rajabi HN, Takahashi C, Ewen ME. Retinoblastoma protein and MyoD function together to effect the repression
of Fra-1 and in turn cyclin D1 during terminal cell cycle arrest associated with myogenesis. The Journal of
biological chemistry 2014;289:23417-27.
713. Liu Q, Boudot A, Ni J, Hennessey T, Beauparlant S, Rajabi H, Zahnow C, Ewen ME. Cyclin D1 and C/EBPbeta
LAP1 operate in a common pathway to promote mammary epithelial cell differentiation. Molecular and cellular
biology 2014;34:3168-79.
714. Shah U, Kritharis A, Evens AM. Paraneoplastic pyoderma gangrenosum with posttransplant lymphoproliferative
disorder. Annals of hematology 2014.
715. Evens AM, Kostakoglu L. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage
disease. Blood 2014;124:3356-64.
716. Ravi D, Bhalla S, Gartenhaus RB, Crombie J, Kandela I, Sharma J, Mazar A, Evens AM. The novel organic arsenical
darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin
lymphoma cells and human xenograft models. Clinical cancer research : an official journal of the American
Association for Cancer Research 2014;20:6023-33.
717. Loughran TP, Jr., Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow
MR, Evens AM, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter
phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 2014.
718. Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil
LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM. Peripheral T-cell lymphomas
in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Annals
of Oncology: official journal of the European Society for Medical Oncology/ESMO 2014;25:2211-7.
719. Kostakoglu L, Evens AM. FDG-PET imaging for Hodgkin lymphoma: current use and future applications. Clinical
advances in hematology & oncology: H&O 2014;12:20-35.
720. Gandhi MD, Evens AM, Fenske TS, et al. Pancreatitis in patients treated with brentuximab vedotin: a previously
unrecognized serious adverse event. Blood 2014;123:2895-7.
195
»» PUBLICATIONS
709. Chiu B, Coburn J, Pilichowska M, Holcroft C, Seib FP, Charest A, Kaplan DL. Surgery combined with controlledrelease doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model. British
journal of cancer 2014;111:708-15.
721. Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI. Frontline
bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin
lymphoma: a multicentre phase II study. British journal of haematology 2014;166:514-20.
722. DeVita MD, Evens AM, Rosen ST, Greenberger PA, Petrich AM. Multiple successful desensitizations to
brentuximab vedotin: a case report and literature review. Journal of the National Comprehensive Cancer
Network: JNCCN 2014;12:465-71.
»» PUBLICATIONS
723. Nabhan C, Aschebrook-Kilfoy B, Chiu BC, Kruczek K, Smith SM, Evens AM. The impact of race, age, and sex in
follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras. American journal of
724. Gentzler RD, Evens AM, Rademaker AW, Weitner BB, Mittal BB, Dillehay GL, Petrich AM, Altman JK, Frankfurt O,
Variakojis D, Singhal S, Mehta J, Williams S, Kaminer L, Gordon LI, Winter JN. F-18 FDG-PET predicts outcomes
for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and
refractory Hodgkin lymphoma. British Journal of Haematology 2014;165:793-800.
725. Nabhan C, Aschebrook-Kilfoy B, Chiu BC, Smith SM, Shanafelt TD, Evens AM, Kay NE. The impact of race,
ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance,
Epidemiology, and End Results analysis in the modern era. Leukemia & lymphoma 2014; 55:2778-84.
726. Reddy NM, Evens AM. Chemotherapeutic advancements in peripheral T-cell lymphoma. Seminars in
727. Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, Vose JM, Bast M, Advani RH, Tibshirani R,
Evens AM, Islam N, Leonard JP, Martin P, Zelenetz AD, Lossos IS. A multicentre study of primary breast diffuse
large B-cell lymphoma in the rituximab era. British journal of haematology 2014;165:358-63.
728. Shin J, Phelan PJ, Chhum P, Bashkenova N, Yim S, Parker R, Gagnon D, Gjoerup O, Archambault J, Bullock PA.
Analysis of JC virus DNA replication using a quantitative and high-throughput assay. Virology
2014;468-470:113-25.
729. Forero A, Giacobbi NS, McCormick KD, Gjoerup OV, Bakkenist CJ, Pipas JM, Sarkar SN. Simian virus 40 large T
antigen induces IFN-stimulated genes through ATR kinase. Journal of immunology 2014;192:5933-42.
730. Hinds PW. A little pRB can lead to big problems. Cancer discovery 2014;4:764-5.
731. Kottakis F, Foltopoulou P, Sanidas I, Keller P, Wronski A, Dake BT, Ezell SA, Shen Z, Naber SP, Hinds PW, McNiel
E, Kuperwasser C, Tsichlis PN. NDY1/KDM2B functions as a master regulator of polycomb complexes and
controls self-renewal of breast cancer stem cells. Cancer research 2014;74:3935-46.
732. Sheng J, Luo C, Jiang Y, Hinds PW, Xu Z, Hu GF. Transcription of angiogenin and ribonuclease 4 is regulated by
RNA polymerase III elements and a CCCTC binding factor (CTCF)-dependent intragenic chromatin loop. The
Journal of biological chemistry 2014;289:12520-34.
733. Kohrt D, Crary J, Zimmer M, Patrick A, Ford H, Hinds PW, Grossel M. CDK6 binds and promotes the degradation
of the EYA2 protein. Cell cycle 2014;13:62-71.
734. Del Giudice R, Monti DM, Sarcinelli C, Arciello A, Piccoli R, Hu GF. Amyloidogenic variant of apolipoprotein A-I
elicits cellular stress by attenuating the protective activity of angiogenin. Cell death & disease 2014;5:e1097.
735. Sheng J, Luo C, Jiang Y, Hinds PW, Xu Z, Hu GF. Transcription of angiogenin and ribonuclease 4 is regulated by
RNA polymerase III elements and a CCCTC binding factor (CTCF)-dependent intragenic chromatin loop. The
Journal of biological chemistry 2014;289:12520-34.
736. Sheng J, Yu W, Gao X, Xu Z, Hu GF. Angiogenin stimulates ribosomal RNA transcription by epigenetic activation
of the ribosomal DNA promoter. J Cell Physiol. 2014; 229:521-529.
737. Saikia M, Jobava R, Parisien M, Putnam A, Krokowski D, Gao XH, Guan BJ, Yuan Y, Jankowsky E, Feng Z, Hu GF,
Pusztai-Carey M, Gorla M, Sepuri NB, Pan T, Hatzoglou M. Angiogenin-Cleaved tRNA Halves Interact with
Cytochrome c, Protecting Cells from Apoptosis during Osmotic Stress. Mol Cell Biol. 2014;34:2450-2463.
738. Kishimoto K, Yoshida S, Ibaragi S, Yoshioka N, Hu GF, Sasaki A. Neamine inhibits oral cancer progression by
suppressing angiogenin-mediated angiogenesis and cancer cell proliferation. Anticancer Res. 2014;
34:2113-2121.
739. Foley CJ, Kuliopulos A. Mouse matrix metalloprotease-1a (Mmp1a) gives new insight into MMP function. Journal
of cellular physiology 2014;229:1875-80.
741. Zhang, P., Covic, L. & Kuliopulos, A. (2014) Antiplatelet Therapy and Cardiovascular Disease. 29-44. Ed. Ron
Waksman. Wiley-Blackwell. Ch. 5. Platelet receptors and drug targets: PAR-1, collagen, vWF, thromboxane, and
other novel targets.
742. Arendt LM, St. Laurent J, Wronski A, Caballero S, Lyle SR, Naber SP, Kuperwasser C. Human breast progenitor cell
numbers are regulated by WNT and TBX3. PloS one 2014;9:e111442.
743. Arendt LM, Keller PJ, Skibinski A, Goncalves K, Naber SP, Buchsbaum RJ, Gilmore H, Come SE, Kuperwasser C.
Anatomical localization of progenitor cells in human breast tissue reveals enrichment of uncommitted cells
within immature lobules. Breast cancer research : BCR 2014;16:453.
744. Phillips S, Prat A, Sedic M, Proia T, Wronski A, Mazumdar S, Skibinski A, Shirley SH, Perou CM, Gill G, Gupta PB,
Kuperwasser C. Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation.
Stem cell reports 2014;2:633-47.
746. Skibinski A, Breindel JL, Prat A, Galván P, Smith E, Rolfs A, Gupta PB, LaBaer J, Kuperwasser C. The Hippo
transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell
reports 2014;6:1059-72.
747. McCready J, Arendt LM, Glover E, Iyer V, Briendel JL, Lyle SR, Naber SP, Jay DG, Kuperwasser C. Pregnancyassociated breast cancers are driven by differences in adipose stromal cells present during lactation. Breast
cancer research : BCR 2014;16:R2.
748. Mathew P. The bifunctional role of steroid hormones: implications for therapy in prostate cancer. Oncology
(Williston Park) 2014;28:397-404.
749. Mathew P. The hemostatic system as a therapeutic target in urothelial carcinoma. Oncology (Williston Park)
2014;28.
751. Kanellis DC, Bursac S, Tsichlis PN, Volarevic S, Eliopoulos AG. Physical and functional interaction of the TPL2
kinase with nucleophosmin. Oncogene 2014.
197
»» PUBLICATIONS
740. Foley CJ, Fanjul-Fernández M, Bohm A, Nguyen N, Agarwal A, Austin K, Koukos
G, Covic L, López-Otín C, Kuliopulos A. Matrix metalloprotease 1a deficiency
suppresses tumor growth and angiogenesis. Oncogene 2014;33:2264-72.
753. Sourvinos G, Morou A, Sanidas I, Codruta I, Ezell SA, Doxaki C, Kampranis SC, Kottakis F, Tsichlis PN. The
downregulation of GFI1 by the EZH2-NDY1/KDM2B-JARID2 axis and by human cytomegalovirus (HCMV)
associated factors allows the activation of the HCMV major IE promoter and the transition to productive
infection. PLoS pathogens 2014;10:e1004136.
»» PUBLICATIONS
754. Sriskantharajah S, Gückel E, Tsakiri N, Kierdorf K, Brender C, Ben-Addi A, Veldhoen M, Tsichlis PN, Stockinger B,
O’Garra A, Prinz M, Kollias G, Ley SC. Regulation of experimental autoimmune encephalomyelitis by TPL-2
kinase. Journal of immunology 2014;192:3518-29.
755. Roper J, Sinnamon MJ, Coffee EM, Belmont P, Keung L, Georgeon-Richard L, Wang WV, Faber AC, Yun J, Yilmaz
OH, Bronson RT, Martin ES, Tsichlis PN, Hung KE. Combination PI3K/MEK inhibition promotes tumor apoptosis
and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Cancer letters 2014;347:204-11.
756. Schmidt JW, Wehde BL, Sakamoto K, Triplett AA, Anderson SM, Tsichlis PN, Leone G, Wagner K. Stat5 regulates
the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis.
Molecular and cellular biology 2014;34:1363-77.
757. Sanidas I, Polytarchou C, Hatziapostolou M, Ezell SA, Kottakis F, Hu L, Guo A, Xie J, Comb MJ, Iliopoulos D,
Tsichlis PN. Phosphoproteomics screen reveals akt isoform-specific signals linking RNA processing to lung
cancer. Molecular cell 2014;53:577-90.
758. Corum DG, Tsichlis PN, Muise-Helmericks RC. AKT3 controls mitochondrial biogenesis and autophagy via
regulation of the major nuclear export protein CRM-1. FASEB journal : official publication of the Federation of
American Societies for Experimental Biology 2014;28:395-407.
759. O’Leary E, Larson E, Lin AY, Reardon S, Lee P, Russell M, Melnitchouk N, Hart S, Ghassemi K, Hecht JR, Wainberg
Z, Yoo J. A Multi-Disciplinary Cancer Program Enhances Hereditary Colorectal Cancer Detection. Am J Dig Dis
2014; 1(1):62-66.
760. Larson ES, Khalil HA, Lin AY, Russell M, Ardehali A, Ross D, Yoo J. Diverticulitis Occurs Early After Lung
Transplantation, J Surg Res 2014; 190(2): 667-71.
199
DEPARTMENT OF MEDICINE 2014 Annual Report
Department of Medicine
800 Washington Street
Boston, MA 02111
Published June 2015

DEPARTMENT OF MEDICINE 2014 Annual

Transcription

Similar documents

Nandita Das

As a Tufts Jumbo

Event Order Form

Hyperprolactinemia - kusm

pico de gallo

Respiration and circulation

colon cleanse colon cleanse advanced

the Evening of Culture Program

Inside - Giving to Tufts

Read the Spring 2016 Tufts Parents Giving Program